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PRO.LC>GU.E 
ORGANIZATION OF THE THESIS 
This thesis deals with myocardial protection during open-heart surgery. The chapters of 
this thesis are based on experimental work published in eight papers, as well as 
additional unpublished data. These studies are discussed in chapters 1 - 7. However, the 
more detailed experimental protocols and results for the different experiments are 
presented in Appendix A (published data), and Appendix B (unpublished data) in order 
to not interrupt the flow of the text 
Chapter 1 provides an introductory overview of both the history and clinical practice of 
myocardial protection today. Although the experimental studies presented in this thesis 
primarily concern the effect of changes in the composition of crystalloid cardioplegic 
solutions, a number of other factors can effect the adequacy of myocardial preservation 
in the clinical situation. It is thus essential that cardiac surgeons be aware of all the 
variables that can alter myocardial recovery following cardiac surgery. Experimental 
studies comparing single or multiple doses of cardioplegia administration (Appendix A-
2) are also discussed in this section. 
The importance of a complete overall strategy of "myocardial protection" is emphasized. 
Chapter 2 discusses the models used in this thesis to evaluate cardioplegic solutions, and 
their limitations. The first model used was the isolated working rat heart. This was used 
to evaluate the addition of glucose to the StThomas' Hospital No 2 cardioplegic 
solution, in either a single dose or multiple dose protocol. The results of which are 
presented in appendix A-2. This model was also used· to study the effects of oxygenating 
a modified StThomas' cardioplegic solution containing glucose (11 mmol/L) with either 
95% 02 5% C02 or alternatively 100% 02, and the effects of including 
perfluorocarbons (appendices A-3 and A-4). Finally, it was used to evaluate the effect 
of altering the concentration of sodium and osmolality (appendix B-3), chloride 
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(appendix B-4), pH (appendix B-2), the addition of the buffer histidine (appendix B-5), 
and colloid (appendix B-7) to a modified StThomas' cardioplegic solution. 
The in vivo primate model, was used to evaluate the efficaGy of cardioplegic solutions 
used in South Africa (appendix A-1). This model was also used to evaluate the effebt of 
glucose (appendix B-1) and histidine (appendix B-6 & B-9) when included in the St 
Thomas' cardioplegic solution. I 
A third model was developed to enable us to study the effects of cardioplegic solutions 
on the endothelium. The results of these studies are presented in appendices A-5, Jnd I 
A-6. 
Chapter 3 reviews the composition of cardioplegic solutions used to provide myoc rdial 
protection during cardiac surgery. The three primary types of cardioplegic solutiods; 
crystalloid - either extracellular or intracellular electrolyte equivalent formulations!. and 
. blood cardioplegic solutions are discussed. In addition, solutions used to preserve Jhe 
isolated heart for transplantation are also discussed. . I 
Chapter 4 reviews techniques and cadioplegic solutions used to protect the myocardium 
. I 
. during clinical open-heart surgery in South Africa. Cardioplegic solutions used in South 
Africa in 1988 were compared with the StThomas' Hospital No 2 cardioplegic solJtion I 
(appendix A-1). The results of a second survey in 1991, of techniques and cardioplegic 
solutions used for myocardial protection currentiy, are also presented. / 
. I 
Chapter 5 discusses the results of experimental modifications to the composition ~f the 
StThomas' Hospital No 2 cardioplegic solution (appendices A-2 to A-4, B-1 to B-1, B-9), 
done in both the isolated rat and in vivo primate models. 
Chapter 6 is divided into two parts. The first section reviews the importance of the 
vascular endothelium to the cardiovascular surgeon. Thereafter, the results of 
experimental studies on the effects of cardioplegic solutions on the endothelium 
(appendices A-5 & A-6) are discussed. 
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Chapter 7 discusses the practicalities of delivering cardioplegic solutions in the clinical 
situation. The results of our studies on the methods of oxygenating commercially 
available cardioplegic solutions are discussed (appendix A-7). In addition, we examine 
the potentially detrimental effect of rewarming of the cardioplegic solution contained in 
the delivery line leading to the operating table (appendix A-8), and how perfusion 
pressure should be monitored during infusion of cardioplegic solutions (Appendix B-8). 
Chapter 8 is a summary of the thesis. 
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ABBREVIATIONS USED IN THE TEXT 
Units of Measurement: 
oc degrees Celsius min 
em centimeter ml 
0 delta (change in) mm 
g gravitational force mmol 
gm gram mOsm 
h hour mV 
kg kilogram N 
k.Pa kilopascal ng 
L liter p 
M molarity (mmol/L) s 
m meter u 
mEq milliequivalent ug 
mg milligram 
Chemical Compounds: 
1 ,3-diphosphoglycerate 1,3 DPG 
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AMP 
ATP 
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CK 
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Ct 
C02 
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CP 
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cu2+ 
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adenosine triphosphate 
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cyclic adenosine 3',5'-monophosphate 
cyclic guanosine 3',5'-monophosphate 
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MB fraction of creatine kinase 
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carbon dioxide 
coenzyme A 
creatine phosphate 
citrate-phosphate-dextrose 
copper 
dihydroxyacetone phosphate 
endothelial cell growth factor 
minute 
milliliter 
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millimole 
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millivolt 
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partial pressure 
second 
Unit 
microgram 
DHAP 
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EDTA 
F-6-P 
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FADH 
FC-43 
FDP 
Fe2+ 
endothelium derived relaxing factor (nitric oxide) 
ethylenediamine-tetraacetic acid 
fructose-6-phosphate 
G-1-P 
G-6-P 
flavin adenine dinucleotide (oxidized form) 
dihydroflavin adenine dinucleotide (reduced form) 
Fluosol-43 emulsion 
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glucose-1-phosphate 
glucose-6-phosphate 
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Hb 
HCl 
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Hg 
HK 
K+ 
LDH 
Mg2+ 
N2 
Na+ 
NAD 
NADH 
NADP 
NADPH 
NaOH 
NH2 
a-KGl 
02 
OAA 
PDH 
PEP 
PFK 
PGI2 
PK 
P043-
S042-
SOD 
THAM 
tPA 
TRIS 
UW-CSS 
glucose-6-phosphate dehydrogenase 
glucose-insulin-potassium 
glyceraldehyde-3-phosphate 
glyceraldehyde-3-phosphate dehydrogenase 
hydrogen 
carbonic acid 
water 
hydrogen peroxide 
haemoglobin 
hydrochloric acid 
bicarbonate 
mercury 
hexokinase 
potassium 
l~ctate dehydrogenase 
magnesium 
nitrogen 
sodium 
nicotinamide adenine dinucleotide (oxidized form) 
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nicotinamide adenine dinucleotide phosphate (oxidized form) 
dihydronicotinamide adenine dinucleotide phosphate 
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ammonia 
a-ketoglutarate 
oxygen 
oxaloacetic acid 
pyruvate dehydrogenase 
phosphoenolpyruvate 
phosphofructokinase 
prostacyclin 
pyruvate kinase 
phosphate 
sulfate 
superoxide dismutase 
tromethamine 
tissue plasminogen activator 
tris (hydroxymethyl) aminomethane hydrochloride 
University of Wisconsin cold storage solution 
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Other Abbreviations: 
AO 
BSA 
CABG 
CI 
co 
DPTI 
e-
ECG 
HR 
IABP 
LA 
LAP 
LV 
LVdp/dt 
LVEDP 
MAP 
PB 
PVR 
sv 
SV( 
SVR 
SWI 
TTl 
aortic flow 
body surface area 
coronary artery bypass graft 
cardiac index 
cardiac output 
diastolic pressure time index 
electron 
electrocardiogram 
heart rate 
intra aortic balloon pump 
let atrium 
left atrial pressure 
left ventricle 
first derivative of LV developed pressure 
left ventricular end diastolic pressure 
mean arterial pressure 
Plasmalyte B electrolyte solutiqn 
pulmonary vascular resistance 
stroke volume 
stroke volume index 
systemic vascular resistance 
stroke work index 
tension time index 
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INTRODUCTIQN 
The first successful cardiac operation was performed by Professor Ludwig Rehn in 
September 1896 in Frankfurt; repair of a penetrating wound of the right ventricle (Rl4). 
However, it was not until September 1952 that the first elective "open-heart" surgical 
procedure was performed; closure of an atrial septal defect by Dr F John Lewis using 
moderate systemiC hypothermia (28°C) and inflow occlusion (L33). The period that the 
vena cavae can be safely occluded without sustaining neurological damage is though 
limited to 8 - 10 min. Further progress in cardiac surgery was thus primarily hindered by 
· the inability to independently maintain cerebral circulation. In addition, the technique 
of inflow occlusion has a sig.nificant risk of systemic air embolism (~33), and there is also 
no adequate means to rewarm the cold non-beating heart (W5). Nevertheless, surface-
induced deep hypothermia and total circulatory arrest without cardiopulmonary bypass 
was used to correct congenital heart defects till the late 1960's, but with a mortality as 
high as 58% (M51). Although hypothermic inflow occlusion is no longer used routinely 
today, inflow caval occlusion can still be a valuable adjuvant technique during modern 
cardiac surgery (111,04). 
The evolution of cardiac surgery required a means of temporarily replacing the function 
of the heart and lungs, and thereby supporting the systemic circulation. Th!ls research at 
this time concentrated on this problem, and an extracorporeal heart-lung apparatus was 
first used clinically in May 1953 by Dr J Gibbon to close an atrial septal defect (G19). 
However, further attempts to repair intracardiac defects utilizing these pump-
oxygenators failed (L37). The only alternative means of temporarily supporting the 
patient's circulation was pioneered by Dr C W Lillehei; controlled cross-circulation from 
a donor parent to the patient (W5). Cross-circulation was used clinically for the first 
time in March 1954, and the mortality in 45 subsequent corrections of congenital heart 
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defects was 37% (L37). Although this high mortality is not good by today's standards it 
was acceptable in 1955, and better than that associated with other methods used at that 
time (M51). 
Nevertheless, the design and function of extracorporeal pumps and bubble oxygenators 
progressively improved and cardiopulmonary bypass became routine in July 1955 
(K21,W5). Thereafter, the scope of cardiac surgery expanded rapidly, and cardiac 
surgery was now only limited by the amount of damage the myocardium could sustain 
during the surgical procedure. Consequently, a great deal of research was therefore 
directed towards ways of protecting and preventing injury to the myocardium whilst the 
surgeon operated upon the heart Nonetheless, there is still no consensus on the ideal 
technique of perioperative myocardial protection. Moreover, certain cardiac operations 
require specific intraoperative techniques because of other constraints. In addition, 
cardiac surgeons should also be aware of the multitude of factors that can alter 
myocardial function during the perioperative period. These factors and diverse 
techniques of protecting the myocardium are therefore reviewed. 
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1.1 MECHANISMS OF MYOCARDIAL INJURY 
The myocardium can be injured by mechanical, ischaemic and pharmacological means 
(Wl2), and postoperative morbidity and mortality increase if injury results in myocardial 
necrosis (K20). 
Mechanical Injury of the Heart 
Mechanical injury of the heart occurs frequently during open-heart surgical procedures 
(Table 1.1). 
Table 1.1 
MECHANICAL INJURY OF THE HEART 
Surgical Incisions (E2) 
Surgical Handling 
Myocardial contusion 
Myocardial lacerations 
Topical Hypothermic Injury 
Epicardial Frostbite (Hl6,S66) 
Ventricular Distension (H49) 
Any surgical incision ofthe myocardium (eg. right ventriculotomy for repair ofFallot's 
tetralogy) will produce local myocardial necrosis. In addition, the incision and its 
subsequent closure can have more profound effects if coronary arteries are 
inadvertently divided, if myocardial geometry is altered thus decreasing the efficiency of 
global contraction (E2). Furthermore, the heart is easily contused and lacerated by 
"rough" surgical handling, and can be injured by "protective mechanisms" such as 
extreme hypothermia (Hl6,R27,S66). Ventricular distention is also harmful as it causes 
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subendocardial ischaemia, and severe distention can result in an irreversible mechanical 
"stretch injury" of the myocardium (H49). Cross-linkages between actin and myosin 
filaments are disrupted and the myocyte is thereafter incapable of contracting. 
Therefore, prerequisite myocardial incisions should be limited as far as possible, the 
heart should be handled with care and ventricular distention avoided. 
Ischaemic Injury of the Heart 
The energy requirements of the heart can be subdivided into the energy required for 
electromechanical work (70% - 88% of energy requirements depending upon the degree 
of work (B76,H50)), as well as basal cellular metabolic requirements . .These energy 
requirements are met by aerobic metabolism in the perfused heart, primarily from 
catabolism of either carbohydrates (38 mmol A TP per mmol extracellular glucose) or 
fatty acids (129 moles of ATP per mole of palmitate) (016). However, if the heart is 
deprived of coronary blood flow and thus oxygen, aerobic metabolism ceases and only a 
limited amount of energy can be supplied by anaerobic metabolism (2 mmol A TP per 
mmol extracellular glucose). Ongoing energy requirements cannot therefore be met and 
myocardial ischaemia occurs. 
Myocardial ischaemia exists whenever the energy demand of the myocardium is greater 
than the energy supply, and is associated with lack of substrates for energy production 
and insufficient removal of potentially toxic end products of metabolism. The effects of 
myocardial ischaemia are multiple, progressive and vary accord~ng to the degree of 
$ 
ischaemia (Hl6). In summary, oxidative mitochondrial metab.olism diminishes rapidly, 
fatty acyl Co A accumulates, anaerobic glycolysis is initially stimulated but then inhibited 
by increasing levels of lactate, NADH, and hydrogen ions (N8,R53), and high energy 
phosphates (ATP, CP) are depleted (B63,H18,N7,R42). Energy dependant systems can 
thus no longer function effectively; electromechanical coupling and contractility 
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declines, cessation of membrane pumps results in changes to intracellular ionic 
concentrations (F13), and da~age occurs to the sarcoplasmic reticulum and 
mitochondria (GZl,M41,018)_ Finally, lipases and proteases are activated and cellular 
necrosis occurs (B53,M37,S27)_ 
Ischaemia thus causes major metabolic, ionic and electrophysiological changes to the 
myocardium and the pathophysiology of these changes interrelate in a complex fashion. 
ATP deficiency and alteredproton and calcium homeostasis (Pl4) appears though to be 
the major damaging factors in the ischaemic process. Initially, ischaemic induced 
cellular changes are potentially reversible, but cell death eventually occurs if allowed to 
progress (B53)_ Nevertheless, myocardial tolerance to ischaemia can be significantly 
. 
increased by favorably. manipulating the ischaemic process; decreasing metabolic 
demands, stabilizing membranes, and maintaining intracellular homeostasis. 
Pharmacologic Injury of the Heart 
Pharmacological drugs can be both beneficial and injurious. Excessive doses of so called 
"protective agents" can result in myocardial damage, as exemplified by the Melrose 
cardioplegic solution (H 16,M23,M29)_ Excessive doses of blood cardioplegic 
reperfusion solutions have also been shown experimentally to be potentiallydeleterious 
(K25)_ In addition, pharmacologic agents may be beneficial only during specific time 
periods, and toxic at others ( eg. beneficial effect of preoperative glucose, insulin and 
potassium which increases myocardial glycogen stores ( 0 ll,V23), but possible 
detrimental effect of glucose and insulin when present during ischaemia (H27,N5,W34)). 
Finally, inappropriate us~o·f drugs ( eg. immediate postischaemic use of inotropic drugs) 
can also increase myocardial ischaemic damage (Kl,L19)_ 
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There are thus a number of different mechanisms whereby the heart can be injured, all 
of which can detrimentally affect postoperative myocardial function. Although 
ischaemia is probably the major cause of intraoperative myocardial damage, all of the 
above potentially harmful factors must be taken into account during open-heart surgery. 
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1.2 MYOCARDIAL PROTECTION DURING OPEN-HEART SURGERY 
The majority of cardiac operations performed today involve cross-clamping the 
ascending aorta, although many cardiac operations can be performed with the heart 
continuously perfused and beating on cardiopulmonary bypass. Cross-clamping the 
aorta facilitates the surgical procedure technically by producing a still, bloodless 
operative field, but also causes myocardial ischaemia. Cardiac surgery is thus dependant 
upon a compromise between the needs of the surgeon; surgical exposure and sufficient 
time to complete the necessary procedure, and the needs of the myocardium for a 
continuous supply of oxygen and substrate (H 16). 
The intraoperative objective during cardiac surgery should therefore be twofold; 
correction of the pathological entity necessitating the operation, but without causing 
additional myocardial damage. Ideally, after the surgical procedure there should be no 
discernable reduction in myocardial function even if temporary. Although the 
previously discussed mechanisms of myocardial injury appear simplistic, a multitude of 
factors must be taken into account if myocardial damage during open-heart surgery is to 
be prevented; preoperative, intraoperative, anaesthetic and pharmacological factors 
(MlO), effects of cardiopulmonary bypass, surgical incisions and handling ofthe heart, 
adjuvant techniques used to reduce the effects of myocardial ischaemia, and 
postoperative care. Thus "myocardial protection" is the responsibility of not only the 
cardiac surgeon but also the anaesthetist and intensivist Furthermore, a fundamental 
principle during open-heart surgery is that myocardial damage is cumulative, and occurs 
whenever and wherever there is an imbalance between myocardial energy supply and 
demand (B73). Adequate myocardial protection can only be achieved if a number of 
principles are followed throughout the entire perioperative period, and conceptually this 
can be broken down into various phases of the surgical procedure 
. (B70,B73,B74,H 16,W12); preoperative period, during cardiopulmonary bypass, whilst 
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the aorta is cross-clamped, the postischaemic period following the release of the aortic 
cross clamp, and the postoperative period. 
No single factor provides "myocardial protection" 
during open-heart surgery. 
Furthermore, despite an enormous amount of basic research already done on myocardial 
protection (M24), only general principles can be tabulated. The "ideal" techniques for 
· protecting the myocardium during open-heart surgery are still being evolved 
(B60,B61,B69,B74,H 14,J24,K20,S77)_ Intraoperatively, there are a number of different 
ways of both protecting the myocardium and of correcting cardiac defects. However, of 
utmost importance is the ·necessity that the surgeon has a sound knowledge of the 
principles and specific details of any one technique. Techniques used successfully at one 
institution may fail at another, because of lack of attention to some "minor" detail (Wl2). 
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1.3 MYOCARDIAL PROTECTION IN THE PREOPERATIVE PERIOD 
The majority of patients undergoing open-heart surgical procedures have already 
sustained some myocardial damage as a result of the pathological condition necessitating 
cardiac surgery. 
Myocardial ischaemia is usually a common <fenominator in the preoperative period. 
Various pathological conditions can result in myocardial ischaemia and conceptually 
ischaemia occurs if the ratio of the area beneath the left ventricular systolic pressure 
curve (tension time index or energy demand) and the area between the aortic and left 
ventricular pressure curves in diastole (diastolic pressure time index or energy supply), is 
less than 0.8 (B73). Examples of this concept are shown in Figure 1.1; the decreased 
energy supply in the myocardium distal to coronary artery stenoses or in aortic 
incompetence, and the increased energy supply provided by intraaortic balloon pump 
counterpulsation. 
An understanding of the pathophysiology of the ischaemic process in these various . · 
pathological conditions will assist in the preoperative medical management ofthese 
patients. The patient's pathology will dictate the importance·of each possible 
preoperative intervention. For example, in valvular heart disease bradycardia must be 
prevented in the presence of aortic incompetence, but encouraged if there is significant 
valvular stenosis. In contrast, in ischaemic heart disease coronary vasodilator therapy 
and adequate preoperative beta blockade is essential (S54). 
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Figure Ll 
Aorta 
Coronary 
LV 
Normal 
Intra aortic balloon pump 
Legend: 
Aortic and left ventricular (LV) pressure curves illustrating the ratio of the energy supply (DPTl- diastolic pressure time index) 
and energy demand (TTl- tension time index) of the normal heart, the heart with aortic incompetence, in the myocardium distal 
to coronary artery stenoses, or during intraaortic balloon pump counterpulsation are shown. Modified from Cardiovasc Clin 
1981; 12(3):9-30 (B73) with permission G D Buckberg and Cardiovascular Clinics. 
Adequate preoperative beta blockade decreases perioperative ischaemia by 
approximately 50% (H?,S52), whereas calcium antagonists do not decrease the 
incidence of ischaemic events during anaesthesia. Furthermore, administration of beta 
blockers (propranolol 0.05 mg/kg) even a few minutes before the aorta is cross-clamped 
reduces perioperative infarct size in both ischaemic and valvular heart disease patients 
(R6). 
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Furthermore, a number of additional beneficial interventions that diminish 
perioperative morbidity and mortality can also be commenced preoperatively (B62) 
(Table 1.2). 
Table 1.2 
POSSIBLE PREOPERATIVE IHTERVENTIONS 
Increase myocardial oxygen supply (K7) 
Oxygen 
Optimize coronary blood flow 
Vasodilator therapy 
Intra aortic balloon pump 
Decrease myocardial oxygen consUJption (K7) 
Optimize heart rate 
Optimize preload & afterload 
Vasodilators 
Beta-blockers (H?,R6,VlS) 
Intra aortic balloon pump 
Decrease catecholamines (H14) 
Metabolic interventions 
Beta-blockers (R6,552 ,554 ) 
Adequate premedication (B60,P22 l 
Anxiolytics 
Increase intracellular glycogen (011) 
Glucose-insulin-potassium (M41) 
Inhibit free fatty acid metabolism 
Nicotinic acid (023 ) 
Prevent free radical generation (M37) 
Allopurinol (B8,C12,S75,W12) 
Discontinue certain drugs 
Digitalis (C44 ,K31 ) 
Amiodarone (K42,L34,V2) 
The "super fit" athlete 
Preoperative metabolic interventions 
Preischaemic metabolic enhancement is generally not used routinely, but might well be 
essential in high risk class IV patients, who have an increased probability of 
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peri operative myocardial necrosis because of depleted myocardial glycogen reserves 
(K19). 
Glucose-insulin-potassium (GIK) infusions were first reported to be beneficial for 
patients with ischaemic heart disease by Sodi-Pallares in 1963 (S58). All three 
components of GIK were necessary, neither single components nor any two components 
were as effective in decreasing the electrocardiographic signs of acute myocardial 
infarction. GIK increases intracellular potassium, glycolysis, gluconeogenesis, improves 
sarcoplasmic reticulum calcium uptake, inhibits lipid metabolism, diminishes potentially 
harmful accumulation of fatty acyl Co A, increases prostaglandins, and possibly 
scavenges oxygen free radicals (H35,M41,019,022). All of these effects would be 
beneficial during or prior to ischaemia. Although routine preoperative substrate 
enhancement is controversial (L28), the majority of patients taking a regular diet will 
have low preoperative levels of glycogen (L28). Preoperative overnight infusions of 
GIK (1 L 20% glucose, 45 mmol KCl, insulin 10 U, heparin 2000 U) will increase 
myocardial glycogen levels ( 011), and high preischaemic myocyte glycogen levels are 
associated with improved tolerance to ischaemia and fewer complications after open-
heart surgery (L46,0 11 ). Moreover, even a short period of metabolic enhancement, 
from induction of anaesthesia till the aorta is cross-clamped (glucose 0.5 - 1 gm, insulin 1 
- 1.5 U, KCl 0.25 mmollkg body weight/h), is beneficial (H4,V23). The trauma of 
surgery and cardiopulmonary bypass also inhibits insulin secretion because of increased 
str~ss hormone release and hypothermia (K40,K41). Therefore, metabolic enhancement -
in the postischaemic period with GIK is also beneficial (G28,S88,S89,V23). 
Nevertheless, close monitoring of serum potassium and glucose concentrations are 
essential both during infusions of GIK, and in addition for 6- 12 h postinfusion as 
rebound hyperkalemia is a noted complication (B38). 
Chronic use of diuretics reduces intracellular potassium and magnesium (D26,G27), 
and decreases sodium-potassium pump function (D22). Thus, low serum levels of these 
electrolytes should be corrected preoperatively. 
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Long chain fatty acid metabolites - acyl CoA - accumulate in ischaemic myocardium 
and impair mitochondrial function (016). Hence, inhibiting fatty acid uptake and 
metabolism prior to ischaemia, by using GIK or nicotinic acid may be beneficial (023). 
High doses of oral nicotinic acid (3.6 gm /24 h) have been used to decrease serum levels 
of free fatty acids after myocardial infarctions, but these doses are associated with 
significant side effects (R56). Nevertheless, smaller intravenous doses may be beneficial 
prior to cardioplegic arrest, by specifically inhibiting myocardial lipolysis without 
altering serum free fatty acid levels (023). 
Oxygen derived free radicals contribute to perioperative tissue injury and are 
generated by a number of mechanisms including the catalysis of hypoxanthine (see 
section 1.6). Therefore, free radical scavengers can be infused into the ischaemic tissue 
to "mop" up free radicals, or alternatively the generation of free radicals can be 
prevented (M37 ,W12). Although the exact role and timing of the administration of free 
radical inhibitors and scavengers is still to be defined, especially as free radicals are 
predominantly generated on reperfusion (see section 1.6), preoperative administration 
of free radical scavengers can he beneficial (B8,S75). Allopurinol has been shown to 
reduce free radical generation if given preoperatively (50 mg/kg for 72 h) (B8,S75), 
although pretreatment at a lower dose (20 mg/kg) only improved recovery 
experimentally after normothermic ischaemia and not after hypothermic ischaemia 
(Cl2). Nevertheless; clinical trials suggest that preoperative allopurinol (300 mg twice 
daily for 2 days and 600 mg on the morning of operation) decreases complications 
following cardiac surgery (110,R7,T2). Moreover, preoperative a~lopurinol also allows 
build up of the metabolites oxypurinol I alloxan thine, which also inhibit xanthine · 
oxidase and scavenge hydroxyl radicals (T2,V18), 
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Drugs that should be discontinued prior to cardiac surgery 
Certain therapeutic agents should be discontinued preoperatively, because of their 
potential detrimental effects during subsequent ischaemia. 
Digitalis should be discontinued preoperatively if possible, as it possibly increases 
cytosolic calcium during ischaemia which impairs postischaemic myocardial function 
(C44,K31). 
Amiodarone is an antiarrhythmic drug, and its preoperative use has been associated 
with increased operative mortality and morbidity; hepatic, pulmonary, and cardiac 
dysfunction are increased after open-heart surgery (K42,L34,V2). However, if 
preoperative withdrawal of amiodarone is not possible because of malignant 
dysrhythmias, then the surgical procedure should be performed without cardioplegia due 
to potentially dangerous interactions of amiodarone and cardioplegic solutions (Cox J; 
personal communication). Furthermore, because of its long halflife (measurable serum 
levels recorded as long as 9 months after discontinuation of amiodarone (L34)), it should 
be stopped for at least 6 months prior to surgery. 
The myocardium of "super-fit" olympic athletes undergoes metabolic alterations, and 
has been associated with irreversible myocardial dysfunction following uncomplicated 
short cardioplegic protected ischaemic periods during arrhythmia surgery (Cox J; 
personal communication). Arrhythmia surgery is possibly the only branch of cardiac 
surgery where the patient can be extremely fit and yet require open-heart surgery. Thus, 
"detraining" of super-fit athletes is now advised, prior to cardiac surgery if cardioplegia is 
necessary. 
The preoperative management of patients undergoing cardiac surgery can thus 
significantly alter postoperative myocardial function, morbidity and mortality. 
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1.4 MYOCARDIAL PROTECTION ONCE ON CARDIOPULMONARY 
BYPASS 
The majority of cardiac operations are performed with the aid of an extracorporeal 
circulation. The systemic venous blood is drained into an extracorporeal oxygenator 
where it is oxygenated and then pumped back into the patient's arterial system by a 
cardiopulmonary bypass machine. The empty heart continues to beat but no longer 
ejects once total cardiopulmonary bypass is commenced, and this beating "non-working" 
state decreases myocardial oxygen consumption by more than 40% (Fig 1.2) (H50). 
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Legend: 
Oxygen consumption of the total heart and left ventricle during beating working, beating empty or spontaneous ventricular 
fibrillation conditions. Modified from Hottenrott et al. J Tborac Cardiovasc Surg 1974; 68:61Hi25 (H50) with permission G D 
Buckberg and Mosby Year Book Inc. 
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Thus extracorporeal support of the systemic circulation decreases myocardial energy 
demands and can assist in reversing myocardial ischaemia. However, although 
cardiopulmonary bypass decreases myocardial energy demands, extracorporeal 
circulation also causes cumulative myocardial damage. Four hours of continuous 
coronary perfusion with no ischaemic stress decreases left ventricular function, 
compared to four hours of cardioplegic protected hypothermic arrest (R25) .. 
Cardiopulmonary bypass induced myocardial damage 
Cardiopulmonary bypass damages all blood components (erythrocytes (Rl6), leukocytes 
(S67), platelets (V7), plasma proteins (V6,Vl6)) by (K21):-
Exposure of blood to unphysiological surfaces, 
Sheer stresses, 
Incorporation of abnormal substances (pyrogens, plastics, micro-emboli etc). 
Furthermore, micro and macro emboli, released vasoactive substances, catecholamines, 
activated complement, sequestrated leukocytes, free fatty acids and denatured proteins, 
which can all cause damage to vario~s organs (Kl8,L28,M2,M55,N17,V3). Thus, 
cardiopulmonary bypass itself can result in. neurologic (Pl,S38,T20), pulmonary, renal 
and myocardial damage (Nl7). Hence, the duration of cardiopulmonary bypass should 
be limited whenever possible. 
Primary factors causing myocardial damage during cardiopulmonary bypass are listed in 
Table 1.3. 
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Table 1.3 
DAMAGING EFFECTS OF CARDIOPULMONARY BYPASS 
Extracorporeal circulation itself (D2l,Kl8) 
Pumping mechanismi 
Roller pump > Centrifugal? 
Oxygenatori 
Bubble >Membrane (D2l,G36,H39,Pl,V6) 
FlOWi 
Non-pulsatile > pulsatile? (Rl5,T20) 
Duration of cardiopulmonary bypass (D21) 
Cardiotomy suckers (turbulence) (V6) 
Micro-emboli (Pl) 
Low perfusion pressures (M20) 
Ventricular fibrillation 
Further aggravated if: 
Continuous electrical fibrillation (H50) 
Myocardial Hypertrophy (H51) 
Ventricular distention (H49) 
Hypothermia (B63,G37,S40) 
Myocardial perfusion pressure 
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The majority of factors listed in Table 1.3 decrease myocardial perfusion directly or 
indirectly. Myocardial blood flow may be diminished directly by decreased perfusion 
gradients or indirectly by changes in coronary vascular resistance and regional blood 
flow. Systemic perfusion pressure is easily controlled, and should be maintained at 
adequate levels throughout cardiopulmonary bypass (50- 70 mm Hg (L28)). At 
normothermia (37°C) the myocardium can compensate for reduced perfusion gradients 
by autoregulation and compensatory vasodilation (M59), provided there are no coronary 
artery occlusions. However, coronary autoregulation is inadequate at hypothermia 
(28oC) (C24,M20), despite adequate perfusion pressures there is decreased collateral 
' blood flow to areas of myocardial ischaemia during cardiopulmonary bypass (M49). 
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Effect of Ventricular Fibrillation 
Ventricular fibrillation increases myocardial wall tension and thus oxygen consumption 
(Fig 1.2) (H50)_ In addition, ventricular fibrillation decreases perfusion to the 
subendocardium ·because of myocardial compressive forces, thus causing subendocardial 
ischaemia (H51)_ Moreover, if perfusion pressures are low or unequally distributed 
between right and left coronary arteries (B56,Nl), if fibrillation is electrically 
maintained (H50), or if there is ventricular hypertrophy (H52), then myocardial injury is 
accentuated. Although, myocardial oxygen uptake during hypothermic (28°C) 
ventricular fibrillation is 52% less than if at normothermia (Fig 1.3), subendocardial 
blood flow is still reduced (B56). Hence, hypothermia does not protect the ventricle 
from subendocardial ischaemia caused by ventricular fibrillation. Furthermore, 
ventricular fibrillation can result in ventricular dilatation, which would itself produce 
further cumulative myocardial damage (H49). However, a short period (3 min) of 
ventricular fibrillation at 28°C prior to cardioplegic arrest is possibly not harmful in 
non vented hearts (S9), but even a shorter period of continuous electrical fibrillation (30 
s) is harmful (S8)_ 
Ventricular fibrillation causes subendocardial ischaemia and should therefore be 
avoided, both prior to aortic cross-:clamping and during the reperfusion period (L42). 
Nevertheless, if a period of ventricular fibrillation cannot be avoided then a ventricular 
vent should be inserted to prevent ventricular distention, an adequate perfusion pressure 
must be maintained, myocardial temperature should be decreased to approximately 
28oc, and the period of ventricular fibrillation should be kept as short as possible. 
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Effect of Ventricular Distention 
Ventricular distention also increases myocardial wall tension (Laplace's law: wall 
tension is proportional to the distending pressure and principal radii of curvature ( G2)), 
which increases myocardial oxygen consumption. In addition, the increased 
intracavitary ventricular pressure decreases subendocardial perfusion thus resulting in 
subendocardial ischaemia (H49)_ Ventricular distension does not have to be severe for 
it to be harmful, although should massive distention occur the resultant overstretch of 
muscle fibres can produce irreversible mechanical damage (see section 1.1). Insertion of 
a left ventricular vent can prevent ventricular distention. However, complete 
ventricular collapse may also be damaging in perfused beating hearts because of changes 
in ventricular geometry and compressive forces (L28), but this can be prevented by 
manipulating the vent 
The following factors are associated with a higher risk of ventricular distension occurring 
during cardiopulmonary bypass :-
- Aortic incompetence, 
- Inadequate systemic venous drainage (B22), 
-Increased bronchial blood flow, 
- Ventricular fibrillation. 
Ventricular distention can also occur whilst the aorta is cross-clamped, during 
cardioplegic arrest However, moderate ventricular distention (LVEDP less than 15 mm 
Hg) during hypothermic cardioplegic arrest is not harmful (L22), and may be beneficial 
if the distending solution is cold. Therefore, routine insertion of a LV vent is not 
necessary, although warm systemic blood allowed to accumulate in the left ventricle will 
increase rewarming of the hypothermic myocardium which could in turn be detrimental 
(see section 1.5). Nevertheless, if an LV vent is not inserted prior to the aortic cross-
clamp period, then left ventricular distention (L VEDP greater than 20 mm Hg) must be 
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prevented if it occurs in the early reperfusion period, as LV distention during 
reperfusion depresses postischaemic myocardial function (L50). 
Thus, the left ventricle need not be routinely vented during open-heart surgical 
· procedures, but only provided appropriate steps are taken should distention be seen to 
occur. Venous drainage should also be ideal and noncoronary flow limited in the 
absence of left ventricular venting, in order to prevent an accumulation of blood on the 
left side of the heart (L22). Alternatively, in certain circumstances venting the 
pulmonary artery as opposed to the left ventricle may be equally effective in 
decompressing the left ventricle (G4,M48). 
Systemic Hypothermia 
Systemic hypothermia, that is lowering the temperature of the entire body, decreases 
oxygen demand of all organs, increases tissue energy states (S90), and thus produces 
specific advantages for the cardiac surgeon (Table 1.4). The first open-heart surgical 
procedure in 1952 was performed without cardiopulmonary bypass, and its success was 
due entirely to the beneficial effects of systemic hypothermia (L33). However, despite 
routine use of cardiopulmonary bypass from 1955 onwards it was not until1958 that 
cardiopulmonary bypass was combined with systemic hypothermia (surface cooling) 
(S32). Today, systemic hypothermia is induced by a heat exchanger incorporated in the 
cardiopulmonary bypass circuit, and initial surface cooling is only occasionally used 
(R21). 
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Table 1.4 
ADVANTAGES OF SYSTEMIC HYPOTHERKIA 
Increases the safe cerebral circulatory arrest ti1e (G29,M57,03,R9,R21) 
3 - 5 min at 37°C 
10 - 15 min at 28°C 
45 - 60 min at 18°C 
cardiopulmonary bypass flow rates can be decreased 
Decreases noncoronary collateral flow (Y1) 
Decreases pump-oxygenator induced damage.(S32) 
Helps maintain profound myocardial hypothermia (B48,C34) 
Diminishes conducted heat from adjacent organs 
Diminishes heat gain from systemic perfusate 
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Early pump oxygenator systems were extremely destructive to blood elements, 
especially at high flow rates. Hence, lower flow rates in conjunction with mild systemic 
hypothermia (30°C) were advantageous (S3l,S32). Total body oxygen consumption at 
28°C is reduced by 50%-60%, and at 18°C by 85%-90% (G29). Thus, normothermic 
flow rates for adults (2.2- 2.5 L/min/m2) can be reduced to 1.6-2.2 L/min/m2 if 
systemic temperature is decreased to less than 28°C (C34,K21). Furthermore, 
malfunctions of early cardiopulmonary bypass systems occasionally occurred, and 
hypothermia provided a measure of safety if the extracorporeal circulation stopped 
inappropriately. 
There are also a number of potential disadvantages to using systemic hypothermia 
(R2l,S91,W19), which can effect the myocardium directly or indirectly (Table 1.5). 
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Table 1.5 
DISADVANTAGES OF SYSTEMIC ~IA 
Leftward shift of oxyhae1oglobin dissociation curve 
-Less oxygen released at lower temperatures (G2), 
but ther~ is increased plasma dissolved oxygen. 
* Optimize pa2: 250 mm Hg (30 - 35 kPa) 
Increased blood viscosity (F33) 
* Haemodilute at hypothermia (Ul), 
haematocrit at 20°c - 25°C: 0.2 - 0.25 
Vasoconstriction 
- Increased peripheral and pulmonary vascular resistance 
partially mediated by alpha-receptors (R21) 
~ Coronary vasoconstriction (B63) 
Decreased coronary autoregulatory vasodilation 
. * Maintain an adequate perfusion pressure (C24,M20) 
Positive inotropic effect (Rl2,S40) 
- Increased intracellular calcium (K43) 
Change in pH of neutrality (Wl9) 
*Alpha-stat pH management (Bl9,S9l,W30) 
Inhibition of insulin release (K40,K4l,R21) 
Time taken to rewarm the patient intraoperatively, 
and 1after-drop1 following adequate rewarming (NlO) 
* Pharmacologic vasodilation during rewarming 
Increased oxygen consumption by shivering in the postoperative period (ZlO) 
* Neuromuscular blockade 
Legend: 
• Measures that should be taken to prevent the deleterious effects of hypothermia. 
However, many of these potentially harmful effects of hypothermia can be 
appropriately counteracted. Some of these possible deleterious effects of hypothermia 
such as increased viscosity of blood, phase changes in lipid components of cell 
membranes and increased activation energy of A TPases increase markedly below 25°C 
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(F33,M26). Thus, possibly 25°C should be the lower limit for routine cardiopulmonary 
bypass procedures. 
Rapid myocardial cooling can also cause coronary vasoconstriction and increased 
contractility as a result of complex hypothermic induced cytosolic changes of calcium . 
flux (B63,K43,S40). Thus, rapid prearrest cooling of the beating heart can decrease 
postischaemic myocardial recovery (Rll) as a result of increased cytosolic calcium 
(G37). Electromecha~ical arrest induced initially at normothermia prior to rapid 
cooling of the myocardium and systemic circulation has therefore been advocated, in · 
addition to other advantages of normothermic arrest (see section 1.5) 
(H48,R40,R44,T10,W31). Furthermore, the temperature difference between the blood 
going into the patient and the patient's actual temperature should not be greater than 
10°C- 14°C during systemic cooling (DlO), in order to prevent bubbles coming out of 
solution; when the well oxygenated cold blood is rapidly rewarmed (becomes 
supersaturated) on contacting the warmer body. 
In clinical practise today, moderate hypothermia (25°C - 28°C) with low flow rates is 
still used for routine cardiac surgery. Low cardiopulmonary bypass flow rates minimize 
noncoronary collateral flow from obscuring the operative field (K21) and help prevent 
rewarming of the hypothermic myocardium (see section 1.5) (C20,C34,Yl). In addition, 
deep systemic hypothermia is used if circulatory arrest during congenital or aortic arch 
operations is necessary (C41,K33,M57,03,R21). If circulatory arrest is required, then 
systemic temperature is lowered to 18°C- 20°C in order to obtain electrocerebral· 
silence and adequate cerebral protection (C38,G29,T20)_ 
Furthermore, a distinction must also be made between the reasons and benefits of 
systemic hypothermia as apposed to profound myocardial hypothermia (see section 1.5). 
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1.5 MYOCARDIAL PROTECTION WHILST THE AORTA IS CROSS-
CLAMPED 
The objective the surgeon wishes to achieve by cross-clamping the aorta is a still, 
bloodless operative field (L3,W35). The advantages being:-
a) The heart is soft and can be retracted more easily, 
b) Microvascular anastomoses can be more accurately constructed, 
c) Cerebral air embolism can be prevented (L3), 
d) Certain cardiac abnormalities can only be corrected 
with prolonged cross-clamping of the aorta:. 
Nevertheless, simple cross-clamping of the aorta produces a still heart as a result of 
anoxic cardiac arrest due to depletion of high energy phosphates, and therefore 
tolerance to ischaemia is limited. Ischaemic tolerance can though be increased by 
maximally decreasing myocardial oxygen demand (basal metabolic and 
electromechanical requirements) during the ischaemic period, and thus decreasing the 
decay of high energy phosphates (B62). This can be achieved by both pharmacologic 
electromechanical arrest (induced by infusing a properly formulated cardioplegic 
solution), and profound myocardial hypothermia (Fig 1.3). 
Cardioplegic arrest of the canine heart at normothermia decreases left ventricular 
myocardial oxygen demand from 5.6 ml 021100 gm/min (beating non-working heart) to 
1.1 ml 0 21100 gm/min; the difference would thus approximate myocardial 
electromechanical energy requirements (B76). If myocardial temperature is then 
decreased to 22°C, oxygen demand diminishes further to 0.3 ml 021100 gm/min; the 
basal myocardial metabolic requirements at hypothermia (Fig 1.3). Profound cardiac 
hypothermia reduces metabolic rate, the rate of decline of high energy phosphates 
(D14,S90), mitochondrial calcium transport (F37}, and rapidity of onset of acidosis 
(H16,T5). 
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Legend: Left ventricular myocardial oxygen uptake of the empty beating nonworking, fibrillating, and cardioplegic arrested 
hearts at different myocardial temperatures. Reprinted with permission Buckberg et al, J Tborac Cardiovasc Surg 1977; 73:87-94 
(B76) and Mosby Year Book Inc. 
Non-cardioplegic methods of myocardial protection 
During the past years a variety of different methods of protecting the myocardium 
during cardiac surgery have evolved (H 16,K20). Although non-cardioplegic methods are 
used more infrequently today, they are still occasionally applicable. 
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1) Continuous cardiac perfusion 
The myocardium is continuously perfused with oxygenated blood via the 
aortic root or during aortic valve surgery by direct cannulation of the 
coronary arteries. This may be performed at either normothermia or 
moderate hypothermia (25°C- 32°C) and with or without electrical 
ventricular fibrillation (to obtain a still operative field).· 
Continuous cardiac perfusion does not produce ideal operative conditions; the heart is 
neither still nor bloodless, and muscular tone hampers manipulation and retraction of 
the heart Certain surgical complications such as posterior left ventricular rupture 
following mitral valve replacement are also increased with this method ( G33). 
Furthermore, continuous cardiopulmonary bypass damages all blood elements and 
produces cumulative myocardial damage and does not prevent myocardial ischaemia 
from occurring (see section 1.4). Although an emptybeating heart has lower myocardial 
oxygen demands (Fig 1.2) (H50), altered compressive forces and ventricular geometry 
impede the distribution of intramyocardial blood flow resulting in subendocardial 
ischaemia (M49). Flow in collateral vessels supplying ischa~mic myocardium is also 
diminished whilst on cardiopulmonary bypass, despite adequate perfusion pressures 
(M49). Hence, hypothermic cardioplegie arrest with either blood (F26,R25) or 
crystalloid cardioplegia (All) is better than an equivalent period of continuous 
perfusion of the beating heart with blood. Furthermore, the potentially harmful effects 
of ventricular fibrillation (used to obtain a still operative field) have already been 
discussed (see section 1.4). Cannulation and perfusion of the coronary ostia during 
aortic valve s~rgery is also associated with vascular injury, inadvertent maldistribution of 
perfusate and consequent myocardial necrosis (N1), and ostial stenosis that can develop 
within a relatively short postoperative period (incidence of 1% - 5% within 6 months) 
(M44). 
Nevertheless, surgery on the continuously perfused beating heart is still essential in 
certain open-heart procedures. It is occasionally necessary to operate on the beating 
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normothermic heart in arrhythmia surgery; to enable monitoring of atrioventricular 
nodal function whilst operating in close proximity to it, whilst mapping arrhythmias, or 
to ensure successful ablation of ischaemic ventricular tachycardias (C40). Thus if 
prolonged continuous perfusion of the beating heart is necessary, the most a traumatic 
cardiopulmonary bypass oxygenators and pumps should be used, adequate perfusion 
pressures must be maintained, and possibly pulsatile flow should also be used. 
In addition, acceptable experimental ( G 31) and clinical results for both elective and 
emergency coronary revascularization have been reported using continuous perfusion 
without cross-clamping the aorta (A14,A15,A16,A17); However, cardioplegic arrest 
would be used by these cardiac units if there was significant aortic regurgitation on 
cardiopulmonary bypass (A14). Technical points to ensure safe continuous myocardial 
perfusion include systemic hypothermia (28°C) with mannitol (25 gm) added to the 
systemic perfusate, local pericardia! cooling with 4°C Ringer's lactate solution, 
maintaining mean perfusion pressure at 80- 100 mm Hg, elective ventricular fibrillation, 
routine left ventricular venting, proximal vein-to-aortic anastomoses done first, local 
vessel occlusion for distal vein-to-coronary anastomoses and avoiding aortic cross-
clamping. Although hospital survival is acceptable, a .significant incidence of central 
nervous system injuries ( 4%) (L31), and postoperative low cardiac output requiring an 
IABP (2.7- 3.2% of elective patients) is reported (A16,A17). 
2) Intermittent cardiac ischaemia 
The aorta is intermittently cross-clamped for short periods (less than 15 
min) with subsequent 5 - 15 min periods of reperfusion of the beating 
heart Normothermia (M56,V4) or moderate cardiac hypothermia 
(25oc - 32oC) is usually used, with or without electrical fibrillation in 
order to obtain a still operative field (B46). 
Surgical exposure is not optimum as myocardial tone is maintained. In addition, the 
risks of both systemic and coronary emboli~ation (air (K20) and particulate matter 
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( 0 12)) are possibly increased because of multiple manipulations of the aorta, and it is 
possible that cumulative repetitive reperfusion injuries are induced by this method 
(K20). Nevertheless, low morbidity and mortality figures have also been reported using 
this method for coronary revascularization procedures (B46). Technical points include 
moderate systemic hypothermia (30°C; lower systemic temperatures may not be 
necessary (V4)), left ventricular venting, intermittent aortic cross-clamping (usually less 
than 8 min per distal anastomosis) and ventricular fibrillation, with defibrillation during 
each reperfusion period. However, cardioplegic arrest is again necessary if long (greater 
than 15 min) continuous periods of ischaemia are anticipated, with all redo coronary 
revascularizations or if the aorta is heavily calcified (B44,B46). 
Clinical studies comparing intermittent aortic cross-clamping ·and hypothermic·· 
cardioplegic arrest have shown equivalent outcome (B16,M56). Moreover, an 
advantage of intermittent global or local ischaemia over cardioplegic arrest is easier 
sizing of the length of bypass grafts when the heart is distended with blood under beating 
conditions (F20,M56). However, high energy phosphates and cellular ultrastructure are 
better preserved in the cardioplegia group, although the use of cardioplegic solutions is 
also associated with an increased incidence of temporary postoperative rhythm 
disturbances (F20). Furthermore, a large number of experimental studies have shown 
cumulative damage as a result of intermittent aortic cross-clamping when compared to 
hypothermic cardioplegic arrest (F26,H16,L2,L32,W35). Hypothermic cardioplegic 
arrest also facilitates the construction of microvascular anastomoses in a still, relaxed, 
bloodless surgical field, and requires minimal manipulation of a calcified aorta ( 0 12). 
3) Prolonged ischaemic cardiac arrest 
The aorta is simply cross-clamped for prolonged periods ( 15 - 60 min) at 
profound myocardial hypothermia (22°C). After 20 - 30 min the 
myocardium becomes electromechanically silent and still, because of 
exhaustion of intramyocardial energy supplies (H16,K20). 
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Normothermic ischaemic arrest can produce irreversible ischaemic contracture of the 
heart; the stone heart (C36). A critical reduction of myocardial A TP content (112) in the 
presence of calcium results in hypercontracture of the myocardium and accelerated A TP 
hydrolysis (HIS). However, the time till onset ofischaemic contracture is variable (22-
110 minutes (C36)), and has been related to the degree of LV hypertrophy and rate of 
A TP utilization (B30). Furthermore, short periods of normothermic ischaemia ( 15 min) . 
cause significant postischaemic myocardial dysfunction (R25), hence the need for 
additional myocardial hypothermia. 
Profound hypothermic ischaemic arrest was pioneered successfully by Norman E 
Shumway (G33,H57,S44), but is now no longer used routinely. A myocardial 
temperature of 15°C - 20°C was induced by irrigating the pericardium with 4°C saline at · 
100- 150 mllmin, in combination with systemic hypothermia (32°C) and diminished 
cardiopulmonary bypass flow rates (1.5 L/min/m2 body surface area) (G33,H57,S44). 
Aortic cross-clamp periods of 16 - 96 min were tolerated with acceptable clinical results, 
but prolonged cardiovascular support was necessary after this period of anoxic arrest 
(G33,H57)_ Nevertheless, a randomized clinical study of aortic valve replacements 
showed hypothermic ischaemic arrest to be superior to continuous coronary perfusion at 
. 32°C (S16). Furthermore, Griepp et al reported a significant decrease in the incidence 
of posterior left ventricular rupture complicating mitral valve replacement using aortic 
cross-clamping combined with profound topical hypothermia (no cardioplegia), in 
contrast to continuous perfusion without cross clamping the aorta (G33). Thus, although 
both aortic and mitral valve replacements can be performed on the continuously 
perfused heart, aortic cross-clamping combined with hypothermia decreases morbidity 
and mo~ality. 
Hypothermic ischaemic arrest may still have a role today in neonatal cardiac surgery 
when combined with deep hypothermic circulatory arrest, as neonatal hearts react 
differently to cardioplegic solutions compared to adult hearts 
(B3,B50,B51,B77 ,M7 ,WlO)_ 
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Protagonists for the continued use of non-cardioplegic methods of myocardial 
protection, unless specifically indicated such as in arrhythmic operations, use these 
methods primarily for primary coronary revascularization procedures. The criticisms 
levelled against hypothermic cardioplegic arrest include:-
Multitude of cardioplegic solutions being used, 
Uneven cooling and distribution of cardioplegic solutions, 
N oncoronary collateral flow washes out the cardioplegia, 
Increased conduction disturbances with cardioplegia (F20)_ 
These criticisms are valid, but to a large extent have been solved today and will be 
discussed in the following pages. Moreover, these same surgeons using non-cardioplegic 
methods do not hesitate to use cardioplegia if indicated. 
Cardioplegic arrest 
Most modern cardiac surgeons agree that if it is necessary to clamp the aorta 
continuously for longer than 15 minutes, then pharmacologic cardioplegic arrest should 
be used to protect the myocardium. Cardioplegic solutions stop all electromechanical 
activity of the heart and thus decrease myocardial energy demands. Interestingly 
though, one of the primary objectives of Melrose et al for formulating the first 
cardioplegic solution in 1955, was to produce elective cardiac arrest in order to decrease 
the incidence of air embolism and not to provide "myocardial protection" as such (M30)_ 
Melrose et al produced elective diastolic cardiac arrest by injecting 2 ml of a 25% stock 
solution of potassium citrate diluted to 20 ml with blood, into the aortic root after 
occluding the aorta (M30)_ This dose of potassium citrate (greater than 200 mEq) far 
exceeded the minimum effective concentration of 1 mg/ml and resulted in a distinctive 
type of myocardial necrosis (M23,M29), and consequently this method fell into 
Myocardial protection during cardiac surgery; Chapter I U 0 Von OppeU 53 
disrepute. Initially a stock solution of potassium citrate had been used, and the actual 
concentration of potassium citrate was inadvertently lowered by precipitation which had 
resulted in less damage than when the solution was later made up fresh (H 16). 
Concurrently, other solutions were also being tried; acetylcholine 10 mg/kg body weight 
(L3), potassium citrate combined with magnesium sulfate and neostigmine (S32)_ 
Nevertheless, cardiac surgeons stopped using cardioplegic solutions for more than 15 
years in the English speaking part of the world, because of their potential toxicity 
(G8,Hl6). However, more controlled research on the formulation of cardioplegic 
solutions continued in the 1960's in Germany. 
Modern principles of elective cardioplegic arrest 
The basic concepts of protecting the ischaemic heart, once the aorta is cross-clamped, 
· are centered on avoiding ischaemic damage by matching myocardial energy demands 
with available energy production, and are summarized in Table 1.6 
(B60,B6l,B63,B69,B73,Hl4,Hl6,J24). 
The majority of myocardial energy expenditure is due to electromechanical activity (Fig 
1.2 & 1.3), hence the benefit of diastolic arrest<B76,H50). However, asystole must be 
produced quickly as a significant amount of A TP can be consumed in the brief period 
between cross-clamping the aorta and obtaining electromechanical arrest (W35), as 
myocardial oxygen reserves are rapidly exhausted. The initial ATP losses can be 
minimized by either precooling the heart by systemic hypothermia, or by an initial 
infusion of cold oxygenated blood, glucose and 0.2% procaine (B63) (to prevent 
hypothermic induced increased muscular tone) prior to infusion of crystalloid 
cardioplegic solutions. Alternatively, cold oxygenated crystalloid or blood cardioplegia 
may also limit A TP losses prior to initiating diastolic arrest (B69). 
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Table 1.6 
PROTECTION OF THE ISCHAEHIC HEART 
Maxi•ize Energy Conservation 
Stop electromechanical activity 
Chemical arrest of the heart in diastole 
Produce immediate arrest 
Must be easily maintained and reversed 
Must not produce myocardial da~age 
Reduce basal metabolic rate 
Hypothermia 
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Maintain intracellular homeostasis without energy consuming membrane pumps 
Prevent Unfavorable Ischaetic Induced Changes 
Modify extracellular ionic environment 
Specifically calcium 
Maintain energy production 
Supply substrates 
Oxygen 
Glucose? 
Amino acids? 
High energy phosphates? 
Remove end products of metabolism 
Counteract acidosis 
Modify pH 
Provide buffers 
Prevent oedema 
Hyperosmolarity 
Colloid oncotic pressure 
Diastolic cardiac arrest can be produced pharmacologically by a number of mechanisms, 
but only five primary mechanisms are used in present cardioplegic solutions either singly 
or in combination (B60,B61 ,B62,B69 ,H 14). 
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Namely infusion of; 
High concentrations of Potassium or Magnesium 
Depletion of extracellular Calcium or Sodium 
Local anaesthetic agents:- Lignocaine, Procaine. 
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Profound myocardial hypothermia used in conjunction with cardioplegic arrest further 
reduces basal metabolism, assists in maintaining electromechanical arrest and provides 
additional myocardial protection (Fig 1.3) (B76,C20,E9,Hl6,H24,H25). Lowering the 
myocardial temperature of the cardioplegic arrested normothermic heart to 22°C 
decreases oxygen consumption a further 72% (B76). Furthermore, adequate 
hypothermia appears to be essential during cardioplegic arrest to ensure effective 
protection of both the atrioventricular conduction tissue ( C 15,C 16,S55), and right 
ventricle (B39,C26,G7,G24). Hypothermic cardioplegic arrest thus provides superior 
postischaemic recovery and better myocardial protection compared to hypothermic 
ischaemic arrest provided a properly formulated cardioplegic solution is used (C34). 
However, one of the clinical objectives when using cardioplegic solutions and 
myocardial hypothermia is to provide and maintain uniform myocardial cooling (Table 
1.7). 
The rationale for systemic hypothermia has already been discussed (see sectio~ 1.4). 
The importance of systemic hypothermia as a "cofactor" for myocardial protection is 
illustrated by the inability of many centers to reproduce the early results of Shumway et 
al (G33), when using hypothermic ischaemic arrest, because systemic flow rates were not 
decreased concurrently with systemic hypothermia (32°C) (Hl6). A systemiC 
temperature of less than 25°C is advised by Borst et al, because of the pronounced effect 
that systemic temperature has on myocardial rewarming (B48). However, temperatures 
below 25oc, unless specifically indicated for neurological protection during circulatory 
arrest, may not be appropriate (see section 1.4). Thus most surgeons would compromise 
and use moderate systemic hypothermia (25°C - 28°C) during periods of cardioplegic 
arrest 
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Table 1.7 
MAINTAINING UNIFORM MYOCARDIAL HYPOTHERMIA 
Syste1ic hypothermia 
Lower cardiopulmonary bypass flow rates can be used: 
Diminishes noncoronary collateral flow 
Decreases conducted heat from adjacent organs 
Infusion of cold (4°C) cardioplegic solution 
Single or multidose infusions 
Antegrade via the aortic root 
Retrograde via the coronary sinus 
Topical 1yocardial hypothermia 
Intermittent irrigation with cold saline 
Continuous pericardia! lavage (L2l,S44) 
Epicardial cooling jackets (B47,D3) 
Inferior pericardia! insulation pads (B48) 
Left ventricular vent (B48) 
Prevents accumulation of warm systemic blood in the heart 
Myocardial rewarming 
Infusion of cold cardioplegic solutions produces quicker and better cooling of the more 
vulnerable subendocardium, than does topical hypothermia (D5). However, a single. 
infusion of cardioplegic solution will not itself be adequate to maintain the induced 
cardiac hypothermia throughout the surgical procedure. Excessive myocardial 
rewarming to 18°C- 22°C can occur within 20 minutes (B48,D3). The inferior surface 
of the heart rewarms the most rapidly by heat conducted through the diaphragm from 
the liver, despite topical hypothermia (B48). The myocardial septum also rewarms as a 
result of systemic blood collecting in th\ h~Jtrt; systemic and bronchial venous return as 
well as non coronary collateral blood f10w (Table 1. 8). 
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Table 1.8 
MYOCARDIAL REWARMING 
Mechanism 
Theater environment (R39) 
Ambient temperature 
Surgical operating lights 
Surgical handling the heart (R39 l 
Adjacent organs (D3) 
Descending thoracic aorta 
Liver 
Systemic blood flow (R39) 
Noncoronary collateral flow 
Bronchial flow 
Systemic venous blood in the right atrium 
Legend: 
Prevention 
Low Theater temperatures (19°C - 22°C) 
Cold light sources 
Minimize handling 
Use cold surgical swabs 
Pericardial insulation pads 
Decrease systemic flow rates 
Vent the left ventricle 
Total cardiopulmonary bypass 
Topical hypothermia and multidose reinfusions of cold cardioplegic solutions are additional universally applicable measures that 
will reverse rewarming of the hypothermic myocardium. 
To counteract myocardial rewarming additional intermittent multidose reinfusions of 
cold cardioplegic solution, and I or topical hypothermia are recommended (D3,D5); 
However, with certain cardioplegic solutions multidose reinfusions are not 
recommended ( G ll,P28,S68), and an alternative method of maintaining hypothermia is 
then essential. 
Topical hypothermia 
The two primary reasons to still use topical hypothermia in addition to cold cardioplegia 
are:-
a) To prevent continued rewarming of the myocardium by radiated, convected and 
conducted heat (Table 1.8) (D3,R39)_ The anterior situated right ventricle and 
inferior myocardial surface being more at risk (B48,C26,G7,G24,Vl4)_ 
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b) To improve myocardial protection when there is heterogeneous delivery of 
cardioplegic solution in the presence of coronary artery disease (L9,L21). 
Therefore, topical hypothermia is still used as an adjunctive method to cardioplegia 
(Table 1. 7), but topical hypothermia itself can also be potentially harmful (Table 1. 9). 
Table 1.9 
DANGERS OF TOPICAL MYOCARDIAL HYPO'l'HERMIA 
Epicardial frostbite injury (Hl6,S66) 
Osmotic considerations (R27) 
Phrenic nerve injury (C45,R26,R36,R49) 
Vagus nerve injury (ElG) 
Increased postoperative respiratory complications (A22,B2l,C45) 
Legend: 
The majority of these harmful effectli can be prevented by using only cold (4°C) saline and not iced slush (C45,R26,R49). 
Postoperative phrenic nerve injury (which is usually left sided) has been related to a 
number of factors (M14), but topical iced slush is probably the most likely incriminating 
factor even if the internal mammary artery is harvested (C45). Although pericardia! 
insulating pads can protect the phrenic nerve from cryo-injury (E16), topical iced slush 
as apposed to 4°C cold saline should not be used (R26,R49)_ 
Continuous pericardia! lavage with 4°C saline is possibly inconvenient, inconsistent, 
noisy (because of the necessity to use sump suction) and can waste blood (B47), but does 
maintain cardiac hypothermia (L9,L21). A possibly superior alternative is the use of 
myocardial cooling jackets (B47,D3,D4), however, these may also be bulky, inconvenient 
and have been associated with cryo-injury if incorrectly used !R49), and furthermore 
cannot be used for all surgical procedures. Thus intermittent application of cold saline 
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(4°C) whenever cardioplegia is reinfused, is a frequently used but possibly poorer 
compromise. 
What is the "ideal" myocardial temperature during hypothermic cardioplegic 
arrest? 
The rate of decline of high energy phosphate compounds is directly related to 
temperature; the lower the temperature the slower the loss (Dl4). The protective 
effects of myocardial hypothermia are only really apparent below 28°C - 25°C 
(F37,H14,H24), and even better at 18°C (G21). However, the lowest possible 
myocardial temperatures will not necessarily produce superior postischaemic recovery 
(B6,K12). 
Keon et al showed that human atrial tissue immersed in a non-cardioplegic solution is 
best preserved at 12°C, a temperature of 4°C was associated with depressed 
.. p·ostischaemic contraction (K12). At very low temperatures there is impaired sodium I 
potassium A TPase activity, which results in changes to intracellular electrolyte 
homeostasis (Ml5) and decreased fluidity of membrane lipids and cell swelling 
(Hl6,L24,T28). Moreover, atrial function is better maintained by hypothermia than 
ventricular function (Nll)_ Other investigators have also shown that the cardioplegic 
arrested heart should be kept at a temperature of 12°C - 14°C, and that any further 
benefit obtained by decreasing the temperature to 4°C is of only marginal benefit 
(B6,Rl,R38)_ The optimal myocardial temperature for hypothermic cardioplegic arrest 
also differs according to whether the heart is in vivo (clinical open-heart surgery), or 
isolated ex vivo during organ storage for transplantation. 
During clinical open-heart surgery it is extremely difficult to achieve and maintain 
myocardial temperatures below 10°C (B6), and temperatures fluctuate because of 
rewarming of the myocardium (Table 1.8). Furthermore, the ideal hypothermic 
myocardial temperature is also influenced by the composition of the cardioplegic 
solution infused. A higher temperature may be more optimal with blood cardioplegia, 
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which may be more effective if infused at a temperature of 20oe (mean myocardial 
temperature 21.7°e), than W0 e (mean myocardial temperature 16.9oe) (M5). 
Nevertheless, the infusion temperature for cold blood cardioplegia recommended by G 
D Buckberg is 4°e - 8°e (B70). However, in our experience temperatures below 8°e 
are rarely obtained at infusion rates used clinically, with the presently available blood 
cardioplegic delivery systems (unpublished data). With crystalloid cardioplegic solutions 
the "ideal" myocardial temperature is W0 e- 15°e (R38,T28), which can be achieved by 
infusing cold cardioplegic solution (4oe- W0 e) into the heart (M5,P27,T28). In 
addition, rewarming of the myocardium above 18°e should be prevented (H 16). 
Magovern et al showed equivalent recovery with both 20°e blood and W0 e crystalloid 
cardioplegia (M5). Thus, with blood cardioplegia additional topical hypothermia with its 
increased pulmonary morbidity (to ensure as cold temperatures as possible), may not be 
necessary (A22)_ 
In contrast, temperatures as low as 0°e can be easily and inadvertently achieved during 
isolated organ preservation (H34), and temperatures below 4°e may be harmful 
(R38,T28). Intracellular sodium-potassium homeostasis must be maintained despite 
hypothermia, and theN a+ /K + pump is possibly inactivated below 4°e- W0 e in the 
heart (M15,P33). In an isolated rat heart study using StThomas' cardioplegia the 
optimal storage temperature was shown to be 7.5°e, lower temperatures being harmful 
(T8). Thus a temperature of 7.5°e- woe is probably the "ideal" temperature for 
isolated organ storage (T7). Nevertheless, other solutions with different compositions 
may be associated with better preservation at ooe (E15,F27,P23,Y6). 
Cardioplegic solutions 
A multitude of different cardioplegic solutions have been formulated, and these will be 
discussed more extensively in chapter 3. The composition of the "gold standard" for each 
of the three major categories of cardioplegic solutions is shown in Table 1.10. We should 
though also distinguish between cardioplegic solutions used in clinical open-heart 
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surgery and solutions used for organ preservation. Although in the clinical situation 
these are often the same solution, they need not be the same solution as the constraints 
surrounding preservation of an in situ heart (continuous myocardial rewarming, 
noncoronary blood flow etc) need not apply to an isolated ex vivo organ. 
Table 1.10 
CARDIOPLEGIC SOLUTIONS 
I Crystalloid Blood 
Intracellular Extracellular 4:1 
(uolfL) Bretschneider st Thomas' Buckberg 
Na+ 15 120 116 - 120 
K+ 10 16 18 - 20 
HCO- · 
--
10 20 - 22 3 
ca2+ 
--
1.2 0.5 - 0.6 
Mg2+ 4 16 1.0 - 1.2 
Cl- 51 160.4 110 - 114 
Glucose -- -- 42 - 44 
THAM -- -- 14 - 15 
Mannitol 30 
Histidine 198 
Tryptophan 2 
KH-2-oxygluterate 1 
Osmolality 
(mOsmjkg H20) 
pH 
298 290 340 - 360 
7.1 7.8 7.7- 7.8 
Legend: 
Concentrations of components contained in the indicated cardioplegic solutions. The delivered electrolyte concentrations for 
blood cardioplegia were calculated from the concentrate used for standard cold induction with blood cardioplegia by G D 
Buckberg (see Table 3.5). With multidose reinfusions of blood cardioplegia the delivered potassium concentration is decreased 
to 8-10 mmol/1. 
Despite hypothermia and cardioplegic arrest, basal myocardial metabolic energy 
requirements remain. Energy requirements can only be further decreased if 
intracellular homeostasis can be maintained without the use of energy consuming 
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membrane pumps. This in part is the reason for using intracellular electrolyte 
equivalent formulations for the preservation of isolated organs. Alternatively, if 
extracellular electrolyte equivalent formulations are used, the membrane pumps must be 
maintained by anaerobic glycolysis. However, anaerobic glycolysis is inefficient and 
therefore the duration of tolerable myocardial ischaemia is limited (B61 ). Blood 
cardioplegia though allows limited but more efficient aerobic metabolism, and thus 
might be the superior extracellular electrolyte formulation. Nevertheless, cardioplegic 
solutions must also be delivered to the myocardium correctly, whatever th~ composition. 
Delivery of cardioplegic solutions 
In order to obtain optimal myocardial protection during the aortic cross-clamp period, 
not only is the composition of the cardioplegic solution important but also of equal 
importance is ensuring uniform delivery of the solution throughout the myocardium and 
maintenance of cardioplegic arrest during the entire ischaemic period (B74). Coronary 
artery stenoses impede the delivery of cardioplegic solutions beyond critical stenoses 
(A3l,B18,S46). However, delivery can also be heterogeneous even in the.absence of 
coronary artery disease (A18). Hence, the importance of ensuring optimal delivery of 
cardioplegic solutions (Table 1.11 ). 
The importance of the correct temperature of the cardioplegic solution in order to 
achieve uniform myocardial hypothermia has already been discussed. The next most 
important factor is to ensure optimal coronary perfusion pressures during infusion of the 
cardioplegic solution, which is the principal determinant of regional flow even in the 
arrested heart (A18). However, the correct infusion pressure also depends upon 
whether the cardioplegic solution is infused antegrade via the aortic root, or retrograde 
via the coronary sinus. 
Myocardial protection during cardiac surgery; Chapter I 
Table 1.11 
OPTIMAL DELIVERY OF CARDIOPLEGIC SOLUTIONS 
A) Te1perature 
Crystalloid cardioplegia 
Temperature of solution •..•.•••.......•••• 
Myocardial temperature 
Blood cardioplegia 
Temperature of solution ••...••.••••...•..• 
Myocardial temperature 
B) Volume of solution 
4°c - 6°c 
12°c - 1s0c 
8°C - 10°C? 
·: 1s0c - 1s0c? 
Extracellular electrolyte equivalent cardioplegic solution 
Induction: 
2- 3 mljgm LV mass·(M1?,T9) 
10 - 25 mljkg body weight; ± 1000 ml in adult patients? 
Multi doses: 
5 - 10 mljkg body weight; ± 200 - 300 ml in adult patients? 
Intracellular electrolyte equivalent cardioplegic solution 
Induction: 
7 - 10 mljgm heart weight; ± 3 - 4 L in adult patients 
C) Antegrade via the aortic root 
Requires a competent aortic valve 
Infusion pressure (A31,B74,J9,T5l:-
Induction: 80 - 130 mm Hg 
Reinfusions: 50 mm Hg 
Affected by coronary vascular resistance 
Stenoses (Wl4) 
Vasoconstriction 
Cold (BG)) 
Potassium (C2l,S7) 
Possible additional vasodilators? 
Nitroglycerine (S4G) 
Adenosine (B4l) 
Magnesium (C21 ) 
D) Perfusion through co1pleted grafts (Bl8,B74) 
E) Retrograde via the coronary sinus (B70) 
Infusion pressure: less than 40 mm Hg (M35,M38) 
Legend: 
The recommended volume to be infused is for extracellular electrolyte equivalent crystaUoid and blood cardioplegic solutions. 
Larger volumes are required for intracellular electrolyte equivalent cardioplegic solutions. 
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Antegrade cardioplegia 
The recommended antegrade pressure for infusing cardioplegic solutions is 80 - 100 mm 
Hg (A3l,B70,J9). Excessive perfusion pressures (greater than 150 mm Hg) will injure . 
the endothelium (J9,M53). However, one must take into cognizance that pressure 
gradients of 30 - 60 mm Hg may exist between the aorta and distal coronary arteries in 
the presence of coronary artery stenoses (R37). In addition, studies in normal sheep 
hearts showed that pressures of 130 mm Hg as opposed to 90 mm Hg delayed the onset 
of myocardial acidosis (T5). Thus, in the presence of coronary artery disease slightly 
higher infusion pressures (up to 130 mm Hg) on induction of antegrade cardioplegic 
arrest may be more optimal. However, a lower pressure of 50 mm Hg is recommended 
during maintenance reinfusions of cardioplegia in the arrested heart, in order to prevent 
oedema formation (B74,P27). 
Pharmacologic vasodilators such as papavarine (S53) and nitroglycerine (1 mg bolus 
injection during infusion of cardioplegia) (M25,S46) have also been added to the 
cardioplegic solution in order to improve antegrade cardioplegic solution distribution, by 
optimally dilating the coronary arteries. However, although these vasodilators decrease 
coronary vascular resistance without altering systemic vascular resistance (M25), in a 
clinical trial these vasodilators did not alter the postoperative surgical results (S53). 
Moreover, it is possible that a "steal" syndrome could be produced by dilating responsive 
coronary arteries and thus decreasing the effective perfusion pressure in arteries with 
fixed stenoses supplying more ischaemic areas. Thus these additional vasodilators are 
probably not indicated in a properly formulated cardioplegic solution. 
Volume of cardioplegia 
The volume of cardioplegic solution infused clinically is usuany·lo- 15 ml/kg body 
weight, if extracellular electro,lyte equivalent formulations are used. However, the dose 
should ideally be rather determined by ventricular mass as opposed to body weight 
(Ml7,T9). The optimal dose for the StThomas' cardioplegic solution is 2.0 mllgm wet 
heart weight experimentally (T9), and in a clinical study of patients with left ventricular 
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hypertrophy 2.5 mllgm LV mass (LV mass was determined angiographically) (M17). 
This dose might have been as much as 25 ml/kg body weight, depending upon the 
patients body weight Other studies have also confirmed the safety and benefit of giving 
high volumes of crystalloid cardioplegia (E14). Nevertheless, Preusse et al have shown 
that temperature equilibration occurs within approximately two minutes of infusion o_f 
cold cardioplegia, but that myocardial oxygen consumption equilibration only occurs 
after a longer period of infusion (P27,P29). Buckberg et al using blood cardioplegia also 
contend that it is the duration of infusion that is more important than volume, as oxygen 
is taken up over time and not by dose, and recommend that cardioplegia is infused for 3 -
5 min at 250-350 mllmin (B74). 
Therefore. when infusing cardioplegic solutions the minimum dose, perfusion pressure 
and duration of infusion should all be taken into account 
Volume infused = Infusion rate X Time 
Infusion rate = Pressure I Resistance. 
If infusion rate is kept constant, blood cardioplegia produce~ higher aortic infusion 
pressures than crystalloid cardioplegic solutions because of its increased viscosity, and 
consequently has an improved distribution (R24). However, if infusion pressure is kept 
constant with crystalloid cardioplegic solutions (which will necessitate higher flow rates 
in order to produce appropriate perfusion pressures), regional myocardial perfusion is 
then better with crystalloid as apposed to blood cardioplegia (E 17). . 
Finally, if intracellular electrolyte equivalent cardioplegic solutions are used, a prolonged 
infusion time of 8 - 10 min is required in order to obtain complete equilibration of 
electrolytes in the interstitial space (B62,P27). Therefore, the recommended dose for 
the Bretschneider cardioplegic solution is an initial volume of 7- 10 ml!gmheart weight 
infused over 8 - 10 min, which would be approximately 3 - 4 L in an average adult patient 
(P27,P28). 
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N oncoronary collateral flow 
Following the induction of cardioplegic arrest, diastolic arrest must be maintained 
throughout the ischaemic cross-clamp period. However, two primary factors can 
u~predictably diminish the efficacy of myocardial protection in the clinical situation:-
i) Noncoronary .collateral blood flow (B57,H36) 
ii) Constant rewarming of the myocardium (Table 1.8) 
Blood flow derived from the bronchial arteries (which can be removed by adequately 
venting the left side of the heart) can be substantial (B42,L 1 )_ In addition, although true 
noncoronary blood flow via posterior pericardia! communicating vessels and pericardia! 
adhesions may be minimal, there is a marked variability of this flow in both normal 
hearts and those with coronary artery obstructions. Noncoronary collateral fl0w can be 
substantial in hearts with left ventricular hypertrophy ( 15% - 20% (B57)), or coronary 
. artery disease (6% (H36)). If significant noncoronary flow is observed (filling of 
coronary arteries with blood during revascularization, backbleeding from the coronary 
ostia, recurrence of electrical activity), then this can be diminished by decreasing 
'systemic flow rates and perfusion pressure (B74). In addition, because of the variability 
of noncoronary flow, as well as the known constant rewarming of the myocardium and 
the presence of small-amplitude electrical activity (F7,L6) occurring prior to visible 
mechanical activity (which is detrimental to myocardial protection) (L7), multidose 
reinfusions of cardioplegic solution are recommended (B54,B74). 
Multidose cardioplegia 
The strategy of administering multidose cardioplegia is recommended clinically (B74), as 
a result of experimental (C35,E9,Sl8,T4) and clinical studies (B54). Myocardial 
rewarming (D3,D5) and washout of cardioplegia by noncoronary flow (B57;H36) is 
counteracted, and in addition metabolic end products are removed and substrates 
resupplied to the myocyte (B74). Intermittent reinfusions of cardioplegic solutions 
correct metabolic acidosis, wash out lactate and allow reactivation of glycolysis (K38)_ 
Myocardial protection during cardiac surgery; Chapter I UOVonOppell 67 
In the isolated rat heart model we demonstrated an independent beneficial effect of 
multidose cardioplegia, as opposed to single dose cardioplegia on postischaemic 
mechanical recovery (appendix A-2). However, multidose reinfusions also increased 
postischaemic washout of lactate dehydrogenase in our model Thus this non-colloid 
containing solution might have increased protein flux from the interstitial tissue, or 
alternatively reinfusions of cardioplegia increased cellular membrane damage despite 
improved mechanical recovery. In our studies the cardioplegic solutions had been 
aerated with 95% 02 5% C02 during preparation, resulting in partial pressures of 
oxygen of approximately 150 mm Hg. It is possible that intermittent reinfusions of 
oxygen containing solutions after periods of ischaemia generated oxygen free radicals 
(B8,S75), especially if partial pressures of oxygen are high ( G5). Free radicals in turn 
can cause damage to cellular membranes (S27), by lipid peroxidation and denaturation 
of proteins (G5,M37,P32) (See section 1.6). 
· Nevertheless, multidose reinfusions of cardioplegia have been shown to be superior to 
single-dose cardioplegia (E9,S18), and should be reinfused approximately every 20 
minutes throughout the cross-clamp period (B74). The volume of each multidose 
reinfusion should be approximately half the induction dose, but infused at a lower 
pressure ( 40 - 50 mm Hg). 
Taken one step further, is the proposal for continuous cold blood cardioplegia (Kl5). 
However, this technique does not produce a "dry" operative field and does not therefore 
facilitate the surgical procedure. 
Various other surgical strategies used during coronary artery revascularization 
procedures can also improve myocardial protection, by improving the distribution of the 
cardioplegic solution and preventing inflow limitation upon reperfusion (C23)_ These 
include:-
Perfusing cardioplegia through the completed distal anastomoses during the 
cross-clamp period. (B74,K9;S46,S48), 
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Perfusing grafts after removal of the cross-clamp, while proximal anastomoses 
are performed with a side-clamp (K9), 
Constructing all anastomoses during one single prolonged cross-clamp period 
(Bl8,C23,Wl4) 
, 
Constructing proximal grafts before aortic cross-clamping. 
Retrograde Cardioplegia 
Retrograde delivery of cardioplegic solutions via the right atrium (Fl).or coronary sinus 
is another effective alternative to ensure uniform distribution of cardioplegia, in the 
presence of coronary artery stenoses (S62)_ An additional experimental method is 
antegrade cardioplegic infusion with simultaneous pressure-controlled intermittent or 
continuous coronary sinus occlusion (L20,S81,S82)_ Although there is a great variation 
in the venous drainage of the myocardium, the majority of blood drains into the 
coronary sinus. The remainder of the myocardial venous blood drains via anterior 
cardiac veins that drain the anterior surface of the right ventricle (Ll7), and Thebesian 
veins that drain blood directly into the chambers of the heart Therefore, retrograde 
cardioplegia may provide inadequate protection to the right ventricle (P6,S42,S78), and 
possibly parts of the septum (S42,S78)_ Nevertheless, there is an extensive valveless 
network of venovenous, arteriovenous and venoluminal anastomoses, that allows 
retrograde coronary sinus perfusates to permeate throughout all major areas of the 
myocardium (M35)_ 
Experimental and clinical studies have confirmed that retrograde cardioplegia is 
superior to antegrade delivery in perfusing areas distal to occluded coronary arteries 
(G4l,Hl,Ml6,S39), and maintains preferential subendocardial flow (P6)_ Cannulation 
of the coro!lary sinus initially had to be performed under direct vision and was 
associated with lacerations and rupture of the coronary sinus (M39)_ However, newer 
auto-inflating catheters can be inserted "blindly" into the coronary sinus (D23,G43) and 
venous injury is prevented if infusion pressures never exceed 50 mm Hg (B70)_ 
Alternatively, retrograde cardioplegia can be infused via the right atrium if both cavae 
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are snared and the pulmonary artery occluded (Dl6,Fl). Although right atrial 
cardioplegia is claimed to be safer (Fl) with improved right ventricular protection (N2), 
it is cumbersome to work with since distention of the RV makes exposure of the 
posterior myocardium difficult Moreover, other studies have shown that right atrial 
retrograde cardioplegia does not provide better right ventricular protection than 
coronary sinus cardioplegia (Dl7,S13). 
Retrograde cardioplegia is a safe effective clinical method of delivering cardioplegic 
solutions (D23,Fl4,G43,M39,S21) and may be the method of choice in redo-
revascularization procedures, by averting prograde embolization of atheromatous 
material from grafts (Fl7,L17,S57). However, induction of cardioplegic arrest with 
retrograde infusion of cardioplegia is associated with a prolonged time before arrest 
occurs (M39). Retrograde Bretschneider cardioplegia, although providing overall good 
protection, was also noted to cause mild extracellular oedema and microvascular 
damage (S21). 
Nevertheless, promptness of arrest and inadequate right ventricular protection can be 
overcome by combining antegrade and sequential retrograde cardioplegia (B70,K2,P5), 
and in a clinical study this strategy improved ventricular recovery following coronary 
bypass surgery (B28). Combined antegrade I retrograde cardioplegia is probably the 
modern myocardial protection strategy of choice for patients with coronary artery 
disease, aortic stenosis, and for redo-revascularization procedures. 
Normothermic cardioplegic arrest 
Normothermic cardioplegic arrest prevents the increased cytosolic calcium and 
increased myocardial tone associated with rapid cooling of the myocardium 
(K43,T10,W31). In addition, enzymatic functions are more optimal at normothermia 
and hence provided there is adequate distribution of the cardioplegic solution, then 
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initial normothermic cardioplegic arrest can be used to provide "preischaemic" metabolic 
enhancement of the myocardium. 
Preischaemic Metabolic Enhancement 
Hearse et al showed that the time till onset of normothermic ischaemic contracture 
could be increased by either reducing myocardial energy demands or increasing energy 
supply (H 18). Thus if hearts are depleted of high energy phosphates prior to the 
ischaemic period, tolerance to ischaemia is diminished. In the clinical situation many 
patients arrive in the cardiac theater with ongoing ischaemia, dependant on intra aortic 
balloon pumps, with recent myocardial infarcts, and the emergent nature may have 
precluded preoperative metabolic enhancement (see section 1.2). Initial repletion of 
energy stores prior to a prolonged ischaemic period would thus increase tolerance to the 
ischaemic cross-clamp period in these "energy depleted hearts". Intravenous GIK 
instituted at the onset of anaesthesia will assist in replenishing energy stores (H4). 
However, tolerance to ischaemia can also be increased by preischaemic normothermic 
arrest and continuous perfusion with an oxygenated substrate containing perfusate 
(Pl7). Normothermic induction of cardioplegic arrest and perfusion with substrate 
enriched blood cardioplegic solutions (Table 1.12), prior to hypothermic cardioplegic 
arrest, has been found to be beneficial both experimentally and clinically 
(B49,H48,R40,R44,T19,W31). 
Furthermore, adequate distribution of this initial normothermic "resuscitating 
reperfusion cardioplegic solution" in the presence of critical coronary stenoses can now 
be overcome by using combined antegrade I retrograde cardioplegic infusions (B70). 
Normothermic induction is though probably not necessary in the standard low risk 
patient (R23)_ 
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Table 1.12 
CONCENTRATE FOR 4:1 BLOOD CARDIOPLEGIA 
WARM INDUCTION 
Additive VolUJJJe ( ml) Delivered concentration 
225 pH : ± 7.6 THAM (300 mmoljL) 
CPO 225 ca++ : ± 0.15 mmoljL 
50% Dextrose H2o 
5% Dextrose H2o 
KCl (2 mmoljml) 
Glutamate (7.32%) 
Aspartate 
Legend: 
40 
220 
40 
125 
125 
Osm : ± 400 mosm/kg H2o 
Glucose : ± 70 mmol/L 
K+ : 20 - 25 mmol/L 
Glutamate : 13 mmol/L 
Aspartate : 13 mmol/L 
Infused at 37°C, at a rate of250- 350 ml/min till arrest, then at 150 ml/min for a total of 5 min. Thereafter, 250-350 ml/min 
standard cold (40C- 8°C) cardioplegia is given for approximately 3 min. CPO: Citrate phosphate dextrose. Modified from 
Buckberg G D, J Cardiac Surg 1989; 4:216-238 (B70). 
Warm heart surgery with continuous warm cardioplegia 
An alternative approach to hypothermic cardioplegic arrest is the concept of 
I 
continuously perfusing the arrested heart at normothermia (P3), either antegrade (L36) 
or retrograde (Sll) with blood cardioplegia. Continuous warm blood cardioplegia is 
though more cumbersome and does not allow optimal visualization of microvascular 
anastomoses (S 1 0), although it reportedly decreases the incidence of postoperative 
conduction disturbances (F38), avoids possible disadvantages of hypothermia, and may 
be better than continuous cold cardioplegia in patients who have limited ischaemic 
tolerance (L35)_ Furthermore, as myocardial energy demands are higher the "safety 
element" is possibly lower, especially as adequate perfusion to all regions of the 
myocardium cannot always be ensured (E8). Thus, continuous warm blood cardioplegia 
must be given as a continuous retrograde technique and not antegrade in the presence of 
coronary artery occlusions, in order to ensure adequate perfusion of all the myocardium 
distal to coronary stenoses (M66)_ Furthermore, metabolic monitoring is possibly 
necessary in order to ensure that the retrograde flow (50- 350 mllmin) adequately 
meets the metabolic requirements of the warm heart In addition, "overdosing" with 
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card-ioplegia (K25) or its components ( eg. K +, THAM) is possible, and therefore a 
different crystalloid concentrate is used for continuous warm cardioplegia as opposed to 
that used for intermittent cold cardioplegia. Continuous warm retrograde cardioplegia 
also does not result in superior myocardial protection when compared to intermittent 
cold combined antegrade and retrograde blood cardioplegia (M67)_ 
Conduction defects following cardioplegic arrest 
Conduction defects, either episodes of transient or permanent atrioventricular block or 
postoperative supraventricular tachyarrhythmias, have been observed following 
cardioplegic arrest Postoperative new atrioventricular conduction block occurs in 18% -
45% of coronary artery bypass graft patients (Bl,Ol,Wl7), but the majority resolve by 
hospital discharge (Bl,Ol)_ These conduction defects have been related to the number 
of vessels bypassed, the duration of both cardiopulmonary bypass and aortic cross-
clamping (B32), preoperative longstanding hypertension, left main coronary artery 
disease, use of digitalis (W17), use of cardioplegia as opposed to hypothermic fibrillation 
( 01), with blood more than crystalloid cardioplegia ( G42), and with intermittent cold 
blood cardioplegia as opposed to continuous warm blood cardioplegia (F38)_ 
Furthermore, endogenous release of adenosine (B20), inadequate cooling of the right 
atrium (M3), air in the atrioventricular nodal artery, and infusions of high concentrations 
of potassium (E5) are factors that have also been implicated in increasing conduction 
defects. Nevertheless, these conduction defects are probably due to ischaemia and 
incomplete protection of the specialized conduction system (M60), although conduction 
tissue has higher concentrations of glycogen, glycolytic capacity (B62) and is possibly 
more resistant to hypoxia than normal myocardium (W34)_ Moreover, low-amplitude 
electrical activity that is not detectable on routine ECG monitoring can occur during 
cardioplegic arrest (F8), and this has been shown to arise from the conduction tissue 
(F?)_ Both sinoatrial and atrioventricular nodal tissue has intrinsic electrical activity, as 
a result of calcium-mediated slow channel activation. Although potassium cardioplegia 
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prevents activation of myocytes by partial depolarization ( -40 m V), this is the potential 
at which slow channel calcium conduction is increased. Thus standard intermittent 
hypothermic potassium cardioplegia provides incomplete protection of the conduction 
system (M3), and continuous warm retrograde blood cardioplegia may more adequately 
prevent ischaemia to the conduction tissue (F38)_ Nevertheless, the incidence of 
atrioventricular dissociation arrhythmias following intermittent hypothermic 
cardioplegia can be decreased by using lower concentrations of potassium in all 
multidose reinfusions of cardioplegia ( D 15,E5)_ Alternatively, conduction system 
activity can also be prevented by using a calcium channel blocker- nifedipine (F7), or 
intracavitory right atrial cooling (M3)_ 
In addition, neither hypothermic cardioplegic arrest with intermittent cold cardioplegia 
nor continuous warm retrograde cardioplegia adequately protects the right atrium 
(Cl8,P15,F38), and poor postischaemic atrial contraction can diminish cardiac output by 
as much as 20% (E5)_ Furthermore, persistent atrial activity during cardioplegia and 
ischaemic injury may cause an increased incidence of postoperative supraventricular 
tachyarrhythmias (M63, Tl3)_ Methods of improving atrial hypothermia by either 
internal or external cooling improves atrial preservation and diminishes conduction 
abnormalities (C15,Cl6,H38)_ The incidence of postoperative supraventricular 
tachycardias can also be decreased by prophylactic magnesium supplementation (F4)_ 
Hence, additional methods of preventing ischaemia during the aortic cross-clamp period 
are important, such as ensuring adequate hypothermia if hypothermic cardioplegic arrest 
is used, especially for the right atrium, right ventricle and specialized conduction tissue. 
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1.6 REPERFUSION OF THE POSTISCHAEMIC HEART 
Myocardial ischaemia causes progressive cellular injury proportional to the duration of 
ischaemia and rapidity of energy depletion, and if severe enough will result in myocyte 
necrosis (B75). However, mild to moderate ischaemia can result in temporary 
postischaemic myocardial dysfunction, despite the absence of irreversible damage or 
structural changes; myocardial stunning (B40,B55). Furthermore, reperfusion of 
previously ischaemic tissue can also accelerate or induce myocyte damage and necrosis, 
that was undetectable prior to the onset of reperfusion; the reperfusion injury 
(B75,G3,H 15,V19). 
Myocardial "stunning" 
The mechanism of myocardial stunning is multifactorial, and has been postulated to be 
due to oxygen free radicals, excitation-contraction uncoupling and impaired calcium 
homeostasis (B40,P14), and may require several days ofreperfusion prior to complete 
reversal (B55,B78)_ Postischaemic injured hearts, even if they were protected with 
cardioplegic solutions, are unable to fully utilize available oxygen in the immediate 
reperfusion period (Bl7,F30,K35,K36), because of diminished mitochondrial function 
(K3). Furthermore, both glucose and free fatty acid uptake are inhibited in the 
postischaemic period partly as a result of stress hormone induced insulin suppression 
(S89), and thus amino acids are the only exogenous substrate taken up by the heart 
during initial reperfusion (S87). Loss of Krebs' cycle and purine metabolites during the 
ischaemic period will also limit postischaemic myocardial function and recovery 
(H3,P7). In addition, a progressive increase in coronary vascular resistance has been 
noted to occur during the reperfusion period clinically (Dl8), and is possibly a 
manifestation of the no-reflow phenomenon (G6). 
Myocardial protection during cardiac surgery; Chapter I UOVonOppell 75 
Reperfusion injury 
When oxygen is reintroduced into the myocardium after a period of anoxia or hypoxia, 
structural cellular changes occur within two minutes of reoxygenation (G3)_ This results 
in release of intracellular enzymes and rupture of the sarcolemma (G3), and is 
associated with mitochondrial calcium uptake (H 19). The pathogenesis of this 
reperfusion injury has been related to a number of factors such as oxygen free radical 
production (B 12), resynthesis of A TP in the presence of intracellular calcium overload 
causing hypercontracture and tearing of cell membranes (P20), and loss of essential 
metabolites and substrates. The reperfusion injury is an exacerbation of cellular damage 
upon reperfusion and can be attenuated by either supplying adequate substrates, 
myocardial oxygenation, maintaining better cellular high energy phosphate levels during 
ischaemia (K6), preventing sudden energy-dependent mitochondrial calcium 
accumulation with respiratory inhibitors (G3), or by supplying calcium chelators (P14) 
during reoxygenation. Hence, the concept of reperfusing the postischaemic myocardium 
with a specific reperfusion solution designed to prevent a reperfusion injury. 
Reperfusion solutions 
Modifying the initial perfusate on reperfusion of ischaemic myocardium can alleviate 
both myocardial stunning and the more severe reperfusion injury. In principal this has 
been based on; maintaining the heart arrested (high potassium) to channel all available 
oxygen to cellular repair, lowering the ionic calcium (0.5 mmol/L) to limit calcium influx 
whil~ membrane permeability is increased (F24), an alkalotic pH (pH 7.8; approximates 
the "ideal pH" at 28°C for optimal enzymatic function (S91,W19)), improved buffering 
(THAM) to counteract acidosis (F25), increased osmolarity (360 mOsm/L) to 
counteract cellular oedema (F24,Sl9), and substrate enhancement with glucose (S4) and 
amino acids (L-glutamate (H3,L18,M32), L-aspartate (B70,El3,R41)) to replace 
intermediates lost during the ischaemic period and for myocardial energy production. 
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The composition of the present reperfusion blood cardioplegic solution recommended 
by Buckberg is tabulated in Table 1.13 (B70)_ Additional substrates that might also be 
beneficial during reperfusion are purine precursors; adenosine and ribose (H3,P7)_ 
Reperfusion of the postischaemic myocardium should also be at a controlled lower 
pressure (less than 50 mm Hg) which prevents oedema formation (S94), diminishes 
endothelial cell damage (Sl7) and improves recovery (A6), and should in addition 
possibly be pulsatile (M58)_ 
Table 1.13 
CONCENTRATE FOR 4:1 BLOOD CARDIOPLEGIA 
Additive 
TRAM (300 mmol/1) 
CPD 
50% Dextrose H2o 
5% Dextrose H2o 
KCl (2 mmol/ml) 
Glutamate (7.32%) 
Aspartate 
Legend: 
REPERFUSION 
SOLUTION 
Volume (11) Delivered concentration 
225 pH : 7.5 - 7.6 
225 ca++ : 0.15 - 0.25 mmol/1 
40 Osm : ± 400 mosmjkg E2o 
200 Glucose : ± 70 mmol/1 
15 K+ : 8 - 10 mmol/1 
125 Glutamate : 13 mmol/1 
125 Aspartate : 13 mmol/1 
Infused at 37°C, at a rate of 150 ml/min antegrade 1.5 min, retrograde 1.5 min. Systemic rewarming commenced 3-4 min before 
delivery. CPO: Citrate phosphate dextrose. Modified from Buckberg G D, J Cardiac Surg 1989; 4:216-238 (B70). 
Although Rosenfeldt et al suggested a low pressure was not necessary, there protocol 
included an initial 2 min period when the reperfusion pressure was gradually increased 
from zero to the test pressure (R37)_ Thus it is possible that this low pressure is only 
important for the first 2 min and not 10 min as used by Swanson et al (S94)_ Although 
Buckberg and co-workers initially reperfused the postischaemic heart at 28°C (F24,F25), 
Swanson et al showed no difference between reperfusion at 28oc or 37°C (S94), and 
reperfusion is now usually done at normothermia (B70,T4)_ However, lower initial 
reperfusion temperatures may be necessary if temperatures during isolated organ 
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storage were very low, or if calcium-free storage solutions (K28) or asanguineous 
reperfusion solutions are used (M31,M32). The dose of the reperfusion solution should 
also be limited, to prevent possible myocardial depression related to excessive 
administration of cardioplegic solution (K25)_ 
In studies on regional ischaemia, which potentially imposes greater reperfusion damage 
than global ischaemia, an even lower calcium concentration (0.15- 0.25 mmol/L) (A19), 
greater hyperosmolarity (greater than 400 mOsm/L), and hyperglycemia (greater than 
400 mg%) ( 09) is beneficial. However, this might also be a manifestation of a diluting 
effect from collateral flow into the regionally reperfused ischaemic myocardium. 
Nevertheless, the importance of decompressing the heart with a left ventricular vent 
(A20,A23,V20), and initial low pressure reperfusion (08) with a blood reperfusate was 
again demonstrated in this model, if optimal functional recovery is to be obtained (A21). 
Asanguineous reperfusion solutions can also improve postischaemic recovery. Both a 
standard cardioplegic solution (R13) and an asanguineous solution with similar 
constituents to that proposed by Buckberg and co-workers have been shown to be 
beneficial, but at 28°C (M31,M32). Thus, the provision of oxygen in a reperfusion 
solution is not the major component that is beneficial (A 7), but rather other factors such 
as calcium content In an asanguineous reperfusate the optimal calcium is also 0.3 - 0.5 
mmol/L (H5)_ In addition, washout of accumulated metabolic end products and 
removal or suppression of oxygen free radicals is possibly of equal importance 
(J13,M31). However1 in contrast to blood reperfusates that contain natural free radical 
scavengers, additional free radical scavengers may be essential in asanguineous 
reperfusates (A8,J13). 
Oxygen free radicals 
A free radical is a molecule with an odd number of electrons, and is therefore unstable 
and chemically reactive (M37). Free radicals occur in vivo and contribute to pathologic 
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processes such as carcinogenesis (P32) and complement mediated pulmonary damage 
(Tl8). Free radical scavengers such as superoxide dismutase (SOD) are found in all 
aerobic organisms (F31), and deficiencies of these endogenous defense mechanisms are 
associated with defects in oxygen tolerance (A30,F31). Furthermore, oxygen free 
radicals are probably formed during ischaemia (lA9,M37) but in addition are generated 
to a much greater extent during reperfusion after an ischaemic period, as their 
production is dependant upon oxygen tension (generation of free radicals is increased if 
the p02 is greater than 150 mm Hg) (G5). Free radicals are thus primarily generated 
when oxygen is reintroduced after a period of ischaemia (Fig 1.4), and cause myocardial 
injury (S27) by lipid peroxidation and denaturation of proteins (G5,M37,P32,S27). The 
hydroxyl radical is considered to be the most cytotoxic of the known oxygen free radicals 
(Cl9,M37), although the superoxide anion possibly causes the most impairment to 
endothelium-dependant functions (Ll6,Vll). 
There are a number of different mechanisms whereby free radicals are generated (P32). 
However, probably the three primary sites of free radical generation in the reperfused 
ischaemic myocardium are:-
Intra -mitochondrial, 
Endothelial; xanthine oxidase mediated, 
Polymorphonuclear leukocyte mediated. 
Mitochondrial cytochrome oxidase transforms 95% of oxygen in a tetravalent reduction 
into water, in the electron transport system. However, 5% of available oxygen is 
diverted toward a univalent reduction pathway in which electrons are gained in a 
sequential fashion with the formation of oxygen free radicals (Fig 1.4) (F31). 
Nevertheless, intracellularly formed free radicals are normally inactivated by 
intracellular defence mechanisms (superoxide dismutase, glutathione) (F31,M33,M37). 
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Figure 1.4 
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Legend: 
The highly toxic hydroxyl radical can be generated by either the univalent reduction pathway of oxygen, or from the comb
ination 
of superoxide anion and hydrogen peroxide by the Haber-Weiss reaction using a transition metal catalyst The sites of act
ion of 
free radical scavengers (italics) are also shown. 
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Myocardial ischaemia results in metabolic changes that predispose to oxygen free radical 
generation. Ischaemic induced free radicals are probably produced by the latter two 
mechanisms of free radical production (xanthine oxidase and polymorhonuclear 
leukocyte mediated (Fig 1.5)) {M37,S27). Adenine-nucleotides are broken down in the 
myocyte only to the stage of inosine during ischaemia ( G 13,S27). Although the enzyme 
required for further degradation (xanthine oxidase) may be present in human 
myocardium in only trace amounts compared to the rat and dog (El), xanthine 
dehydrogenase is found in endothelial cells of capillaries (J3,J4,S27). Xanthine 
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dehydrogenase can then be converted to xanthine oxidas~ by cytosolic proteases (M22). 
In addition, ischaemia damages the endothelium (Fl2,H55) and thus increases the 
release of xanthine dehydrogenase which is rapidly converted to xanthine oxidase in the 
interstitium (J3,R58). Myocyte rele'ased inosine can therefore be degraded to 
hypoxanthine, that in turn is oxidized by endothelial cell released xanthine oxidase, 
which generates the superoxide anion in the presence of oxygen (P32). 
Figure 1.5 
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Free radicals are generated during reperfusion from inosine released from ischaemic myocytes, reacting with xanthine oxidase 
released from endothelial cells. and iron released from polymorphonuclear leukocytes. 
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In addition, injured endothelial cells attract and activate polmorphonuclear leukocytes 
(K24,M28,R46), which release proteolytic enzymes and generate oxygen free radicals 
(D20,K24). Moreover, leukocytes by releasing lactoferrin make "free" iron available 
that catalyzes the Haber-Weiss generation of the hydroxyl radical (Fig 1.5) (C19,M37). 
Cardiopulmonary bypass itself also activates complement, neutrophils (F5), and· 
generates free radicals that have been implicated in cardiopulmonary induced 
pulmonary damage (Kl\R54,Tl8). Free radicals in turn will result in further 
endothelial injury (T18,T24). Thus the primary sites of action of free radical scavengers 
during postischaemic reperfusion are probably the vascular endothelium and leukocytes, 
and not the myocyte (11). 
Free radical scavengers 
Free radicals are generated during ischaemia and during reperfusion with the 
reintroduction of oxygen (B8,IA9,S75). The metabolic changes that would otherwise 
lead to oxygen free radical generation:· upon postischaemic reoxygenation could be 
prevented by providing adequate myocardial oxygenation during the ischaemic period 
(B9,C6). However, this is probably rarely achievable and thus the importance of 
additional free radical scavengers. A number of compounds can reduce free radical 
mediated cellular injury; low molecular weight antioxidants (Vitamin E), heavy metal 
chelators (deferoxamine) (Cl9) and enzymatic scavengers (superoxide dismutase, 
catalase, reduced glutathione, peroxidase) (M37). Moreover, some of these substances 
such as histidine can act at a number of sites and unlike mannitol (G5,M4) in low 
concentrations (Cl9) (Fig 1.4). However, superoxide dismutase scavenges the 
superoxide anion (F31) by catalyzing its conversion to hydrogen peroxide. Thus 
superoxide dismutase can also enhance biological damage by increasing the formation of 
hydrogen peroxide which is the substrate for the generation of the hydr~xyl radical, 
unless the hydrogen peroxide formed is also reduced (Cl9). Free radical scavengers are 
thus beneficial in both cardioplegic and reperfusion solutions, but must be present 
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before the onset of reperfusion (B9). Moreover, one of the salutary effects of blood 
cardioplegic and reperfusion solutions are the natural oxygen free radical scavengers 
contained in erythrocytes (J13,Vl)_ 
Measures can alsp be taken in the preoperative period to decrease the postischaemic 
generation of free radicals. Preoperative administration of allopurinol as well as 
increasing concentrations of its metabolite oxypurinol prevent the formation of free 
radicals by inhibiting xanthine oxidase (Fig 1.5) (S27), scavenge the hydroxyl radical 
(T2), and decrease perioperative complications after cardiac surgery (see section 1.3). 
The addition of allopurinol to both blood cardioplegia (1 mmol/L (VIS)) and crystalloid 
cardioplegia (StThomas'; 0.15 mmol!L (Cl2)) has also been shown to improve 
postischaemic functional recovery, and diminish free radical induced chromosomal 
aberrations (0.75 mmol!L) (E6)_ However, Myers et al showed that catalase (1. 7 ug/ml) 
was more efficacious than allopurinol ( 1 mmol /L) in the asanguineous St Thomas' 
solution (M65). Superoxide dismutase by its-elf is ineffective (M33,M65) as it results in 
increased hydrogen peroxide (Cl9). However, the combination of superoxide dismutase 
and catalase in crystalloid cardioplegic solutions (B9,G17,G18,G32,Jl5,S76) and blood 
reperfusates (024)have been shown to improve myocardial preservation. The best 
protection against free radicals is possibly provided by both inhibiting the production of 
the superoxide anion (allopurinol) and enhancing the degradation of hydrogen peroxide 
(M65) (catalase, peroxidase, reduced glutathione (10 mmol/L (Cll)). 
Leukocyte induced free radicals can also be inhibited by administering systemic heavy 
metal chelators such as deferoxamine (10- 30 mg/kg), which remove the catalyst 
required for the Haber-Weiss reaction (Fig 1.4 & 1.5) (C33,M36)_ Deferoxamine has 
also been added to crystalloid cardioplegic solutions (0.04- 1.5 mmol/L) both 
experimentally (M34) and clinically (FlO,M36) and this improved myocardial 
preservation. Metal chelators may well be even more salutatory in the presence of 
blood and therefore leukocytes (M65); i.e. blood cardioplegic (I2) or reperfusion 
solutions, than crystalloid solutions that do not contain leukocytes. Alternatively, either 
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preventing leukocyte activation with phosphodiesterase inhibitors (antileukocyte action 
mediated by increased cAMP (C13)) or leukocyte depletion via polyester filters can 
ameliorate both free radical mediated lung injury (B7) and myocardial reperfusion 
injury (B58,Cl3,Pl9). However, leukocyte depletion is not as efficacious as a substrate-
enriched blood reperfusion solution (K26). 
There is thus strong evidence for both the production of oxygen free radicals and the 
benefit of using free radical scavengers in both cardioplegic, reperfusion and organ 
preservation solutions. 
Clinical management of the postischaemic myocardium 
In non-emergency open-heart surgical procedures reperfusion solutions are not used 
routinely by probably the majority of cardiac surgeons. Nevertheless, correct 
management of the postischaemic myocardium can also significantly improve 
myocardial recovery. 
In the early postischaemic period haemodynamic stresses should be avoided (F30)_ 
' 
Ventricular fibrillation should be prevented by either components added to the 
cardioplegic solution such as lignocaine (F 15), procaine or calcium channel blockers, or 
by a systemic bolus of lignocaine (2 mg/kg) infused immediately prior to the release of 
the aortic cross-clamp (F3). Furthermore, allowing the heart to remain asystolic in the 
immediate reperfusion period is beneficial by preventing energy from being "wasted" on 
electromechanical contraction, provided ventricular distention does not occur 
(Al2,L30). Thereafter, while remaining on cardiopulmonary bypass myocardial energy 
demands should be maintained as low as possible, in order to allow available energy to 
be channeled to reparative processes. Thus the heart should be allowed to beat but in a 
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non working state, that is not ejecting, which decreases 02 demand by more than 40% 
(Fig 1.2) (B73), and perfusion pressure and oxygenation should be optimized. 
Persistent postoperative insulin resistance due to catecholamine induced trauma 
metabolism can also be overcome with postoperative glucose-insulin-potassium 
infusions (S88,S89). Furthermore, instead of using inotropic agents which increase 
myocardial oxygen demand and may aggravate trauma metabolism, heart rate should be 
optimized with external pacemakers, and preload and afterload optimized by the 
appropriate use of volume expanders and vasodilators. However, excessive volume or 
pressure loading of the ventricle will also increase myocardial oxygen demands·(V17), 
which should be kept as low as possible in the postoperative period (F30). 
There are a number of causes of postoperative low cardiac output (Table 1.14 ). 
Although, inadequate intraoperative myocardial protection and myocardial stunning are 
major causes of postischaemic low cardiac output, other possible causes must first be 
actively excluded. 
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Table 1.14 
ETIOLOGY OF POSTOPERATIVE LOW CARDIAC OUTPUT 
Haemodynanc: 
Inappropriate preload, 
Hypovolaemia, 
Hypervolaemia; LA pressure > 20 mm Hg. 
Inappropriate afterload, 
Vasoconstriction; SVR > 1500 dynes·s·cm-5, 
Excessive vasodilation; SVR < 600 dynes·s·cm-5. 
Arrhythmias 
Bradycardia, or tachycardia, 
Loss of synchronized atrial contraction. 
High Pulmonary vascular resistance 
PVR.> 250 dyne·s·cm-5 
Cardiac Tamponade 
Metabolic causes: 
Hypoxia, hypercarbia, acidosis, adrenal insufficiency. 
Coronary Air or Particulate Matter Elbolism: 
A small amount of air remaining in the left side of the heart can easily 
enter the coronary arteries (L33). 
Surgical causes; 
Myocardial ischaemia 
Acute myocardial infarction 
Stenosis, kinking, or spasm of coronary artery. bypass grafts, 
Incomplete myocardial revascularization, 
Mitral valve replacement induced loss of LV function. 
Residual uncorrected cardiac defect 
Inadequate Myocardial Protection: 
Composition of cardioplegic solution, 
Inadequate distribution of cardioplegic solution, 
Rapid rewarming of the myocardium; 
other causes: 
Temperature of cardioplegia, 
Noncoronary collateral flow, 
High systemic flow rates. 
Pre-existing ventricular dysfunction 
Allergic reactions 
Urinary retention. 
Legend: 
Post operative low cardiac output is defmed to be present if the cardiac index is less than 2.0 L/minim
2 in the presence of an 
adequate preload. 
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A period of at least 15- 30 min of optimal reperfusion following the release of the aortic 
cross-clamp should be allowed prior to introducing inotropic agents, as premature 
postischaemic use of calcium (A2) and inotropic agents accentuates myocardial damage 
and impairs functional recovery (K1,L19). Furthermore, an additional therapeutic 
intervention that could ·be considered for postoperative low cardiac output is 
triiodothyronine supplementation (C29,D27,H45,N13). If myocardial failure persists, 
despite above mentioned resuscitative measures, an intra aortic balloon pump (K5) 
should be inserted. An IABP both increases myocardial energy supply (Fig 1.1) and 
decreases myocardial energy demands (S 15). Thereafter, if a low cardiac output persists 
then a left ventricular assist device can be inserted, if indicated (A9). 
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MODELS USED TO FORMULATE SOLUTIONS 
Cardioplegic solutions need to ·be developed and evaluated in animal models prior to 
human use. Thereafter, multivariate clinical trials of experimentally investigated 
solutions are valuable and necessary. However, the multitude of uncontrolled variables, 
as a result of the disease processes necessitating cardiac surgery, makes evaluation of 
cardioplegic solutions difficult in the clinica:l situation. 
In animal studies, it is important to undertake evaluations in more than one species 
because ofinterspecies differences. Hearse D J, Jynge P and co-workers evaluated the 
StThomas' Hospital N~ 2 cardioplegic solution in both rat and canine models (J23)_ 
However, the ideal species for evaluating solutions intended for human use is possibly 
·the primate, as it is one of the closest species to man. In this thesis three models were 
used to assess the efficacy of cardioplegic solutions used in South Africa, and 
experimental modifications of the StThomas' Hospital cardioplegic solution. 
All experimental animals used in our laboratory received care according to the 
"Principles of laboratory animal care" of the National Society for Medical Research and 
the "Guide for the care and use of laboratory animals" prepared by the National 
Academy of Sciences (NIH Publication No 80-23, revised 1978). In addition, · 
experimental protocols were reviewed and authorized by the Animal Research Review 
Committee of the University of Cape Town. 
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2.1 ISOLATED RAT HEART 
The isolated perfused rat heart was used as the experimental model for the majority of 
studies in this thesis. This model has two components; the Langendorff preparation and 
the working heart model. 
Langendorff preparation 
The Langendorff model was originally described in 1895 (L10), and since then has been 
used extensively to study cardiac metabolism in a number of different animals (H16). 
Male rats of the Long Evans strain and maintained on a standard diet were used for our 
experiments. 
The rat was anaesthetised with diethyl ether, heparinized with 200 U heparin injected 
. 
I 
into the exposed femoral vein, and the heart was then carefully but rapidly excised and 
placed into cold (4°C- 10°C) Krebs-Henseleit buffer (Table 2.1). The cold 
temperature arrests the heart and thus provides some protection to the myocardium 
during this initial ischaemic period. The aorta was then cannulated and the heart 
mounted on the perfusion apparatus (Fig 2.1), within one minute of excision. 
Normothermic (37°C) Krebs-Henseleit buffer oxygenated with 95% 02 5% C02 (p02 
greater than 600 mm Hg) was filtered through a cellulose filter (0.8 urn size pores; 
Millipore corporation, Bedford, Massachusetts, USA) and then allowed to flow 
retrograde into the aorta at a constant pressure of 100 em H20 (75 mm Hg), thus 
establishing coronary perfusion. Normal sinus rhythm recommenced immediately. The 
pulmonary artery was then incised to ensure adequate drainage of coronary effluent, and 
the heart was maintained at 37°C in a water jacketed chamber. This model thus allows 
the perfused heart to continue beating in a nonworking mode, and was used to stabilize 
the experimental hearts prior to conversion to the working model. In addition, this mode 
of perfusion was also used for the initial reperfusion of the postischaemic heart 
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Figure 2.1 
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Legend: 
Three way taps (T) allow easy conversion to either Langendorff mnde, the working heart circuit or infusion of cardioplegic 
solutions. Reprinted from J Thorac Cardiotborac Surg 1991; 102:405-412 (appendix A-2) with permission Mosby Year Book Inc. 
Working heart model 
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In order to allow the heart to perform external work so that mechanical performance 
could be monitored, the Langendorff model was then converted to the working model 
originally described by Neely and colleagues (N6). The left atrium was cannulated 
through the pulmonary veins, and filled with oxygenated Krebs-Henseleit buffer at a 
constant pressure of 20 em H 2 0 ( 15 mm Hg). The left ventricle then spontaneously 
ejects the perfusate against a hydrostatic pressure of 100 em H20 (75 mm Hg), and the 
coronary flow was collected and recirculated. Aortic pressure, aortic flow, coronary 
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flow, and heart rate were then recorded in the control working period, pri6r to the 
ischaemic period, and also in the postischaeinic recovery period 
Cardioplegic solutions were infused into the aorta at a pressure of 80 em H2o (60 mm 
Hg) prior to the ischaemic period, by simultaneously closing the aortic and atrial 
cannulae (Fig 2.1 ), and infusing the cardioplegic solution through a side arm of the aortic 
cannula. Constant hypothermia (10°C) was maintained throughout the ischaemic period 
by another separate cold ( 10°C) water-jacketed chamber. 
Table 2.1 
KREBS-HENSELEIT BUFFER 
Co1pound uol/L qt/L Electrolyte uol/L 
KaCl 118 6.9 Ka+ 143 
KaHC03 25 2.1 K+ 6 
KCl 4.8 0.36 ca2+ 1.25 
KH2P04 1.2 0.16 Mg2+ 1.2 
cac12·2H2o 1.25 0.18 Cl- 125.3 
MgS04'7H20 1.2 0.3 PO 3- 1.2 4 
D-Glucose·H2o 11.1 2.2 Glucose 11.1 
Experimental protocols 
All hearts were stabilized for 10 minutes in the Langendorff mode, prior to changing to 
the working model Preischaemic control haemodynamic parameters were measured at 
2, 5 and 10 minutes during this working period. Any heart that was unstable during this 
period was rejected. The 10-minute values were then recorded as the preischaemic 
controls for future comparisons. 
Cardioplegic arrest was induced by infusing 10 ml of cold (10°C) cardioplegic solution 
into the aorta. In the experiments in which multidose reinfusions of cardioplegia were 
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provided, 6 ml of cardioplegia was reinfused every 30 min throughout the 3-hour 
ischaemic period. 
At the end of the ischaemic period each heart was reperfused in the Langendorf{ mode 
with standard oxygenated Krebs-Henseleit buffer (37°C) for 10-20 min at a pressure of 
80- 100 em H20 (60 -75 mm Hg) according to individual experimental protocols. The 
hearts were then converted to the working model for a further 10 minutes, at which time 
the postischaemic haemodynamic parameters were recorded. The coronary sinus 
effluent was collected during the ischaemic period when multidose cardioplegia was 
administered, as well as during the postischaemic Langendorff reperfusion period. At 
the end of the experiments the hearts were freeze-clamped with Wollen burg tongs to 
determine their high-energy phosphate content 
Exclusion Criteria: 
In the preischaemic control period the following values were used to discard ·hearts:-
Aortic output< 30 ml!min 
Coronary flow> 22 mllmin 
Heart rate< 200 beats/min, or irregular rhythm 
In the postischaemic period any heart whose coronary flow increased significantly by 
more than 50% - suggesting a left atrial leak - was exCluded. 
Parameters of recovery. 
To evaluate the efficacy of myocardial protection both mechanical, metabolic and 
morphological parameters may be measured (Hl6)_ However, ultimately the most 
important parameter is mechanical recovery, which was measured under controlled 
conditions (both preload and afterload), in this isolated rat heart model. 
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Haemodynamic parameters 
Cardiac output (CO) in this preparation is the sum of aortic flow (AO) and coronary 
flow. Stroke volume (SV) was then calculated using the following formula: 
SV =CO I HR (mllbeat) 
Values obtained during the postischaemic working period were expressed as a 
percentage of their individual preischaemic control values. Results were then presented 
as percentage means and standard errors of percentage means. 
Metabolic parameters 
Myocardial enzyme leakage (creatine kinase, CK; lactate dehydrogenase, LDH) 
although not cardiospecific, are thought to indicate damage to cellular membranes. 
High levels are thought to indicate severe cellular damage although there is a degree of 
enzyme leakage in nonischaemic healthy tissue (H16). CK-MB levels of greater than 
133 U IL within 15-hours of operation will identify 96% of perioperative infarcts in 
clinical studies (V5). The enzyme LDH (mU lgm) was used in the studies in this thesis, 
and was measured enzymaticallyby the method of Bergmeyer and Bernt (B24). End 
products of glycolytic metabolism were also measured in some experiments: lactate 
(umol!gm) was measured by the method of Gutmann and Wahlefeld (G44), and oxygen 
uptake by subtracting venous from arterial oxygen content (B63). 
The weight of the rat hearts was calculated from their body weights using a formula 
derived from previous laboratory measurements of both heart and body weight of rats Of 
this strain (unpublished data). 
Heart weight = (Rat weight + 75.18) I 359.71 
Loss of myocardial high energy phosphate stores is an integral component of ischaemia, 
and Bretschneider and co-workers predicted poor recovery if A TP levels fell below 4 
umollgm wet weight (B63). ATP levels have been used in clinical studies and correlate 
with postoperative outcome (H6). However, other studies have demonstrated that 
postischaemic levels of A TP of less than 2 umol I gm wet weight neither predict recovery 
of contractile function nor irreversible damage (R42,V13). Thus, although newer "on 
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line" nuclear magnetic resonance techniques of measuring A TP may provide valuable 
information, one cannot predict functional recovery from these values (R42,S5). High 
energy phosphates were measured in the studies in this thesis by freeze-clamping the 
hearts with Wollenberg tongs, freeze drying the samples and levels were then 
determined by the method of Lamprecht and Trautschold, expressed as umol/ gm wet 
weight (L4). Preischaemic control values for ATP and CP were derived from hearts 
subjecte.d to the same initial experimental protocol ie. 10 min Langendorff and 10 min 
working heart modes, but thereafter immediately freeze clamped. Tissue A TP and CP 
levels were then also measured at the end of the ischaemic period in some of the studies, 
by freeze clamping a second set of hearts prior to reperfusion. In addition, high energy 
phosphate levels were also measured in most of the studies after reperfusion, at the end 
of the experimental protocol. 
Statistics 
Extreme observations or "outliers" were tested for by Dixon's criteria (S56), in order to 
exclude major experimental errors, and if found those hearts were then excluded from 
further analyses. 
The statistical tests used to compare differences between groups were the An ova one-
way, two-way or three-way analyses of variance. However, the An ova depends upon an 
assumption of common variance amongst observations within each treatment group. 
Therefore, if variance was not consistent necessary adjustments for the violation of 
common variance were made. If statistical significance was obtained with AN OVA then 
pairwise comparisons of means were performed using either t-statistics with a nominal 
level of significance set at 5 %, or by the f-test Appropriate tables were then used to 
determine p-values for comparisons of interest Statistical significance was assumed 
when the p-value was less than 0.05. 
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2.2 IN VIVO PRIMATE MODEL 
Juvenile and adult Chacma baboons (Pap.io ursinus) were used in the primate 
experiments in this thesis. An in vivo model using cardiopulmonary bypass to simulate 
the clinical situation as close as possible was used. 
Experimental protocol 
The animals were premedicated with intramuscular ketamine hydrochloride (10 mg/kg 
body weight). An endotracheal tube was then inserted, which was stabilized and secured 
with a cardboard ring and elastoplast A narcotic analgesic; morphine sulfate (0.25 
mg/kg), an antisialogogue; atropine sulfate (0.5 mg) and a neuromuscular blocker; 
pancuronium bromide (0.1 mg/kg) were administered intravenously. Anaesthesia was 
maintained with a mixture of nitrous oxide (7 L/min), oxygen (3 L/min), and 0.5% 
halothane, administered via a Bird Mark 8 respirator (Bird Corporation, Palm Springs, 
California, USA) at a respiratory rate of 10-20 breaths/min. Tidal volume was adjusted 
accordingto animal size, ventilator pressures kept at 15-20 em H20, and blood gases 
were monitored throughout the experiment and ventilation adjusted accordingly. The 
animals were also monitored for signs of insufficient anaesthesia (hypertension, 
bradycardia, tachycardia, pupillary dilatation, lacrimation, salivation and muscular 
tension), and the level of anaesthesia appropriately adjusted. Intra-arterial and central 
venous lines were inserted into the femoral vessels. 
Immediately prior to performing the median sternotomy a second dose of morphine 
sulfate was given. After full heparinisation (500 U /kg) the heart was cannulated in 
preparation for cardiopulmonary bypass. Venous blood was drained via a single venous 
cannula inserted into the right atrium, oxygenated by a bubble oxygenator (Polystan 
Venotherm Oxygenator, low prime adult I paediatric Cat 012500, or infant Cat 011200; 
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Polystan A IS, Vaerlose, Denmark), temperature controlled with a heat exchanger 
incorporated in the oxygenator, and the blood was then returned by the 
cardiopulmonary bypass machine (Polystan A IS; Vaerlose, Denmark), via a cannula 
inserted into the ascending aorta. A Swan-Ganz thermodilution catheter (American 
Edwards 7F; American Edwards Laboratory, American Hospital Supply corporation, 
Santa Ana, California, USA) was inserted through the superior vena cava and positioned 
in the pulmonary artery for the measurement of cardiac output Cannulae was also 
inserted into the left atrium, left ventricle and a thermistor probe (Microprobe 
thermometer Model BAT -12; Physitemp, Clifton, New Jersey, USA) positioned in the 
ventricular septum. 
Systemic temperature was 1owered and maintained at 26°C after commencing 
cardiopulmonary bypass. The aorta was then cross-clamped and cardioplegic solution 
( 15 ml /kg) infused via a separate cannula inserted into the ascending aorta, at a constant 
pressure of 80 mm Hg. In addition, the pericardia! cavity was irrigated with iced saline 
during each infusion of cardioplegic solution. Multidose maintenance cardioplegia ( 100 ' 
ml/dose) was reinfused every 30 minutes throughout the 180-minute cross-clamp period. 
Systemic rewarming was commenced 30 minutes before the release of the ·aortic cross-
clamp, and continued throughout the 15-minute reperfusion period until normothermia 
was obtained. The left ventricle was vented during the cross-clamp period and initial 
reperfusion period to ensure left ventricular decompression, by a cannula inserted via 
the right superior pulmonary vein. The animal was then weaned from cardiopulmonary 
bypass without the use of any inotropes. 
The animals were euthanased while still under full anaesthesia by the intravenous 
infusion of a strong solution of potassium chloride, thereby effecting immediate cardiac 
arrest at the completion of each experiment 
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Parameters of recovery 
Myocardial temperature and haemodynamic parameters- heart rate, arterial blood 
pressure, right and left atrial pressure, first derivative ofleft ventricular developed 
pressure (LV dp/dt), and cardiac output (by thermodilution) were recorded with a 
Honeywell AR-6 Simultrace Recorder (Electronics for Medicine, Honeywell Inc, 
Pleasantville, New York, USA). Preischaemic haemodynamic parameters were 
recorded after the positioning of all cannulae prior to the commencement of 
cardiopulmonary bypass. A left ventricular function curve was plotted by recording 
these parameters at increasing left atrial filling pressures (5, 10, 15, 20 mm Hg), obtained 
by infusing cardiopulmonary bypass prime into the animal In addition, a left ventricular 
transmural needle biopsy was taken from the apex of the left ventricle for determination 
of high-energy phosphates and transmission electron microscopic assessment 
Postischaemic haemodynamic and -biochemical parameters were again taken at 5 and 30 
minutes after termination of cardiopulmonary bypass, (a postischaemic LV function 
curve was only obtained at the 30 minute postischaemic period). 
Analysis of data 
Values were expressed as an index, to exclude the influence of animal size. The 
following formulae were used to derive cardiac index (CI), stroke volume index (SVI), 
and left ventricular stroke work index (SWI). 
BSA (cm2) = Weight0.425 (kg) X Height0,725 (em) X 71.84 (D25). 
CI (L/min/m2) =CO (L/min) I (BSA X 10-4 m2/cm2) 
SVI (mllbeat/m2) = (CI X 1000 ml/L) I HR (beats/min) 
SWI (gm·m/beat/m2) = SVI X (LV systolic pressure (mm Hg)- LVEDP 
(mm Hg)) X 0.014348 (S6) 
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Postischaemic values were then expressed as a percentage of each individual 
preischaemic control, and the same statistical tests as previously described in section 2.1 
were used. 
For statistical comparisons of SWI left ventricular function curves, the SWI at each left 
atrial filling pressure was expressed as a percentage of the stroke work achieved in the 
preischaemic control curve for each individual animal. Mean percentages and standard 
errors of mean percentages were then compared by ANOV A. However, for display 
purposes an average preischaemic control left ventricular function curve was derived by 
pooling the data from all control function curves. Postischaemic function curves for 
each group were then normalized to the average preischaemic curve; by multiplying the 
mean percentage recoveries and their standard errors for each group, at each left atrial 
filling pressure from 0 - 20 em H 2 0, by the average control SWI at the corresponding 
pressure. 
The volume of cardioplegia administered to each animal (15 ml/kg) was related to heart 
weight by using the following formula derived from previous multiple measurements of 
both indices, in primates of this species in our laboratory (unpublished data). 
Heart weight= (body weight X 8.33)- 37.03. 
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2.3 LIMITATIONS OF ANIMAL STUDIES 
There are several limitations of the isolated rat heart model The most important being 
that a non-blood perfusate and small mammalian "normal" hearts are used. 
Species · 
Small mammalian hearts, especially the rat, guinea pig and rabbit have been used 
extensively to study the effect of cardioplegic solutions, because of low cost, ease of 
handling, and possibility of studying large numbers (H16)_ However, physiological 
differences clearly exist between species (B31,G 1,H20,H21), and tolerance to 
normothermic ischaemia varies between species ( G 1). Furthermore, cardioplegic 
protection may be beneficial in one species (rat), but provide no protection in others 
(ferret and guinea pig) ( G 1), and susceptibility to reperfusion damage also differs (H20)_ 
Major physiological differences also exist between these smaller mammals and larger 
animals (pig, canine, primate); eg. smaller animals have high resting heart rates (rat- 355 
beats I min, guinea pig - 273 beats I min), and the oxidative capacity of the myocardium of 
smaller animals is significantly higher, although the glycolytic potential of mammalian 
myocardium is possibly fairly uniform (B31)_ Smaller animals also have 'higher levels of 
basal metabolism, oxygen consumption (H53), and may have considerably different 
electrophysiological properties (B60)_ 
Amongst larger animals there are also differences; the pig has extremely limited 
collateral flow between different regions of the myocardium and develops cardiac 
oedema rapidly. The calf heart exhibits considerably higher resistance to ischaemia than 
the dog heart, which is somewhat less than a healthy human heart (B60)_ The canine 
heart is less tolerant to cardiopulmonary bypass and develops myocardial oedema more 
predictably and frequently than the human (R35). 
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In addition, differences in susceptibility to ischaemic injury also depend upon the 
maturity of the animal (P30), and cardioplegic solutions used in adult hearts may not 
have equivalent efficacy in neonatal hearts (B3,B4_). 
The primate though, has a close evolutionary relationship to man, and is therefore 
probably the closest available experimental model to man for evaluating the efficacy of 
cardioplegic solutions. Nevertheless, direct extrapolation of animal experiments to the 
human clinical situation requires caution. 
Ex Vivo Models 
Experimental conditions can be rigidly controlled in ex vivo models (Hl6). However, 
the "unphysiological" crystalloid perfusates used in the majority of these models allows 
only limited recovery after ischaemic contracture, and also increases compliance and 
causes slow deterioration ofthe heart with time (Gl,N6). Furthermore, bubble 
oxygenation of the crystalloid perfusate denatures added proteins and may cause 
microemboli. Trace amounts of heavy metals in the reagents of the perfusate can also 
affect the stability of the model (N6), and Neely et al add Ca-EDTA 0.5 mmol/L to the 
Krebs-Henseleit perfusate to improve the stability of their model Thus, alternative 
paracorporeal and in vivo models using blood perfusates are more physiological, 
although more complex and expensive (W7). 
In vivo models in contrast to ex vivo models, maintain the involvement of metabolic, 
nervous, hormonal and other factors such as noncoronary collateral flow. However, 
metabolic, hormonal, biochemical alterations such as ionized calcium concentration 
(D24) and haematological parameters (haematocrit) in these paracorporeal models can 
also effect myocardial function and therefore outcome. Cardiac output can also be 
altered by heart rate, preload and afterload in the in vivo model. Although the former 
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two variables can be ke~t constant, afterload can be difficult to keep stable and thus can 
affect the results. Therefore, isovolumic measurements of contractility may be more 
relevant in this model, and a mor~ sensitive indicator of ischaemic damage may be 
postischaemic oxygen utilization (K37)_ 
Nevertheless, the clinical situation of cardiopulmonary bypass, with its associated 
damaging effects, can be closely simulated with in vivo models. 
Experimental Protocol 
The experimental protocol used to evaluate the efficacy of cardioplegic solutions is 
extremely important Cardioplegic solutions should be evaluated in models that 
simulate the clinical situation, and two fundamental aspects are the temperature during 
the ischaemic period and the energy state of the experimental heart 
Hypothermia alters the physiological environment; "fluidity" of proteins and lipids, 
activity of enzymes (P33), calcium homeostasis (Kl2,S40), coronary autoregulation 
(C24,M20), and the neutral pH of water (Wl9). Therefore, one should critically 
question the validity of normothermic evaluations of cardioplegic solutions, destined to 
be used in hypothermic conditions (J2l,Kll). Nevertheless, it is important to also be 
aware of the efficacy of cardioplegic solutions at different temperatures ( 121), as 
temperatures may vary during open-heart procedures. In all studies in this thesis, the 
cardioplegic solutions were evaluated at hypothermia (10°C). 
The majority of experimental animals have "normal hearts", whereas in the clinical 
situation operations are performed on diseased hearts. Thus models simulating coronary 
stenoses to study cardioplegic distribution (G41,L20), or models using energy depleted 
hearts (by adding an initial ischaemic insult) (R44), hypertrophied hearts (B30), and 
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cyanotic hearts (F32), are extremely relevant and important (B71). However, when 
studying the effects of cardioplegic solution composition on functional recovery, an 
initial ischaemic insult may impose an additional reperfusion injury which itself induces 
additional physiological changes. Nevertheless, because of the excellent performance of 
better formulated cardioplegic solutions, an initial normothermic ischaemic insult may 
be necessary. An ischaemic insult was added to the experimental protocol in a later 
study in this thesis, in order to produce energy deficient hearts. 
Other experimental variables 
The preparation of the cardioplegic solution itself can introduce experimental variables. 
For example, particle induced coronary vasoconstriction must be prevented (H17,R30), 
and therefore all experimental cardioplegic solutions should be filtered through an 0.8 
urn sized cellulose filter (Millipore corporation; Bedford, Massachusetts, USA). 
Heavy metal contamination 
Contaminated salts of the various components of the cardioplegic solution to be 
evaluated can alter its efficacy. We noted significant myocardial depression if the · 
standard St Thomas' cardioplegic solution was prepared with magnesium chloride 
obtained from one company (MgCl2·6H20- AnalaR, Product 10149; BDH Chemicals 
Ltd: Poole, England), in contrast to another (MgCl2·6H20- Product 5833; Merck Ltd: 
DarJ.?.stadt, Germany). We presumed that this was due to the higher quantities of heavy 
metal contaminants allowed with the former product Heavy metals can be used as 
cofactors in the generation of oxygen free radicals (C19,M37), and other investigators 
have also noted the detrimental effect of heavy metal contaminants (Wicomb W: 
personal commu·nication). Thus, calcium or sodium EDTA (0.5 mmol!L) has been 
added to perfusates (N6) and cardioplegic solutions (W27), in order to chelate residual 
traces of heavy metals. 
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Oxygen content of cardioplegic solutions , 
The majority of solutions prepared in the laboratory are routinely gassed with 95% o2 
5% C02 during their preparation, in order to prevent precipitations of calcium salts. 
Thereafter, depending upon how these solutions are stored and the length of elapsed 
time prior to use, the oxygen content can vary significantly. Thus "non-oxygenated" 
cardioplegic solutions may contain significant quantities of dissolved oxygen if 
equilibration to atmospheric pressure has not yet occurred (appendix A-7). 
Furthermore, some commercial cardioplegic solutions (Bretschneider HTK4) are stored 
in vacuum in glass bottles, and are therefore anoxic if infused immediately upon opening 
the container. Hence, the amount of oxygen dissolved in "non-oxygenated" solutions can 
result in experimental variations. 
Processing of samples for electron microscopy 
Morphological studies have consistently been in broad agreement with both enzymatic 
and functional assessments (H 16)_ Characteristic mitochondrial changes correlate well 
with functional recovery and adequacy of myocardial preservation (S51). However, 
processing of tissue for transmission electron microscopy is critical, as fixation 
techniques may alter structural findings (S5l,V12). Fixation of tissue samples in these 
studies was with 5 % buffered glutaraldehyde and processing was by routine techniques 
employed in our laboratory (osmic acid and dehydration in graded alcohols and 
embedded in araldite) (R34). 
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2.4 MONOLAYER ENDOTHELIAL CELL CULTURES 
The vascular endothelium is an extremely important component of all organs (see 
section 6.1 ), and is the first structure that infused cardioplegic solutions contact Various 
isolated cellular and subcellular preparations have been used to evaluate the effect of 
cardioplegic solutions, but very few evaluations have been made of the effect of 
cardioplegic solutions on the endothelium (Hl6). We developed a model of cultured 
human endothelial cells (Fig 2.2) in order to assess the direct effect of cardioplegic 
solutions on the endothelium. 
Figure 2.2 
MONOLAYER CULTURE OF ENDOTHELIAL CELLS 
Legend: 
Confluent monolayer of human venous endothelial cells. A typical "cobblestoned" surface with no intercellular gaps is observed. 
Light micr05eopy X 100. Reprinted from ADD Thorac Surg 1990; 50:902-910 (appendix A~) with permission The Society of 
Thoracic Surgeons. 
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Technique of endothelial cell cultures 
Human adult saphenous vein remnants (2- 3 em) normally discarded after coronary 
bypass graft surgery, or saphenous veins obtained from organ transplantation donors 
were used. The segment of vein was cannulated, flushed with incomplete culture 
medium (Medium 199- Earle's salts (Flow Laboratories, Irvine, Scotland)), and then 
filled with 0.1% collagenase (CLS II; Cooper Biomedical, Malvern, Pennsylvania) and 
incubated at 37°C for 15 min (Z3,Z4). The collagenase-cell suspension was then 
inactivated by flushing with culture medium containing 30% foetal calf serum (Delta 
Bioproducts, Johannesburg, South Africa), collected and centrifuged for 10 min at 120 g. 
The pellet was then resuspended in 2 ml complete culture medium (Medium 199 plus 
20% foetal calf serum and endothelial cell growth factor (ECGF)- (Collaborative 
Research Incorporated, Lexington, Massachusetts)), and plated into a 9.6 cm2 well of a 
six-well culture plate precoated with human fibronectin (lnotech, Zurich, Switzerland, 
18 ug/ml). All cultures were incubated at 37°C in a 5% C02 atmosphere. 
To remove erythrocytes and cell debris the primary cultures were rinsed after 24 hr, with 
Dulbecco's phosphate buffered saline (Flow Laboratories, Irvine, Scotland). Thereafter, 
complete culture medium (2 ml) was added, and 50% of the supernatant was replaced 
twice weekly with fresh complete culture medium. Endothelial cells were passaged at 
80% partial cell coverage, designated by a microgrid technique (Z3,Z4). This partial cell 
coverage was usually obtained 10 days after endothelial cell harvest In order to reduce 
the cell damaging effect of multiple passages (Wl1), primary cultures were passaged at a 
ratio of 1:22, using trypsin EDTA (Flow Laboratories, Irvine, Scotland). These first 
passage endothelial cells were either seeded into a 175 cm2 flask precoated for 12 hours 
with gelatin (Difco Laboratories, Detroit, Michigan, 10 ng/ml in 0.1 M NaHC03 buffer), 
or onto 9 mm glass cover-slips for immunohistochemical staining of von Wille brand 
factor (Factor VIII related Antigen) (Z3), which is a typical cell marker for endothelial 
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cells 0 2). Cultures were managed as before, and confluence again obtained within 10 
days. The cells were passaged once more, but in a 1: 1 ratio into 12 well culture plates 
(3.5 cm2 per well), precoated with gelatin. Confluence of second passage monolayers 
was obtained after 2 - 3 days. Individual wells were assessed microscopically for 
completeness and homogeneity of cell coverage, and unevenly covered wells were 
excluded. 
Experimental Protocol 
A baseline in situ grid count of each well was performed (Z3,Z4), using an inverted 
phase contrast microscope (ID-02-MT, Zeiss, West Germany). The cell count in "20 grid 
squares" was the total number of cells seen in each four corner squares of a marker grid 
and counted in five different areas of each well. The culture medium was then removed 
and the preservation solution applied initially as a rinse, to ensure removal of all 
medium, and then a one ml aliquot reapplied. 
The cells were exposed to the preservation solutions for predetermined periods, and the 
morphology of the cells was then examined by light microscopy. Thereafter, the solution 
was removed and the cells rinsed with incomplete culture medium, and one ml complete 
medium but not containing ECGF was reapplied. All cell cultures were again placed in 
a 37°C, 5% C02 incubator, to assess cell survival and allow for any delayed expression 
of cell damage. A post exposure cell count was performed after rinsing the cells with 
incomplete culture medium, to remove debris and dead cells, at 24 h and again at 36 h. 
The percentage of surviving cells in each well, at the 24 h and 36 h post exposure time 
periods, was derived from the ratio of each individual post exposure count to the 
corresponding initial pre exposure count for that well. 
In order to ensure reproducibility each solution was tested in different culture plates, 
and on endothelial cells obtained from separate human donors. 
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Limitations of this model 
This model uses morphology and cell survival to assess the effects of cardioplegic 
solutions on endothelial cells, although endothelial functions such as the release of 
vasoactive substances are not assessed. Indirect measurements of endothelial function, 
such as vasoresponsiveness to infused substances (C2l,S7), require both endothelial and 
vascular smooth muscle function (Bl4). Whereas in our model the direct effect of 
cardioplegic solutions on the endothelium alone, were evaluated. Furthermore, venous 
as opposed to arterial endothelial cells were used in our experiments and differences do 
exist between different vascular beds (D9,L5I,W2). However, extrapolation to the 
arterial system is probably justified as similarities also exist between vascular beds 
(Jl,P8), and basic morphological changes were evaluated in our model. Nevertheless, 
extrapolation of these isolated cellular studies to the human clinical situation should be 
done with caution. 
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COMPOSITION OF CARDIOPLEGIC SOLUTIONS 
Cardioplegic solutions were initially formulated in the mid 1950's in order to produce 
elective cardiac arrest (L3,M30,S32), but these solutions also caused myocardial damage 
(M23,M29), and clinical use was therefore discontinued (G8,H16). However, 
experimental work continued and the basic physiological and biochemical effects of 
cardioplegic arrest were more extensively determined (B63,G9,Hl6). Thus, cardioplegic 
solutions were reintroduced in clinical open-heart surgery in the 1970's 
(B54,B63,G8,K22). 
Cardioplegic solutions were initially used at normothermia by both Kirsh et al (K22) and 
Gay et al (Table 3.1) ( 09). How ever, the effectiveness of a high magnesium solution 
similar to tbat of Kirsh, diminishes markedly after 30 min normothermia (W4). 
Nevertheless, acceptable clinical results (S20) were also obtained by the tecbnique of 
Bleese and Rodewald et al in Hamburg, who used the Kirsh solution to initially arrest 
the heart at normothermia, but tben cooled the heart with a cold oxygenated perfusate 
(B32). Hypothermia used in conjunction with cardioplegia was then soon reintroduced 
routinely in the clinical situation (B32,B63,C34,G8,H16). 
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Table 3.1 
CARDIOPLEGIC SOLUTIONS USED AT 
NORMOTHERMIA 
Kirsh (B32,J22,K22) 
MagnesiUJ-1-Aspartate 
Procaine-Bel 
Sorbitol 
Osmolality: 
Legend: 
Volume infused: I -2 ml/lcg body weight (30- 140 ml) 
HaCl 
HaHC03 
KCl 
Glucose 
Osmolarity: 
Legend: 
Gay (G9) 
gm% 
2.5 
0.3 
4.5 
gm% 
0.4 
0.1 
0.25 
0.2 
± 238 mOsmjL 
Volume infused: 100 ml in combination with blood in an approximate ratio of 1:1 (canine hearts). 
nol/L 
160.9 
11 
247 
uol/L 
68 
12 
34 
10 
A plethora of different cardioplegic formulations have since been used clinically. 
Cardioplegic solutions are now subdivided into either pure crystalloid (intracellular or 
extracellular electrolyte equivalent formulations), or blood cardioplegic solutions. 
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3.1 CRYSTALLOID CARDIOPLEGIC SOLUTIONS 
Crystalloid cardioplegic solutions were initially the predominant category of cardioplegic 
solution used. However, each cardiac center developed their own "cardioplegic solution" 
(Table 3.2, 3.3, 3.4). In addition to these "named cardioplegic solutions", many surgeons 
used cardioplegic solutions made up by merely adding potassium with or without 
bicarbonate to commercially available standard intravenous electrolyte solutions 
(R29,Appendix A-1). 
Table 3.2 
CARDIOPLEGIC SOLUTIONS USED AT HYPOTHERMIA 
nol/L Guy & Ebert ( G8) Roe's (R33) Tyers (T27) Kirklin (UAB) (K20) 
Ha+ 48.5 27 138 110 
~ 40 20 25 30 
HCO- 10 - 20 27 3 
ca2+ 
- -
0.5 0.5 
. 
Mg2+ 
-
1.5 1.5 -
Cl- 78.5 47 98 85 
Glucose 278 278 . -· 27.7 
Mannitol - - - 54.39 
TRIS - 2 - -
Acetate - - 27 -
Gluconate - - 23 -
Oslolality 
(.OS1jkg H20) 320 347 275 330 
pH 7.7 7.6 7.8 7.5 
Comparisons between some of these "named cardioplegic solutions" have been done, 
however, often with various modifications of these solutions or with inappropriate 
techniques, making detailed comparative analysis difficult For example, the StThomas' 
Hospital No 2 cardioplegic solution (Table 3.3) provides better myocardial protection 
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than Tyers' (R29) or Kirsh solutions (with or without additional hypothermia), both 
clinically (S20) and experimentally (J22)_ A comparison of solutions containing low 
sodium concentrations showed that Roe's solution was inferior to Bretschneider HTK 
(Table 3.4), and resulted in progressive acidosis and depletion of ATP in a hypothermic 
(27°C) canine model (W33)_ 
Although comparisons of all known solutions have not been performed, there are 
primarily two "gold standard" crystalloid cardioplegic solutions which have been 
extensively investigated and characterized; Bretschneider HTK4 and St Thomas' 
Hospital No 2 cardioplegic solutions. These two cardioplegic solutions should therefore 
be used as the baseline for all future comparisons of "new" crystalloid cardioplegic 
formulations. 
StThomas' Hospital Cardioplegic Solutions 
Extracellular electrolyte equivalent cardioplegic solutions rely primarily on high 
concentrations of potassium ( 10 - 40 mmol /L) to partially depolarize the cellular 
membrane, thereby inactivating sodium channels and preventing the genesis of an action 
potential (B69,Hl6). However, it is not only the potassium concentration that is 
important, but also the concentrations of all components of the cardioplegic solution 
(Hl4,H24)_ Poorly formulated solutions provide incomplete myocardial protection 
(B5,K30). 
Jynge P, Hearse D J and colleagues performed dose response curves to determine the 
"ideal" concentration of each component of the StThomas' cardioplegic solution, in the 
isolated rat heart model (H28,J17,J23). Thus, the StThomas' Hospital No 2 cardioplegic 
solution, which is better than the St Thomas' No 1 cardioplegic solution (L26), can be 
considered to be the best characterized extracellular electrolyte equivalent cardioplegic 
solution and hence the "gold standard" for this group of cardioplegic solutions. 
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Table 3.3 
STTHOMAS' HOSPITAL CARDIOPLEGIC SOLUTIONS 
st Tho1as' st Tho1as' Ringer's MacCarthy 
(uol/L) No 2 (J23 ) No 1 (L26) Solution Ampoule 
Na+ 120 144 144 -
K+ 16 20 4 16 
HCO- 10 - - -3 
ca2+ 1.2 2.4 2.4 -
Mg2+ 16 16 - 16 
cr 160.4 201.8 152.8 49 
Procaine-HCl - 1 - 1 
OsJolality 
(raOslfkg H20) 282 300 - -
pH 7.8 5.5- 7.0 - -
A cardioplegic solution is infused in order to manipulate the extracellular ionic 
concentrations which in turn: 
i) Causes electromechanical arrest, 
ii) Prevents an increase of intracellular calcium during the ischaemic period. 
The interactions between the different ions contained in cardioplegic solutions are 
extremely complex, and changes in the concentration of one ion can markedly effect the 
efficacy of another. Hence the importance of both understanding these relationships 
and establishing dose response curves for each individual electrolyte. 
Calcium content 
Calcium is probably the single most important ion in terms of protecting the ischaemic 
myocardium, both during ischaemia (Hl6) and during reperfusion (H5,020)_ An 
increase in intracellular calcium is detrimental because it activates A TPase, ·proteases, 
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lipases, accumulates in the mitochondria (Hl6), and consumes energy independent of 
excitation-contraction when taken up by the sarcoplasmic reticulum (Rl9). Intracellular 
calcium concentrations can be altered via a number of mechanisms; the slow calcium 
channel, sarcolemmal sodium-calcium exchange, sarcolemmal calcium pumps, and by 
uptake by the sarcoplasmic reticulum and mitochondria (021). Calcium fluxes are also 
intimately related to both pH and the other cations; low extracellular sodium, high pH 
or high potassium concentrations promote calcium influx (Hl6,Lll,Ll2,017), whilst 
magnesium inhibits sarcoplasmic reticulum release of calcium (K8). 
Intracellular calcium increases during both ischaemia and reperfusion (P31), and thus a 
primary function of a cardioplegic solution is to prevent this increase in calcium. 
However, calcium is also essential for maintaining the integrity of the cell membrane 
(Hl6), and removal of all extracellular calcium predisposes the heart to the calcium 
paradox. The calcium paradox is the term used to describe the irreversible cellular 
damage that occurs when a heart is reperfused with a calcium-containing solution after a 
short period of calcium-free perfusion (H 19,J20,R55). The likelihood of the calcium 
paradox occurring is increased by" either normothermia (RIO), ischaemia (Jl8), high 
potassium concentrations, alkalosis (H31), prolonged myocardial washout of calcium 
(K32), or presence of calcium-binding anions (citrate, phosphate, gluconate) 
(C27,J16,J18). The calcium paradox also occurs in all species (Hl6), and in organs other 
than the heart (Nl8). The original Melrose cardioplegic solution (M23,M29,M30) 
contained exceptionally high concentrations of the calcium-binding anion citrate, and 
thus the calcium paradox was the probable cause of the myocardial damage induced by 
this solution. The calcium paradox can be prevented from occurring by maintaining a 
minimal calcium concentration of 0.025 mmol/L in the extracellular fluid (H32). 
Calcium-free cardioplegic solutions have been used successfully clinically (B37), 
however, some of these cardioplegic solutions may not have been truly calcium-free as 
even "deionized distilled water" contains trace amounts of calcium (H 16,Appendix A-6). 
The highly variable noncoronary collateral flow also probably prevented complete 
calcium depletion in the clinical situation (RIO). Nevertheless, calcium-free cardioplegic 
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solutions are potentially dangerous, and the StThomas' Hospital No 2 cardioplegic 
solution contains 1.2 mmol /L of calcium. 
The optimal concentration of calcium in the St Thomas' cardioplegic solution was 
originally shown to be 1.2 mmol/L (Y2,Z8) in a normothermic model (R28)_ However, 
in hypothermic models the optimal concentration is 0.3-0.6 mmol/L (B2,R31,R32). 
Furthermore, the known complex hypothermic induced changes to cellular calcium 
fluxes (K43,S40), suggest that the latter results are more appropriate to the clinical 
situation. 
Sodium content 
Sodium tends to accumulate intracellularly during ischaemia (P31), as a result of 
opening of sodium channels ( 0 17), and as the A TP dependant sarcolemmal sodium-
potassium pumps fail This intracellular sodium accumulation can be prevented by using 
a sodium-poor cardioplegic solution. However, this imposes other constraints on the. 
composition of the cardioplegic solution, such as the necessity for it to be calcium-free 
(H14,L12) (see next section; Bretschneider cardioplegic solutions). 
Hearse et al elected to formulate a calcium containing cardioplegic solution that avoided 
extremes in ionic concentrations and thus used a sodium concentration approximating 
that of extracellular fluid, for the StThomas' cardioplegic solution (J23)_ The optimal 
sodium concentration of the St Thomas' cardioplegic solution was found to be 100 - 120 
mmol/L, in a 30 min normothermic ischaemic model (117). A sodium concentration of 
60 mmol /L or less increased creatine kinase release, thus indicating cellular damage 
probably due to an induced increased calcium influx (Ll2). 
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Potassium content 
High extracellular potassium concentrations (30- 40 mmol/L) reduce the resting 
membrane potential from approximately -8,5 mV (017) to -40 to -30 mV (H16). 
Although this membrane potential inactivates the sodium channel and thus prevents an 
action potential, this membrane potential also activates the calcium channel (017). 
Therefore, high extracellular potassium concentrations promote calcium influx which is 
harmful during ischaemia. In addition, these high potassium concentrations damage the 
endothelium (F23,J7,Mll,S7), cause coronary vasoconstriction (C2l,H25), increase 
postoperative conduction arrhythmias (Dl5,E5), and accelerate atherogenesis (013). 
However, a potassium concentrations of20 mmol/L reduces the membrane potential to 
approximately -50 mV which still produces electromechanical arrest, but without the 
unfavorable calcium effects (H16). 
Another disadvantage of potassium induced partial depolarization is that sodium 
channels open at -70 mV to -60 mV (017), and therefore partial depolarization still 
allows sodium influx (H16), which in turn also incre~ses intracellular calcium (017). 
However, sodium influx can be partly inhibited by Class I antiarrhythmic agents such as 
lignocaine (H22,017). Kyo et al showed that a normokalaemic lignocaine (400 mg/L) 
cardioplegic solution resulted in higher end-ischaemic adenosine triphosphate content 
with good functional recovery, than hyperkalaemic cardioplegic solutions (K45). 
Potassium induced partial depolarization is thus theoretically inferior to polarized arrest, 
which decreases metabolic demands more than depolarized arrest (S73). 
Nevertheless, the minimum concentration of potassium needed to obtain arrest at 
normothermia with an asanguineous solution is 15 mmol/L (R51), and with blood 
cardioplegia 20-25 mmol/L (B74). However, myocardial hypothermia potentiates 
potassium arrest as hypothermia (4oc- 10°C) induces membrane depolarization of 
approximately 10 mV (K43). Therefore, the potassium concentration in cardioplegic 
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solutions can be decreased to 8 - 10 mmol/L with subsequent multidose reinfusions, 
once the myocardium is hypothermic (B74)_ 
Magnesium content 
Magnesium is a major intracellular cation, a cofactor for a number of enzymatic 
reactions, and the majority of intracellular magnesium is complexed with adenine 
nucleotides (P24). High extracellular magnesium concentrations inhibit sarcotubular 
calcium release and calcium influx (K8), decrease potassium efflux during ischaemia, 
decrease intracellular sodium and limit intracellular magnesium loss (S41). These 
effects of magnesium are advantageous during ischaemia and magnesium is therefore an 
important protective ion in cardioplegic solutions (B68,H28). The addition of 
magnesium to a cardioplegic solution also suppresses mitochondrial nonphosphorylating 
oxygen consumption (S83), prevents calcium-induced increased myocardial tension 
(G 12) and mechanical activity (T22) during initial infusion of the cardioplegic solution. 
The optimal concentration of magnesium in an extracellular cardioplegic solution used 
at either normothermia or hypothermia is 16 mmol/L (B68,H28,Rl8), which 
approximates the reported intracellular magnesium concentration of 16- 17 mmol!kg 
cell H2o (P24). Although magnesium may not to be necessary in low calcium containing 
cardioplegic solutions (Kl6), other studies have shown that magnesium is beneficial in 
. 
the presence of both high and low calcium concentrations (B68). 
The StThomas' Hospital No 2 cardioplegic solution contains a magnesium concentration 
of 16 mmol/L, and therefore a bolus of 16-32 mmol of magnesium (1- 2 L 
cardioplegia) is infused systemically if the cardioplegic solution is allowed to drain into 
the systemic venous blood during clinical open-heart surgery . This results in a 70 -
130% increase in serum magnesium levels from 0.7-0.95 mmol/L to 1.34- 1.86 mmol/L, 
which return to normal within 24 h (Ml2). Although high magnesium concentrations 
may depress myocardial contraction, cause bradyarrhythmias and heart block, 
116 U 0 Von Oppell PhD Thesis; University of Cape Town, 1992 
cardiovascular toxicity only occurs at higher levels (2.5 mmol/L) (E4)_ Moreover, this 
magnesium load might be beneficial by correcting preexisting or cardiopulmonary 
bypass associated hypomagnesemia, by decreasing systemic vascular resistance and 
catecholamine response in the postischaemic period (ClO), and by suppressing 
postoperative supraventricular tachyarrhythmias (F4)_ 
Local anaesthetic agents 
Lignocaine can be added to the St Thomas' cardioplegic solution in a concentration of 
0.05 mmol/L (14.4 mg/L; 0.72 ml2% Lignocaine~ HCl) (H22)_ Equivalent 
postischaemic recovery is also obtained with procaine 0.05 mmol /L. These local 
anaesthetic agents "stabilize membranes" and may act as cardioplegic agents (prevent 
depolarization by inhibiting the fast inward sodium channel), as well as inhibiting 
potassium conductance. Procaine also prevents both hypothermic induced prearrest 
myocardial contraction which is harmful (Rl2) and coronary vasoconstriction (B63,S79), 
and has also been shown to be beneficial in kidney preservation (C32). However, 
procaine has also been shown to be injurious to the endothelium (S60), and hinders the 
permeation of H + and lactate ions thus reducing the effectiveness of potential buffers 
(B62). Nevertheless, residual postischaemic amounts of procaine or lignocaine can also 
help prevent arrhythmias during reperfusion (H24)_ 
The StThomas' cardioplegic solutions No 1 & No 2 
The StThomas' Hospital No 1 cardioplegic solution (MacCarthy solution; Table 3.3) is 
available commercially as a concentrated ampoule that is added to standard nonlactated 
Ringer's solution (Cardioplegic solution 20 ml: John Bell & Croyden; London, United 
Kingdom). Whereas, the superior StThomas' No 2 cardioplegic solution is also available 
commercially (Plegisol: Abbott Laboratories; North Chicago, Illinois, USA) and in South 
Africa (StThomas' Hospital Cardioplegic Solution: Sabax Ltd; Aeroton, Johannesburg). 
Both of these commercial StThomas' No 2 cardioplegic solutions require 10 m18.5% 
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sodium bicarbonate (10 mmol) to be added to each liter prior to use. The sodium 
bicarbonate is not included in the initial formulation because of stability and shelf 
storage reasons. 
The efficacy of the St Thomas' cardioplegic solution is primarily due to its 
concentrations of potassium and magnesium (J19) and the effectiveness of the St 
Thomas' cardioplegic solution is independent of temperature and infusion volume 
(C20,J21), although enhanced by hypothermia. Furthermore, as extremes in electrolyte 
concentrations are avoided (J23), equilibration is simpler (Hl4) and its effectiveness is 
not diminished as much by noncoronary collateral flow compared to other cardioplegic 
solutions (W7). Therefore, it is an ideal crystalloid cardioplegic solution for clinical 
open-heart surgical procedures. Furthermore, the St Thomas' No 2 cardioplegic 
solution has been shown to provide both superior myocardial protection (L26), and be 
less cytotoxic than the StThomas' No 1 cardioplegic solution (C4). 
Bretschneider cardioplegic solution 
The Bretschneider cardioplegic solutions can be classified as intracellular electrolyte 
equivalent solutions (H 16), and Bretschneider HTK4 should be considered the "gold 
standard" of sodium-poor cardioplegic solutions (Table 3.4 ). The composition of the 
Bretschneider cardioplegic solutions has been progressively altered on the basis of 
experimental data. However, the Bretschneider cardioplegic solution was originally 
designed to arrest the heart by markedly diminishing the extracellular sodium 
concentration (Bretschneider No 3) (B63). A low extracellular sodium concentration 
that approximates that of the intracellular compartment prevents the genesis of an 
action potential (B63)_ Procaine was initially included in these solutions, to inhibit the 
hypothermic induced contraction that occurs when suddenly infusing a cold solution into 
the heart (B63), however, procaine hinders the permeation of H + and therefore reduces 
the effectiveness of potential buffers (B62). Histidine which is a powerful physiologic 
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buffer was then added to the solution in order to artificially double the buffering 
capacity of the myocardium (G 10), and thereby delay acidosis and ATP breakdown by 
allowing ongoing anaerobic metabolism. The buffering capacity of homogenized 
• 
ventricular myocardium is 40 mmol HCIIL/ o pH (K34), and the buffer capacity of 
Bretschneider HTK4 cardioplegia is more than double this value; 100 mmol/L/ o pH 
(appendix B-5). 
Table 3.4 
BRETSCHNEIDER CARDIOPLEGIC SOLUTIONS 
Bretschneider Bretschneider Bretschneider 
(uol/L) 110 3 (J22,S63) -HTK (1980) (Gll) -HTK4 (1984) (Gll) 
lla+ 12 15 15 
K+ 10 10 10 
Mg2+ 2 8 4 
cr 26 46 51 
Procaine-HCl 7.4 - -
Mannitol 239 20 30 
Histidine - 195 198 
Tryptophan - 2 2 
KH-2-oxygluterate - - 1 
' 
Os1olality 
(mOsmfkg H20) 320 300. 298 
pH (25°C) 5.5- 7.0 7.2 7.1 
The Bretschneider cardioplegic solution contains a low concentration of sodium and 
therefore must be calcium-free (extracellular calcium less than 0.01 mmol/L (G 10)) in 
order to be effective (Hl4), as intracellular calcium influx is promoted by a low sodium 
concentration (Ll2). The addition of as little as 0.024 mmol/L of calcium reduces the 
protective effect of Bretschneider cardioplegia ( G 10,1 19). The presence of calcium in a 
sodium-free solution was the probable cause of the intramitochondrial occlusions 
observed by Kyosola et al in Helsinki, with their cardioplegic solution (K46). However, 
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a calcium-free solution in turn predisposes the heart to the calcium paradox (discussed 
above). 
Bretschneider HTK or St Thomas'? 
The Bretschneider cardioplegic solution should only be used under well controlled 
constant hypothermic conditions (J22), as temperatures below 27°C prevent the calcium 
paradox from occurring (RlO)_ Experimental comparisons to determine the superiority 
between Bretschneider and St Thomas' cardioplegic solutions under normothermic 
conditions are therefore invalid (J21,Kll)_ In hypothermic canine models, 
Bretschneider HTK provides better myocardial protection than the St Thomas' 
cardioplegic solution (S25,W7)_ However, in the isolated rat heart model StThomas' 
cardioplegia is associated with superior hypothermic preservation compared to the 
Bretschneider No 3 solution (admittedly less efficacious than the latest Bretschneider 
HTK4 solution) (119,122)_ 
We compared Bretschneider HTK4 and a modified StThomas' plus glucose (10 
mmol!L) cardioplegic solution in the isolated rat heart model (appendix B-5)_ 
Postischaemic mechanical recovery was similar in both groups, but Bretschneider HTK4 
was associated with lower A TP 'content at the end of the ischaemic period and greater 
sarcolemmal damage. The recommended high volume induction dose for Bretschneider 
HTK4 cardioplegia (P28) was used in this study, and although the recommended dose 
forSt Thomas' cardioplegia is lower than that used in this study, high volumes of St 
Thomas' cardioplegic solution are not detrimental (T9)_ Furthermore, as a single dose 
cardioplegic infusion was used in this model (appendix B-5), the inclusion of glucose in 
the St Thomas' cardioplegic solution might have decreased recovery in the St Thomas' 
group ·(see section 5.1). Other studies using isolated rat hearts have also shown 
Bretschneider HTK to be inferior to extracellular electrolyte equivalent cardioplegic 
solutions (H32,J20,J22)_ Nevertheless, the suitability of using calcium-free infusates in 
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the isolated rat heart model has been questioned (W7), as canine studies have shown 
excellent protection with Bretschneider HTK (S25,W7). 
Schnabel and co-workers demonstrated that Bretschneider HTK4 retards A TP decay 
twice as much as a modified StThomas' cardioplegic solution (B62,S25). However, in 
our study Bretschneider HTK4 was associated with increased A TP decay. Differences in 
susceptibility to ischaemic injury and responsiveness to myocardial protection exist 
between species, and it is possible that this could account for some of the discrepancies 
between these studies ( G 1 )_ Nevertheless, although smaller animals have a higher 
oxidative capacity (B3l), it is not yet known which species is most representative of man. 
Bretschneider HTK cardioplegia produces acceptable clinical results equivalent to the St 
Thomas' cardioplegic solution (S20), especially if combined with topical hypothermia 
(S68). However, the myocardium should not be exposed to Bretschneider HTK at or 
near normothermia because of the potential for the calcium paradox. Bretschneider 
cardioplegia also requires a more complex and prolonged method of administration; 
precooling of the heart with a mixture of blood and glucose (B63,S63), thereafter 
infusion of cold (5°C - 10°C) oxygenated Bretschneider for 8 - 10 min, initially at 80-
100 mm Hg, then 40 - 50 mm Hg to ensure full equilibration (P27), with an initial total 
tnfused volume of3- 41iters (P28) (7- 10 mllgm heart weight (P27)). Furthermore, 
during clinical open-heart surgery conditions are often "uncontrolled", because of 
constant and occasionally rapid rewarming of the myocardium from the surgical 
environment and noncoronary collateral flow. Warnecke et al showed that noncoronary 
collateral flow decreases the efficacy of the Bretschneider solution, but improves 
postischaemic recovery with the StThomas' Hospital No 1 cardioplegic solution (W8). 
Multidose reinfusions of Bretschneider cardioplegia also diminish its efficacy, although 
this has possibly been corrected by lowering the magnesium concentration in 
Bretschneider HTK4 (GlO,Gll). Nevertheless, in controlled isolated hypothermic 
conditions Bretschneider HTK4 cardioplegia is associated with superior preservation of 
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adenosine triphosphate, thus it may be the more "ideal" solution for preservation of the 
isolated heart for transplantation, as opposed to routine clinical open-heart surgery. 
f. 
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3.2 BLOOD CARDIOPLEGIA 
There are certain theoretical advantages for blood as the vehicle for delivery of 
cardioplegic solutions (B70,13,Wl2):-
The heart is kept oxygenated while it is being arrested, 
Oxygen and other substrates are resupplied with each reinfusion thus allowing 
intermittent aerobic metabolism, 
Improved buffering capacity (W9), 
Improved oncotic properties, 
Free radical scavenging properties (V 1), 
Rheological influences; in the absence of particulate matter (red blood cells), 
flow occurs primarily in arteriovenous capillaries and there is restricted flow 
in true capillaries (Z7). 
A number of experimental and clinical studies have shown blood cardioplegia to be 
superior to crystalloid cardioplegic solutions (B73,C8,Cl7,C30,E12,F28,I4,S50). 
Unfortunately, the majority of these studies compared blood cardioplegia to inferior 
crystalloid cardioplegic solutions by today's standards (C8,Cl7,E12,F28,I4,S50). 
Moreover, few comparisons have been done between blood cardioplegia and oxygenated 
crystalloid cardioplegic solutions. Both blood (haematocrit; 10% - 20%) and oxygenated 
crystalloid cardioplegic solutions maybe equally effective (R48), and crystalloid possibly 
superior at low temperatures (M5). Nevertheless, the salutary effects of blood 
cardioplegia are not solely reliant on its oxygen carrying capacity (B71), but also other 
biochemical properties of the red cell membrane (B29,13,S79)_ Blood also ·has a much 
higher buffering capacity than the majority of crystalloid cardioplegic solutions (W9), 
and erythrocytes can decrease free radical mediated damage as they contain significant 
quantities of free radical scavengers (Vl) and can also take up and remove hypoxanthine 
(B26). Furthermore, although Weisel et al showed incomplete preservation of ATP with 
blood cardioplegia clinically (Wl5), other studies have shown almost complete . 
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preservation of myocardial ATP (C8,E12) and possibly better cellular protection 
compared to the StThomas' cardioplegic solution (C30)_ 
The "gold standard" for blood cardioplegia should probably be the solution developed by 
G D Buckberg and colleagues (Table 3.5) (B70,F26), even though there have been very 
few comparisons between different blood cardioplegic compositions. 
Table 3.5 
CONCENTRATE FOR4:1 BLOOD CARDIOPLEGIA 
Additive 
THAH (300 mmoljL) 
CPD 
5% Dextrose in 
1/4 N Saline 
KCl (2 mmoljml) 
Legend: 
COLD INDUCTION 
Volwae ('11.) Delivered concentration 
200 pH 7.7- 7.8 
50 ca++ 0.5 - 0.6 mmol/L 
Glucose : ± 43 mmol/L 
550 Osm : ± 350 mOsm/kg H2o 
30 K+ 18 - 20 mmol/L 
Infused at4°C- 8°C, at a rate of300- 350 ml/min antegrade for2 min, then 200-250 ml/min retrograde for2 min. CPD: Citrate 
phosphate dextrose. Modified from Buckberg G D, J Cardiac Surg 1989; 4:216-238 (B70). 
Additive 
THAH (300 mmol/L) 
CPD 
5% Dextrose in 
1/4 N Saline 
KCl (2 mmoljml) 
Legend: 
MULTIDOSE 
CARDIOPLEGIA 
VolUJle (11) Delivered concentration 
200 pH 7.7- 7.8 
50 ca++ 0.5 - 0.6 mmol/L 
Glucose : ± 43 mmol/L 
550 Osm : ± 350 mOsm/kg H2o 
10 K+ 8 - 10 mmol/L 
Infused at40C- 80C, at a rate of200 ml/min antegrade for I min, retrograde for I min, at approximately20 min intervals. CPO: 
Citrate phosphate dextrose. Modified from Buckberg G D, J Cardiac Surg 1989; 4:216-238 (B70). 
Blood cardioplegia should be dilute in order to prevent increased viscosity with 
hypothermia, whiCh could be harmful (see section 1.4). Therefore, blood cardioplegia is 
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usually delivered in either a 2:1 or 4:1 ratio (blood: crystalloid concentrate). In addition, 
haemodilution of the systemic perfusate is usually the norm during hypothermic 
cardiopulmonary bypass (see section 1.4). The cardioplegic delivery system for clinical 
use of blood cardioplegia, although more costly than that required for crystalloid, has 
also now been simplified (B70). 
Blood cardioplegia provides excellent left ventricular protection, but right ventricular 
protection is reported to be superior with crystalloid cardioplegia (M62). The anterior 
situated right ventricle is much more dependant on adequate hypothermia (G24), and 
the colder delivery temperatures of crystalloid cardioplegia produce consistently colder 
right ventricular myocardial temperatures (M62). Blood cardioplegia is also associated 
with more postoperative conduction disturbances ( G42), and is probably contraindicated 
if cold-reacting autoantibodies are present (H46). However, modified blood 
cardioplegic solutions can be used for normothermic "resuscitation" of energy depleted 
hearts (Table 1.12) (R43,R44), and as the basic composition for reperfusion solutions 
(Table 1.13) (see section 1.6) (B70). 
Nonetheless, blood cardioplegia is the least temperature dependant solution should 
myocardial rewarming occur during clinical open-heart surgery (Wl2). A properly 
formulated blood cardioplegic solution probably provides better overall myocardial 
protection than crystalloid solutions today, especially if ischaemic periods are prolonged 
(Hl6). 
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3.3 PRESERVATION OF THE HEART FOR TRANSPLANTATION 
The principals for protecting the myocardium during clinical open-heart surgery, also 
apply to preservation of the heart for transplantation. However, the surrounding 
environment can be much better controlled when preserving the isolated heart:-
- Low (4°C) temperatures are easily maintained, 
- There is no washout by noncoronary collateral blood flow, 
- Hearts for transplantation are usually "healthy normal" hearts, free of 
coronary artery stenoses. · 
Donor hearts 
Donor hearts are usually free of organic disease. However, donor hearts can incur 
damage as a result of endogenous catecholamine release at the time of brain death, 
which can cause myocardial calcium uptake and myocyte necrosis (N15,Nl6)_ Brain 
ischaemia and death deplete myocardial A TP and glycogen stores, and decreases 
myocardial function (W22)_ These metabolic changes are possibly related to reductions 
in circulating insulin, cortisol, triiodothyronine and thyroxine levels (Nl4)_ Hence, , 
donor hearts may not be entirely "normal", and may benefit from normothermic 
cardioplegic arrest with a substrate-enriched blood cardioplegic solution prior to 
hypothermic storage (Tl9)_ 
Heart storage for transplantation 
The majority of clinical transplantation programs transport and store the donor heart by 
simple hypothermic storage. Furthermore, the preservation solution for storage of the 
heart is usually the standard cardioplegic solution used at that institution. However, this 
policy should probably be reevaluated, because of the differences between isolated 
organ storage and clinical open-heart surgery. In clinical practise, hypothermic storage 
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of the donor heart is usually limited to less than 4 - 6 hours, because the heart must be 
able to support the entire circulation at the end of the surgical procedure. However, 
experimental hypothermic heart storage possibly has an upper limit of approximately 18 
hours, in terms of energy stores (Til). In contrast, continuous hypothermic perfusion 
storage methods can maintain myocardial energy stores for more prolonged periods, but 
involve more complex systems and can also be damaging (Tll). Alternative methods 
such as supercooling, freezing, and hyperbaric oxygenation have been tried 
experimentally, but are not used clinically (C37). 
Isolated hypothermic storage 
During isolated hypothermic organ storage, there is no continued supply of substrates or 
washout of metabolic end-products in order to allow ongoing energy production. 
Therefore, ionic pumps eventually cease to function and passive diffusion of electrolytes 
will occur. Furthermore, severe ·hypothermia (less than 4°C- 10°C) suppresses the 
activity of the N a+ I K + pump (M 15,M26), and this may also alter intracellular 
homeostasis. 
Intracellular electrolyte equivalent solutions, by attempting to abolish all ionic gradients, 
further reduce metabolic requirements and maintain intracellular ionic homeostasis 
(Rl7). These intracellular solutions were originally designed and used to store kidneys 
for up to 30 hours (C32). Nevertheless, Reitz et al were able to obtain survival of 
orthotopic transplanted hearts following 18-26 hour storage of donor canine hearts with 
both the Collins and Sacks solutions (Table 3.6) (Rl7). These results could be 
reproduced by other investigators using modifications of these solutions (S92,Tl5), and 
hypocalcaemic reperfusion solutions improved survival further (D8,S92). 
The primary factors that have improved the efficacy of renal preservation solutions are 
thought to be high osmolality (400 mOsm/kg H20), impermeate solutes but preferably 
not glucose (A24), and replacement of chloride by impermeate anions (G30). This was 
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partly the basis for the composition of the solution formulated for pancreatic, hepatic 
and renal preservation by Belzer and co-workers: UW-CSS; University of Wisconsin 
Cold Storage Solution (1_'23,W3)_ Adenosine and free radical scavengers were also 
considered essential (S65)_ 
(IDOl/L) 
Na+ 
K+ 
Mg2+ 
HCO-3 
Cl-
so 2-4 
PO 3-4 
Glucose 
Mannitol 
Lactobionate 
Raffinose 
Adenosine 
Glutathione 
Allopurinol 
Pentastarch ( gm/L) 
Dexamethasone (mg/L) 
Insulin (U/L) 
Bactri• (11/L) 
Osmolality 
(J.Os:afkg H20) 
pH 
Table 3.6 
INTRACELLULAR STORAGE SOLUTIONS 
Collins Sacks Stanford 
_ c (C32) 
2 
(S1) Univ. Sol. (595) 
10 14 20 
115 126 27 
30 8 -
10 . 20 20 
15 16 27 
30 - -
57.5 60 -
139 - 255 
-
206 63 
. 
-
- -
-
- -
-
- -
- -
-
-
- -
-
- -
-
- -
-
- -
-
- -
300 430 > 400 
7.0 7.0 -
(25°C) (2°C) -
Belzer 
uw-css ( W3) 
30 
125 
5 
-
-
-
25 
-
-
100 
30 
5 
3 
1 
50 
8 
100 
0.5 
320 
7.4 
(25°C) 
Preservation of the heart has also been improved by hyperosmolarity (D8) and addition 
of colloid oncotic pressure to the preservation solution (D8,T2l)_ In addition, 
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preservation might be more optimal if the myocardium is first arrested with an 
extracellular electrolyte equivalent cardioplegic solution, and then flushed and stored in 
an intracellular electrolyte equivalent solution (K27). The "intracellular" Bretschneider 
HTK cardioplegic solution maintains pH, and delays A TP decay more than the 
"extracellular" StThomas' Hospital No 1 cardioplegic solution (E15). However, glucose 
containing but better buffered "extracellular" cardioplegic solutions might provide even 
better protection at 0°C (E15). The UW-CSS solution provides superior experimental 
storage of hearts when compared to Bretschneider (010), StThomas' (W24,Y3), 
Stanford (S95,W24) or modified Collins (S95) solutions, and this might be due to its 
reported superior preservation of the endothelium ( C 1). 
Nevertheless, the majority of clinical transplant centers presently use either the Stanford 
University solution or other extracellularbas;d formulations (G26). 
Continuous organ perfusion 
Continuous perfusion of the isolated heart is technically more difficult, than isolated 
hypothermic storage. In addition, although it is associated with superior preservation of 
high energy phosphates, the perfusate can cause myocardial damage (Tll). Continuous 
hypothermic perfusion with oxygenated Bretschneider HTK (F19), and other perfusates 
has allowed successful experimental transplantation after 24 hour (K17,M40,W21,W22) 
and 48 hour storage (W25,W26), and has also been used for clinical heart transplantation 
(W23)_ Low perfusion pressures (8- 12 em H20) must be used to prevent myocardial 
oedema, the maximum pressure being 20 em H20, and colloid is an essential component 
of the perfusate if this method is used (K17). Continuous perfusion of the beating heart 
at or near normothermia with modified blood perfusates, has also allowed experimental 
storage of hearts for 12-24 hours (C22,S61). 
Nevertheless, continuous perfusion systems for storage of hearts are not widely accepted 
clinically, primarily because of a concern that any inadvertent technical mishap could 
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result in unnoticed loss of protection. The transplanted heart must be capable of full 
function immediately after insertion into the recipient (C37), and therefore a method of 
assessing viability such as quantitative birefringence (D6) or intramyocardial pH 
(Kl4,T6) would probably be essential if these more complicated systems are to be used. 
The ideal technique for storage of the donor transplant heart has not yet been 
determined, despite a large number of experiments. Simple hypothermic storage with an 
extracellular electrolyte equivalent cardioplegic solution remains the most widely used 
clinically method, at present However, attention should also be direCted to the 
preharvesting management of potential donor hearts, the initial solution used to arrest 
the heart while at normothermia, hypothermic storage and transport solution (H33), 
storage temperature (7.5°C- 10°C) (H34,R38,T7,T8,T28), the reinfusion of cardioplegic 
solution during implantation (S93), and the use of a reperfusion solution 
(B72,D8,M46,S92)_ 
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4 
MYOCARDIAL PROTECTION IN SOUTH AFRICA 
Cardiac Surgery in South Africa 
The population of South Africa in 1991 was 26.5 million people, made up of 10 separate 
ethnic groups (S69)_ However, only 7.1 million of the population are covered by medical 
aid health schemes, and hence can afford private medical care (Fig 4.1) (A27)_ 
Figure 4.1 
Population of South Africa 1991 
26 504 191 
§ Not economically active 
58% 
73.1% 
Provincial Hospitals - 9 
Cardiac Surgeons - 20 
Legend: 
• Economically active 
42% 
Covered 
by 
Medical 
Aid 
26.9% 
Private Hospitals - 14 
Cardiac Surgeons -27 
The percentage of the population treated in either provincial or private hospitals, and the total number of cardiac surgeons in 
South Mrica are shown. The 1986 statisti~ for the economically active population · 42% (S64) were extrapolated onto the 
provisiona11991 population census figures (S69). Furthermore, the assumption was that 50% of dependants on medical aid 
schemes (A27) were also economically active. 
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The health care of the remaining 73.1 % of the population is provided by provincial 
government funded hospitals, consisting of both academic hospitals with attached 
University administered medical schools and non-academic hospitals. 
Cardiac surgery is performed in 9 provincial and 14 private hospitals in South Africa in 
1991, and an estimated 7 000 open-heart surgical procedures are performed annually. 
Twenty percent of the total deaths in South Africa in 1988 ( ± 7. 9 deaths I 1000 
population) were due to diseases of the circulatory system, a third of which were 
classified as either ischaemic or rheumatic heart disease (S64)_ However, ischaemic 
heart disease was the cause of 14.8% of the deaths in the more affluent population 
groups, as apposed to 0. 8% in the remainder of the population. Hence, ischaemic heart 
disease surgery is the predominant type of cardiac surgery performed in the private 
sector. Whereas, in the provincial hospitals more rheumatic valvular, congenital and 
traumatic induced cardiac surgical procedures are performed, in addition to all 
postgraduate training. Applied research is also only undertaken at the government 
supported provincial hospitals attached to universities. 
Cardioplegic solutions used in South Africa: 1988 
A survey of the type of cardioplegic solutions used in South Africa was obtained in 1988, 
and revealed that approximately 70% of hospitals performing cardiac surgery in South 
Africa were using crystalloid cardioplegic solutions, and the remainder various 2: 1 blood 
cardioplegic formulations (see Appendix A-1). Neither retrograde cardioplegia, 
. normothermic induction, nor reperfusion cardioplegic solutions were used. At Groote 
Schuur Hospital we had recently changed to the StThomas' Hospital No 2 cardioplegic 
solution (Table 3.3), and were the only unit using this cardioplegic solution at that time. 
Published objective evaluations, either experimentally or dinica:Uy, of the crystalloid 
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cardioplegic solutions being used in the remainder of the country have never been 
reported (Table 4.1). 
Table 4.1 
CRYSTALLOID CARDIOPLEGIC SOLUTIONS: 
SOUTH AFRICA- 1987 
uolfL SABA X GSH PB-1 PB-2 
Ha+ 141 15 130 140 
K+ 24 I 12 20 34 34 
HCO- 38 15 27 37 3 
ca2+ 0.9 1.0 - -
Mg2+ 1.5 12 1.5 1.5 
cr 119 46 140 140 
Glucose 51 240 - 56 
Mannitol 68 14 - -
Os1olality 416 350 302 357 
(J0s1jkg H20) 
pH 7.7 7.6 7.7 7.8 
Legend: 
SABAX; commercial cardioplegic solution available from Sabax Ltd. A high potassium solution is used for induction of 
cardioplegic arrest and a second low potassium solution for all subsequent multidoses. GSH; cardioplegic solution previous
ly 
used at Groote Schuur Hospital PB-; cardioplegic solutions made up by adding potassium and glucose to aliter ofPiasmal
yte B 
intravenous electrolyte solution. 
We evaluated both the SABAX and GSH cardioplegic solutions in the in vivo primate 
model, and compared them to the StThomas' Hospital No 2 cardioplegic solution (see 
Appendix A-1). Postischaemic haemodynamic recovery was superior with the St 
Thomas' Hospital No 2 cardioplegic solution, although no differences in high energy 
phosphate content could be demonstrated between the different cardioplegic solutions. 
In a separate study these cardioplegic solutions (SABAX, StThomas', PB-1, PB-2) were 
exposed to monolayer.cultures of human venous endothelial cells at room temperature 
(220C) for 12 hours, as described in Chapter 2 (see Appendix A-5). This temperature 
was selected for this study, as intraoperatively the temperature of the myocardium 
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usually varies from 15°C to 20°C (D3) and the major beneficial effect of hypothermia 
occurs below 28°C (Fl8,H24)_ Adequate post-exposure endothelial cell survival was 
only obtained with the StThomas' No 2 and Bretschneider HTK4 cardioplegic solutions 
(Fig 4.2). All other crystalloid cardioplegic solutions used in South Africa resulted in 
loss of adherence, disruption, and cell death of the endothelial cells. 
Figure 4.2 
ENDOTHELIAL CELL SURVIVAL 
20% 
+ + + + 
PB-1 PB-2 SBX ST+G ST B-HTK4 
Legend: 
Endothelial cell survival24 hours and 36 hours after a 12-hour exposure to cardioplegic solutions at 22°C. ST, StThomas' 
Hospital No 2 cardioplegic solution with or without glucose (G; 10 mmol/L); B-HTK4, Bretschneider HTK4 cardioplegic 
solution; SBX, Sabax cardioplegic solution; PB-, cardioplegic solutions formulated by adding glucose and potassium chloride to a 
balanced intravenous electrolyte solution Plasmalyte.B. Means and standard errors of means are presented. 
+- p < 0.001 compared to the respective ST or B-HTK4 time period. 
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Plasmalyte B cardioplegic solutions 
Plasmalyte B cardioplegic formulations were cytotoxic in the endothelial cell model. 
This cytotoxicity was shown to be due to these solutions being calcium-free and having 
excessively high potassium concentrations (appendix A-5). One cardiothoracic unit in 
South Africa had modified the PB-1 solution by adding 200 ml pump blood; that is dilute 
blood cardioplegia as proposed by Daggett et al (D2,H31), and this unit had subjectively 
observed improved recovery (personal communication). However, this was probably as 
a result of the addition of trace amounts of calcium to a calcium-free solution (H29), 
although red blood cells do provide other beneficial factors (B29,13,S79,Z7). The 
dangers and limitations of a calcium-free solution, specifically with regard to the calcium 
paradox, have already been discussed in Section 3.1 (H19,J20,R55). Furthermore, 
Plasmalyte B cardioplegic formulations with additional calcium have also been shown to 
be inferior to the StThomas' Hospital No 2 cardioplegic solution (L41). 
In addition, these Plasmalyte B formulations contain excessively high potassium 
concentrations which shift the resting membrane potential into the range where calcium 
channels are opened ( 0 17), and this potassium content is well above the optimal 
potassium concentration for extracellular electrolyte equivalent cardioplegic solutions 
(see section 3.1) (R51). In addition, the magnesium content of these Plasmalyte B 
cardioplegic solutions is well below the optimal concentration of this important cation in 
cardioplegic solutions (see section 3.1) (H28,Rl8). 
We did not evaluate the Plasmalyte B cardioplegic solutions in either the isolated rat 
heart or in vivo primate model_s, however, both our endothelial study and literature 
review support the conclusion that the Plasmalyte B cardioplegic solutions used in South 
Africa (Table 4.1) are both potentially harmful and less efficacious than the StThomas' 
Hospital No 2 cardioplegic solution. 
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SABAX cardioplegic solution 
In the in vivo primate model the StThomas' Hospital No 2 cardioplegic solution 
provided better myocardial protection and superior postischaemic haemodynamic 
recovery than the SABAX cardioplegic solution (appendix A-1). The SABAX 
cardioplegic solution (Table 4.1) has a high potassium concentration (24 mmol/L) for 
induction of cardioplegic arrest and then a lower concentration (12 mmol/L) for all 
multidose reinfusions of cardioplegia, which is theoretically beneficial (B74 ). 
Nevertheless, the multidose SABAX cardioplegic solution with the lower concentration 
of potassium was evaluated in the endothelial cell model, and found to be cytotoxic to 
the endothelium (appendix A-5). This endothelial cytotoxicity was thought to be due to 
the low concentration of magnesium, which is well below the optimal concentration 
recommended for crystalloid cardioplegic solutions (H28,Rl8). Furthermore, the 
concentration of both mannitol and glucose contained in this cardioplegic solution has 
been shown to be harmful in crystalloid solutions (H27,appendix A-2), although we were 
unable to demonstrate a deleterious effect of high glucose (50 mmol/L) in our 
endothelial model (appendix A-5). 
The SABAX cardioplegic solution is also hyperosmolal, and although hyperosmolality 
has been shown to be beneficial during reperfusion of the postischaemic myocardium 
(Sl9), excessive hyperosmolality is not beneficial in cardioplegic solutions (H27) and 
should probably never exceed 400 mOsm/kg H2o (A24,W28). Although we did not add 
methylprednisolone to the SABAX solution we evaluated as practised by some units in 
South Africa (personal communication), steroids have not been shown to be beneficial 
in cardioplegic solutions (K23). 
The SABAX cardioplegic solution is therefore both potentially harmful and less 
efficacious than the StThomas~ Hospital No 2 cardioplegic solution. 
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GSH cardioplegic solution 
In the in vivo primate model, the GSH cardioplegic solution provided "myocardial 
protection" that was no better than a "non-cardioplegic" solution (standard Krebs-
Henseleit buffer) (appendix A-1)_ The GSH cardioplegic solution was not evaluated in 
the endothelial cell model. 
This cardioplegic solution previously used at Groote Schuur Hospital, is a prime 
example of the dangers of" adding a bit of this and a bit of that" without understanding 
the important inter-relationship of the different ionic components. GSH cardioplegic 
solution was originally based on the eatly Bretschneider cardioplegic formulations 
(Table 3.4), but was then progressively altered. Calcium and magnesium where added to 
the original formulation, presumably because of concern for the calcium paradox 
subsequent to perfusion with calcium-free solutions (H19,120), and reported beneficial 
effect of the cation magnesium (H28)_ The basic premise that a cardioplegic solution 
with a low sodium content must be calcium-free (G 10) was not taken into account (see 
section 3.1 ). This "modified" cardioplegic solution was then used clinically, despite no 
experimental or clinical evaluations of this specific formulation. 
The GSH cardioplegic solution is an extremely poor formulation for a cardioplegic 
solution, and is no better than a hypothermic buffered physiological saline soluti.on. 
Other crystalloid cardioplegic solutions used in South Africa 
All questionnaires in the 1988 survey of cardioplegic solutions used in South Africa were 
not returned. Nevertheless, one other additional cardioplegic solution is being used in 
South Africa; the StThomas~ Hospital No 1 cardioplegic solution (Table 3.3). 
The StThomas' Hospital No 2 cardioplegic solution provides better myocardial 
protection than the StThomas' No 1 cardioplegic solution (L26). Furthermore, I doubt 
whether in South Africa the imported "MacCarthy ampoule" (Cardioplegic solution 20 
ml: John Bell & Croyden; London, United Kingdom) has even been used to formulate 
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the correct St Thomas' No 1 solution. This ampoule of potassium, magnesium and 
procaine (Table 3.3) should be added to Ringer's solution (L26); a balanced electrolyte 
solution which is not freely available in South Africa. The addition of the "MacCarthy 
ampoule" to other balanced electrolyte solutions (Ringer's lactate, Plasmalyte B) would 
not result in the correct formulation of the StThomas' No 1 cardioplegic solution (Table 
4.2). 
Table 4.2 
STTHOMAS~ HOSPITAL NO 1 CARDIOPLEGIC SOLUTION 
St Thomas' MacCarthy Ringer's Ringer's Plasmalyte B 
uol/L No 1 Alpoule Solution Lactate 
Na+ 144 - 144 131 130 
K+ 20 16 4 5.4 4 
HCO- - - - - 27 3 
ca2+ 2.4 - 2.4 2.0 -
Mg2+ 16 16 - - 1.5 
Cl- 201.8 49 152.8 111 110 
Procaine 1.0 1.0 - - -
Lactate - - - 29 -
Legend: 
The StThomas' Hospital No I cardioplegic solution is made up by adding the MacCarthy ampoule to Ringer's solution. 
Moreover, the MacCarthy ampoule is not registered with the Medical Control Council 
of South Africa and thus the commercial sale and use. of this cardioplegic ampoule is at 
present illegal in South Africa (personal communication). 
The addition of the MacCarthy ampoule to Ringer's lactate, although approximating the 
StThomas' No 1 formulation, will thus contain the anion lactate. Lactate may be 
harmful during global ischaemia, although lactate possibly does not enhance damage 
during normothermic ischaemia (G14), and may be beneficial in the prime solution of 
the cardiopulmonary bypass circuit (T-19). Nevertheless, lactate ions can induce 
morphological mitochondrial changes (A29), and there is thus a potential danger of 
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including lactate in crystalloid cardioplegic solutions (H26). Lactate containing 
cardioplegic solutions provide inferior myocardial protection compared to the St 
Thomas' Hospital No 2 cardioplegic solution (R29). 
The addition of the MacCarthy ampoule to the Plasmalyte B electrolyte solution would 
result in a calcium-free cardioplegic solution, the dangers of which have already been 
discussed (see section 3.1) (H19,J20,R55). 
In conclusion, the best crystalloid cardioplegic solution presently available in South 
Africa is the StThomas' Hospital No 2 cardioplegic solution (StThomas' Hospital 
Cardioplegic Solution: Sabax Ltd, Johannesburg:- 10 ml8.5% sodium bicarbonate (10 
mmol) must be added to each vacoliter before use, as sodium bicarbonate is not inCluded 
in the vacoliter because of stability and shelf storage considerations). 
Myocardial protection in South Africa: 1991 
Another questionnaire regarding techniques of myocardial protection, was forwarded to · 
all cardiac surgeons in South Africa in 1991; 80% of questionnaires were returned. The 
approximate distribution of open-heart surgical procedures presently performed in 
South Africa is shown in Table 4.3. 
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Table4.3 
DISTRIBUTION OF OPEN-HEART SURGICAL PROCEDURES 
Provincial Hospitals 
± 270 I month 
55% 
26% 
16% 
< 2% 
< 1% 
Legend: 
Procedures 
Valvular heart surgery 
CABG 
Congenital heart surgery 
Transplantation 
Arrhythmia heart surgery 
Private Hospitals 
± 400 I month 
23% 
63% 
14% 
The estimated number and type of open-heart surgical procedures presently being performed in South Africa is shown. CABG-
coronary artery bypass grafting. 
Cardioplegic solutions: 1991 
The majority of cardiac surgeons in the provincial hospitals now use the StThomas' 
Hospital No 2 cardioplegic solution (Table 4.4). 
Table 4.4 
CARDIOPLEGIC SOLUTIONS USED IN SOUTH AFRICA: 1991 
Provincial Surgeons 
(N = 20) 
16 
3 
1 
Cardioplegic Solution 
st Thomas' No 2 cardioplegic solution 
Blood Cardioplegic solutions 
other crystalloid cardioplegic solutions 
Private SUrgeons 
(N = 27) 
4 
6 
17 
Clinical use of the StThomas~ Hospital No 2 cardioplegic solution 
The subjective clinical experience of cardiac surgeons using the StThomas' Hospital No 
2 cardioplegic solution has been variable. Most surgeons reported good results with this 
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cardioplegic solution. However, criticisms about the StThomas' Hospital No 2 
cardioplegic solution put forward are: 
i) A high incidence of the occurrence of ventricular fibrillation and therefore the 
need for defibrillation following the release of the aortic cross-clamp. 
ii) Resumption of electrical activity within 15 - 20 min of cardioplegic arrest 
This was in contrast to the experience of surgeons using the StThomas' Hospital No 1 
cardioplegic solution, who reportedly rarely need to use defibrillation. 
The StThomas' No 1 cardioplegic solution contains the local anaesthetic and 
antiarrhythmic agent procaine-HCl (1 mmol/L), which additionally has a prolonged 
duration of action, and its use is associated with prolonged asystole during reperfusion of 
the postischaemic myocardium Nevertheless, the incidence of spontaneous normal 
sinus rhythm, following the use of the StThomas' No 2 cardioplegic solution and release 
of the aortic cross-clamp, can be increased by the addition of lignocaine or procaine to 
this solution as well. The recommended dose of lignocaine or procaine that can be 
added to the StThomas' No 2 cardioplegic solution is 0.05 mmol/L (H22) (0.72 nil/L of 
2% lignocaine-HCl for intraveiwus use; 14.4 mg/L: see section 3.1). This amount of 
lignocaine or procaine was recommended as a result of a dose response curve for 
postischaemic myocardial recovery performed on isolated rat hearts. However, it is 
possible that a greater amount oflignocaine or procaine (similar to that used in the St 
Thomas' No 1 cardioplegic solution) may be necessary, for the prevention of ventricular 
fibrillation during the reperfusion of the postischaemic human myocardium. A dose of 
lignocaine in the St Thomas' No 2 cardioplegic solution of 0. 7 mmo1/L ( 10 ml2% 
lignocaine-HCl; 200 mg/L) is being used by two cardiac surgeons, who report that the 
majority of their patients return spontaneously to normal sinus rhythm after a period of 
asystole following the release of the aortic cross-clamp. However, caution should be 
taken as to the total dose of cardioplegic solution administered if this amount of 
lignocaine is used in order to prevent possible lignocaine toxicity. Therefore, we will be 
shortly commencing a clinical trial of the addition of different doses of lignocaine to the 
St Thomas' No 2 cardioplegic solution. 
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Two cardiac surgeons reported early resumption of electrical activity with the use of the 
StThomas' No 2 cardioplegic solution. However, this is not the experience ofthe 
majority of surgeons using this solution. In addition to the composition of the 
cardioplegic solution being used, there are a multitude of additional factors that also 
must be attended to if adequate myocardial protection is to be obtained (see chapter 1). 
Blood cardioplegia used in South Africa 
The blood cardioplegic solutions being used in South Africa are delivered to the patient 
in a 1:1 ratio of "pump blood" to crystalloid concentrate. Two different crystalloid 
concentrates are being used (Table 4.5). The calculated delivered concentrations of the 
indicated variables would differ slightly from those indicated in Table 4.5 in the clinical 
situation because of systemic haemodilution while on cardiopulmonary bypass (see 
section 1.4) 
Co1ponent 
Plas1alyte B 
15% KCl 
Table 4.5 
CONCENTRATE FOR 1:1 BLOOD CARDIOPLEGIA 
Quantity 
1 L 
13.5 ml 
CONCENTRATE 1 
Delivered concentration 
7 g% 
: ± 1.2 mmol/L 
17.8 mmol/L 
Ost : ± 300 mOsmfkg H2o 
OCcasional additional additives 
50% MgS04 
50 % Dextrose 
6 ml Mg2+ : 6.6 mmolfL 
10 - 20 ml Glucose : 17 - 31 mmol/L 
OS1 : 310 - 340 mOSmfkg H20 
Legend: 
Calculated delivered concentrations, assuming no haemodilution and normal serum levels; ie. Hb 14 g %, ca2 + 2.4 mmoi/L, K + 
4.6 mmoi/L, Mg2+ 0.9 mmoi/L, Glucose 6 mmol/L. (NB: Plasmalyte B contains K+ 4 mmoi/L, Mg2+ I.S mmol/L) 
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CONCENTRATE 2 
Component Quantity Delivered concentration 
Ringer's Lactate 1 L Hb : 7 g% 
15% KCl 
50% MgS04 
8.5% HaHC03 
25% Mannitol 
20% Albumin 
Lignocaine 
Legend: 
20 ml 
8 ml 
50 ml 
10 ml 
50 ml 
200 mg 
ca2+: ± 2.2 mmol/L 
K+ : 25 mmol/L 
Mg2+: 8.7 mmol/L 
Ost : ± 340 mOSm/kg H2o 
Calculated delivered concentrations, assuming no haemodilution and normal serum levels; ie. Hb 14 g %, ca2 + 2.4 mmol/L, K + 
4.6 mmol/L, Mg2+ 0.9 mmoi/L, Glucose 6 mmol/L. (NB: Ringer's Lactate contains K+ 5.4 mmoi/L, ca2+ 2.0 mmoi/L). The 
fraction of delivered ionized ca2 + might be less than that estimated because of calcium binding to albumin. 
Other crystalloid cardioplegic solutions in South Africa 
Various other crystalloid cardioplegic solutions are still being used in South Africa. 
These include the previously discussed SABAX cardioplegic solution (at least 4 
surgeons), the StThomas' Hospital No 1 cardioplegic solution (at least 3 surgeons), and 
another formulation made up from Plasmalyte B but having a final electrolyte 
composition similar to the StThomas' No 2 cardioplegic solution (5 surgeons). The 
following is added to a liter of Plasmalyte B:- 10 or 6 milS% KCl (20 or 12 mmol), 7.1 
ml50% MgS04 (14.5 mmol) and 1.76 mllO% CaCl2 (1.2 mmol), to make a final 
composition of Na +- 130 mmol/L, K+- 24 or 16 mmol/L, ca2+- 1.2 mmol/L, Mg2+-
16 mmol/L & HCOf- 27 mmol/L (A composition similar to the StThomas No 2 
cardioplegic solution, except for a higher bicarbonate content). The higher potassium 
concentration is used in the initial solution for induction of cardioplegic arrest and 
thereafter the lower potassium concentration for subsequent multidose reinfusions. 
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Strategy of myocardial protection 
Approximately 11 % of cardiac surgeons institute a preoperative adjuvant therapy in 
selected patients in order to improve myocardial protection. This includes preoperative 
GIK (3 surgeons), and I or preoperative allopurinol (3 surgeons) in selected patients. 
Possibly the most significant advance in the field of myocardial protection during the 
past few years has been the introduction of retrograde administration of cardioplegic 
solutions via the coronary sinus (see section 1.5). A Strategy of combined antegrade I 
retrograde infusion of cardioplegic solutions in selected patients, specifically CABG and 
aortic valve patients, is now being used by approximately 47% of surgeons in South 
Africa. Modified reperfusion solutions are also being used by± 8% of surgeons, 
although a further 19% infuse a bolus of either lignocaine or potassium into the aortic 
root prior to the release of the aortic cross-clamp in an attempt to modify the initial 
reperfusion period and to decrease the incidence of reperfusion ventricular fibrillation. 
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MODIFICATIONS OF THE STTHOMAS' HOSPITAL CARDIOPLEGIC 
SOLUTION 
The electrolyte content of the StThomas' Hospital No 2 cardioplegic solution (Table 
3.3) is based on careful dose response curves for each individual cation, and is a well 
formulated cardioplegic solution (see section 3.1). However, the StThomas' No 2 
cardioplegic solution does not contain a substrate for ongoing energy production, has a 
poor buffering capacity, is isotonic and lacks colloid oncotic pressure. We therefore 
evaluated various modifications of the St Thomas' cardioplegic solution, in order to 
assess whether these and other perceived deficiencies in its composition could be 
corrected. 
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5.1 SUBSTRATE IN THE STTHOMAS' CARDIOPLEGIC SOLUTION 
The principal source of energy for the heart is free fatty acids (N3)_ However, the well 
oxygenated heart is not a "fussy eater" and can also utilize both glucose and lactate 
(M41,016). Nevertheless, during anoxia and ischaemia some fuels can no longer be 
used because of major alterations in energy metabolism (R53). 
Glucose and Fatty acid metabo1ism 
Glucose metabolism in aerobic conditions 
The cell membrane of the myocyte is not freely permeable to glucose (M41) and glucose · 
uptake requires a sarcolemmal glucose carrier which though does not utilize energy 
(014). Insulin, epinephrine and hypoxia all increase glucose uptake (M41,016). 
Intracellular glucose is then converted to glucose-6-phosphate by utilizing ATP, and 
from here further metabolism can proceed in three directions (Fig 5.1) 
(L27,M4l,N3,014): 
Glycogenesis, 
Glycolysis, Krebs' cycle, Oxidative phosphorylation, 
Hexose-mono-phosphate shunt 
Glucose-6-phosphate is metabolized in the cytoplasm by glycolysis to pyruvate. Pyruvate 
is converted to acetyl Co A in the mitochondria which is then oxidized in the tricarboxylic 
acid cycle (Krebs' cycle) to C02, H20 and NADH, and finally ATP is produced by 
oxidative phosphorylation in the electron transport chain. NADH formed in the 
cytoplasm during glycolysis can also be transported into the mitochondria by the 
aspartate-malate shuttle, where it can also undergo oxidative phosphorylation (S3). 
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Figure 5.1 
MYOCARDIAL METABOLISM OF GLUCOSE 
G-1-P ---• Glycogen 
t C&ytaplttsm ~ HK (J-8-PDH 
Glucose ---+ G-6-P ---• Hexose-P-Shunt ~ t ICN~ 
F-6-P ··-----;>"'"....,_.J NAOPH 
PFK tATP 
002 
FOP I N~H---N~ 
.:.. GI-3-P ••-----IL--_..,.. DHAP a-Glycerophosphate 
La•tac. t c NAD (J/-3-PDH 
Legend: 
NADH 
1,3 DPG 
t c ADP 
f ATP 
PEP 
PK t c ADP 
f ATP 
Pyruvate 
LDH t c NADH 
f NAD 
Lactate 
.. itadyanbria 
The primary rate limiting enzymes arc PFK, phosphofructokinase; GI-3-PDH, glyceraldebyde-3-phosphate dehydrogenase; and 
other important enzymes are HK, hexokinase; G~PDH, glucose~phosphate dehydrogenase; PK, pyruvate kinase; PDH, 
pyruvate dehydrogenase; LDH,Iactate dehydrogenase. Factors that inhibit specific enzymes or processes are shown in square 
boxes. and stimulating factors in oval boxes. 
A TP produced in the mitochondria is then transported back into the cytoplasm via a 
carrier; adenine nucleotide translocase. Thus complete oxidation of a molecule of 
extracellular glucose produces 38 molecules of ATP (D7,016). Glycolysis is controlled 
by the cytoplasmic levels of A TP and citrate produced by oxidative phosphorylation and 
the levels of ADP and AMP produced by the hydrolysis of A TP (D7), which causes 
feedback inhibition or stimulation of rate limiting glycolytic enzymes (Fig 5.1). 
Alternatively, glucose-6-phosphate can be converted to glycogen in the presence of 
insulin (014). 
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Glucose metabolism during anoxia 
Oxidative phosphorylation cannot occur in the absence of oxygen. Thus, in anoxia the 
only source of A TP is from anaerobic glycolysis, but now each molecule of extracellular 
glucose produces only two molecules of A TP. Glucose uptake and phosphofructokinase 
activity is stimulated during anoxia, and cytosolic NADH is used to reduce -both pyruvate 
to lactate, and dihydroxyacetone phosphate to a-glycerophosphate (Fig 5.1). Thus both 
intracellular lactate increases (approximately twofold), as the sarcolemma is not freely 
permeable to lactate, as well as extracellular lactate (approximately tenfold) (R53). In 
perfused nonischaemic hypoxic or anoxic hearts the metabolic end products of 
glycolysis; NADH, protons, and lactate, are removed, and an increased rate of glycolysis 
is maintained (R53,S22). Thus glucose and insulin are beneficial during anoxia or 
moderate ischaemia if metabolic end products are removed (A28). Nevertheless, 
anaerobic glycolysis can produce only 10% - 20% of the normal aerobic cellular ATP 
requirements (D7,N3), and thus adult hearts cannot maintain normal function by 
accelerated anaerobic glycolysis (J5,J6,Y5). However, hypoxic induced accelerated 
glycolysis is greater in neonatal hearts. Nonischaemic hypoxic neonatal hearts can thus 
maintain normal myocardial ATP levels (J5) and normal mechanical function (J6) with 
minimal damage to mitochondrial function (Y5), by accelerated anaerobic glycolysis. 
Glucose metabolism during ischaemia 
If the myocardium is ischaemic as well as hypoxic or anoxic, there is diminished blood 
flow and thus inadequate washout of metabolic end products. Furthermore, we should 
also make a distinction between regional ischaemia and total global ischaemia, both of 
which are associated with slightly different metabolic effects ( 0 15). Following the onset 
of global ischaemia there is an initial increased glycolytic flux due to rapid 
glycogenolysis. However, this is followed by feedback inhibition of glycolysis (R53), as a 
result of accumulation of both extracellular (hundredfold) as well as intracellular 
(tenfold) lactate (R53), protons (N8), NADH, and a-glycerophosphate (D?). The 
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glycolytic enzyme glyceraldehyde-3-phosphate dehydrogenase is inhibited primarily by 
increased NADH levels (N3), as well as by increased protons and lactate (M50,R52). 
Lactate ions may also impair mitochondrial function (A29). Increased protons result in 
intracellular acidosis which also inhibits the activity of phosphofructokinase (K39,014), 
the malate-aspartate shuttle, alters calcium homeostasis and the permeability of plasma 
membranes (W32). Furthermore, intracellular acidosis is not secondary to only lactic 
acid accumulation, as protons are also generated by hydrolysis of ATP and from C02 
retention (G 16)_ 
Ischaemia thus markedly inhibits both the capacity of the cell to produce energy from 
glycolysis and also impairs other cellular functions as a result of accumulation of 
· metabolic end products. Furthermore, diminished postischaemic myocardial recovery 
has been related to increased lactate, protons and NADH levels rather than to reduced 
A TP levels (N5). 
Lipid metabolism in aerobic conditions 
Triglycerides cannot pass through the cell membrane and must be first hydrolyzed by 
lipoprotein lipase located in the capillary endothelium. Free fatty acids then enter the 
cell by either passive diffusion or a carrier mediated mechanism. Intracellular fatty 
acids are activated to fatty acyl CoA (A TP dependant reaction), whieh is transferred into 
the mitochondria by a carnitine carrier where beta-oxidation produces A TP (Fig 5.2) 
(M41,014,018). 
An intimate relationship exists between lipid and carbohydrate metabolism, for example 
insulin stimulates glycolysis but inhibits fatty acid oxidation. Furthermore, regardless of 
whether oxidation of either carbohydrate or lipid predominates at any one moment, a 
certain amount of carbohydrate is always converted to lipid (Fig 5.2) (C3)_ Myocardial 
accumulation of lipid also occurs from uptake of exogenous free fatty acids and in 
hypoxia from glycolytic derived a-glycerophosphate and pyruvate (G22,S23,S30). 
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However, conversion of lipid to carbohydrate is not possible in animal tissue, because 
the conversion of pyruvate to acetyl Co A is thought to be an irreversible reaction (L27). 
Figure 5.2 
INTERRELATIONSHIP OF GLUCOSE, LIPID and 
AMINO ACID METABOLISM 
C!tytnplasm 
Ghacopnlc 
Amino acids 
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~NADH 
ATP FADH 
/ 002 
Beta - ozldatlon 
Legend: 
Ketones 
t 
Ketogenic 
Amino acids 
Interrelationship of the primary myocardial fuels; fatty acids, glucose, lactate, and glucogenic or ketogenic amino acids is shown. 
Beta-oxidation, the Krebs' cycle and oxidative phosphorylation aU take place in the mitochondria, and the transfer of acetyl or 
acyl Co A across the mitochondrial membrane requires the carrier camitine. 
Lipid metabolism during anoxia and ischaemia 
The inability to reoxidize NADH in the mitochondria as a result of diminished oxidative 
phosphorylation during ischaemia, ~mpairs beta-oxidation of fatty acyl Co A which 
therefore accumulates and increases esterification of fats ( 0 18). Furthermore, pyruvate 
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is strongly ketogenic in isolated mitochondria when oxaloacetate or other tricarboxylic 
acid cycle precursors are absent and carbon dioxide assimilation is impossible (C3), 
which results in increased lipogenesis ( G22). The subsequent accumulation of acyl Co A 
(D7) inhibits adenine nucleotide translocase, which decreases both the transfer of ATP 
into the cytosol and inhibits the production of A TP as less extra-mitochondrial ADP is 
transported back into the mitochondria (M41,018). In addition, acyl carnitine 
accumulates (D7,018), which is arrhythmogenic and inhibits the sodium-potassium 
pump (014). Furthermore, beta-oxidation remains inhibited during postischaemic 
reperfusion, as the high concentrations of NADH are not rapidly reversed (D7). 
Thus the cellular uptake or production of fatty acids is harmful (B65) and should be 
prevented during ischaemia (023). 
Carnitine 
Carnitine (trimethylbetaine of B-hydroxy, r-aminobutyrate) has a specific function 
intimately related to lipid metabolism and is essential for oxidation of fatty acids. 
Carnitine levels in the cytosol decrease during experimental ischaemia and acyl CoA and 
acyl carnitine accumulates in the mitochondria (018), which as previously discussed is 
potentially harmful Thus, supplementing carnitine during total global ischaemia could 
be harmful, by further increasing intramitochondrial acyl carnitine. Carnitine is 
therefore not beneficial in cardioplegic solutions, and causes a dose dependent decrease 
of postischaemic myocardial function (B61,H23). However, Silverman et al showed a 
beneficial effect of preischaemic administration of carnitine added to the systemic 
perfusate (100 mg/kg, 30 min normothermic arrest), but this beneficial effect may have 
been due to the increased carnitine levels present during reperfusion (S47). 
Nevertheless, additional carnitine may be necessary once aerobic metabolism resumes 
during reperfusion, as the myocyte cannot synthesize carnitine and is dependant on an 
extracellular supply (M41). 
152 UOVonOppell PhD Thesis; University of Cape Town, 1992 
Thus, carnitine may be beneficial in the preischaemic and reperfusion periods when 
aerobic lipid metabolism can take place, but carnitine is probably not beneficial in a 
crystalloid cardioplegic solution during total global ischaemia. 
Glucose in cardioplegic solutions 
Glucose and increased glycolysis is beneficial during hypoxia provided there is no 
ischaemia and metabolic end products are constantly removed (J5,J6,R53,Y5). Glucose· 
is also beneficial prior to ischaemia by increasing intracellular glycogen stores 
(M41,011), as well as during the postischaemic aerobic reperfusion period (09). 
However, it is controversial whether glucose is beneficial in a cardioplegic solution · 
during global ischaemia. We therefore investigated the effect of adding glucose to the St 
Thomas' cardioplegic solution. 
Isolated rat heart model 
In the isolated rat heart model, subjected to a 3-hour hypothermic (10°C) cardioplegic 
protected ischaemic period, we showed that glucose is beneficial when added to the St 
Thomas' cardioplegic solution (appendix A-2). However, glucose was only beneficial in 
the concentration range 7 - 11 mmol/L and provided multidose cardioplegia was 
administered (Fig 5.3). 
In contrast, Hearse and co-workers showed a dose dependent decrease in postischaemic 
function if glucose was added to the StThomas' cardioplegic solution (H27). However, 
these experiments where carried out at 28°C with a 70-minute ischaemic period and no 
rein fusions of cardioplegia. During total global ischaemia increased glycolysis results in 
progressive accumulation of end products of metabolism (A28,N8,R53), which 
subsequently inhibits further glycolysis (M50,N3,R52) and causes other potentially 
harmful effects (discussed previously) (W32). However, a single dose of a similar 
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cardioplegic solution containing 20 mmol /L glucose was beneficial in an isolated rabbit 
model (G38)_ 
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Dose response curve for the addition of glucose to the StThomas' Hospital cardioplegic solution. Multidose rein fusions of 
cardioplegia were given every 30 min throughout a 3-hour 10°C ischaemic period. Values represent the mean postischaemic 
recovery of aortic flow (aortic output) and cardiac output, expressed as a percentage of each individual preiscbaemic value. The 
vertical ban; represent the standard errors of the percentage means. Reprinted from ·J Thorac Cardiovasc Surg 1991; 102:405-412 
(appendix A-2) with permission Mosby Year Book Inc. 
*- p < 0.005 compared to 0 mmol/L and 20 mmol/L glucose concentration. 
If only a single dose of cardioplegia was given prior to the ischaemic period in our 
model, then the addition of glucose to the St Thomas' cardioplegic solution did not 
improve postischaemic mechanical recovery and increased postischaemic loss of lactate 
dehydrogenase (appendix A-2)_ We did not though observe a decrease in mechanical 
recovery, as observed by Hearse et al (H27)_ However, a lower temperature was used 
during the ischaemic period in our study, which would have decreased the rate of 
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glycolysis (D14). Nevertheless, we can conclude that glucose is not beneficial during 
total global ischaemia if end products of metabolism are not removed (A28). 
In contrast, if end products of glycolytic metabolism are intermittently removed by 
frequent reinfusions of cardioplegia as suggested by Apstein et al (A28), then the 
addition of glucose ( 7- 11 mmol/L) to the StThomas' cardioplegic solution is beneficial 
(appendix A-2). The addition of glucose resulted in increased glycolysis as indicated by 
the higher efflux of coronary sinus lactate during each reinfusion of cardioplegia 
(appendix A-2), and this glycolytic derived A TP could be important because of 
postulated compartmentation of ATP (B64,B65,W16). However, the beneficial effect of 
glucose might have not been solely due to increased anaerobic glycolysis. Multidose 
cardioplegia can also result in intermittent aerobic metabolism, as cardioplegic solutions 
exposed to the atmosphere will contain oxygen (p02 ± 150 mm Hg) (see section 2.3 & 
7.1). Intermittent aerobic metabolism not only increases ATP levels but also removes 
end products of glycolytic metabolism (07,appendix A-3). In the study by Oguma et al, 
the protective effects of a cardioplegic solution containing glucose and insulin were 
completely lost with deoxygenation of the cardioplegie solution ( 07). Steinberg et al 
showed that glucose (28 mmol/L) and insulin was beneficial in both anoxic and 
oxygenated high volume hypothermic multidose cardioplegic solutions (S72). However, 
in this study insulin augmented recovery if anoxic cardioplegia was used but did not 
further improve the oxygenated glucose containing cardioplegic solution. Schwalb et al 
also showed the salutary effects of glucose ( 11.1 mmol/L) in an oxygenated St Thomas' 
cardioplegic solution (S29) in the isolated rat heart model, during a normothermic 
ischaemic period protected with high volume multidose cardioplegia. 
However, a higher concentration of glucose in a cardioplegic solution (111.1 mmol/L) 
was not beneficial in a canine model despite multidose cardioplegia (A13). We also. 
determined a dose response curve for the concentration of glucose in the StThomas' 
cardioplegic solution. Glucose concentrations lower than 7 mmol/L had no significant 
effect, perhaps because of insufficient glycolysis or an altered threshold for glucose 
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•uptake during hypothermia (appendix A-2). The reported threshold for glucose uptake 
at normothermia in the absence of insulin is 3.3 mmol/L, (W34 ). Glucose 
concentrations above 11 mmol/L also did not improve postischaemic function, possibly 
because of insufficient washout of increased metabolic end products. The study by 
Steinberg et al showed the beneficial effect of a higher glucose concentration (28 
mmol/L), but used higher volumes and more frequent reinfusions of cardioplegia (S72). 
Glucose containing cardioplegic solutions have been used clinicaliy, and are associated 
with better preservation of postischaemic glycogen levels and good clinical results (S12). 
Thus glucose is beneficial in a cardioplegic solution, but its beneficial effect is dependent 
upon the balance between the rate of glycolysis and efficiency of removal of the 
potentially harmful metabolic end products by either metabolic pathways (intermittent 
aerobic metabolism) or tissue washout 
Endothelial cell model 
Cultured human venous endothelial cells were exposed to cardioplegic solutions for 12 
hours at 22°C (see section 2.4). The addition of either 10 mmol/L or 50 mmol/L 
glucose, to the St Thomas' cardioplegic solution did not alter post exposure endothelial 
cell morphology or survival, when compared to the standard StThomas' Hospital No 2 
cardioplegic solution (appendix A-5). However, there was a relatively large volume of 
cardioplegic solution compared to endothelial cell mass in this ~odel, and therefore it is 
unlikely that there was any significant increase of metabolic end products as would occur 
in vivo. 
In vivo primate model 
The StThomas' plus glucose (10 mmol!L) cardioplegic solution was also compared to 
the standard StThomas' Hospital No 2 cardioplegic solution in the in vivo primate 
model (appendix B-1). Multidose cardioplegia was reinfused every 30 min throughout a 
3-hour hypothermic ischaemic period on cardiopulmonary bypass. The addition of. 
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glucose (10 mmol/L) to the StThomas' cardioplegic solution caused a decrease in 
postischaemic myocardial mechanical recovery (Fig 5.4 ). Furthermore, although the 
addition of glucose resulted in better preservation of A TP during the ischaemic period, 
ATP production was suppressed in the postischaemic period (appendix B-1). 
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Left ventricular stroke work index (gm.m /beat/m2) at increasing left atrial pressures before and after a 3-hour hypothermic 
ischaemic period protected with multidose StThomas' cardioplegia with or without glucose (10 mmoi/L). A pootischaemic left 
ventricular function curve of stroke work index was obtained 30 min after weaning from cardiopulmonary bypass, and compared 
to a similar preischaemic curve in each group (N = 6). Mean percentage postiscbaemic .recovery was calculated from each 
individual postiscbaemic and preischaemic ratio. An average preischaemic control function curve (Control; N = 12) was derived. 
by pooling the data from both groups, and postischaemic function for each group normalized to this curve for display purposes. 
+ - p < 0.05 compared to preischaemic contra~ 
o- p < 0.01 compared to preischaemic control, 
S- p < 0.01 compared to StThomas' group. 
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Furthermore, the addition of the powerful buffer histidine to the St Thomas' plus 
glucose cardioplegic solution also did not ameliorate the harmful effects of the inclusion 
of glucose in this model (see section 5.4) (appendix B-6). 
Thus in the primate model, glucose decreased postischaemic myocardial mechanical and 
metabolic function when added to the St Thomas' cardioplegic solution despite 
multidose administration of cardioplegia. Increasing the buffer capacity of the 
cardioplegic solution also did not prevent the glucose induced postischaemic myocardial 
depression. 
Discussion 
We have shown that glucose (7- 11 mmol/L) is beneficial in the StThomas' cardioplegic 
solution provided end products of metabolism are removed in the isolated rat heart 
model, but not in the in vivo primate model However, higher concentrations of glucose 
(greater than 11 mmol/L) were also not beneficial in the isolated rat heart model 
Why do high concentrations of glucosein a cardioplegic solution depress 
postischaemic recovery? 
One postulate is that high concentrations of glucose result in intracellular accumulation 
of metabolic end products (lactate, protons, NADH). High concentrations oflactate 
ions can induce mitochondrial changes (A29), and may be harmful in globally ischaemic 
hearts (N5). However, in an isolated myocyte preparation similar concentrations of 
lactate do not cause cellular damage (Gl4). Increased buffering to prevent the harmful 
effects of possible increased proton accumulation was also of no benefit in the primate 
model (see section 5.4). Furthermore, we have not been able to show increased 
intracellular accumulation of either lactate or protons as a result of a high glucose 
concentration in cardioplegic solutions in the isolated rat heart model in our laboratory 
(P Owen: unpublished data). Anaerobic glycolysis is inhibited by increased 
concentrations of NADH, lactate, and protons at two levels; glyceraldehyde-3-phosphate 
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dehydrogenase, and phosphofructokinase, and thus feedback inhibition possibly prevents 
excessively high levels of these metabolic end products. 
A second postulate is that high glucose concentrations in cardioplegic solutions result in 
accumulation of fatty acids (acyl CoA and acyl carnitine) during ischaemia, which would 
be harmful (D7,M41,014). NADH produced by anaerobic glycolysis is reoxidized by 
reducing pyruvate to lactate, and by converting dihydroxyacetone phosphate to a-
glycerophosphate. In turn, a-glycerophosphate is used in the intracellular biosynthesis 
oftriglycerides from fatty acids (C3,014,018). Thus enhanced anaerobic glycolysis, by 
increasing a-glycerophosphate will encourage esterification of intracellular free fatty 
acids (B53). Moreover, glucose catabolism by the hexose mono-phosphate shunt 
produces NADPH which is used in the reductive biosynthesis of fatty acyl Co A from 
acetyl CoA (C3,L27). Glycolysis also produces pyruvate which is used for lipogenesis 
during anaerobic conditions (C3,G22). In anoxic conditions excessive acetyl CoA, that 
cannot be degraded by the Krebs' cycle, is transferred out of the mitochondria 
(014,018), and can thus be reduced to fatty acids in the cytoplasm. Furthermore, the 
rate of production of lactate correlates with the rate of lipogenesis during anaerobic 
conditions (G22). Therefore, it is possible that during ischaemia high levels of glucose 
may increase the synthesis of acyl Co A and acyl carnitine, which is potentially harmful 
(discussed above). This postulate would also correlate with our findings in the in vivo 
primate model, in that high A TP levels could be maintained during the ischaemic period 
when anaerobic metabolism predominates. However, in the aerobic postischaemic 
period mitochondrial and myocardial function would be depressed as a result of the 
secondary effects caused by accumulation of acyl CoA and acyl carnitine during the 
ischaemic period. 
Why was StThomas' plus glucose (10 -11 mmol/L) beneficial in the isolated rat 
heart model but not in the in vivo primate model? 
Glucose (11 mmol!L) was beneficial in the StThomas' cardioplegic solution in the 
isolated rat heart model if multidose cardioplegia was provided, but not in the in vivo 
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primate model This discrepancy can possibly be explained as a result of interspecies 
differences in dependence on either lipid or glycolytic metabolism. Guilbeau et al (G38) 
and Hearse et al (H27) used virtually identical solutions and protocols and yet single 
dose cardioplegia with glucose (20 mmol/L) was beneficial in the rabbit but detrimental 
in the rat Differences exist in the capacity for anaerobic glycolytic flux, and 
mitochondrial oxidative metabolism between species (B3l,H20,H21) and also at 
different stages of maturity (H44,J5,J6). Foetal and neonatal animals which have a 
greater dependence and capacity for glycolytic metabolism (H44), have a greater 
tolerance to ischaemia (B3,B50,B51,Y5). In contrast, the primary fuel for energy in 
adult animals is lipids, and increased lipolysis is harmful during ischaemia. 
In addition to a possible interspecies and maturity differenc;e, the amount of "washout" 
of end products of metabolism provided by the multidose reinfusions of cardioplegic 
solution might have been different in the two models. Relatively more "washout" would 
have been provided in the isolated rat model (reinfusions of cardioplegia (6 ml); 15 - 24 
mllkg body weight, 4.5-6.7 ml/gm wet heart weight), than the primate model 
(reinfusions of cardioplegia (100 ml); 4.2- 6. 7 ml/kg body weight, or 0.6- 1.1 mllgm 
heart weight) (appendix B-1). Thus relatively lower volumes of cardioplegia were 
reinfused in the primate model, and decreased washout of metabolic end products could 
have contributed to the poor recovery associated with the glucose containing 
cardioplegic solution in this model Other studies using higher volumes and more 
frequent reinfusions of cardioplegia have also shown beneficial effects of cardioplegic 
solutions containing higher concentrations of glucose than in our isolated rat heart study 
(S72). Nevertheless, the volumes used in the primate model simulate the clinical 
situation more closely than those used in the isolated rat heart model 
In conclusion, until more is known about the mechanism of the harmful effects of 
glucose during ischaemic arrest protected with or without multidose crystalloid 
cardioplegic solutions, glucose should not be added to the StThomas' Hospital No 2 
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cardioplegic solution. Adequate removal of end products of glycolytic metabolism by 
either metabolic pathways or by washout appears to be essential if glucose is included in 
cardioplegic solutions. Multidose reinfusions of cardioplegic solutions also have other 
beneficial effects. However, simply increasing the buffering capacity of the cardioplegic 
solution does not alone prevent the potentially harmful effects of the inclusion of 
glucose in a cardioplegic solution. Nevertheless, preischaemic metabolic enhancement 
with glucose is beneficial (GIKregime) (H4,H35,lA6,011,V23), as is glucose in the 
reperfusion period (S4,S88). 
Amino acids 
Amino acids are used by cells to manufacture tissue proteins, enzymes and hormones as 
well as specialized products such as purines, pyrimidines, and creatine. The metabolism 
of amino acids involves oxidative deamination, transdeamination and transamination 
(C3). The nitrogen contained in amino acids may be used in synthetic pathways or 
disposed of as ammonia or urea, while the carbon skeleton is used in glucogenic, 
ketogenic and synthetic pathways (Table 5.1). 
Table 5.1 
AMINO ACIDS 
Glucogenic 
Alanine 
Arginine 
Aspartate 
Glutamate 
Histidine 
Oxaloacetate 
Taurine 
a-Ketoglutarate 
Legend: 
Ketogenic 
Leucine 
Isoleucine 
Phenylalanine 
Tyrosine 
The ketogenic amino acids, except for leucine, can also be metabolized via glucogenic pathways. Only a few of the more 
important gtucogcnic amino acids are shown. 
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Aspartate and glutamate are the most active amino acids involved in transamination 
reactions (C3), catalyzing:-
L-Glutamate + Oxaloacetate =a-Ketoglutarate + L-Aspartate, 
L-Glutamate +Pyruvate= a-Ketoglutarate + L-Alanine. 
Furthermore, both glutamate and aspartate play a major role in the malate aspartate 
cycle (Fig 5.5), which is used to transfer NADH and NAD between the cytosol and 
mitochondria and to coordinate cytosolic and mitochondrial energy metabolism (S3). 
Figure 5.5 
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Legend: 
NAD and NADH are transferred across the mitochondrial membrane by a carrier mechanism, the malate- aspartate shuttle. 
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Although the primary metabolism of amino acids requires aerobic conditions, amino 
acids can also produce high energy phosphates anaerobically independent to glycolysis in 
the mitochondria (B25,H56,P16,R8,Sl4). Tissue glutamate and aspartate decrease 
during ischaemia or hypoxia (P21), and the supply of exogenous glutamate in this 
situation is beneficial (M18). In patients with ischaemic heart disease glutamate is 
extracted by the heart with simultaneous loss of alanine (M61,T16). 
Perfusion of rabbit interventricular septa before or during anoxia with L-arginine or L-
glutamate ( 1 mmol /L) increases recovery of mechanical performance in the absence of 
glucose (R8). Furthermore, perfusion before and after global ischaemia with L-
aspartate, L-glutamate, L-ornithine or L-arginine enhanced recovery, but this 
enhancement could be prevented if transamination was metabolically inhibited. Lysine, 
glycine, methionine and glutamine were ineffective. Thus, only amino acids that 
accumulate in the cytoplasm, are involved in transamination reactions, and are available 
for the malate-aspartate cycle are effective. Other investigators have also confirmed 
that mitochondrial energy production can take place during anaerobic conditions from 
an extraglycolytic source, usually with concomitant accumulation of succinate 
(Pl6,S14,T3). The mechanism of anaerobic ATP production is by conversion of either 
a-ketoglutarate to succinate or malate to succinate in the mitochondria (Figure 5.6). 
These reactions are also dependant upon transamination of aspartate and glutamate 
(B25,H43,T3), and may possibly be enhanced if glucose is also present (Sl4). If amino 
acid transamination is prevented during ischaemia, then ischaemic tolerance decreases 
(114)_ 
During initial aerobic reperfusion of the postischaemic myocardium, amino acids are the 
only exogenous substrate taken up by the heart (S87). Amino acids are used to replenish 
Krebs' cycle intermediates lost during ischaemia (H3), and for myocardial energy 
production (S8?)_ 
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Figure 5.6 
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Legend: 
The metabolism of glucose~phosphate to lactate produces cytoplasmic A TP (Nett: 3 mmol ATP /mmol G~P~ Alternatively, 
the simuhaneous metabolism of both glucose~phosphate and the amino acid aspartate will produce both cytoplasmic and 
mitochondrial A TP anaerobically (Nett; 7 mmol ATP/mmol G~P) without an accumulation ofNADH, but with the production 
of succinate and COz. 
Amino acids are thus potentially beneficial both during anoxia or ischaemia and during 
aerobic reperfusion, but by different mechanisms. 
Amino acids in cardioplegic solutions 
Anaerobic transamination of amino acids during ischaemia can augment intracellular 
high energy phosphates. Enrichment of the StThomas' Hospital cardioplegic solution 
with L-aspartate (20 mmol/L) decreased high energy phosphate decay during an 8-hour 
hypothermic (4oC) global ischaemic period protected with single dose cardioplegia, and 
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improved postischaemic mechanical recovery (C25). However, addition ofL-glutamate 
to this enriched solution did not result in further improvement and glutamate alone was 
ineffective in this model The amino acid fumarate was shown to be more beneficial 
than succinate, malate, and glutamate at higher concentrations (100 mmol/L) in another 
hypothermic crystalloid cardioplegic solution (R47). However, other investigators have 
shown that L-glutamate (20- 100 mmol/L) in multidose crystalloid cardioplegic solution 
decreases high energy phosphate decay (E10), and improves postischaemic recovery 
(B2~). Branch chain amino acids added to an oxygenated modified St Thomas' 
cardioplegic solution containing glucose ( 11.1 mmol /L) also improved recovery after a 
normothermic cardioplegic protected ischaemic period (S29). However, this study did 
not separate the specific beneficial effects of branched chain amino acids (leucine, 
isoleucine, valine), from the other amino acids contained in their formulation. 
Moreover, ketogenic amino acids (leucine, isoleucine) can be metabolized to fatty acids, 
and fatty acids are harmful during ischaemia (discussed previously) (B65). Nevertheless, 
from these studies we can conclude that anaerobic amino acid transamination metabolic 
reactions as discussed above, but specifically glucogenic amino acids, improves 
preservation during cardioplegic protected hypothermic ischaemia. 
The addition ofL-glutamate (4- 25 mmol/L) to oxygenated blood reperfusion solutions 
also improves postischaemic recovery (H3,H2,L18), and further synergistic enhancement 
with L-aspartate (13 mmol/L) results in extra recovery (E13,R41). However, aerobic 
metabolism takes place during reperfusion, in contrast to cardioplegic protected 
ischaemia. Thus, amino acid enhancement during reperfusion possibly acts by improving 
oxidative metabolism through both replenishment of Krebs' cycle intermediates and 
improved transportation of cytoplasmic NADH into the mitochondria via the malate-
aspartate shuttle. Metabolic enhancement during reperfusion is also possibly of greater 
importance than the presence of free radical scavengers (L23). 
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The amino acids L-glutamate and L-aspartate are present in low concentrations in 
human serum, less than 0.05 mmol/L (S71), and supplementation of these amino acids 
during both anoxia and reoxygenation is beneficial (Ml8). 
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5.2 OXYGENATION OF CRYSTALLOID CARDIOPLEGIC SOLUTIONS 
The cardioplegic arrested heart has a basal metabolic requirement, despite profound 
hypothermia. This basal oxygen requirement is; 0.3 ml 02 I 100 gm I min at 22°C 
(B76), 0.27 ml 02 I 100 gm I min at 15°C and 0.13 ml 02 I 100 gm I min at soc in the 
dog heart (B63)_ However, the more efficient aerobic metabolic pathways only continue 
to function if oxygen is available, and the oxygen storage capacity of the myocardium is 
limited (myoglobin; 0.6 volume %) (B60)_ Once all available oxygen has been used, the 
basal myocardial energy requirements can only be partially met by ongoing anaerobic 
metabolism. However, oxygen can also be supplied intermittently throughout the 
ischaemic period by either multidose blood or oxygenated crystalloid cardioplegic 
solutions. In an isolated rat heart preparation, approximately 3 ml 02 I 100 gm was 
taken up with each reinfusion of a poorly formulated oxygenated crystalloid cardioplegic 
solution, reinfused for one minute after every 10 minutes of ischaemia (Dll)_ If one 
extrapolates from the known oxygen demands of the hypothermic cardioplegic arrested 
canine heart, although the dog has a lower normothermic basal metabolic demand than 
the rat (H53), the metabolic demands for each 10 minute ischaemic period were nearly 
met by intermittent accelerated aerobic metabolism. 
In a crystalloid cardioplegic solution all dissolved oxygen is available to the myocardium 
(D19), in contrast to blood cardioplegia where less oxygen is available at low 
temperatures because of the leftward shift of the oxygen-dissociation curve (G2). 
Furthermore, crystalloid cardioplegic solutions are usually infused at temperatures of 
4oc- 10°C (see section 1.5), and at these low temperatures the maximum oxygen 
content of the cardioplegic solution increases to 3.7 ml 02 %(at 760 mm Hg) (Bl3)_ . 
Thus, at low temperatures oxygenated crystalloid cardioplegic solutions can deliver as 
much oxygen as blood cardioplegic solutions (Dl9)_ Moreover, oxygenation of 
crystalloid solutions is much simpler, and bubble oxygenation of crystalloid cardioplegic 
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solutions easily achieves oxygen contents greater than 3.0 ml o2 % (appendices A-3,A-
7). 
In the isolated rat heart model, we showed that oxygenation of a crystalloid cardioplegic 
solution (StThomas' plus 11.0 inmol/L glucose) improved postischaemic mechanical 
recovery and decreased washout of lactate dehydrogenase compared to an anoxic 
solution (Fig 5. 7) (appendices A-3,A-4). 
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Legend: 
Postischaemic mechanical recovery, expressed as mean ratios of individual preischaemic values, of isolated rat hearts after 3-
hour JOOC cardioplegic arrest Hearts were protected with multidose StThomas' plus glucose (II mmoi/L) cardioplegic solution 
gassed with either 100% N2 (N =6), 100% ~ (N = 8), 95% N2 5% C~ (N = 7) or95% ~ 5% C~ (N = 9). The vertical bars 
represent standard errors of means. Modified from Ann Thorac Surg 1991; 52:903-907 (appendix A-4) with permission The 
Society of Thoracic surgeons. 
o- p < 0.01 compared to the respective N2 group, 
+ - p < 0.05 compared to the respeetive N2 group. 
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Other investigators have also shown that oxygenation of both the St Thomas' and other 
crystalloid cardioplegic solutions retards degradation of myocardial high energy 
phosphates and enhances postischaemic mechanical recovery (B33,C3l,G45,L25). 
Clinical studies have shown both no benefit of oxygenating crystalloid cardioplegic 
solutions (W13), and others significant beneficial effects especially if the aortic cross-
clamp period is longer than 28 minutes (G45). These discrepancies may imply that the 
minimum amount of oxygen required in a cardioplegic solution may yet have to be 
determined, as non-oxygenated but "aerated solutions" also contain oxygen. In our study 
we did not compare an oxygenated cardioplegic solution to an aerated solution 
(appendix A-3). Furthermore, the "aerated" StThomas' plus glucose cardioplegic 
solution (appendix A-2) resulted in similar percentage recovery of aortic flow, cardiac 
output and stroke volume if compared to the oxygenated (95% 02 5% C02) St Thomas' 
plus glucose cardioplegic solution (appendix A-3). However, these studies in appendix 
A-2 and appendix A-3 were undertaken at different time periods, and the "aerated" 
solution in the former study had been gassed with 95% 02 5% C02 during preparation 
and although not oxygenated thereafter, oxygen contents (which were not measured) 
could have remained high (see section 2.3). Thus, this comparison does not necessarily 
refute the proposal of oxygenating crystalloid cardioplegic solutions. 
Oxygenation of crystalloid cardioplegic solutions is beneficial as it allows intermittent 
aerobic metabolism with each reinfusion of cardioplegia, which is more efficient for 
energy production. Furthermore, the beneficial effects of oxygen in crystalloid 
cardioplegic solutions is proportional to their oxygen content ( D 11), and the protective 
effects of some crystalloid cardioplegic solutions are primarily due to the oxygen 
dissolved therein (07). 
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Oxygen carriers - Perfluorocarbons 
Inert perfluorochemical emulsions have been used experimentally as blood 
replacements because of their capacity to carry oxygen, as well as for rheological 
properties (F6). However, although these emulsions are inert, large particles can be 
potentially toxic and perfluorocarbons also accumulate in reticulo-endothelial cells. 
Fluosol-43 emulsion (FC-43) is possibly the most suitable perfluorochemical emulsion, 
although not for human use (F6)_ The high solubility coefficient for oxygen in FC-43 
(0.077 ml 02 I ml at 10°C (F6)) increases the oxygen carrying capacity of crystalloid 
solutions, and at normothermia increases oxygenation of myocardial myoglobin (M8). 
In addition, all oxygen carried byFC-43 can be released as the oxygen-dissociation curve 
is linear (F6). 
Fluorocarbons have been used experimentally as artificial blood perfusates during 
cardiopulmonary bypass (Cl4,Ell), and for long term storage of isolated hearts by 
hypothermic (4°C) continuous perfusion (B9,G23,Kl7). Oxygenated perfluorocarbon 
cardioplegic solutions enhance oxygen utilization during multidose cardioplegic arrest 
and can provide adequate myocardial protection at 4°C- 10°C (M6). Furthermore, 
perfluorocarbon cardioplegic solutions have been shown to be superior to both blood 
and crystalloid cardioplegic solutions (H37,K4,N12). However, in these studies the 
crystalloid cardioplegic solutions were not oxygenated and had different electrolyte 
compositions to the fluorocarbon cardioplegic solutions. Thus these studies only showed 
the beneficial effect of supplying oxygen. 
In the isolated rat model (appendix A-3), we show that an oxygenated perfluorocarbon 
cardioplegic solution with an identical electrolyte composition to a good oxygenated 
crystalloid cardioplegic solution (StThomas' plus 11 mmol /L glucose), conferred no 
extra protection despite an increased oxygen-carrying capacity (Fig 5.8). 
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Figure 5.8 
STTHOMAS' CARDIOPLEGIC SOLUTION PLUS 
PERFLUOROCARBONS 
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Legend: 
Postischaemic mechanical recovery, expressed as Iriean ratios of individual preischaemic values, of isolated rat hearts after 3~ 
hour lQOC cardioplegic arrest Hearts were protected with multidoses of either StThomas' plus glucose (II mmol/L) 
cardioplegic solution (ST +G; N = II) or a pcrfluorocarbon containing cardioplegic solution (FC-Card; N = 6) having an 
electrolyte content identical to ST +G. Both solutions were gassed with 95% 02 5% C02. The vertical bars represent the 
standard errors of the means. 
Thus, in agreement with other studies we do not recommend the use of perfluorocarbons 
in hypothermic crystalloid cardioplegic solutions (R50,Tl)_ 
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Potential harmful effects of oxygenating crystalloid cardioplegic solutions 
The beneficial effect of supplying oxygen in cardioplegic solutions is no longer 
questioned. However, oxygenation of crystalloid cardioplegic solutions can potentially 
also be harmful:-
Formation of air emboli 
If a solution is fully saturated with a gas at a low temperature, rewarming of the solution 
will alter the temperature dependant dissociation constant for that gas, resulting in the 
gas coming out of the now supersaturated solution, as bubbles (see section 7.1, 7.2 
(appendices A-7,A-8)). 
Induced pH changes 
The introduction of any gas into a solution containing bicarbonate alters the partial 
pressure of carbon dioxide in that solution, thereby producing a change in hydrogen ion 
concentration and thus pH (Fig 5.10). Oxygenation without carbon dioxide will induce 
an alkalotic pH shift, and this would increase the potential for the calcium paradox if the 
cardioplegic solution is calcium-free (H31). Bicarbonate containing cardioplegic 
solutions should be oxygenated with 95% 02 5% C02 and not 100% 02. (see section 
5.3 (appendices A-3,A-4)). 
Generation of oxygen free radicals 
Oxygen free radicals cause myocardial injury (S27), and are generated when oxygen is 
reintroduced into previously hypoxic or ischaemic tissue (see section 1.6 (B8,S75)). Free 
radical generation is also increased by exposure to high partial pressures of oxygen (p02 
greater than 150 mm Hg (G5)). Therefore, it is possible that free radicals are generated 
with intermittent reinfusions of multi dose oxygenated crystalloid cardioplegic solutions. 
172 U 0 Von Oppell PhD Thesis; University of Cape Town,l992 
5.3 CARDIOPLEGIC SOLUTION pH 
"Life is a struggle, not against sin, 
but against hydrogen ions". 
H L Mencken- Exuent Omnes 1919 (B53) 
Intracellular metabolic processes continually generate protons, which are removed by 
oxidative phosphorylation during aerobic metabolism (G 16)_ However, protons 
accumulate as a result of glycolysis, A TP hydrolysis, and lipid metabolism, during 
hypoxia and ischaemia, and the resulting cytoplasmic acidosis affects myocardial 
function ( G 16)_ Intracellular acidosis decreases myocardial contractility (P25,S70), 
decreases energy production both by inhibiting the transfer of reducing equivalents into 
the mitochondria and by inhibiting glycolysis (W32), alters calcium binding and calcium 
flux (P18,V22,W32), and finally activates degradative enzyme systems. 
The pH of a solution is the negative logarithm of the hydrogen ion concentration, and 
maintaining a stable pH in body fluids is essential for life ( G2)_ The normal pH of 
extracellular fluids at normothermia is 7.4, although a pH range from 7.0 to 7. 7 is 
compatible with life. Intracellular pH which is difficult to measure directly, 
approximates the neutral pH of water; pH 7.0 at normothermia (S91,W19). This is the 
optimal intracellular pH for the majority of metabolic reactions, which are very sensitive 
to changes in pH; eg. ATP disappears most rapidly at or below pH 6.3 (B53). 
Intra myocardial pH measurements obtained during hypothermic cardioplegic arrest 
correlate with the degree of ischaemic damage, and thus pH can be used to assess the 
adequacy of intraoperative myocardial protection (Kl4)_ An interstitial pH ofless than 
7.0 at the end of ischaemia is associated with depressed postischaemic left ventricular 
functional recovery, following either normothermic or hypothermic global ischaemia 
without _cardioplegia (T6)_ In an intraoperative study using a bicarbonate containing 
crystalloid cardioplegic solution, intramyocardial pH increased with infusions of this 
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alkalotic solution and the magnitude of rise or integrated mean intramyocardial pH 
correlated with the clinical postoperative assessment of the adequacy of myocardial 
preservation (Kl4). However, although intramyocardial pH and the degree of acidosis is 
an index of the metabolic status of the myocardium, this does not imply that cardioplegic 
solutions must be alkalotic. Myocardial pH can be maintained at the correct level by. 
using an appropriate buffer (see section 5.4). Furthermore, when assessing the correct 
pH of a cold cardioplegic solution the effect of temperature on pH must also be taken 
into account 
pH and Temperature 
Biological neutrality is defined to occur when the ratio of hydroxyl and hydrogen ions 
equals one (S91), and in water and intracellular fluids occurs at pH 7.0 at37°C. 
However, the dissociation constant for water decreases as temperature decreases, thus 
reducing the concentration of hydrogen ions. The neutral intracellular pH at 10°C is 
therefore pH 7.46 (S91,Wl9). Similarly, if biological neutrality is to be maintained in 
blood, normothermic neutral blood pH 7.4 should be pH 7.8 at 10°C. 
Although, the "correct" systemic blood pH during hypothermic cardiopulmonary bypass 
has been a contentious point in the literature, most studies support using the alpha-stat 
concept during hypothermia (Bl9,M2l,S91,T26,W30). Poikilotherms maintain biological 
neutrality by allowing pH to rise and pC02 to fall when body temperature drops ("alpha-
stat" concept of acid base management; (S91)). ·Maintaining biological neutrality as 
temperature changes optimizes enzymatic reactions, helps maintain constant cellu.Iar 
volume (W19), and improves cardiac metabolism and function (M21). In contrast, 
homeotherms including hibernators maintain blood at pH 7.4 regardless of temperature 
("pH-stat" concept), by increasing the C02 and thus hydrogen ion content This, 
"acidotic" blood pH of 7.4 at 10°C possibly inhibits metabolism and conserves energy. 
However, whilst biological neutrality and its advantages might be appropriate for 
174 U OVon Oppel! PhD Thesis; University of Cape Town, 1992 
hypothermic systemic perfusate pH, the aim of cardioplegic induced ischaemic arrest is 
to diminish metabolic demand maximally. Therefore, the "metabolic inhibitory" effect 
of a relatively "acidotic" pH might be more appropriate for cardioplegic solutions. 
An additional factor that must be taken into account when interpreting pH values, is that 
all blood gas analyzers measure the partial pressures of gases and pH at 37°C. 
Therefore, the true pH for the temperature of the sample in question must be calculated 
from the "meter reading pH" (KlO), now done automatically by most modern blood gas 
analyzers. 
pH and Cardioplegic solutions 
Although Becker et al using blood cardioplegia showed depression of postischaemic 
myocardial performance if systemic pH was kept at 7.4, as opposed to an "alpha-stat" 
alkalotic pH, this study did not separate the effect of cardioplegic solution pH from the 
effect of systemic pH during reperfusion (B 19)_ In contrast, studies with crystalloid 
cardioplegic solutions have shown a beneficial effect of a relatively "acidotic" 
hypothermic cardioplegic solution; pH 7.0-7.1 (B27,N19)_ However,' an "acidotic" 
cardioplegic solution is essential for a calcium-free cardioplegic solution as used by 
Nugent et al (Nl9), in order to limit the potential for the calcium paradox (H31,Jl6)_ 
Nevertheless, a reduction ofintracellular pH markedly decreases sarcolemmal calcium 
transport by Na +I ca2+ exchange (Pl8), and decreases K +efflux (P25). Furthermore, 
ca2+ binding to the phospholipid of sarcolemmal sites is pH dependent; At a 37°C pH 
of 5.5 there is 0% calcium binding, 50% at pH 7.0, and 100% binding at pH 8.5 (Lll). In 
contrast, extracellular alkalosis could promote intracellular calcium accumulation by 
Na+ 1 H+ and ca2+ INa+ exchange (D13)_ These ionic effects would support the use 
of a slightly acidotic cardioplegic solution. 
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"Metabolic acidosis" - induced pH s~ift 
In the isolated rat heart model we examined the effect of altering the pH of a modified 
StThomas' plus glucose (11 mmol/L) cardioplegic solution (appendix B-2). Equivalent 
postischaemic recovery was obtained with pH 7.4 and pH 7.8 (measured at 370C), and a 
pH of 7.0 or less was associated with diminished postischaemic mechanical recovery (Fig 
5.9) (appendix B-2). 
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Figure 5.9 
EFFECT OF "METABOLIC" INDUCED pH SHIFTS 
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Legend: 
Postischaemic mechanical recovery, expressed as mean ratios of individual preischaemic values, of isolated rat hearts after 3-
hour 10oc cardioplegic arrest HeartS were protected with multidoses of StThomas' plus glucose (II mmol/L) cardioplegic 
solution titrated to the indicated pH's with either 1 N HCI or NaOH. The vertical bars represent the standard errors of the 
means.. 
o- p < 0.05 compared to pH 7.4 
+- p < 0.01 compared to pH 7.4 
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However, in this model pH was altered by adding HCl or NaOH, and therefore the 
"acidotic" solutions (pH less than 7.4) would also have had an associated decrease in . 
buffering capacity. The associated diminished buffering capacity could have had a 
significant effect on postischaemic recovery, as the StThomas' cardioplegic solution 
contains a weak buffer; bicarbonate. 
"Respiratory acidosis" - induced pH shift 
Another study was undertaken in the isolated rat heart model to examine the effect of 
alterations of pH independent to any alterations of buffer capacity (appendices A-3,A-
4). The effect of pH changes were studied in the presence and absence of oxygen 
without altering either the composition or buffering capacity of the solution, by gassing 
the cardioplegic solution with or without 5% C02. Oxygenating St Thomas' cardioplegic 
solution with 100% 02 results in an alkalotic pH of 9.2 at W°C, whereas oxygenation 
with 95% 02 5% C02 results in an equivalent p02 but a pH of 7.0 at W°C (Fig 5.10). 
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Figure 5.10 
The effect of temperature and oxygenation 
on the pH of the 
1 o St Thomas' plus Glucose Cardioplegic Solution 
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Legend: 
The StThomas' plus glucose (II mmoi/L) cardioplegicsolution was gassed with either 100% ~- 97% ~ 3% C02 or95!11i 02 
S% C~. and the pH measured at different temperatures. The pH of intracellular neutrality (neutral pH of H20) and neutral 
pH ofhlood is also indicated. Reprinted from J Thorac Cardiovasc Surg 1991; 102:396-404 (appendix A·3) with permission 
Mosby Year Book Inc. 
A cardioplegic solution pH of 7.0 at 10°C in the presence of oxygen (induced by 
oxygenating with 95% 02 5% C02), was associated with increased oxygen uptake from 
the cardioplegic solution, better maintenance of membrane integrity, and improved 
postischaemic mechanical recovery (Figure 5.11; (appendices A-3,A -4 )). If anoxic 
cardioplegic solutions were used, postischaemic mechanical recovery also improved at 
pH 7.0. However, increased postischaemic washout of lactate dehydrogenase suggested 
increased sarcolemmal damage at pH 7.0 during anoxia, which was possibly due to 
inhibition of anaerobic glycolysis at this pH. A pH of 6.8 at 37°C (pH < 7.25 corrected 
to 10°C) inhibits hypoxic accelerated glycolysis (R52)_ 
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Figure 5.11 
EFFECT OF CARDIOPLEGIC SOLUTION pH 
Postischaemic Mechanical recovery 
100%N2 
pH 9.1 
95%N2 5%C02 1 00%02 
pH 7.0 pH 9.3 
* 0 
95%025%C02 
pH 7.0 
~Cardiac output -Stroke Volume 
Postiscbaemic mechanical recovery, expressed as mean ratios of individual preiscbaemic values, of isolated rat hearts after 3-
hour 10°C cardioplegic arrest Hearts were protected with multidose StThomas' plus glucose (II mmol/L) cardioplegic solution 
gassed with either IOOlli N2 (N =6), 95 lli N2 S lli COz (N = 7), IOOlli Oz (N = 8) or 9Slli Oz S lli COz (N = 9), which induced the 
indicated pH shifts. The vertical bars represent the standard errors of the means. Reprinted from Ann Tborac Surg 1991; 
52:903-907 (appendix A-4 l with permission The Society of Thoracic Surgeon~ 
•-p < 0.01 compared to9Slli N2Slli COz and lOOlli Oz, 
o-p < O.OScompared to9Slli N2 Slli COz and IOOlli Oz. 
The observed beneficial effects of oxygenating with 95% 02 5% C02 (pH 7.0 at 10°C) 
were as a result of the increased pC02 and induced pH shifts. Acid-base alterations 
primarily effect myocardial contraction by altering intracellular pH (C28), which can be 
rapidly modulated by the free sarcolemmal passage of C02 (P25). Therefore, a so-
called ••respiratory acidosis" (increased C02) will have a more pronounced effect on 
intracellular pH than ·a "metabolic" acidosis (C28,P25). 
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Changes in extracellular pH by altering sodium bicarbonate (metabolic acidosis) and 
maintaining pCOz constant do not alter myocardial contractility significantly, in contrast 
to changes in pCOz even if pH is maintained constant (C28). Thus the previously 
observed detrimental effect of pH 7.0 (Fig 5.13) induced by adding HCl to the 
cardioplegic solution, was probably due to the associated decrease in buffer capacity 
(see section 5.4) than to a change in intracellular pH. Lochner et al also demonstrated 
deleterious effects of oxygenating crystalloid cardioplegic solutions with 100% Oz, and 
suggested that this was due to complex ionic interactions (IAl). 
A relatively "acidotic" cardioplegic solution pH of 7.0 at 10°C in the StThomas' plus 
glucose cardioplegic solution was better than an alkalotic pH, provided the buffering 
capacity was maintained constant The optimal pH for calcium-free cardioplegic 
solutions such as the Bretschneider HTK4 solution is also less than 7.0 (370C) (B60,P27), 
but slight acidosis is essential in this solution in order to prevent the calcium paradox 
from occurring (H31,J16). Nevertheless, Bernard et al also showed that pH 7.0 (20°C) 
was better than pH 7.4 or 7. 7 using a cardioplegic solution containing calcium and 
glutamate (20 mmol/L) (B27). Furthermore, the same group also showed that in the 
reperfusion period a glutamate containing reperfusate was more effective at a pH of 7. 7 · 
(28°C) (M32). This thus supports the hypothesis that during cardioplegic arrest 
inhibition of metabolism by slight "aCidosis" is the correct strategy, but that during 
reperfusion biologic neutrality should be maintained, in order to now optimize 
enzymatic function. 
In conclusion, the St Thomas' cardioplegic solution should be oxygenated with 95 % Oz 
5% co2 which induces a relatively acidotic pH of 7.0 at 10°C, and not 100% Oz. In 
addition, all bicarbonate containing calcium-free cardioplegic solutions should also be 
oxygenated with 95% o2 5% COz to prevent an alkalotic induce~ increased potential 
for the calcium paradox(H31). 
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5.4 CARDIOPLEGIC SOLUTION BUFFERS 
Buffers in blood 
A buffer is a substance that can bind or release hydrogen ions, thus maintaining the pH 
of a solution relatively constant despite the addition of considerable quantities of acid or 
base. The major intracellular buffers in muscles are soluble proteins, histidine related 
compounds and phosphate, which increase the anaerobic potential of tissues (A4,P4). In 
blood, the major buffers are plasma proteins, haemoglobin (has six times the buffering 
capacity of plasma proteins, primarily due to its histidine residues), carbonic acid-
bicarbonate system (enhanced by the enzyme carbonic anhydrase contained in red blood 
cells), and the mono and dibasic phosphate system (Table 5.2) (G2). 
The buffering capacity of blood is relatively constant between pH 6.4 and 7. 8 at 30 mmol 
HCI!L/ o pH (C02 constant, and at 27°C) (K34). Nevertheless, the buffering capacity 
of any single system is greatest when the amount of free anion is equal to the amount of 
undissociated acid, and this occurs when the pH of the fluid equals the pK for that buffer 
system. 
Table 5.2 
BUFFER SYSTEMS IH BLOOD 
Protein Buffers 
. R - ODOR <--> R - coo- + n+ 
R- NH3+ <--> R- NH2 + n+ 
Haeaoglobin 
Hb - imidazole H <--> Hb - imidazole- + n+ 
carbonic acid - Bicarbonate : (pK = 6.3) 
+ -H2co3 <--> H + HC03 
n2co3 <--> co2 + H2o (Carbonic anhydrase) 
Mono & Dibasic Phosphate : (pK = 7.2) 
- + 2-H2P04 <--> H + HP04 
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Buffers in cardioplegic solutions 
Providing a strong buffer in a cardioplegic solution facilitates removal of hydrogen ions 
from the myocyte during the ischaemic period, and thus maintains a stable intracellular 
pH. In addition, the buffer chosen for a cardioplegic solution should have its greatest 
buffering capacity (pK) close to the optimal pH for that crystalloid cardioplegic solution. 
The phosphate buffer system is potentially harmful in a cardioplegic solution, because 
phosphate binds calcium; precipitation of calcium phosphate may occur, and in calcium-
free solutions the potential for the calcium paradox may be increased because of binding 
of remaining traces of calcium (H 16)_ Therefore, the three buffers primarily used in 
crystalloid cardioplegic solutions are; bicarbonate, tromethamine (THAM I TRIS) and 
histidine. However, both bicarbonate (27 mmol/L) which has a maximum buffering · 
capacity of 15 mmol HCl/L/o pH at pH 6.3, and THAM (27 mmol/L) with a maximum 
buffering capacity of 15 mmol HCl/L/ o pH but at pH 8.1 (27°C), have a narrow optimal 
zone of buffering bracketing their pK (K34)_ Moreover, Tris has a negative inotropic 
effect that is maintained after removal" of the buffer and possibly inhibits anaerobic 
glycolysis and oxidative metabolism (G20)_ In contrast, histidine (161 mmol/L) has a 
buffering capacity greater than 20 mmol HCl/L/ o pH between pH 5.5 and 8.0, and a 
maximum buffering capacity at pH 6.0 of 60 mmol HCl/L/ o pH (K34)_ 
Crystalloid cardioplegic solutions with high buffering capacities provided by the 
imidazoles glyoxaline (25 mmol/L; pK 7.0 at 25°C) or histidine (195 mmol/L) delay 
ATP decay during ischaemia and improve postischaemic functional recovery, in contrast 
to poorly buffered solutions (D12,T4,V9,W33)_ Furthermore, multidose reinfusions of 
poorly buffered cardioplegic solutions also do not prevent acidosis from developing 
during ischaemia (T4)_ Thus, histidine is possibly a better buffer for cardioplegic 
solutions than bicarbonate. Furthermore, histidine can also be transported into the cell 
by a carrier mediated system and therefore possibly provides intracellular buffering 
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(L29), and has free radical scavenging properties (C19,G5). The major catabolic 
pathways of histidine are; deamination by histidase to urocanate and thence to 
glutamate, methylated to 1- or 3-methyl-histidine, and decarboxylated to histamine, and 
is a naturally occurring substance (C3). 
In the isolated rat heart model we investigated whether a modified St Thomas' 
cardioplegic solution with an increased buffer capacity provided by histidine (50 
mmol/L), would be beneficial (appendix B-5). The sodium content of the StThomas' 
cardioplegic solution was decreased to 100 mmol/L, in order to make osmotic space 
available for the addition of histidine. 
A pilot dose response curve for the sodium concentration of the St Thomas' cardioplegic 
solution confirmed the optimal sodium content to be 80- 120 mmol/L (appendix B-3), 
similar to the findings of P Jynge (117). In addition, changes to the osmolality of the St 
Thomas' cardioplegic solution were also evaluated; if the sodium content was 120 
mmol/L then a higher osmolality (350 mOsmol/kg H20) was beneficial, if the sodium 
content was 100 mmol/L a higher osmolality (340 mOsmol/kg H20) was also not 
detrimental (see section 5.5) (appendix B-3). Therefore, the StThomas' cardioplegic 
solution was modified by decreasing the sodium content to 100 mmol/L and the 
osmolality increased to 320 mOsmol/kg H20, which allowed the addition of 50 mmol/L 
of histidine and 10 mmol/L of glucose (see Appendix B-5). 
The buffering capacity of this modified St Thomas' cardioplegic solution containing 
histidine was 30 mmol HCl/L/ o pH at its pK 6.0-6.3 (Figure 5.12) (appendix B-5). In 
contrast, the buffering capacity of the control StThomas' plus 10 mmol!L glucose 
cardioplegic solution was significantly lower at 6 mmol HCl/L/ o pH at pK 6.0, and 
Bretschneider HTK4 which contains 198 mmol/L histidine was greater at 100 mmol 
HCl /L/ o pH at its pK 5.8- 6.6. 
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Legend: 
Tbe buffering capacity of each cardioplegic solution; StThomas' plus glucose (ST+G), Bretschneider HTK4 (B-HTK), and 
ST +G +Histidine, was calculated as the instantaneous three point derivative slope of the titration curve, obtained by titrating 
each solution with I N HCl 
7.5 
The addition, of histidine (50 mmol/L) to the StThomas' plus glucose (10 mmol/L) 
cardioplegic solution, increased the buffering capacity of the St Thomas' plus glucose 
solution fivefold, delayed A TP decay during a 3-hour ischaemic period and improved 
postischaemic mechanical recovery (Fig 5.13 (appendix B-5)). 
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Legend: 
Postischacmic mechanical recovery, expressed as mean ratios of individual preischaemic values, of isolated rat hearts after 3· 
hour 10°C cardioplegic arrest Hearts were protected with a single dose of ~ither StThomas' plus 10 mmol/L glucose (ST+G), 
ST +G plus histidine (50 mmoi/L), ST +G plus Sucrose (SO mmol/L) or Bretschneider HTK4 (B-HTK4) cardioplegic solutions. 
The vertical bars represent the standard errors of the means. 
o- p < 0.01 compared to ST +G +Histidine, 
+- p < 0.05 compared to ST+G+Histidine. 
The beneficial effect of including histidine was not due to the associated osmolality or 
sodium changes, as a similar St Thomas' plus glucose plus sucrose cardioplegic solution 
was no more effective than St Thomas' plus glucose cardioplegic solution. In addition, 
Bretschneider HTK4 with a buffering capacity 16 times that of the St Thomas' 
cardioplegic solution did not improve either A TP preservation or postischaemic 
recovery, and increased sarcolemmal damage (appendix B-5). 
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We also compared the efficacy of StThomas', StThomas' plus Histidine (50 mmol/L), 
and StThomas' plus 10 mmol/L glucose plus histidine (50 mmol/L) cardioplegic 
solutions, in a pilot study in the in vivo primate model (appendix B-6). Although only a 
limited number of animals were used (N = 3) in this pilot study, making statistical 
analysis difficult, the trend in postoperative myocardial function between the groups is 
notable (Figure 5.14). 
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THE ADDITION OF HISTIDINE TO THE STTHOMAS' 
CARDIOPLEGIC SOLUTION: PRIMATE STUDY 
Control 
StThomas' 
ST + Hlat 
<D 60 
""0 ST + Hfat + Glucose 
c 
;:y::_ 
I.... 
0 :s: 40 
~ 
0 
I.... 
Cl) 20 +•o +o 
••••••••••••••••••••••••••••••••••••••••• •••••••••••••••••••••••
•••••••••••••••••• ooooooo••••••••••••••••ooooou•••••uou 
0~~~--------r------------+------------~----------~ 
0 5 10 
Left Atrial Pressure 
Legend: 
15 
mm Hg 
20 
Left ventricular stroke work index (gm.m/beatfm2) at increasing left atrial pressures before and after 3-hour hypothermic ischaemia 
protected with either multidose StThomas' (N = 3), StThomas' plus histidine (N = 3) or StThomas' plus histidine (50 mmoi/L) plus 
glucose (10 mmoi/L; N = 2) cardioplegic solution. A postischaemic left ventricular function curve of stroke work index was obtained 30 min 
after weaning from cardiopulmonary bypass, and compared to a similar preiscbaemic curve. Mean percentage postiscbaemic recovery was 
calculated from each individual postischaemic and preischaemic ratio. An average preischaemic control function curve (Control; N = 8) 
was derived by pooling the data from all groups, and postischaemic function for each group normalized to this curve for display purposes. 
•- p < 0.01 compared to StThomas', 
+ - p < 0.05 compared to StThomas' plus Histidine, 
o- p < 0.05 compared to Control 
186 U 0 Von OppeU PhD Thesis; University of Cape Town, 1992 
The St Thomas' cardioplegic solution already provided good myocardial preservation in 
this model, thus we felt that further significant improvements would be difficult to 
obtain. Therefore, we elected not to continue with this model and changed to a model 
using preischaemic energy deficient hearts (see appendix B-9). Nevertheless, the 
addition of histidine to the St Thomas' cardioplegic solution tended to improve 
postischaemic function. However, the addition of glucose (10 mmol/L) to this modified 
St Thomas' cardioplegic solution containing a greater buffering capacity again decreased 
postischaemic recovery (appendix B-6) (see section 5.1). The increased buffer capacity 
provided by histidine did not prevent the depression of myocardial function in the 
primate model noted previously with the addition of glucose (10 mmol/L) to the St 
Thomas' cardioplegic solution (appendix B-1). We could though conclude that the 
addition of histidine to the St Thomas' cardioplegic solution was not deleterious in the 
primate model 
In a separate in vivo primate study, we examined the efficacy of a modified St Thomas' 
cardioplegic solution containing both histidine (50 mmol/L) and adenosine (1 mmol/L), 
and a lower calcium content (0.6 mmol/L) in energy depleted hearts (see Appendix B-
9). The hearts were made globally ischaemic and fibrillated for 20 min prior to a 3-hour 
period of cardioplegic arrest The optimum concentration of calcium in the St Thomas' 
Hospital No 2 cardioplegic solution is 0.6 mmol/L and not 1.2 mmol/L (B2,R31,R32) 
(see section 3.1). Furthermore, the optimum concentration of adenosine in the St 
Thomas' cardioplegic solution was established in our laboratory to be 1 mmol/L (D 
Boehm; unpublished results). We therefore felt justified for both financial reasons and 
because of our preceding results to introduce all three modifications to the St Thomas' 
cardioplegic solution. This modified cardioplegic solution containing both a higher 
buffering capacity, a lower concentration of calcium and adenosine was associated with 
improved postischaemic recovery compared to the standard StThomas' Hospital No 2 
cardioplegic solution (appendix B-9) (Figure 5.15). 
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Figure 5.15 
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Animals were subjected to a 20-min period of ventricular fibrillation witb global ischaemia at 32°C prior to 3-hour hypothermic 
cardioplegic arrest witb multidose reinfusions of either tbe StThomas' Hospital No.2 cardioplegic solution (N ~ 8) or a modified 
StThomas' cardioplegic solution (StThomas' + Hist +Aden; N ~ 6) containing a lower concentration of calcium (0.6 mmol/L), 
histidine (SO mmol/L) and adenosine ( 1 mmol/L). A postiscbaemic left ventricular function curve of stroke work index was 
obtained 30 min after weaning from cardiopulmonary bypass at increasing left atrial pressures, and compared to a similar 
preiscbaemic curve. Mean percentage postiscbaemic recovery was calculated from each individual postiscbaemic and 
preischaemic ratio. An average preiscbaemic control function curve (Control; N = 14) was derived by pooling tbe data from botb 
groups, and postiscbaemic function for each group normalized to tbis curve for display purposes. 
o- p < 0.05, +- p < 0.01; compared to StThomas' No 2, •- p < 0.01 compared to Control 
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In conclusion, the buffering capacity of an extracellular electrolyte equivalent solution 
such as the St Thomas' cardioplegic solution, can be increased without significantly 
altering its ionic formulation. An intracellular electrolyte formulation such as 
Bretschneider HTK4 is not necessary, in order to provide osmotic space for sufficient 
buffer. 
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5.5 OSMOLALITY AND COLLOID ONCOTIC PRESSURE IN 
CARDIOPLEGIC SOLUTIONS 
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Myocardial oedema can occur secondary to both hypothermia (E7) and ischaemia 
(F21,L24), because of failure of ATP dependant cellular homeostasis. Ischaemia results 
in accumulation of end products of anaerobic metabolism and is reported to increase 
intracellular osmotic pressure by 40 mOsm /L during the first 50 min of ischaemia (T23). 
Fluid is then shifted from the extracellular to the intracellular space, resulting in cellular 
oedema. Induced changes in myocardial water content are usually less than 4%. 
However, this would imply large changes in left ventricular mass; an increase of up to 
22% (R35). In the clinical situation, sternal closure is occasionally not possible because 
of cardiac compression (following difficult prolonged procedures that resulted in severe 
myocardial oedema (M43,05)). Hence, there is a need to prevent myocardial oedema 
Tissue fluid is compartmentalized; intravascular fluid, interstitial fluid and intracellular 
fluid, and each compartment has a different composition ( G2). The capillary wall 
separates the intravascular and interstitial compartments, and allows diffusion and 
ultrafiltration. At this interface, the majority of fluid is filtered according to Starling's 
forces; capillary hydrostatic pressure ( 40 - 15 mm Hg) and colloidal oncotic pressure (25 
mm Hg) (S24 ). Thus the colloid oncotic pressure exerted by intravascular proteins is the 
primary means of retaining water in the intravascular space and preventing interstitial 
oedema, as the majority of proteins do not pass through the capillary walL In the 
absence of plasma proteins there are no forces drawing fluid back into the capillaries, 
and fluid can only return into the vascular compartment by lymphatics. 
The interstitial fluid is in turn separated from the intracellular compartment by the semi-
permeable cell membrane. Ions are distributed across the cell membrane according to 
both their concentration and electrical gradients, and water then diffuses according to 
the effective osmotic pressure (G2). 
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All fluid compartments are in osmotic equilibrium; and plasma isotonicity corresponds 
to an osmolal concentration of290 mOsm/kg H20. Interstitial and intravascular 
hypotonicity would cause water to move into the intracellular compartment and thus 
result in intracellular oedema. Swelling of cells is not only a· manifestation of injury but 
may also contribute to the process leading to cell necrosis (L24). Postischaemic 
myocardial oedema depresses left ventricular function and increases coronary vascular 
resistance (F22,P26,W29), and thus should be prevented during cardiac surgery. 
Colloid Oncotic Pressure 
Colloid; either albumin, hydroxy ethyl starch or pentastarch, are used clinically both as 
the priming fluid for cardiopulmonary bypass circuits and for volume expansion, in order 
to prevent somatic and pulmonary fluid accumulation (L47,Ml3,S2). In addition, 
dextran has been used systemically to prevent the deleterious effects of both systemic 
and myocardial hypothermia; that is increased viscosity, haemoconcentration, sludging, 
and cellular oedema both experimentally and clinically (A5,F33,M51). 
We therefore evaluated the effect of adding either 2% or 3% dextran-40 to the St 
Thomas' Hospital No 2 cardioplegic solution in the isolated rat heart model (appendix 
B-7). The oncotic pressure was increased from below 0,2 mm Hg in the standard St 
Thomas' cardioplegic solution to 15 and 25 mm Hg respectively. In this model (3-hour 
hypothermic (IQOC) ischaemia protected with a single dose of cardioplegia), the addition 
of either 2 % or 3 % Dextran did not improve postischaemic mechanical recovery. 
Furthermore, there was no difference in the myocardial water content following 
reperfusion between the three groups (appendix B-7). 
In contrast, Foglia et al prevented potassium cardioplegia induced postischaemic 
myocardial oedema by adding albumen ( oncotic pressure 21 mm Hg) to the cardioplegic 
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solution (F22). However, the canine is thought to be more susceptible to 
cardiopulmonary bypass and ischaemic induced myocardial oedema than humans (R35). 
This is substantiated by the significant amount of oedema induced in their model in a 
short 10-minute ischaemic period. Moreover, in clinical trials no difference in 
postischaemic myocardial function or outcome could be demonstrated by including 
either 3.5% dextran-40 or albumin (5 gm %) in a crystalloid cardioplegic solution 
(B34,L39). Our study would support the conclusion that colloid does not appear to be 
necessary in crystalloid cardioplegic solutions, when administered as either single or 
multiple doses during clinical open-heart surgery. However, colloid may still.be 
necessary during prolonged hypothermic perfusion of isolated stored hearts, when a 
continuous hydrostatic pressure would otherwise induce interstitial oedema (see section 
3.3) (K17)_ 
Crystalloid osmotic pressure 
Sixty percent of body weight consists of water, of which 80% is intracellular (G2). 
Hence, the osmotic pressure of fluids infused intravascularly are of great importance, as 
osmotic pressure is a primary determinant of intracellular volume. 
In the isolated rat heart model using a 3-hour hypothermic (10°C) ischaemic period 
protected with multi dose of cardioplegia, we evaluated the effect of changes in the 
osmotic pressure of modified StThomas' cardioplegic solutions (appendix B-3). Th~ 
osmolality of the St Thomas' cardioplegic solution was altered by adding sucrose, an 
inert substance that is not metabolized intravascularly. Although these studies were 
performed as pilot studies to determine if the available osmotic space could be increased 
in the St Thomas' cardioplegic solution, significance was obtained despite the low 
numbers in each group (N = 4). In this model, the osmotic pressure of a modified St 
Thomas' cardioplegic solution with a sodium concentration of either 100 or 120 mmol/L 
could be increased from 300m0sm/kg H20 to 340-350 mOsm/kg H20 (appendix B-
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3)_ Postischaemic mechanical recovery was either not altered or increased with this 
moderate hypertonicity (Fig 5.16). Similar to the findings of Foglia et al (F22), 
cardioplegic solution hypotonicity (osmolality- 260 mOsm/kg H20) was harmful 
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Postischaemic recovery of cardiac output expressed as a mean ratio of each individual preischaemic value, of isolated rat hearts 
after 3-hour 10°C cardioplegic arrest Hearts were protected with multidose cardioplegic infusions of either the StThomas' 
Hospital No 2 cardioplegic solution which has a sodium concentration of 120 mmol/L, or a modified StThomas' solution with a 
sodium concentration of 100 mmol/l. Osmolality was then altered in each solution by the addition of sucrose. 
o- p < 0.05 compared to 300 mOsm/kg H20, sodium- 120 mmol/L, 
+- p < 0.05 compared to 310 mOsm/kg H20, sodium -100 mmol/l. 
Hearse et al suggest that the composition of cardioplegic solutions should not differ 
markedly from normal extracellular values (Hl4,H16), and showed that an increase of 
osmolality of± 20 mOsm/kg H20 did not alter mechanical recovery significantly (H27), 
and the addition of mannitol (50 mmol/L) diminished postischaemic recovery. 
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Nevertheless, Goto et al enhanced myocardial protection by increasing the osmolarity of 
the St Thomas' cardioplegic solution to 360 m Osm /L by the addition of mannitol ( G25). 
Moreover, isotonicity of crystalloid cardioplegic solutions is associated with 
postischaemic myocardial oedema (F22,T23)_ 
In the canine model, which might be more prone to myocardial oedema (R35), 
cardioplegic osmolality of 370 mOsm/kg H20 produced± 2.3% dehydration (F22). 
However, excessive hypertonicity (osmolality greater than 350 mOsm/kg H20) in our 
model tended to diminish postischaemic recovery. Furthermore, in the normothermic 
working heart moderate hypertonicity (increases of20- 40 mOsm/kg H20) are 
beneficial in ischaemic myocardium (P26,W29), but hyperosmolality greater than 400 
mOsm/kg H20 is harmful (W28)_ Nevertheless, a clinical study failed to show a 
beneficial effect of increasing cardioplegic solution osmolality to 347 mOsm/kg H20 
with mannitol, although there was possibly more rapid postischaemic metabolic recovery 
(B43)_ 
We would suggest that cardioplegic solutions should never be hypotonic, but rather 
isotonic or moderately hypertonic (300- 350 mOsm/kg H20). More marked 
hyperosmolality may though be beneficial in reperfusion of the postischaemic 
myocardium (F9,F24,025,S19). However, the majority ofthese studies have used 
mannitol to increase tonicity, and mannitol has additional effects other than preventing 
swelling of cells (P26), such as free radical scavenging properties (F9,M4,025)_ 
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5.6 ANIONS IN CRYSTALLOID CARDIOPLEGIC SOLUTIONS 
The formulation of cardioplegic solutions has been centered predominantly on the 
cation content of the solution. Nevertheless, the associated anions can influence the 
efficacy of the solution. The included anions can act in buffer systems (HC03 -, Po42-), 
as metabolic substrates (acetate, lactate, aspartate, glutamate), chelators (citrate), or 
merely as counterions (Cn. 
Undesirable anions 
Phosphate salts are potentially dangerous in calcium containing cardioplegic solutions, 
because of the possibility of precipitates of calcium phosphate. Lactate is also 
potentially harmful (H26). Citrate inhibits glycolysis and has a strong affinity for 
calcium, and' will thus change the calcium content of the final cardioplegic solution. 
Potassium citrate as apposed to potassium chloride is associated with diminished 
postischaemic recovery, and the citrate ion should therefore also be avoided in 
crystalloid cardioplegic solutions (H25). 
Potentially useful anions 
Hearse et al showed that either the chloride or sulfate salt of magnesium could be used 
in the StThomas' cardioplegic solution (H28). However, the chloride salt was chosen 
for the final composition because chloride salts have high solubility coefficients. 
Although Hearse et al suggested that the aspartate salt did not improve the efficacy of 
the solution (H24), aspartate and glutamate have since been shown to be potential 
substrates for both anaerobic and aerobic metabolic pathways (B27,E10,E13,M18,R41). 
In contrast, the chloride anion has been implicated in the production of cellular oedema, 
as it is a freely permeable anion. A significant proportion of intracellular anions are 
nondiffusable, and this hinders the diffusion of cations and favours intracellular 
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diffusion of chloride ions (Donnan effect) (G2). Ischaemic induced increases in 
intracellular cations will tend to shift chloride ions into the intracellular space, which will 
concomitantly draw water intracellularly to maintain isotonicity (R20). The replacement 
of chloride ions by non permeable high molecular weight anions (lactobionate, 
gluconate) therefore helps regulate cellular oedema (W3). 
In the isolated rat heart model using a 3-hour hypothermic (10°C) ischaemic period 
protected with a single dose of cardioplegic solution, we evaluated whether partially 
replacing the chloride ion in the St Thomas' cardioplegic solution would be beneficial 
(appendix B-4). The chloride concentration in the StThomas' cardioplegic solution was 
reduced from 160.4 mmol/L to 34.4 mmol!L, by using sodium and potassium gluconate. 
However, neither postischaemic mechanical recovery nor postreperfusion water content 
was altered by this modification (appendix B-4 ). 
We also evaluated the effect of this modified StThomas' cardioplegic solution 
containing a low chloride content on the endothelium (appendix A-6). In this model, 
exposure of monolayer cultures of human endothelial cells to the low chloride 
concentration cardioplegic solution improved endothelial survival at hypothermia 
(10°C), but not at normothermia. However, gluconate also binds calcium (C27) and 
therefore alters the free ionized calcium concentration in the solution. Nevertheless, we 
demonstrated that a change in calcium content was not the mechanism for the improved 
survival with this low chloride solution (appendix A-6). 
In conclusion, a low concentration of chloride in the St Thomas' cardioplegic solution 
does not adversely effect postischaemic myocardial function. Furthermore, a low 
chloride content may well have alternative beneficial effects, and should probably 
therefore be investigated further. 
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Ch.a.pt·~x- 6 
THE CARDIAC SURGEON AND THE ENDOTHELIUM 
The first barrier between the blood stream and the extravascular space is a monolayer of 
squamous epithelial cells; the vascular endothelium (Fig 6.1 ). 
Figure 6.1 
Legend: 
Phase contrast microscopy appearance of a confluent monolayer o~human saphenous vein endothelial cells,_ which demonstrates 
the typical cobblestone morphology. (Magnification X 100). Reprinted from Applied Cardiovascular Biology 1990, Vol2, 
1991:(in press) with permissionS Karger AG, Basel 
In the average adult the endothelium occupies a surface area of approximately 1000 m2, 
and performs a multitude of functions without which we could not survive (Jl). In fact, 
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the endothelium should be considered as an "organ" in its own right, although distributed 
throughout the entire body. The endothelium also responds to various stimuli not only 
as a target for injury, but also by altering its function, metabolism and structure and 
thereby influencing secondary responses to injury (C39,R45). Injury to any organ results 
in concurrent damage to the vascular endothelium of that organ. Hence, the function, 
response to injury and preservation of the endothelium should be an important 
consideration of all cardiovascular surgeons. Furthermore, of specific importance to the 
cardiac surgeon is the effect on the endothelium of ischaemia and "protective" solutions 
infused into the coronary circulation, and the preservation of the endothelium of 
saphenous veins harvested for coronary artery bypass grafts. The patency of prosthetic 
grafts used to replace portions of the vascular system or bypass small diameter vessels 
can also be improved by autologous endothelialization of their internal surfaces. 
(Z3,Z4,Z5). Moreover, rapid acute endothelialization of vessels denuded of 
endothelium as a result of injury or endarterectomy, may also improve vascular surgical 
results (S26). 
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~1 THEFUNCTIONOFTHEENDOTHEUUM 
The vascular endothelium consists of a haemocompatable monolayer of cells that 
synthesize subcellular stroma, regulate angiogenesis, modulate capillary permeability, 
inflammation, the immune response, haemostasis, and vascular smooth muscle tone 
(C39,F2,P8). The endothelium modulates these biologic systems by a number of 
mechanisms: converting circulating precursors into vasoactive products, degrading 
vasoactive substances, secreting vasoactive substances into both the blood stream and 
subcellular matrix, and also by binding various substances (Bl4,B59,Jl,R57) (Table 6.1). 
Furthermore, the endothelium interacts continuously with circulating platelets, 
leukocytes, and vascular smooth muscle cells (G35,H42,M27). 
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Table 6.1 
FUNCTIONSOFTHEENDOTHEUUM 
Regulates Bae1ostasis and Throlbosis 
Antithrolbotic activities 
Secretes 1 expresses: 
EDRF 
Prostacyclin (PGI2) 
Thrombomodulin 
Beparan sulfate 
Antithrombin III 
Plasminogen activator (tPA) 
Adenosine 
13-HODE 
Inactivates: · 
Thrombin 
ATP, ADP 
Serotonin 
Prostaglandins 
Procoagulant activities 
Secretes 1 expresses: 
Collagen 
Fibronectin 
Thromboxane A2 
Thromboplastin 
Von Willebrand factor 
Factor V 
Inhibitor of tPA 
Platelet activating factor 
Binds: 
Thrombin 
Fibrinogen 
Factors Va, IXa, Xa 
Modulates the Infla11atory Process 
Modulates adhesion-of leukocytes 
13-HODE, PGI2, EDRF 
Secretes: 
Interleukin-1 
Platelet-derived growth factor 
Platelet activating factor 
Manifests: 
ABO blood groups 
HLA antigens 
complement binding receptors 
Vasodilator properties 
Secretes: 
EDRF 
Prostacyclin 
Adenosine 
Inactivates vasoactive substances 
Angiotensinase 
Monoamine oxidase 
Kinase II 
I11unoreactivity 
Modulates Vascular Tone 
Vasoconstrictive properties 
Secretes: 
Endothelins 
Thromboxane A2 
Activates Angiotensin I: 
Angiotensin converting 
enzyme 
Myocardial protection during cardiac surgery; Chapter 6 U 0 Von Oppelt 20 J 
Antithrombotic and haemostatic functions 
The normal quiescent endothelium is antithrombogenic, as a result of complex 
endothelium-mediated mechanisms that either interfere with platelet aggregation, 
thrombus formation or activate fibrinolysis (Table 6.1). The primary mechanism is 
probably the inhibition of platelet adhesion and aggregation by both intracellular 
endothelial13-hydroxy-9,11-octadecadienoic acid (13-HODE), and a continuous 
endothelial release of both prostacyclin (PGI2) and endothelium derived relaxing factor 
(EDRF) (D20,G35,Ml)_ PGI2 and EDRF discourage both platelets and leukocytes 
from adhering to the endothelial lining by increasing intracellular platelet and leukocyte 
.levels of cAMP and cGMP (D20,R2,R3)_ 
Nevertheless, endothelial cells also play a dyn'amic role in haemostasis; the formation of 
. a platelet plug, fibrin clot and its subsequent intravascular limitation and dissolution, 
should the vascular endothelium be damaged (Table 6.1). The basal release ofPGI2 and 
EDRF are lost if the endothelium is denuded or damaged and platelets therefore 
aggregate and adhere (P8)_ In addition, the subendothelial extracellular matrix which 
contains collagen, fibronectin, von Willebrand factor etc, is produced by the endotheiium 
(J2,Wl,W6), and activates the clotting cascade ~nd enhances platelet adhesion if exposed 
to blood. Platelet aggregation in turn potentiates both further platelet aggregation and 
clot formation by the release of vasoactive substances contained in platelets (~DP, A TP, 
serotonin, thromboxane A2, platelet activating factor (G 15,P8,V10)). Moreover, the 
clotting cascade is further enhanced by endothelium binding of various activated clotting 
factors (P8) and release of the platelet aggregator thromboxane A2 (R4). 
The endothelium is thus not only antithrombogenic but in addition promotes coagulation 
if it is damaged, and thereafter modulates the clotting process by inactivating platelet 
released factors, and by activating fibrinolysis through the release of plasminogen 
activator and PGI2 ( G 35,lA8) (Table 6.1 ). Furthermore, endothelial activation by injury 
--- --~~----~~ ~ ,_ <----~ --- . --- ·-·-- ~ 
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However, the vasodilator activity of the majority of vasoactive agonists is dependent 
upon the endothelium for their vasodilating effects (Bl4,F16,F35,G35). In contrast, the 
simultaneous vasoconstrictive effects of these same vasoactive agonists are due to a 
direct action on the vascular smooth muscle, although possibly requiring higher 
concentrations. Thus, vasoactive substances such as acetyl choline and serotonin will 
. 
. 
cause vasodilation of a vessel in the presence of intact functioning endothelium 
(endothelium-dependent vasodilation), but vasoconstriction in the absence of the 
endothelium (endothelium-independent vasoconstriction). In contrast, endothelium-
. independent vasodilators (papaverine, sodium nitroprusside) cause vasodilation in the 
presence ur absence of the endothelium. 
The endothelium also metabolizes and removes many circulating vasoactive substances 
from the blood stream. Vasoconstrictor responses are therefore enhanced if endothelial 
function is impaired, and the endothelium is thus an essential structure that modulates· 
vascular tone. 
Endothelium-dependent vasodilation 
The primary mechanism of endothelium-dependent vasodilation is the release of EDRF 
and PG I2 in response to a number of stimulants (B 14,P9). Furthermore, it is postulated 
that the endotheli~m provides a constant vasodilator tone, which prevents vasospasm by 
circulating or platelet released vasoconstrict~rs (G35,S74). Moreover, arteries and vein$ 
demonstrate differences in their vasomotor responses, and this difference is due to the 
variability of EDRF release by different vascular beds (L5l,S34,Tl7). 
PGI2 is produced by both endothelial and smooth muscle cells, has a longer half-life 
than EDRF, inhibits platelet aggregation, has cytoprotective and fibrinolytic properties 
and relaxes vessels b)' increasing platelet and smooth muscle cAMP, in response to 
various stimuli (G35,S28) (Fig 6.2). Furthermore, the endothelium utilizes prostaglandin 
precursors released from platelets to form additional PGI2 (D20). The rate of synthesis 
of PGI2 also possibly accounts for differing incidences of atherosclerosis in the 
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population; increased atherosclerosis in men and transplant recipients from testosterone 
and cyclosporine inhibition of PGI2 (035,833), and in different vascular beds; the low 
incidence of atherosclerosis of the internal mammary artery (R45). Thus, PGI2 is a 
factor contributing to the internal mammary being the ideal conduit for coronary artery 
bypass grafts (Al,S80). 
Nevertheless, EDRF is thought to be the dominant endothelium-dependent vasodilator, 
·has a half life of less than six seconds in vivo and has now been identified as nitric oxide 
(P2). EDRF induces smooth muscle relaxation by stimulating guanylate cyclase and thus 
increasing cGMP which in turn decreases smooth muscle cytosolic calcium (Fl6,F34), in 
similarity to the nitrovasodilators (sodium nitroprusside, glyceryl trinitrate ). The release 
of EDRF though requires oxygen, and EDRF induced vasodilation can be inhibited by· 
anoxia, free haemoglobin (binds nitric oxide and inhibits guanylate cyclase) and 
methylene blue (inhibits guanylate cyclase) (Bl4,B59). Furthermore, oxygen free 
radicals and more specifically the superoxide anion destroys EDRF (L16,Vll), whereas 
the free radical scavenger superoxide dismutase increases the stability of EDRF (Bl4). 
Endothelium-dependent vasoconstriction 
The endothelium also synthesizes and releases a potent vasoconstrictor; a 21-amino acid 
peptide- endothelin, which increases cytosolic calcium (N4). Endothelin can thus 
produce severe coronary vasoconstriction (El8,H41), as well as a positive chronotropic, 
inotropic and direct arrhythmogenic effect in the heart (N4,Y4). Furthermore, 
endothelin has a mitogenic effect on vascular smooth muscle and therefore may be a 
mediator of atherosclerosis, in contrast to EDRF which inhibits mitogenesis 
(N4,R2,W20). Nevertheless, endothelin also stimulates the release of EDRF and PGI2, 
which counteracts its effects to a certain extent (W36). However, endothelin has a slow 
sustained effect in contrast to EDRF, which has a rapid short duration of action. 
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Endothelium-dependent relaxation of vascular smooth muscle usually dominates over 
the endothelium-independent constrictor effects. Moreover, physiochemical factors 
such as shear stress, pulsatile flow and hypoxia induce endothelium-dependent 
vasodilation, and endothelial cells can thus act as flow sensors. Peripheral resistance 
arterioles, where endothelium-dependent vasodilation is more pronounced, can 
therefore respond to more proximal increases of blood flow (B14). The endothelium is 
thus an essential structure that normally induces a constant "background tone" of 
vasodilation. Any imbalance between endothelium released vasoactive substances 
(endothelin, EDRF, PGI2), as well as platelet, leukocyte and circulating vasoactive 
substances would effect vascular tone both locally and globally, 
The endothelial response to injury 
Removing the endothelium from a vessel is obviously harmful; the barrier effect of the 
endothelium is lost, local endothelium-dependent vasodilation is lost, blood is exposed to 
the thrombogenic subcellular matrix, and both platelets and leukocytes aggregate and 
adhere to the site of injury. However, the endothelium also responds to various stimuli 
not only as a target for injury, but also by altering its function, metabolism and structure 
and thereby influencing secondary responses to injury. Thus, sublethal injury of the 
endothelium without disruption of monolayer integrity can also be harmful (C39). 
Endothelial injury can then as discussed above, result in the endothelium becoming 
procoagulant, immunoreactive, adhesive to platelets and leukocytes, as well as 
increasing vascular permeability and promoting vasoconstriction. 
Reendothelialization of denuded arterial endothelium although dependent upon the 
I 
severity of the initial trauma (L40), occurs in 7- 10 days (H13,L44). Nevertheless, the 
function of regenerated endothelium remains abnormal for 4 - 12 weeks, and is 
characterized by a reduced ability to release EDRF and increased endothelium-
dependent vasoconstriction (C42,C5,D20,L38,S43). Furthermore, even in the absence of 
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initial denudation of the endothelium, ischaemic induced injury endothelial dysfunction 
can also persist for a prolonged period (Fl2,P12,Pl3). Endothelial injury thus produces 
an immediate as well as a more prolonged predisposition (up to 3 months) for both 
thrombosis and vasospasm. In addition, endothelial injury in combination with platelet 
and leukocyte interactions are mechanisms for the pathogenesis of atherosclerosis 
(B52,D20,R45,W20), and intimal hyperJ>lasia in arterialized saphenous veins (B23,E3). 
A multitude of factors can cause endothelial dysfunction and injury (B52), and these 
include direct mechanical factors such as probes (J8), angiographic catheters, 
angiographic contrast media (HlO), endothelial hypoxia (06), diabetes, cigarette 
smoking (Z6), low density lipids (Z9), radiation, endotoxins, immune complexes and 
haemodynamic stresses. In addition, both the underlying pathology resulting in the need 
for cardiac surgery (atherosclerosis), and cardiac surgery itself can damage the 
endothelium. 
Atherosclerosis 
Atherosclerosis is not only the result of endothelial injury, but atherosclerosis also causes 
further progressive impairment of endothelial vasoactive functions (Zl). For example, 
in normal coronary arteries both acetyl choline, sympathetic stimulation and shear 
stresses all cause vasodilation, but in the presence of atherosclerosis these normal 
vasodilator responses are lost and vasoconstrictive responses then predominate 
(V2l,Z2)_ Furthermore, overt atherosclerotic plaques need not be present as 
endothelial dysfunction also occurs in both "angiographically normal" coronary arteries 
and "normal" collaterals, in patients with hypercholesterolaemia or evidence of 
atherosclerosis elsewhere (S36,S37,Z 1)_ Therefore, in patients with atherosclerotic 
induced angina pectoris and myocardial infarctions, loss of endothelial-mediated 
vasodilation may contribute to vasospasm (Bl4,D20,H42). 
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"Elective" cardiac ischaemia and reperfusion 
Surgically induced cardiac ischaemia and subsequent reperfusion produces both myocyte 
and endothelial damage (F 12,S85). Ischaemia and hypoxia cause endothelial changes 
that result in increased endothelial permeability and procoagulant properties (H40,06), 
and reperfusion with initial high pressures also increases endothelial cell damage (S17). 
Furthermore, ischaemic induced myocardial damage occurs primarily in the interstitium 
(H55) and endothelial interface during the first few minutes ofreperfusion (T24,T25), 
and the endothelium is possibly more vulnerable to ischaemia than the myocyte (S86). 
The reperfusion injury is produced by oxygen free radicals (see section 1.6) (T24,T25) 
generated by endothelial and leukocyte intenictions (M37), which in addition induce 
further endothelial damage. 
Endothelial injury thus results in increased endothelial permeability, platelet 
aggregation, leukocyte adhesion and migration (K24,M28,S86), increased production of 
endothelium-derived contracting factor (P 1 0), impaired endothelium-dependent 
relaxation in response to aggregating platelets and vasoactive drugs (Pll,Pl2,V8), 
vasoconstriction and procoagulant properties which in turn causes further secondary 
myocardial damage. Moreover, dysfunction of endothelium-dependent vasodilation 
primarily alters postischaemic blood flow to the more vulnerable subendocardium (P13). 
Plasma levels of the powerful vasoconstrictor endothelin are also increased for 2 - 3 days 
after surgery (N4). In fact, it is possible that myocardial stunning and the reperfusion 
injury are merely manifestations of the consequence of endothelial injury. 
Hence, there are a multitude of factors that can potentially injure the vascular 
endothelium during cardiac surgery, and ideally, endothelial injury and its potentially 
disastrous consequences should be prevented (Figure 6.3). Furthermore, endothelial 
dysfunction may be present as a result of preexisting pathology; atherosclerosis, and 
occasionally endothelial injury cannot be prevented; endarterectomies of severely 
diseased vessels. 
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Consequences of Endothelial Injury 
A number of factors may injure the vascular endothelium during cardiac surgery, and the injured endothelium and vessel waD 
then interacts with both platelets and leukocytes causing the tabulated possible consequences. Endothelial injury induces both 
early and late myocardial dysfunction. 
Therefore, pharmacologic modifications of endothelium, platelet and leukocyte 
interactions with aspirin, beta-blockers, calcium antagonists, nitrates, thromboxane 
synthetase inhibitors and thromboxane receptor antagonists, are therefore possibly 
essential for up to 3 months after any injury to the endothelium (D20). In addition, low 
dose eicosapentaenoic acid (cod-liver oil) may also be beneficial by facilitating 
endothelium-dependent vasodilation (G35), inhibiting atherosclerosis and in the long 
term by decreasing intimal hyperplasia (D20,L5). 
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6.2 PRESERVATION OF SAPHENOUS VEIN ENDOTHELIUM 
Cardiac surgeons possibly first became aware of the importance of preserving the 
endothelium when harvesting saphenous veins for use as coronary artery bypass grafts, 
in order to decrease the incidence of early graft occlusion. Rough dissection techniques, 
excessive distention, low storage temperatures, and the composition of solutions used for 
irrigation and storage, have all been implicated in damaging the endothelium of 
saphenous vein grafts. 
However, in addition to this surgically induced endothelial dysfunction, vein grafts also 
. undergo endothelial cell loss, smooth muscle hyperplasia (S49), medial fibrosis (B67,C2), 
lipid uptake (B35) and functional changes (B79,Fll,K29,M45) as a result of 
implantation into the arterial side of the circulation; arterialization of vein grafts (H30). 
These changes associated with arterialization of vein grafts can though be limited by 
optimum harvesting techniques (AlO). Increased endothelial damage at operation may 
predispose to both early graft occlusion as a result of endothelial cell dysfunction (C42), 
endothelial cell loss, platelet and leukocyte adherence (L44), as well as late occlusion 
due to increased myointimal hyperplasia ( 02,R5), lipid uptake (B45) and atherogenesis 
(B66,013,S84)_ Arterialized vein grafts have also though been shown to secrete high 
concentrations of prostacyclin from the media despite significant endothelial loss, which 
would help counteract the effects of endothelial damage(B79,H47,H30). 
Each aspect of the harvesting of saphenous veins has been ev:aluated in order to prevent 
saphenous vein endothelium damage. 
Dissection techniques 
Standard dissection techniques, consisting of adventitial stripping and uncontrolled 
manual distention results in decreased release of EDRF and endothelial cell loss (A25). 
Therefore, atraumatic dissection techniques are essential In addition, venous side 
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branches must be ligated away from the vessel wall in order to prevent intraluminal 
stenoses due to protrusions of the intima and media (040). Furthermore, despite 
reversal of saphenous veins, venous valves are associated with thrombosis and late 
fibrosis and stenosis due to turbulent flow (M47,S84). Therefore, routine incision of 
valves with a valvutome has been advocated (M47,M52,S84). 
Storage temperature 
Cold induces venous constriction, which is harmful Veins stored at 4°C compared to 
21 °C or 37°C have been shown to have increased morphological changes (L45,S59) and 
thereafter red~ced secretion of both EDRF (Ll5) and PGI2 (B80). However, if topical 
or infused papaverine is used during harvesting to prevent venospasm then storage 
temperature is possibly not a significant factor (BlO), although initial distention with a 
hypothermic solution may still be damaging (L45). Moreover, Gundry et al reported 
better preservation of veins stored at 4°C as apposed to 28°C, but no statistical analyses 
were performed on these limited morphological studies (G39,G40). Nevertheless, the 
consensus appears to be that veins are best stored at room temperature (Bll,Ll4). 
Distention 
Uncontrolled distention of saphenous veins to check for leaks can easil)' produce 
pressures in excess of 600 mm Hg (A3). Distending venous grafts with pressures of 400-
500 mm Hg is harmful to both the endothelium (B45,C2,L15,M9), and tunica media 
(A26,R5), and is possibly the most harmful variable during harvesting of vein grafts 
(K44). Therefore, the pressure used to distend saphenous veins should be restricted to 
less than 300 mm Hg, by using a pressure limiting device (B45,L43). Nevertheless, for 
optimum preservation venous distention should probably be limited to physiological 
pressures of not more than 100- 150 mm Hg (A26,G39,G40), although distention to 
either 125 mm Hg or 350 mm Hg does not alter lipid uptake (B35). 
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Prevention of venospasm 
Venospasm causes intimal tears and endothelial detachment (H ~2). Despite careful "no-
touch" dissection techniques venous contracture and collapse occur often during 
harvesting of saphenous veins, and this can be prevented by perivenous infiltration with 
papaverine (Plasmalyte A, papaverine 0.12 mg/ml, heparin sodium 4 U /ml) (H12,L45), 
and flushing of the vein with the same solution (L43). Alternatively; intermittent 
irrigation and topical spraying of the vein every 2 - 3 min as soon as it is exposed, with 
Plasmalyte and papaverine (0.05- 0.6 mg/ml) during harvesting might be equally 
effective (B 15). This method produced superior early graft patency rates clinically, than 
atraumatically harvested veins stored in blood (C9). Papaverine (0.12- 1 mg/ml) though 
has now also been added to autologous heparinized (10 U /ml) blood with reported good 
preservation of the endothelium (AlO,B10). However, Roberts et al showed that the 
addition of papaverine to an electrolyte solution used to flush saphenous veins lowered 
the release of unstimulated prostacyclin release, although no differences in morphology 
could be found (R22). However, the interpretation of this observation is debatable (C7), 
as prostacyclin production can be similar in the presence or absence of endothelium 
(H30), and other studies have shown that the addition of papaverine does not alter the 
release of EDRF (L15). Nevertheless, the consensus appears to be that the use of 
papaverine before and during harvesting of saphenous veins is beneficial Papaverine 
can be added to either blood or a balanced electrolyte solution, but the solution should 
be slightly acidic in order to prevent the formation of precipitates (C43). 
Irrigation and storage solution 
Blood or tissue culture media have been found to be superior to normal saline, 
regardless of temperature (B80,G39,G40,L45,02,R5). The use of tissue culture medium 
though carries an increased risk of contamination (B11). Storage in heparinized blood as 
apposed to a balanced electrolyte solution (Hartmann's solution), has though also been 
associated with a time-related reduction in EDRF release (A25). Storage in 10°C blood 
· may also produce more endothelial damage than storage in 10°C Plasmalyte (B 15). 
However, Lawrie et al showed equivalent EDRF release in veins stored in either 
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heparinized blood or Plasma-Lyte (Ll5). Nevertheless, although blood may be an 
adequate preservation medium (AlO), it also contains platelets and leukocytes which 
could become activated and adversely interact with the saphenous vein endothelium 
(Ll4). Although there is no consensus as to whether veins should be stored in blood or a 
balanced electrolyte solution, a balanced electrolyte solution containing papaverine 
provides excellent endothelial preservation. 
Furthermore, following the completion of distal coronary artery to saphenous vein graft 
anastomoses, many surgeons infuse cardioplegic solutions through the vein grafts to 
improve myocardial protection (see section 1.5). Hence, it is possible that these 
reinfusions of cardioplegic solution could also damage the endothelium of the vein grafts 
(H8,M19,S49), and lead to accelerated atheromatous degeneration (013). 
In conclusion, minimizing both endothelial and medial damage of saphenous veins 
harvested for use as coronary artery bypass will help improve both short and long term 
vein graft patency. A traumatic surgical techniques, prevention of venospasm by the use 
of papaverine in a balanced electrolyte solution, limitation of venous distention to less 
than 100- 150 mm Hg and storage at room temperature are advised. Furthermore, it is 
possible that aspects of endothelial preservation learned in these saphenous vein studies 
could also be applicable to the coronary vasculature. 
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6.3 CARDIOPLEGIC SOLUTIONS AND THE ENDOTHELIUM 
Cardioplegic solutions are infused into the heart prior to periods of ischaemia in order to 
maximally decrease myocardial energy demands, and thereby limit ischaemic induced 
myocardial damage (see section 1.5). The primary determinant when formulating the 
composition of cardioplegic solutions has therefore been their ability to induce 
reversible myocardial electromechanical arrest (see chapter 3). Nevertheless, 
cardioplegic solutions should also be nontoxic to bot~ the myocyte and endothelial cells. 
Hyperkalaemic (K- 30 mmol/L) crystalloid cardioplegic solutions were first shown to 
cause endothelial damage by Follette et al in 1980 (F23). Intermittent infusions of an 
unspecified hypothermic ( 16°C) crystalloid cardioplegic solution, every 20 minutes 
throughout a 2-hour ischaemic period, caused arterial endothelial disruption and fibrin 
deposition which could be minimized by the addition of blood to the cardioplegic 
solution. Harjula A, Mattila S and co-workers also showed that the addition of either 
blood, albumen .or Fluosol DA to a crystalloid cardioplegic solution reduced both 
coronary artery and saphenous vein graft endothelial damage, experimentally 
(H9,H ll,Ml9) and clinically (H8). However,the crystalloid cardioplegic solution 
evaluated in these studies was a sodium-poor calcium-rich solution; a poorly formulated 
potentially damaging composition for a cardioplegic solution (see section 3.1 & 3.2), and 
hence we cannot infer that the addition of blood or colloid (which would also have 
altered the electrolyte composition) is an essential prerequisite for a cardioplegic 
solution from these studies. Nevertheless, these early studies highlighted the potential 
for "myocardial protective" cardioplegic solutions to damage the vascular endothelium. 
Endothelial damage could increase myocardial reperfusion injury, predispose to 
peri operative coronary artery spasm and thrombosis, increase myocardial ischaemia and 
hence decrease postischaemic myocardial function (see section 6.1). 
Myocardial protection during cardiac surgery; Chapter 6 U 0 Von OppeU 215 
The majority of research on the efficacy of cardioplegic solutions has been centered on 
improving postischaemic myocardial recovery, and few studies have been performed to 
evaluate the effect of cardioplegic solutions on the endothelium. Furthermore, 
endothelial changes induced by both hypothermia and the composition of cardioplegic 
solutions should be assessed separately. 
Effect of hypothermia on the endothelium 
Extreme hypothermia was shown to be detrimental to th.e endothelium of saphenous 
veins, but possibly as a result of hypothermic induced venospasm. Nevertheless, 
hypothermia alters intracellular endothelial homeostasis by inhibiting the function of the 
sodium-potassium pump and results in increased detachment of cultured endothelial 
cells (L13). Hypothermic induced alterations of the cytoskeleton are thought to be due 
to increased cytosolic calcium levels, occurring secondary to intracellular sodium 
accumulation (L13). Furusho et al demonstrated increased acetyl choline induced 
coronary vasoconstriction after hypothermic as apposed to normothermic perfusion with 
either Krebs Henseleit buffer or a calcium-free cardioplegic solution (F36). However, 
significant endothelial damage had probably already occurred prior to commencing their 
experimental protocol, as acetyl choline induced vasoconstriction and not endothelium-
dependent vasodilation (Bl4,F16,F35,G35) was present in their pre-exposure controls. 
Nevertheless, hypothermia possibly accentuated endothelium-independent 
vasoconstriction. 
We evaluated the effect of the StThomas' Hospital No 2 and Bretschneider HTK4 
cardioplegic solutions on cultured human venous endothelial cells at different 
temperatures (appendices A-5 & A-6). Endothelial cell survival increased following 12-
hour hypothermic as apposed to normothermic exposure to the calcium-free 
Bretschneider HTK4 cardioplegic solution (Fig 6.4). In contrast, the extracellular 
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electrolyte equivalent St Thomas' car~ioplegic solution was associated with superior 
endothelial cell survival at normothermia. 
Figure 6.4 
CYTOTOXICITY OF CARDIOPLEGIC SOLUTIONS: EFFECT OF 
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Cultured human venous endothelial cell surviva124 hours after 12-hour exposure at the indicated temperatures, to either ST 
Thomas' Hospital No 2 or Bretschneider HTK4 cardioplegic solution~ Cell survival is expressed as a mean percentage of each 
individual pre-exposure cell coun~ Vertical bars represent sundard errors of percenuge mean~ 
+ • p < 0.01 compared with the same solution at22oc. 
o • p < 0.01 compared with StThomas' cardioplegic solution at that temperature. 
Furthermore, in contrast to the minimal endothelial cell morphological changes 
observed after normothermic exposure to the St Thomas' cardioplegic solution, 
hypothermic exposure to either the St Thomas' or Bretschneider HTK4 cardioplegic 
solutions caused cellular contraction and intercellular gaps (Fig 6.5). However, as also 
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shown by Solberg et al (S60) these effects were reversible after reincubation in culture 
medium (see appendix A-6). 
Hypothermia thus has an independent effect on the endothelium and may cause 
endothelial cell contraction and dysfunction. 
Effect of the composition of cardioplegic solutions on the endothelium 
The composition of an infused cardioplegic solution can produce cytotoxic effects on the 
vascular endothelium (C4), although as discussed above, these effects may also be 
temperature dependent 
Evaluation by cell cultures 
Carpentier et al were the first to evaluate the cytotoxic potential of various cardioplegic 
·solutions by tissue culture (C4). The StThomas' Hospital No 2, Bretschneider No 3 and 
Roe's cardioplegic solutions were the least cytotoxic to both fibroblasts and endothelial 
cells, although no statistical analyses were performed. Furthermore, the addition of 
blood attenuated the more toxic cardioplegic solutions evaluated. 
We evaluated the cytotoxicity of various hypothermic cardioplegic and organ 
preservation solutions on cultured human venous endothelial cells (see appendices A-5 
& A-6). When various cardioplegic solutions used in South Africa were evaluated at 
22oc (appendix A-5), both StThomas' No 2 and Bretschneider HTK4 cardioplegic 
solutions produced the best endothelial cell survival following 12-hour exposure to these 
solutions. However, intr-acellular electrolyte equivalent formulations were superior to 
the St Thomas' cardioplegic solution when evaluated at 10°C, and Bretschneider HTK4 
provided the overall best endothelial cell protection at this temperature (appendix A-6). 
However, the UW-CSS which has extended the storage period of donor livers for 
r 
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transplantation, was associated with the best morphological preservation of the 
endothelium (Fig 6.5). 
This concurs with the findings of other investigators that the UW-CSS provides superior 
hypothermic endothelial protection compared to the Euro-Collins and other organ 
preservation solutions (Cl,F29), who postulated that superior endothelial protection 
might be the reason for the superiority of UW-CSS. 
Figure 6.5 
A 
Legend: 
Phase contrast microscopy appearance of monolayers of endothelial ceUs after 12-hour exposure to either St Thomas' Hospital 
No 2 (A), Bretschneider HTK4 (B) cardioplegic solutions, or University ofWJScnnsin cold storage solution (C), at 4- IOOC. 
Contracted endothelial ceUs with condensed cytoplasmic granulations, wide intercellular gaps and disruption of monolayer 
integrity are observed in A & B, whereas inC there is minimal morphological changes the endothelium. (Magnification X 100). 
Reprinted from Applied Cardiovascular Biology 1990, Vol2, 199l:(in press) with permissionS Karger AG, Baset 
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Furthermore, in our model cytotoxicity could be related to the following factors:-
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PRACTICALITIES OF DELIVERING CARDIOPLEGIC SOLUTIONS 
Adequate myocardial protection can only be ensured if the multitude of factors 
discussed in the preceding chapters are all considered. The composition of the 
cardioplegic solution to be used being a major consideration. However, the cardioplegic 
solution must also be delivered to the patient at the correct temperature, pressure and 
volume (Table 7.1) (see section 1.5). 
Table 7.1 
OPTIMAL DELIVERY OF CARDIOPLEGICSOLUTIONS 
Te1perature of cardioplegic Solution (B70,M5,P27,128) 
Crystalloid cardioplegia: 4°C - 6°C 
Blood Cardioplegia: 8°C - 10°C? 
Optimal Myocardial Temperature (M5,R38,T28) 
Crystalloid Cardioplegia: 12°c - 15°C 
Blood Cardioplegia: 1s0c - 18oc? 
Voluae Infused (M17 ,T9) 
Crystalloid (Constant Pressure) 
Induction: 10 - 25 ml/kg body weight 
Multidose: 5 - 10 ml/kg body weight 
Blood (Constant Infusion Rate) (B70) 
Induction: 300 - 350 ml/min (3 - 5 min) 
Multidose: 200 ml/min (2 min) 
Infusion Pressure of Cardioplegic Solutions 
Antegrade (A31,B70,B74,J-3): 
Induction: 80 - 130 mm Hg 
Multidose: 50 mm Hg 
Retrograde (B70,M35,M38): 
Less than 40 mm Hg 
oxygenated (B33,C3l,G45,L25,appendices A-3,A-4) 
No Particulate Hatter or MicroeJboli (Hl7,R30) 
Cardioplegic filter: 0.2 um pore size 
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These secondary variables are easily controlled and monitored in the experimental 
laboratory. However, in the clinical situation the cardiac surgeon is usually more 
concerned with the complexities of the operation and may therefore not be able to give 
as much attention to these variables. Hence, practical means of delivering cardioplegic 
solutions in the clinical situation are necessary, and if possible should require minimal 
control from the operating surgeon. 
There are two primary categories of cardioplegic solutions; viz. blood and crystalloid 
cardioplegic solutions, both of which can carry oxygen (D19). Blood cardioplegia, a 
combination of a crystalloid concentrate and oxygenated blood withdrawn from the 
cardiopulmonary bypass circuit, will supply oxygen bound to haemoglobin. The delivery 
system for blood cardioplegia has been fairly well standardized, and depends upon the 
ratio in which the crystalloid concentrate is added to the blood component, either as a 1:2 
or 1:4 dilution. The composition of the crystalloid concentrate would thus depend upon 
the intended delivery ratio. The international gold standard is the 1:4 blood cardioplegia 
developed by G D Buckberg (B70), and delivered by using tubing of differing internal 
diameters passed through the same "roller-pump head" (Fig 7.1). A heat exchange ·. 
mechanism, either a coil in ice or an integral heat exchanger is included in the system to 
ensure that the final mix of blood cardioplegia is delivered to the patient at the correct 
temperature. 
Crystalloid cardioplegic solutions on the other hand, can and are delivered by various 
methods; roller pump infusion, simple gravity infusion or "pressure bag" infusion. 
Furthermore, it is more essential with crystalloid cardioplegic solutions as apposed to 
blood cardioplegia that these solutions are infused into the heart at a cold enough 
temperature (see section 1.5), correct perfusion pressure (see section 1.5), and the 
efficacy of crystalloid cardioplegic solutions can be increased by oxygenation (see 
section 5.2). 
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Blood cardioplegic solution delivery system. One revolution of a standard roller-pump using 1:4 delivery, would provide 15 ml of 
"blood cardioplegia" by combining 3 ml of crystalloid concentrate (1/8" tubing) and 12 ml oxygenated blood (1/4" tubing) 
withdrawn from the cardiopulmonary bypass oxygenator. Reprlnted·with permission from Cardiovasc 1 South Afr 1991;.2:108-
114 (appendix A-7). 
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7.1 OXYGENATING CRYSTALLOID CARDIOPLEGIC SOLUTIONS 
Oxygenation of crystalloid cardioplegic solutions improves postischaemic myocardial 
recovery (B33,C31,G45,L25,appendices A-3,A-4) (see section 5.2). 
Commercial crystalloid cardioplegic solutions will be either anoxic if bottled in vacuum 
in glass (Bretschneider HTK4; Dr F Kohler Chemie GmbH, Alsbach, Germany), or the 
oxygen content will approximate atmospheric pressures (Table 7.2) if non-vacuum 
packed in plastic (StThomas' Hospital cardioplegic solution: Sabax Ltd; Johannesburg, 
South Africa). 
Table 7.2 
PARTIAL PRESSURES OF ATMOSPHERIC GASES 
Jgy air Saturated with H2o 
Percent Partial Pressure Partial Pressure 
02 20.98% 159.4 149.6 
C02 0.04% 0.3 0.3 
N2 78.06% 593.3 556.6 
H20 0% 0 47 
Legend: 
Partial pressures (mm Hg) of atmospheric gases in dry air and air saturated with water at 37°C, at sea level (I atmosphere; 760 
mm Hg) (02)_ ~ 
The quantity of oxygen dissolved in a solution depends upon both the partial pressure 
and solubility coefficient for oxygen in that fluid (G2). Furthermore, the solubility 
coefficient for a gas is inversely proportional to temperature (Table 7.3). Thus, the 
oxygen content of a solution can be increased by both increasing the partial pressure 
(oxygenating with 95 % - I 00% 02) and by decreasing the temperature of the solution 
(B13). Therefore, crystalloid cardioplegic solutions should be oxygenated at low 
temperatures (4°C- 6°C), in order to maximally increase the dissolved oxygen content 
in the solution. 
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Table 7.2 
SOLUBILID COEFFICIENT FOR OXYGEN 
4°c 4.256 24°C 2.768 
10°c 3.689 26°c 2.670 
12°c 3.524 2s0c 2.578 
14°c 3.373 3o0c 2.495 
16°c 3.216 32°c 2.428 
1s0c 3.107 34°c 2.361 
20°C 2.989 36°c 2.300 
22°c 2.875 37°c 2.273 
~: 
The solubility coefficient for oxygen in a physiological saline solution at different temperatures: milliliters of oxygen dissolved 
per lOOm! ofO.lSS NNaClat760 mm Hg pressure (BI3). 
Various methods of oxygenating crystalloid cardioplegic solutions have been proposed, 
and include:-
1) Bubble oxygenating systems, 
2) Hyperbaric bubble oxygenation; 15 em H20 positive pressure during bubbling 
(D1) 
' 
3) Hyperbaric pressurization athypothermia (M42,W18), 
4) Membrane oxygenating systems (L8), 
5) Hypothermic recirculating oxygenating systems (Fig 7.2). 
We compared the oxygen content of "unoxygenated" StThomas' Hospital No 2 · 
cardioplegic solution (0.45- 0.84 ml 02 I 100 ml solution), with the oxygen contents 
obtained by various oxygenating methods at different gas flow rates (appendix A-7). 
Oxygenating the StThomas' cardioplegic solution with 95% 02 5% C02 at 1.0 Llmin at 
hypothermia (40C) in a standard lliter glass vacolitre kept in ice, produced an oxygen 
content of 3.48 ± 0.14 ml 02 I 100 ml solution within 30 min. This oxygen content was 
no different to the oxygen content obtained with the more complex and expensive 
hypothermic recirculating oxygenating method (Fig 7.2) (appendix A-7). Furthermore, 
after 30 min of oxygenation and provided the cardioplegic solution was kept in ice (4°C) 
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arid not rewarmed, the oxygen content in the glass vacolitre did not decrease during a 
subsequent 2-hour period. 
Figure 7.2 
HYPOTHERMIC RECIRCULATING OXYGENATING SYSTEM 
Legend: 
crystalloid 
cardioplegia 
roller pump 
ice 
Delivery system for crystalloid cardioplegia that ensures both cold (40C) cardioplegia and maximal oxygenation, by contioually 
recirculatiog the cardioplegic solution through a cooling coil placed in ice (CCAS·OC; American Bentley, Irvine, California, 
USA). The removal I application of the indicated clamps aUows the cardioplegic solution to be continuously recirculated or 
intermittently delivered to the patient Reprinted with permission from Cardiovasc 1 South Afr 1991; 2:108-114 (appendix A·7). 
Alternative techniques of oxygenating cardioplegic solutions such as overnight cold 
pressurization require broaching of the sterility seal of the vacolitre well prior to the 
procedure (M42,W18), and thus may increase the risks of bacterial contamination. 
Membrane oxygenating systems for crystalloid solutions are more expensive than simple 
bubble oxygenation, and have no additional advantage if there are no proteins in the 
solution (L8)_ 
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Potential dangers of maximally oxygenating cardioplegic solutions 
If a solution is fully saturated with a gas at a low temperature, rewarming of the solution 
may result in the gas coming out of the now supersaturated solution as bubbles. In the 
clinical situation, cardioplegic solution contained in the cardioplegic delivery line leading 
to the patient rewarms to the prevailing theater temperature (19oc- 24oC) in the period 
between each rein fusion of cardioplegia (see section 7.2} If gaseous emboli are then 
formed in the cardioplegic delivery line they could be harmful if infused with subsequent 
-
doses of cardioplegia Therefore, if crystalloid cardioplegic solutions are maximally 
oxygenated, then the delivery system should incorporate a means of removing these 
bubbles prior to subsequent reinfusions. Bubbles can be removed by either a microfiltet . · 
(CAS-filter; American Bentley, Irvine, California, USA) inserted immediately before 
the ascending aorta, or alternatively the "warm cardioplegic solution containing gaseous 
emboli in the line" can be removed through an aortic vent, before administering each 
subsequent dose of cardioplegic solution. 
Alternatively, if the cardioplegic solution is oxygenated at a temperature equal or higher 
than it is likely to be rewarmed to (ie. room temperature), the solution would not 
become supersaturated and bubbles would not come out of solution. However, the · 
solution would then have to be cooled to the correct temperature (4°C- 6°C) prior to 
infusion. In addition, this method would imply accepting an oxygen content 
approximately 40% lower than if the cardioplegic solution was oxygenated at 4°C 
(appendix A-7)_ Sub-maximal cardioplegic solution oxygen contents have been 
associated with a parallel decrease in the effectiveness of the cardioplegic solutions' 
ability to protect the myocardium (Dll). Nevertheless, we showed that only 
approximately 50% of the oxygen available in a hypothermic maximally oxygenated 
cardioplegic solution is taken up by the myocardium (appendices A-3,A-4). Moreover, 
all oxygen contained in a crystalloid cardioplegic solution is theoretically available to the 
myocyte as oxygen is released in a linear fashion from crystalloid solutions (Dl9). 
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An additional danger of maximally oxygenating crystalloid cardioplegic solutions is that 
high partial pressures of oxygen may increase the formation of free radicals ( G5). Thus 
the optimal content of oxygen contained in a crystalloid cardioplegic solution may yet 
need to be determined. 
In conclusion, simple oxygenatio~ of cold (4°C) StThomas' Hospital No 2 cardioplegic 
solution with 95% 02 5% C02 at 1.0 L/min in its original glass vacolitre is as effective 
as more complex hypothermic recirculating oxygenating delivery systems, in producing a 
· maximal oxygen coritent However, if maximally oxygenated cardioplegic solutions are 
used then measures.should be taken to ensure that gaseous emboli, that mayform in the 
cardioplegic delivery line, are not infused into the coronary circulation with subsequent 
doses of cardioplegia. 
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7.2 TEMPERATURE OF INFUSED CARDIOPLEGIC SOLUTION 
Profound cardiac hypothermia is an essential component of the majority of techniques 
used to protect the myocardium during the aortic cross-clamp period (see section 1.5). 
However, myocardial temperatures fluctuate during the ischaemic cross-clamp period 
because of continued rewarming of the myocardium (R39). Rewarming of the 
myocardium can though be prevented by either multidose reinfusions of cold 
cardioplegia or by myocardial protection jackets (see section 1.5). Cold (4°C) crystalloid 
cardioplegic solutions are therefore intermittently reinfused into the heart throughout 
the aortic cross-clamp period (B54,B74,E9,S18,appendix A-2), in order to maintain 
myocardial temperatures at 12°C- 15°C (R38,T28). Multidose reinfusions of 
cardioplegia also have other beneficial effects such as replenishing substrates and 
removing metabolic end products (see section 1.5). 
We th.erefore evaluated whether methods of infusing crystalloid cardioplegic solutions 
deliver the solution to the myocardium at the correct temperature, that is less than 6°C 
(appendix A-8). Crystalloid cardioplegic solutions stored in a standard fridge are often 
too warm (11.1 ± 0.6°C). Therefore, solutions stored in a fridge should in addition be 
immersed in ice for at least 30 min before use, to ensure a sufficiently low temperature. 
Simple infusion of the cold cardioplegic solution, without any accessory cooling coils, · 
will then deliver the cardioplegic solution at the recommended temperature independent 
of flow rate (100- 500 mllmin). Alternatively, if cardioplegic solutions are stored or 
oxygenated at room temperature then a cooling mechanism must be used in the delivery 
system. However, a cooling coil immersed in ice may not adequately cool the 
cardioplegic solution at cardioplegic flow rates greater than 200 ml I min (appendix A-
8). 
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Rewarming of solution in delivery lines 
Cardioplegic solution contained in the delivery lines leading to the patient rewarms 
towards ambient room temperature (19°C- 23°C) during the interval (10 min- 30 min) 
in between each reinfusion of cardioplegia (14.1 ± o.soc and 20.1 ± 0.6°C respectively) 
(Figure 7.3). 
() 
o. 
I 
Figure 7.3 
Temperature of Cardioplegic s·olution 
at Aortic Root with Reinfusions 
f--------------
20-
15-
10 
5 
Room 
Temp 
•I 
., 
_., 
., 
:. , 
·' , 
•\ I • 
:r: 
--r- -,..-~ 
. "1···J .. --"--r--
I··I-+· ?" 0 .. ~~~~_,-,-,~ 
F I o Induction 
Legend: 
lnt 
o Multidose 
Time - minutes 
lnt. 
___
 ""T" ____ _ 
0 Multidose 
The temperature of the cardioplegic solution at the 'aortic end" of the cardioplegic delivery line was measured. Cardioplegic 
solution removed from the fridge (F) was kept in ice for 30 min (I) to ensure a temperature of less than 4°C. An "induction dose" 
was infused (250 ml/min for I min) immediately after flushing the lines. Thereafter, a seeond and third multidose ofcardiop1egia 
(250 ml/min for I min) were infused after either a 10 min (A) or 30 min (B) interval (lot). Means and standard error.; of means 
(vertical bars) for N = 6 observations are presented. The recommended temperature at which crystalloid cardioplegic solutions 
should be infused (6°C) and the temperature range of operating theater.; are indicated. Reprinted with permission from 
Cardiovasc} South Afr 1992; (in press) (appendix A-8). 
• - p < 0.01 compared to A at corresponding time. 
• - p < 0.05 compared to A at corresponding time. 
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Thus with subsequent reinfusions of cardioplegia a significant volume of each dose could 
consist of "warm cardioplegia" (ie. cardioplegia with a temperature of greater than 6oc 
that was contained in the delivery lines) (appendix A-8). Moreover, this volume of 
"warm cardioplegia" could be as much as 50% of the total dose of cardioplegic solution 
reinfused, and can decrease the efficacy of myocardial protection. 
One must therefore ensure that cardioplegic solutions are always at a sufficiently low 
.... temperature prior to infusion, and in addition "dead space" in delivery lines should be 
reduced as far as possible. Furthermore, if the "warm cardioplegic solution" contained in 
the delivery line forms a significant percentage of subsequent multidose reinfusions, this 
volume should be vented to waste before each reinfusion; by using a special aortic 
cardioplegic infusion catheter (aortic root cannula with vent- DLP; Grand Rapids, 
Michigan, USA). 
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7.3 INFUSION PRESSURE OF CARDIOPLEGIC SOLUTIONS 
An adequate perfusion pressure to ensure uniform delivery of cardioplegic solutions is 
essential (A18). Nevertheless, coronary artery stenoses can result in heterogeneous 
delivery of cardioplegic solutions despite adequate perfusion pressures (A3l,B18,S46). 
However, excessive perfusion pressures (greater than 150 mm Hg) promote myocardial 
I 
oedema, decrease postischaemic functional recovery (19), and damage the vascular 
endothelium (M53). Thus, prograde infusion of cardioplegia into the ascending aorta 
should be at pressures of 80- 130 mm Hg (measured in the ascending aorta) on induction 
of cardioplegic arrest (B69,M54), and at 50 mm Hg with subsequent doses (B74,P27) 
(see section 1.5). Furthermore, a proximally monitored perfusion pressure may not 
correlate with the actual ascending aortic root pressure, because of resistances in the 
cardioplegic delivery line (S45). This was therefore evaluated in the clinical situation. 
Crystalloid cardioplegic solutions can be delivered by a variety of means (G34): infusion 
by gravity (infused from a height of ± 178 em; 133 mm Hg), external pressurization of 
the vacolitre of cardioplegia (external pressure bag inflated to 300 mm Hg), or by roller-
pump. We compared the delivered ascending aortic pressure during clinical 
administration of cardioplegia, with proximally monitored cardioplegic line pressures 
with each of the three delivery systems (appendix B-8). 
A wide range of aortic root pressures were measured during infusion of cardioplegia 
with all three methods (42- 126 mm Hg) (Fig 7.4) (appendix B-8). Furthermore, there 
was a poor correlation between the proximal cardioplegic "line pressure" and the actual 
aortic root pressure, as observed by Sievertsen et al (S45). Thus, cardioplegic infusion 
pressures should be monitored directly in the ascending aorta as the proximal 
cardioplegic line pressure is unreliable. Excessive pressures (greater than 150 mm Hg) 
were not observed with either the gravity or pressure bag method. However, higher 
pressures would b~ obtained if larger cardioplegic root cannulas were to be used (M53). 
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Furthermore, in contrast to the gravity or pressure bag infusion methods, the roller 
pump delivery system could to a certain extent prevent high and compensate for low 
aortic root pressures. 
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The aortic root pressure was measured during administration of cardioplegia by three different methods and compared to the
 
proximal cardioplegic line pressure. Cardioplegia was infused by gravity· (N = 6) from a height of 178 em H2 0 ( 133 mm Hg) . · 
above the right atrium. If a pressure bag was used (N = 6), this was inflated to 300 mm Hg. Ahernatively, a roller pump was used 
(N = 12), in which case the perfusionist attempted to maintain the measured aortic root pressure between 80- 100 mm Hg. 
Thus in agreement with other studies, the roller pump is the superior method of 
delivering cardioplegi~ solutions during clinical open-heart surgery (G34)_ If ascending 
aortic pressures are not monitored then the cardioplegic solution should be initially 
infused at a rate of250- 300 ml/min with a roller pump (for adult hearts only), and then 
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the rate increased if the ascending aortic pressure was insufficient by manual palpation. 
However, when harvesting donor hearts at outlying hospitals, cardioplegia can be 
infused simply by gravity (height of 173 em above the right atrium). This method 
ensures that excessive infusion pressures will not be obtained, without monitoring 
ascending aortic root pressures. In contrast, pressurization of the cardioplegic solution 
container can result in excessive infusion pressures, should different perfusion cannulae 
be used. 
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7.4 CONTAMINATION OF CARDIOPLEGIC SOLUTIONS 
Particulate matter 
The majority of commercial intravenous crystalloid solutions contain particulate matter 
(2- 20 urn in diameter), which may cause coronary vasoconstriction and consequent 
maldistribution of cardioplegic solution (H 17,R30,S35). These particles cause coronary 
vasoconstriction during infusion of cardioplegic solutions and decrease postischaemic 
myocardial recovery if large doses of cardioplegia are administered. Particle induced 
coronary vasoconstriction can be prevented by either a microfilter of at least 0.8 urn pore 
size, or alternatively attenuated by including either nifedipine, A TP, procaine, 
lignocaine, dipyridamole or steroids in the cardioplegic solution (H 17 ,S35). 
Nevertheless, Munsch et al using both a canine model and a clinical study failed to 
demonstrate particle induced coronary vasoconstriction, and suggested that 0.2 urn pore 
size cardioplegic line filters are not necessary (M64). However, the cardioplegic 
solutions in the studies by Hearse and Robinson contained significantly higher numbers 
of2- 10 urn sized particles (Table 7.4) (H17,R30), and their results suggested that the 
critical size range for particle induced deleterious effects was 8 - 10 urn pore size ( H 17). 
Therefore, the study by Munsch et al does not refute the findings of the previous studies, 
as in their study cardioplegic solutions with significantly lower particulate counts were 
used. 
A particulate matter count was done on the StThomas' No 2 cardioplegic solution 
formulated by Sabax Ltd (Aeroton, Johannesburg, South Africa) with a HIAC Model PC 
320 "Criterion" particle size analyser (HIAC I Royco Instruments, Pacific Scientific 
Company, Menlo Park, California), and the results are shown in Table 7.4. The St 
Thomas' solution formulated by Sabax contains significantly fewer particles than the 
cardioplegic solutions tested by Hearse, Robinson and co-workers. 
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Table 7.4 
Particle Particle Count I ml 
Size (urn) Hearse Robinson Munch Sabax 
> 2 772 379 - 1505 36 67 
> 5 188 81 - 165 7 17 
>10 7 2 - 8 2 4 
>15 2 2 2 3 
Legend: 
Particulate counts in cardioplegic solutions reported by Hearse (Hl7), Robinson (R30), Munch (M64) and in the StThomas' No 2 
cardioplegic solution prepared in South Africa by Sabax Ltd. 
Bacteriological contamination 
Bacteriological contamination of cardioplegic solutions can result in clinical septicaemia, 
despite aseptic preparation under laminar flow hoods (H54). Thus, sterility of 
cardioplegic solutions is essential and the solution should be kept at hypothermia and for 
no longer than a few hours after additives are added to commercial solutions. In line 
cardioplegic filters (0.2 urn pore size) would also minimize the potential risk, should 
there have been inadvertent contamination of the cardioplegic solution during 
preparation. 
Microemboli 
Oxygenation of crystalloid cardioplegic solutions can result in gaseous micro-emboli 
which may be harmful (see section 5. 7). Rewarming of cardioplegic solution, contained 
in the delivery line leading to the operating table in between each reinfusion of 
cardioplegic solution, may cause the formation of bubbles (see section 7.1). Therefore, 
we suggest that a microfilter (0.2 urn CAS-filter; American Bentley, Irvine, USA) should 
be included in the cardioplegic delivery systems if hypothermic oxygenation of the 
cardioplegic solution is used. 
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Heavy Metal Contamination 
Heavy metals, specifically iron and copper can act as cofactors for the generation of 
oxygen free radicals (see section 1.6). Removal of intravascular physiological quantities 
of these metals reduces free radical generation and the postischaemic reperfusion injury 
(C33,M36)_ We noted diminished efficacy ofthe standard StThomas' cardioplegic 
solution when formulated with magnesium chloride containing higher levels of heavy 
metals (see section 2.3). Hence, contamination of cardioplegic solutions with heavy 
metals is potentially dangerous. Strict quaiity control of the production of cardioplegic 
solutions is therefore essential. 
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B 
SUMMARY 
The scope of cardiac surgery has increased primarily as a result of two factors; the 
development in 1953 of a temporary means of replacing the function of the heart and 
lungs, and improvements during the 1970's and 1980's in techniques of protecting the 
ischaemic myocardium whilst the aorta is cross-clamped Nevertheless, poor myocardial 
protection still contributes to both the mortality and morbidity of cardiac surgery, and is 
the topic of this thesis. 
The myocardium is injured bymechanical, ischaemic and pharmacologic factors during 
cardiac surgery, and not only myocytes but also endothelial cells need to be protected. A 
review of techniques used to provide myocardial protection during open-heart surgery 
highlights the concept that no single factor provides "myocardial protection" during 
open-heart surgery. Preoperative, intraoperative and postoperative interventions must 
all be considered in order to obtain optimal myocardial protection. Nevertheless, one of 
the principle components of modern techniques of intraoperative myocardial protection 
is the use of cardioplegic solutions, which are infused into the heart to .stop 
electromechanical activity and thereby diminish myocardial energy demands whilst the 
aorta is cross-clamped and thus the myocardium rendered ischaemic. Some cardiac 
surgical procedures can be accomplished without cross-clamping the aorta, however, 
cross-clamping the aorta often facilitates the surgical procedure technically and is thus 
commonly used. 
Crystalloid cardioplegic solutions in clinical use in South Africa were evaluated in an in-
vivo primate model that simulated clinical open-heart surgery. Baboon hearts were 
subjected to 3-hour hypothermic cardioplegic arrest whilst on cardiopulmonary bypass, 
and thereafter postischaemic haemodynamic recovery was assessed. The best available 
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crystalloid cardioplegic solution in South Africa was the StThomas' Hospital No 2 
cardioplegic solution. The effect of these various cardioplegic solutions on cultured 
human venous endothelial cells was also assessed. The StThomas' Hospital No 2 
cardioplegic solution which is an extracellular electrolyte equivalent formulation, was 
the least cytotoxic solution when exposed to endothelial cells at normothermia. The St 
Thomas' cardioplegic solution also provided endothelial cytoprotection equivalent to the 
Bretschneider HTK4 cardioplegic solution (an intracellular electrolyte equivalent 
formulation) at 22°C, but at 10°C Bretschneider HTK4 was the least cytotoxic 
cardioplegic solution. The University of Wisconsin cold storage solution though, 
although not associated with the best postexposure endothelial cell survival at 10°C, 
caused the least morphologic alterations to the endothelial cells at this temperature. 
The best currently available crystalloid cardioplegic solution- the StThomas' Hospital 
No 2 cardioplegic solution - was then used as the basic formulation for further 
experimental modifications. The St Thomas' cardioplegic solution does not contain a 
substrate for ongoing energy production, has a poor buffering capacity, is isotonic and 
lacks colloid oncotic pressure. Therefore, experimental modifications of the St Thomas' 
cardioplegic solution that "corrected" these perceived deficits were evaluated. 
Glucose was shown to be a beneficial additive to the StThomas' cardioplegic solution in 
the isolated rat heart model, but only at a concentration of 7- 11 mmol /L and provided 
multidose reinfusions of cardioplegia were administered. This concentration of glucose 
also did not alter the previously assessed endothelial cytotoxicity. However, the addition 
of glucose (10 mmol/L) to the StThomas' cardioplegic solution depressed postischaemic 
myocardial recovery in the in vivo primate model, possibly because of either insufficient 
washout of metabolic end products or interspecies differences. Thus, although both 
preischaemic and postischaemic metabolic enhancement with glucose is beneficial, we 
would not advise the addition of glucose to the StThomas' Hospital No 2 cardioplegic 
solution in the clinical situation. 
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An alternative means of increasing myocardial energy supplies during the ischaemic 
cross-clamp period is to promote aerobic metabolism, by intermittently reinfusing 
oxygenated crystalloid cardioplegic solution whilst the aorta is cross-clamped. 
Oxygenating the St Thomas' cardioplegic solution was shown to be beneficial in the 
isolated rat heart model. However, oxygenation could also induce potentially harmful, 
pH shifts of the cardioplegic solution as a result of altering the pC02 of this bicarbonate 
containing cardioplegic solution. Consequently, the St Thomas' Hospital No 2 
cardioplegic solution should be oxygenated with 95% 02 5% C02, which optimizes the 
pH of the solution at pH 7.0. Oxygenating with 100% 02 caused the pH of the St. 
Thomas; cardioplegic solution to shift to pH 9.3, which was associated with depressed 
postischaemic myocardial recovery. The addition of perfluorocarbon oxygen carriers to 
the well oxygenated St Thomas' cardioplegic solution was also shown to provide no 
additional myocardial protection. 
The efficacy of the StThomas' Hospital cardioplegic solution was also improved 
experimentally by increasing the buffering capacity of the St Thomas' solution fivefold, 
by the addition of histidine. Osmotic space for this additive _was obtained by decreasing 
the sodium concentration of the StThomas' solution from 120 mmol!L to 100 mmol/L, 
and increasing the crystalloid osmolality from 295 mOsm/kg H20 to 320 mOsm/kg 
H20. This moderate hypertonicity was also shown to have an independent salutary 
effect The addition of histidine (50 mmol/L) to the StThomas' cardioplegic solution 
independently improved the postischaemic recovery of isolated rat hearts subjected to 3-
hours hypothermic cardioplegic arrest Furthermore, a pilot study in the in vivo primate 
model tended to show improved postischaemic recovery although statistical significance 
was not achieved in the experimental model used. This experimental cardioplegic 
solution was further modified by decreasing the calcium content to the optimal value of 
0.6 mmol /L and the addition of adenosine 1 mmol /L, and evaluated in the in vivo 
primate model. Energy depleted baboon hearts were subjected to 3-hour hypothermic 
multidose cardioplegic arrest, and this modified St Thomas' cardioplegic solution was 
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associated with superior postischaemic myocardial recovery when compared to the 
standard St Thomas' No 2 cardioplegic solution 
Further modifications evaluated in the isolated rat heart model were the addition of the 
colloid Dextran-40, and the effect of decreasing the chloride content of the St Thomas' 
cardioplegic solution. No conclusive advantage of adding 3 % Dextran-40 to the St 
Thomas' cardioplegic solution and thus increasing the colloid oncotic pressure from 0 
mm Hg to 25 mm Hg could be demonstrated. However, this might have been because 
only single dose and not multidose cardioplegic solution was administered in this 
experimental model In addition, decreasing the concentration ofthe chloride anion in 
the St Thomas' cardioplegic solution was neither advantageous nor detrimental in the 
isolated rat heart model However, a low chloride concentration decreased the observed 
endothelial cytotoxicity, and should therefore be further evaluated. 
Finally, methods of delivering cardioplegic solutions to the patient in the clinical 
situation were evaluated. Adequate oxygenation of the StThomas' cardioplegic solution 
can be obtained by simple bubble oxygenation of the cardioplegic solution in its original 
packaged container, and complex oxygenating systems are not necessary for crystalloid 
cardioplegic solutions. However, techniques either preventing or removing bubbles 
formed in the cardioplegic delivery lines should be employed. Furthermore, the 
potential harmful effect and rapidity of rewarming of the cardioplegic solution 
contained in the delivery lines leading to the patient were identified. Thus, in the 
clinical situation the cardioplegic solution contained in the delivery lines, the volume of 
which could be as much as 50% of each subsequent dose of cardioplegia, should be 
vented to waste prior to each reinfusion of cardioplegia, in order to ensure that the 
cardioplegic solution is infused at a sufficiently cold temperature. 
In summary, we would advise that for clinical open-heart surgery the best presently 
available crystalloid cardioplegic solution is the StThomas' Hospital No 2 cardioplegic 
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solution. Furthermore, the efficacy of the St Thomas' cardioplegic solution can be 
improved by simple oxygenation with 95% 02 5% C02. Blood cardioplegic solutions 
were not evaluated· in the studies in this thesis and might also provide equivalent and 
possibly superior myocardial protection. Additional potentially beneficial experimental 
modifications of the St Thomas' cardioplegic solution are the addition of the buffer 
histidine, increasing the osmolality and possibly decreasing the concentration of chloride 
ions of the St Thomas' cardioplegic solution, which though require further evaluation. 
Nevertheless, not only should the foremost cardioplegic solution be used during clinical 
open-heart surgery, but a number of additional perioperative factors must be considered 
as well in order to ensure optimal myocardial protection. 
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(Reprinted with permission the Cardiovascular Journal of Southern Africa) 
The following 'typographical errors should be corrected in this manuscript: 
Page 12 
In Table I, the sodium concentration of the StThomas' Hospital No 2 cardioplegic 
solutions should read 120 mmol!L, and the glucose concentration of PI B(3) is 0 
mmol/L. 
Page 13 
In the paragraph titled "Expression of Results", the units of SVI should read ml· be.ac l.m-
2, and the formula for SWI is:-
SWI = SVI X (LV systolic pressure- LVEDP) X 0.014348 
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Cardioplegic solutions used in South Africa 
An experimental comparison 
D.H. BOEHM, P.A. HUMAN, U. VON OPPELL, H. REICHENSPURNER, P. OWEN, L.H. OPIE, 
A.G. ROSE, B. REICHART . 
Abstract 
Cardioplegic solutions are routinely used to arrest and pro-
tect the myocardium during open-heart surgery. Most of 
the hospitals performing cardiac surgery in South Mrica 
employ various crystalloid cardioplegic solutions as opposed 
to blood cardioplegia. In this report we compare the lo-
cally manufactured cardioplegic solution (obtainable from 
SABAX Ud) and a modified Bretschneider solution previ-
ously employed at Groote Schuur Hospital with the cur-
rent international standard, the St Thomas' Hospital 
cardioplegic solution No. 2. 
Cbacma baboon hearts were sUbjected to a >-hour in v.ivo 
ischaemic period during which the myocardium was pro-
tected with each of these cardioplegic solutions. Post-
ischaemic recovery was assessed in tenns of haemodynamic 
variables (stroke volume index, cardiac index, stroke work 
index, and lEft ventricular function curves), levels of adeno-
sine triphosphate and creatine phosphate, and refunction 
time. In the model used, the post-ischaemic functional 
recovery of hearts protected with the St Thomas' Hospital 
cardioplegic solution No. 2 was superior. 
Cold chemical cardioplegic solutions are almost universally 
used to protect the myocardium during bloodless open-heart 
surgery while the ascending aorta is cross-clamped. 1 Im-
proved cellular protection has enhanced myocardial. recovery 
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and thus contributed to a reduction in surgical mortality over 
the years. In addition, as longer ischaemic periods are now 
more easily tolerated, the complexity and extent of cardiac sur-
gery has increased. The cardiac surgeon today can cross-clamp 
the aorta, infuse a cardioplegic solution, and then unhurried-
ly operate on the protected, cold, non-beating heart. At the 
end of the procedure the aorta is undamped and a rapid recov-
ery of myocardial function is expected. 
The primary function of a cardioplegic solution is to halt 
all myocardial electromechanical activity, thereby conserving 
energy. 1•2 This is achieved by manipulating the extracellular 
concentrations of the important cations (sodium, potassium, 
magnesium, calcium). Myocardial hypothermia, obtained by 
infusing the solution into the coronary arteries at a tempera-
ture of 4 °C, lowers energy demands even further. 2 Since the 
use of a hyperkalaemic. cardioplegic solution by Melrose et 
al. in 19553 an ever-increasing number of formulations are 
being used experimentally and clinically, thus complicating the 
objective comparison of solutions and reported beneficial 
additives. A vast amount of basic research has, however, 
demonstrated the complex interrelationship of all components 
in a cardioplegic solution and highlighted the need for careful 
experimental assessment before any alterations are made to 
existing solutions. 
In 1988 a questionnaire was forwarded to all perfusion tech-
nologists registered with the South African Society of Cardio-
vascular Perfusion Technology regard!ng the cardioplegic 
solution used by their unit. Eighty per cent of the question-
naires were returned, and the answers revealed that three 
hospitals performing cardiac surgery in South Africa were 
using a form of blood cardioplegia while a further seven 
employ various formulations of crystalloid cardioplegic 
solutions. The solution prepared by SABAX Ltd (Samuel Evans 
Road, Aeroton, Johannesburg) was used by three units, a bas-
ic solution of Plasmalyte B plus 30 mmol potassium chloride 
and various additives was employed by a further three, and 
only Groote Schuur Hospital was at that time using a modi-
fied Bretschneider solution made up by the hospital dispensary 
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TABLE I. CRYSTALWID CARDIOPLEGIC SOLUTIONS USED IN SOUTH AFRICA (mmol/l') 
Na K Ca 
ST2 110 16 1,2 
SABA X 141 24/12* 0,9 
GSH 15 20 1,0 
PI B(1) 140 34 
PI B(2) 130 34114t ±0,4t 
PI B(3) 130 34 
KHB 143 5,9 1,25 
S12 - St Thomas' Hospital cardioplegic solution No. 2. 
SABAX - cardioplegic solution available from SABAX Ltd. 
Mg HC03 Glucose Mannitol Osmolarity 
16 10 ±300 
1,5 38 51 68 ±450/432* 
12 15 240 14 ±350 
1,5 Yl 56 ±400 
1,5 Tl ±4t ±330 
1,5 Tl 42 ±370 
1,2 25 11 ±300 
GSH - cardioplegic solution previously used at Groote Schuur Hospital. 
PI B - cardioplegic solution made up by the addition of 30 mmol KCI, ± sodium bicarbonate to I litre of Plasmalyte B solution. 
KHB - Krebs-Henseleit physiological buffer solution used as a non-cardioplegic control solution. 
• In the maintenance cardioplegia the potassium concentration is diminished to 12 mmol/1. 
t The maintenance cardioplegia has only 10 mmol KCI added to 200 ml pump blood per 800 ml crystalloid solution. This would thus change 
the solution from an acalcaemic solution to one with an approximate calcium content of 0,4 mmol/1 and an approximate glucose concentration 
of4 mmol/1. 
(GSH). The composition of these solutions is tabulated in Ta-
ble I. In principle, the St Thomas' Hospital solution No. 2 
relies on a high-potassium, high-magnesium system; the GSH 
solution on a high-potassium, low-sodium system, and the SA-
BAX solution has a high-potassium composition. 
The majority of these clinically used cardioplegic solutions 
have, however, never been adequately or objectively evaluated, 
neither experimentally nor clinically. This study was there-
fore undertaken to compare the efficacy of two crystalloid 
cardioplegic solutions used in this country with an interna-
tionally accepted and extensively investigated solution, the 
StThomas' Hospital cardioplegic solution No. 2 (S12).4·7 In 
addition, a solution containing normal extracellular concen-
trations of the major cations, and therefore unable to induce 
chemical cardiac arrest, was employed as a control in order 
to highlight the effects of cardioplegic solutions as opposed 
to the beneficial effects of hypothermia. The physiological 
saline solution, Krebs-Henseleit buffer (KHB), was selected 
as the control non-cardioplegic solution (Table I). 
The S12 cardioplegic solution used in this study is the im-
proved St Thomas' Hospital solution No. 2 (Plegisol; Ab-
bott Laboratories, North Chicago, Illinois) and not the 
original StThomas' hospital solution No. 1 (MacCarthy). 7 
This solution has previously been shown in the rat heart to 
be superior to other solutions such as Ringer-lactate solu-
tion with added potassium and balanced saline solution with 
glucose and potassium. 6 
In contrast, the SABAX solution, although used clinically 
in South Africa, has not been reported to have been ex-
perimentally evaluated or clinically compared with other at-
tested solutions. 
The GSH cardioplegic solution was. originally based on the 
initial Bretschneider solution which was formulated with an 
'intracellular' concentration of electrolytes, specifically 
sodium. 8 Over the years the GSH solution was altered with-
out any reported experimental or clinical trials, resulting in 
the composition indicated in Table I. The Bretschneider 
HTK-4 solution in clinical use in Europe today differs 
markedly from both the GSH solution and the original 
Bretschneider solution. 
Materials and methods 
The chacma baboon (Papio ursinus) was selected because of 
its close evolutionary relationship to man. All animals 
received care according to the Ethical Considerations in 
Medical Research, revised edition, 1987, set out by the South 
African Medical Research Council. 
Animals weighing 13-28 kg were anaesthetised with keta-
mine hydrochloride (10 mg/kg body weight intramuscular-
ly). Following intubation with an appropriately sized 
endotracheal tube the animals were ventilated by means of 
a Bird Mark 8 positive-pressure ventilator. Anaesthesia was 
maintained with nitrous oxide (70%) and oxygen (30%). Mor- · 
phine sulphate (0,5 mg/kg intravenously) and pancuronium 
bromide (0,1 mg/kg intravenously), together with atropine sul-
phate (0,5 mg intravenously) was administered. Central 
venous and femoral arterial lines were then inserted. Prior 
to aortic cannulation blood pressure was controlled by the 
addition of halothane {0,5-1,0%). 
A median sternotomy was performed and after full 
heparinisation (1 000 U/kg) the heart was cannulated in prepa-
ration for cardiopulmonary bypass. Extracorporeal circula-
tion could be commenced by draining venous blood from a 
single venous cannula inserted into the right atrium, oxygena-
ting it with a Polystan Venotherm low-prime adult/paediatric 
No. 011520 bubble oxygenator (blood temperature controlled 
with a heat exchanger), and finally returning the blood to the 
body via a cannula inserted into the ascending aorta. 
A Swan-Ganz thermodilution catheter (American Edwards 
7F) was inserted through the superior vena cava and posi-
tioned in the pulmonary artery for the measurement of cardiac 
output. Cannulas were also inserted into the left atrium via 
the left atrial appendage, into the left ventricle through the 
apex, into the pulmonary artery and into the ascending aorta 
for haemodynarnic measurements. Finally, a thermistor probe 
was positioned in the intraventricular septum to monitor myo-
cardial temperature. During the aortic cross-clamp and initial 
recovery period the left ventricle was vented by means of a 
cannula inserted via the right superior pulmonary vein. Con-
trol haemodynarnic measurements were recorded after posi-
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tioning of all cannulas, prior to commencement of 
cardiopulmonary bypass. _ 
Cardiopulmonary bypass was commenced and systemic 
temperature lowered and maintained at 26°C. The aorta was 
then cross-damped and cold ( 4 oq cardioplegic solution (15 
ml/kg) infused through a separate cannula inserted into the 
ascending aorta. In addition, iced saline (4°C) was used for 
topical hypothermia. The cardioplegic solution was delivered 
via a separate roller pump at constant pressure (80 mmHg), 
measured in the ascending aorta. All topical cold saline was 
removed after infusion of cardioplegia to. simulate the clini-
cal situation. Maintenance cold cardioplegia (100 ml) together 
with topical cold saline was re-infused every 30 minutes 
throughout the 180-minute ischaemic cross-clamp period. 
Systemic rewarming of the animal was commenced during 
the ischaemic period, 30 minutes before the release of the 
aortic cross-clamp, and continued throughout the 15-minute 
reperfusion period until normothermia was obtained. The 
animal was then weaned from cardiopulmonary bypass and 
haemodynamic measurements were taken 5 and 30 minutes 
after termination of cardiopulmonary bypass. At the end of 
the experiment, while under full general anaesthesia, the 
animals were administered a lethal dose of potassium 
chloride. 
Haemodynamic measurements 
The following variables were measured with a Honeywell 
AR-6 six-channel simultrace recorder: heart rate, arterial 
blood pressure, right atrial pressure, left atrial pressure, the 
first derivative of the left ventricular. developed pressure (LV 
dP/dt), and cardiac output (CO). All control and post-
ischaemic haemodynamic values were taken with the animal 
volume-loaded to a left atrial pressure of 5 mm/Hg to stan-
dardise the preload on the left ventricle. No attempt was made 
to control the heart rate. 
Tissue high-energy phosphates 
Left ventricular drill biopsy specimens were taken from 
the apex of the left ventricle for determination of myocardial 
high-energy phosphate content. Samples were taken before 
commencement of cardiopulmonary bypass at the time of con-
trol haemodynamic measurements, after the 3-hour ischaemic 
period prior to release of the cross-clamp, and 5 and 30 
minutes after termination of cardiopulmonary bypass. The 
samples were immediately frozen by immersion in liquid 
nitrogen and subsequently stored in liquid nitrogen. Deter-
mination of adenosine triphosphate (ATP) and creatine phos-
phate (CP) content was by enzymatic analysis. 9 
Electron microscopy 
Drill biopsy specimens from the apical area of the left ven-
tricle were assessed for ultrastructural changes. Samples were 
taken at the same time for the determination of tissue high-
energy phosphate content. Following fixation in 5% buffered 
glutaraldehyde the samples were processed according to the 
technique routinely employed in our laboratory. 10 
Crystalloid cardioplegic solutions tested 
The composition of the tested solutions is given in Table 
I. The ST2 cardioplegic solution and the control non-
cardioplegic KHB were prepared in the laboratory and flltered 
through a 0,8 ,urn filter to remove any bacteria and all parti-
culate matter. The SABAX solution was kindly donated by 
SABAX Ltd. The GSH solution was the standard solution 
made by the hospital pharmacy at Groote Schuur Hospital. 
Expression of results 
Cardiac index (CI) was calculated from the formula: 
CI = CO/body surface area 
[£.min-1.m-2] 
Stroke volume index (SVI) from the formula: 
SVI = CI/heart rate x 1 000 
[ml.min-1.m-2 .beat-1] 
Stroke work index (SWI) from the formula: 
SWI = SVI/(0,01438 >< LV systolic pressure 
- LV end-diastolic pressure) 
[g.m.m - 2• beat-1] 
Haemodynamic values obtained during· the post-bypass 
period are expressed as a percentage of the individual pre-
ischaemic control values. Tissue high-energy phosphate con-
tent is expressed in absolute values (,umol.g-1 wet weight). 
Statistical methods 
All data were expressed as means ± standard error. Com-
parison of haemodynamic and biochemical data between the 
post-ischaemic periods was by two-way analysis of variance. 
Comparison of data between groups at 30 minutes after 
cardiopulmonary bypass was by one-way analysis of variance. 
Individual comparisons were by Student's t-test for unpaired 
data with the Bonferonni correction for multiple compari-
sons. Statistical significance was assumed with a P value 
< 0,05. 
Results 
The myocardial hypothermia produced by the above ex-
perimental protocol· was uniform in all animals. Ventricular 
septal temperature consistently fell to 10°C with each infu-
sion of cardioplegic solution. The myocardium then rewarmed 
to approximately 20°C in the 30 minutes between each re-
infusion. 
Haemodynamic recovery 
Since there were no differences between haemodynamic 
recovery at 5 minutes and 30 minutes, as determined by two-
way analysis of variance, only tlie functional recovery at 30 
minutes is presented in Table II. 
Functional recovery as assessed by SVI in the ST2 group 
was superior to that in all the other groups. The recovery 
of CI and SWI of the ST2-treated animals was significantly 
better than that of animals treated with GSH and KHB. CI 
and SWI for ST2-treated animals, although higher than that 
for SABAX-treated animals, were not statistically different. 
However, when comparing the functional recovery (SVI, 
CI, SWI) of hearts treated with SABAX to GSH cardio-
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TABLE ll. HAEMODYNAMIC RECOVERY (PERCENTAGE OF PRE--ISCHA.EMIC CONTROL) OF BABOON HEARl'S 
AT 30 MINUTES AFTER RELEASE OF AORTIC CROSS-CLAMP 
N CI SVI SWI LV dP/dt 
ST2 8 94,75 ± 5,81 113,95 ± 8,30 97,14 ± 12,68 87,00 ± 12,39 
SBX 7 84,30 ± 5,79 81,35 ± 7,84* 71,67 ± 14,03 83,96 ± 10,22 
GSH 7 73,58 ± 3,01* 80,21 ± 6,02* 51,91 ± 2,52* 71,43 ± 6,49 
KHB 7 59,86 ± 9,93* 55,61 ± 10,00** 34,98 ± 9,24** 54,72 ± 6,82 
The percentage recovery of CI, SVI, LV dP/dt and SWI compared with the pre-ischaemic control, at 30 minutes after termination of cardiopulmo-
nary bypass at a left atrial pressure of 5 mmHg, following a 3-hour ischaemic period. The hearts were protected with the mentioned solutions 
delivered every 30 minutes at 4 •c during this period in addition to topical cold saline. 
• P <0,05 v. ST2. 
•• P <0,01 v. ST2. 
plegia or KHB buffer, SABAX cardioplegia was not superior 
to either the KHB control solution or the GSH solution. 
LV function curves were determined at the end of the ex-
perimental protocol in some animals. The SWI was meas-
ured at different preloads by varying the left atrial pressure 
between 5 rnmHg and 20 mmHg (Fig. 1). The post-ischaemic 
LV function curve of hearts perfused with ST2 solution ap-
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Fig. 1. Post-ischaemic LV function of hearts protected during 
a 3-hour ischaemic period with StThomas' Hospital cardio-
plegic solution No. 2 (-0-), Groote Schuur Hospital cardio-
plegia (- 1:::. -), or Krebs-Henseleit non-cardioplegic physiologi-
cal buffer (- 0-) compared with a pre-ischaemic control LV 
function curve(- • -). LV function assessed as stroke work in-
dex (SWI) was measured at 30 minutes after termination of 
cardiopulmonary bypass at a varying left atrial pressure (LAP). 
For hearts treated with SABAX solution (-0-) SWI was only 
measured at LAP of 5 mmHg. Values are expressed as 
means (g/min/m2/beat) and standard error of the means. 
proximated the basal pre-ischaemic LV function curve meas-
ured in some animals prior to the 3-hour ischaemic period. 
This finding was in contrast to the depressed post-ischaemic 
curve for hearts protected with GSH cardioplegia or KHB 
buffer. This technique was not available for the animals treated 
with SABAX solution due to technical reasons. 
Recovery of high-energy phosphates 
The ATP and CP content of all hearts decreased during 
the 3-hour ischaemic period despite maintenance doses of 
cardioplegia (Table III). This loss of ATP was not different 
between the various groups. However, after release of the 
aortic cross-clamp there was a marked post-ischaemic re-
covery of high-energy phosphate levels. The ATP content 5 
minutes after cardiopulmonary bypass in hearts treated with 
ST2 solution was slightly better than that in hearts perfused 
with SABAX solution, but the differences were not statis-
tically significant. Also, at 30 minutes after bypass, there was 
no difference in the ATP content of hearts treated with any 
of the solutions. 
The CP levels at 5 minutes and 30 minutes post-bypass were 
similar in all groups. However, levels in the ST2-treated hearts 
tended to be slightly superior compared with hearts perfused 
with SABAX and GSH solution. In addition, at 5 and 30 
minutes, the CP content of the non-cardioplegic KHB-treated 
hearts was not lower than that of hearts perfused with any 
of the cardioplegic solutions (Table III). 
Ultrastructure 
Only a limited number of samples could be assessed so 
far. All groups showed mild to moderate changes after 3 hours 
of ischaemia (Fig. 2) which were partially reversible after 
reperfusion (Fig. 3). Further details will be published 
elsewhere. 
Comparison of time to induce cardiac arrest and 
refunction time 
Comparison of the time intervals taken by each solution 
to induce complete cardiac arrest revealed no statistical differ-
ences, and all solutions stopped electromechanical activity 
within 8-11 seconds (ST2 8,3 ± 1,4 s, SABAX 10,7 ± 2,5 
s, and GSH 7,9 ± 1,9 s). The average time to wean the 
animals off CPB, which is also referred to as 'refunction time', 
and which is considered to be an index of myocardial pro-
tection, 11 was longest for the GSH solution (9,4 ± 3, 9 min). 
Animals in the SABAX group had a mean refunction time 
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TABLE ill. ATP AND CP CONTENT 
Control ACC 5' 30' 
ATP (~t mol/g wet wt) 
STI 4,08 ± 0,49 2,68 ± 0,23 3,09 ± 0,45 2,57 ± 0,33 
(5) (5) (5) (3) 
SBX 3,78 ± 0,50 2,98 ± 0,45 2 ,58 ± 0,51 2,40 ± 0,20 
(5) (5) (5) (5) 
GSH 3,75 ± 0,35 3,24 ± 0,45 2,77 ± 0,49 2,86 ± 0,53 
(7) (7) (7) (4) 
KHB 3,89 ± 0,28 1,92 ± 0,21 2,23 ± 0,34 2,11 ± 0,54 
(7) (5) (7) (7) 
CP (~tmol/g wet wt) 
STI 6,59 ± O,fJ? 1,98 ± 0,53 6,78 ± 0,80 6,10 ± 0,36 
(5) (5) (5) (3) 
SBX 7,32 ± 0,84 2,50 ± 0,74 4,88 ± 0,67 3,90 ± 0,74 
(5) (5) (5) (5) 
GSH 7,18 ± 0,65 1,43 ± 0,44 4,61 ± 0,96 5,21 ± 0,96 
(7) (7) (7) (4) 
KHB 6,81 ± 0,46 0,49 ± 0,27 5,69 ± 0,88 5,76 ± 0,52 
(7) (5) (7) (7) 
Measurements were taken prior to commencement of cardiopulmonary bypass (control), prior to the release of the aonic cross-clamp (ACC) 
after a 3-hour ischaemic period, at 5 minutes and at 30 minutes after termination of cardiopulmonary bypass. Number of heans fo r each mean 
is given in parentheses. 
Fig·. 2. Ultramicroscopic appearance of a portion of a myo-
cyte of a baboon heart after perfusion with SABAX solution 
following an ischaemic cross-clamp period of 180 minutes. 
There is evidence of swelling of the mitochondria with an ab-
normal crystal arrangement and intracytoplasmic oedema. 
(Electron photomicrograph x 51 000.) 
of 6,9 ± 1,8 min compared with 4 ,6 ± 1,3 min in the S12 
group. In addition, the average energy required to cardiovert 
the hearts back to sinus rhythm after ischaemia (defibrilla-
tion energy) was highest in the SABAX group (85,7 ± 23,8 
joules), whereas animals in the GSH and S12 groups required 
34 ,3 ± 15,9 and 38,8 ± 6,7 joules respectively. 
Electrocardiographic criteria 
Transient Sf-segment elevations in the postcischaemic ECG 
Fig. 3. Relatively normal appearance of mitochondria is evi-
dent in this myocyte of a baboon heart wh ich has undergone 
3 hours cardiac arrest and perfusion with SABAX solution fol-
lowed by 1 hour reperfusion with blood. (Electron photomicro-
graph x 51 000.) 
recordings were observed in all groups (417 cases for the GSH 
solution, 417 cases for the SABAX solution and 4/8 cases 
for the S12 solution). New Q waves were not discernible in 
any of the cardioplegic groups. All animals in the SABAX-
treated group recovered in normal sinus rhythm after defibril-
lation. Of the hearts treated with GSH solution, one remained 
in atrial fibrillation , whereas in the group treated with S12 
solution, one heart recovered with multiple unifocal ventric-
ular extrasystoles. 
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Discussion 
This study, which closely resembles the clinical situation, 
shows that the indices of haemodynamic recovery (CI, SVI 
and SWI) in hearts protected with ST2 was above 95%, in 
hearts protected with SABAX solution recovery was 70-85%, 
with the GSH solution it was 52-80%, and with KHB 
35-60% . ST2 was superior to the SABAX solution in SVI 
and to the GSH solution in the majority of measured hae-
modynamic variables. LV function curves of SWI calculated 
at left atrial pressures of 5, 10, 15 and 20 mmHg showed that 
hearts protected with ST2 had good recoveries, in constrast 
to those treated with GSH solution and KHB. These find-
ings confirm the importance of thorough laboratory testing 
of any cardioplegic solution. ST2 was extensively investigat-
ed in two different animal species and the electrolyte con-
tent was formulated according to dose-response curves for 
each ion . 4•5•8•12 
Although there was no significant difference in the vari-
ous series in the post-ischaemic recovery of ATP at 5 and 
30 minutes, previous studies have shown that ATP levels are 
not the only factor controlling viability, 13 and that the rate 
of ATP synthesis may be more important. 
Although ATP and CP levels decreased during the 
ischaemic period, they were quickly restored to acceptable 
levels during reperfusion in hearts protected with ST2. 
However, post-ischaemic ATP and CP levels observed in the 
other groups in this study do not correlate with functional 
recovery. 
The Plasmalyte B with added potassium used in some 
centres in South Africa has a similar electrolyte content to 
Ringer's lactate except that Plasmalyte B is acalcaemic. Coro-
nary perfusion with a calcium-free solution may lead to in-
creased sarcolemmal permeability to calcium, and when the 
myocardium is reperfused with a calcium-containing solu-
tion a massive influx of calcium can occur, causing severe 
cellular damage. 14' 17 The addition of 200 rnl pump blood to 
the maintenance Plasmalyte B (thus introducing a minimal 
concentration of calcium), as practised by one unit, could 
prevent this calcium paradox and consequently be beneficial. 
In addition, Plasmalyte B contains a high potassium concen-
tration. It has been shown that the optimal potassium 
concentration for a crystalloid cardioplegic solution is ap-
proximately 15 mmol/1 and that higher potassium concen-
trations may be damaging. 18'2° For these reasons this solution 
was not included in this study. 
In the clinical situation, because of the large number of 
variables such as coronary artery anatomy, LV dysfunction, 
cross-clamp time, non-collateral flow and the extent of the 
procedure, it is difficult to objectively evaluate the perfor-
mance of any one myocardial protection regimen. 12 Variabil-
ity of non-collateral coronary flow in the diseased heart may 
influence the rate of 'wash-out' of the cardioplegic solution, 
so diminishing its advantages; likewise the 'wash-in' of sub-
stances (e.g. calcium) may be beneficial when using an acal-
caemic cardioplegic solution. It is not yet known whether 
undetected myocardial damage, resulting from poor myocar-
dial protection, will result in late myocardial fibrosis and 
decreased left ventricular function. Therefore, we should con-
tinue to seek improvements in our techniques of myo<;ardial 
preservation. 
Conclusion 
The result of this comparative control study, in conjunction 
with other reports in the literature, lead us to propose that 
the optimum crystalloid cardioplegic solution for use in South 
Africa today should be based on the St Thomas' Hospital 
cardioplegic solution No. 2. Even minor alterations to this 
solution should be fully evaluated experimentally before clin-
ical use. The Cardio-Thoracic Department at Groote Schuur 
Hospital now uses St Thomas' solution No. 2 plus glucose 
(10 mmol/1) cardioplegic solution. The beneficial effect of 
adding glucose to the St Thomas' Hospital solution No. 2 
at this concentration has been confirmed in our laboratory 
(unpublished data). 
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St. Thomas' Hospital cardioplegic solution 
Beneficial effect of glucose and multidose reinfusions of cardioplegic 
solution 
The intention of this study was to determine whether glucose is beneficial in a cardioplegic solution 
when the end products of metabolism produced during the ischemic period are intermittently removed. 
The experimental model used was the isolated working rat heart, with a 3-hour hypothermic 10° C 
cardioplegic arrest period. Cardioplegic solutions tested were the St. Thomas' Hospital No. 2 and a 
modified Krebs-Henseleit cardioplegic solution. Glucose (11 mmolfL) was beneficial when multidose 
cardioplegia was administered every 30 minutes. Including glucose in Krebs-Henseleit cardioplegic 
solution improved postischemic recovery of aortic output from 57.0% ± 1.8% to 65.8% ± 2.2%; 
p < 0.025. The addition of glucose to St. Thomas' Hospital No. 2 cardioplegic solution improved aortic 
output from 74.6% ± 1.9% to 87.4% ± 1.9%; p < 0.005. Furthermore, a dose-response curve 
showed that a glucose concentration of 20 mmoi/L gave no better recovery than 0 mmol/L, and 
glucose in St. Thomas Hospital No. 2 cardioplegic solution was beneficial only in the range of 7 to 11 
mmoi/L In addition, we showed that multidose cardioplegia was beneficial independent of glucose. 
Multido5e St. Thomas' Hospital No. 2 cardioplegia, as opposed to single-dose cardioplegia, improved 
aortic output recovery from 57.4% ± 5.2% to 74.6% ± 1.9%; p < 0.025, and with St. Thomas' 
Hospital No. 2 cardioplegic solution plus glucose (11 mmolfL) aortic output recovery improved from 
65.9% ± 2.9% to 87.4% ± 1.9%; p < 0.005. Hence, at least in this screening model, , the St. 
Thomas' Hospital cardioplegic solution should contain glucose in the range of 7 mmoi/L to 11 
mmoi/L, provided multidose cardioplegia is given. We cautiously suggest extrapolation to the human 
heart, on the basis of supporting clinical arguments that appear general enough to apply to both rat 
and human metabolisms. · 
Ulrich 0. von Oppel!, MB, ChB, FCS,a Eugene F. Du Toit, MSc, Linda M. King, BSc(Hons), 
Patricia Owen, PhD, Timothy Dunne, FIS, PhD,b Bruno Reichart, MD,a and 
Lionel H. Opie, MD, PhD, Cape Town, Republic of South Africa 
Crystalloid cardioplegic solutions of markedly varying 
compositions are used both clinically and experimentally 
From the Ischaemic Heart Disease Laboratory, Department of Car-
diothoracic Surgery." and the Department of Mathematical Statis-
tics,b University of Cape Town Medical School, Observatory, Cape 
Town, Republic of South Africa. 
to aid in the prevention of intraoperative myocardial 
damage. 1 This diversity has resulted in difficulties when 
attempting to attribute improvements to a specific com-
ponent because of inseparable interactions with other 
constituents. In particular, controversy exists as to the 
beneficial effect of glucose.2•5 
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There are two ·fundamental types of crystalloid car-
dioplegic solutions: those with an "intracellular" ionic 
equivalent composition, notably Bretschneider's 
solution,6 and those with an "extracellular" form. In the 
latter group the St. Thomas' Hospital No. 2 · (ST) 
cardioplegic solution has been fully characterized with 
respect to each individual cation-sodium, potassium, 
magnesium, and calcium'· 7• 8-and is used internation-
ally. Hearse, Stewart, and Braimbridge2 showed that the 
addition of glucose to a solution similar to ST was dam-
405 
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Fig. 1. Isolated working rat heart perfusion apparatus. Three-way taps (T) provide easy conversion to either -the 
Langendorff mode or the working heart circuit and allow for infusion of cardioplegic solution. Oxygenation (02) of 
the perfusion fluid (Krebs-Henseleit buffer) is with 95% oxygen:5% carbon dioxide. 
Table I. Cardioplegic solutions 
Na K Mg Ca HC01 Glucose 
· KC cardioplegic solution 143 16 1.2 1.25 25 0 or II 
ST cardioplegic solution 120 16 16 1.2 10 0 or II 
KC cardioplegic solution, modified Krebs-Henseleit solution; ST cardioplegic solution, StThomas' Hospital No.2 cardioplegic solution. (The standard solution 
does not contain glucose.) Values are given in millimoles per liter. 
aging in a 70-minute 28° C ischemic model protected 
with single-dose cardioplegia.2 However, accumulation of 
glycolytic end products, as a result of total ischemia, is 
known to cause detrimental feedback inhibition of 
metabolism.9 
The object of this study was to determine the effects of 
glucose, included in an "extracellular" cardioplegic solu-
tion, on postischemic metabolic and mechanical function-
al recovery after hypothermic cardioplegic arrest. In 
addition, we examined the necessity for intermittent rein-
fusions of cardioplegic solution throughout the ischemic 
period to wash out metabolic end products. The initial 
experiments were performed with a modified physiologic 
perfusion solution (Krebs-Henseleit; KC) but with addi-
tional potassium ( 16 mmoljL) to produce diastolic arrest, 
withorwithoutglucose, 11 mmoljL(KC + GversusKC; 
Table 1). The final experiments followed a similar proto-
col but used ST, with and without glucose, 11 mmoljL 
(ST + G versus ST; Table 1). 
A dose-response curve for glucose in ST was also per-
formed to determine the concentration range in which 
glucose was beneficial in the ST solution. 
Materials and methods 
All animals received care according to the "Principles of 
Laboratory Animal Care" formulated by the National Society 
for Medical Research and the "Guide for the Care and Use of 
Laboratory Animals" prepared by the National Academy of 
Sciences and published by the National Institutes of Health 
(NIH Publication No. 80-23, revised 1978). 
Experimental protocol. The isolated perfused rat heart was 
used as our experimental model 10 (Fig. I). Male (Long Evans) 
rats (250 to 400 gm) were anesthetized with diethyl ether; 200 
IU of heparin was injected into the exposed femoral vein and the 
hearts were rapidly excised and placed into 4° C Krebs-Hense-
Jeit buffer (NaHC03, 25 mmoljL; NaCJ, 118 mmoi/L; 
KH2P04, 1.2 mmoljL; KCI, 4.8 mmoljL; MgS04, 1.2 mmol/ 
L; CaCI2, 1.25 mmoi/L; and glucose, 11.1 mmoi/L). 
The aorta was cannulated within 1 minute, and Langendorff 
perfusion at a constant pressure of 100 em of water was com-
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menced. The pulmonary veins were then identified, the left atri-
um cannulated, and the pulmonary artery incised to ensure 
ejection of coronary effluent. The Krebs-Henseleit buffer was 
gassed with 95% oxygen:5% carbon dioxide and maintained at 
37° C. The hearts were stabilized for I 0 minutes before chang-
ing to the working mode. The left atrium was then filled at a 
pressure of20 em H20, and the perfusion fluid was ejected from 
the left ventricle against an afterload pressure of 100 em H20. 
The aortic pressure was measured by a Statham P23dB pressure 
transducer (Spectramed Inc., Critical Care Division, Oxnard, 
Calif.) connected to a sidearm of the aortic cannula. After 1 0 
minutes of work (control period) the aortic and coronary flow, 
peak systolic aortic pressure, and heart rate were recorded. Any 
heart that was unstable was rejected. 
At the end of the control work period the atrial and aortic 
cannulas were closed off and 10 ml of 10° C cardioplegic solu-
tion was infused into the aorta at a pressure of 60 mm Hg. The 
hearts were maintained at constant hypothermia for 3 hours by 
means of a 10° C water-jacketed chamber. In the groups 
receiving multidose cardioplegia, 6 ml of I 0° C cardioplegic 
solution was reinfused every 30 minutes throughout the arrest 
period. At the end of the ischemic period each heart was reper-
fused for I 0 minutes at 37° C in the Langendorffmode, followed 
by the working mode for an additional 10 minutes to measure 
postischemic functional recovery. During the ischemic and 
postischemic reperfusion periods the coronary effluent was col-
lected, and at the end of the experiment the hearts were freeze 
clamped with Wollenberg tongs to determine their high-energy 
phosphate content, expressed as micromoles per gram wet 
weight. 
Preischemic control values for adenosine triphosphate and 
creatine phosphate were derived from hearts (n = 6) subjected 
to the same initial experimental protocol, that is, 10-minute 
Langendorff and I 0-minute working heart modes, but thereaf-
ter immediately freeze-clamped. 
Expression of results. Cardiac output (CO) in this prepara-
tion is the sum of aortic flow (AO) and coronary flow, while 
stroke volume (SV) is CO/heart rate. Values obtained during 
the postischemic working period were expressed as a percentage 
of their individual preischemic control values. Results are pre-
sented as percentage means and standard errors of percentage 
means. 
Exclusion criteria. In the preischemic control period the fol-
lowing values were used to discard hearts: AO <30 ml/min; 
coronary flow >22 ml/min; heart rate <200 beats/min, or 
irregular rhythm. In the postischemic period any heart whose 
coronary flow significantly increased by more than 50% (sug-
gesting a left atrial leak) was excluded. No extreme observations 
were detected with the use of Dixon's criteria, and therefore no 
additional hearts were discarded. 
The statistical test used to compare differences between the 
factors, cardioplegic solution (KC or ST), addition of glucose, 
and provision of multidose cardioplegia, was the three-way 
analysis of variance (ANOV A). However, the ANOV A 
depends on an assumption of common variance among obser-
vations within each treatment group. In this study the variance 
within groups was not consistent. Therefore, when focusing on 
specific comparisons of interest after ANOV A was conducted, 
necessary adjustments for the violation of common variance 
were made. Pairwise comparisons of means with no assumption 
of common variance were performed using t statistics with a 
nominal level of significance set at 5%. 
A consequence of multiple comparisons at a specified nom-
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Table II. Crystalloid cardiop/egic solution 
Single-dose cardioplegia 
KC (n = 6) KC+ G (n = 7) 
Preischemic control values 
AO (ml/min) 45.3 ± 1.3 39.7 ± 2.7 
CO (mlfmin) 62.3 ± 2.4 54.6 ± 3.4 
SV (ml) 0.24 ± 0.01 0.23 ± 0.02 
AP (mm Hg) 107 ±I 104 ± 2 
Postischemic functional recovery 
AO 50.6% ± 1.5% 51.7% ± 1.7% 
co 56.5% ± 1.8% 60.9% ± 2.7% 
sv 60.1% ± 3.5% 60.3% ± 4.4% 
AP 92.4% ± 1.4% 89.5% ± 2.4% 
Multidose cardioplegic solution 
KC (n = 6) 
Preischemic control values 
AO (mlfmin) 38.7 ± 2.3 
CO (ml/min) 54.8 ± 4.4 
SV (ml) 0.21 ± 0.02 
AP (mm Hg) 104 ± 4 
Postischemic functional recovery 
AO 57.0% ± 1.8% 
co 70.5% ± 3.0%t 
sv 71.3% ± 3.9% 
AP 96.3% ± 1.7% 
KC+ G (n = 7) 
43.4 ± 3.9 
60.0 ± 5.3 
0.22 ± 0.02 
108 ± 3 
65.8% ± 2.2%* 
73.3% ± 2.4%:j: 
76.8% ± 4.4%:j: 
94.6% ± 1.8% 
NS 
NS 
NS 
NS 
p < 0.025 
NS 
NS 
NS 
Mean preischcmic control values and postischemic functional recovery (expressed 
as a percentage of each individual preischemic value) and standard errors of per-
centage means in isolated rat hearts after 3-hour 10° C cardioplegic arrest. All 
hearts were protected with an initial I 0 ml dose of Krebs-Henseleit cardioplegic 
solution (KC), with or without II mmolflglucose(G),at theonsetoftheischemic 
period. In the indicated groups, 6 ml boluses of multidose cardioplegic solution 
were infused every 30 minutes throughout the arrest period. AO, Aortic output; 
CO, cardiac output; SV, stroke volume; AP, maximum developed systolic aortic 
pressure; NS, not significant at 5% level. 
*p < 0.005 compared with single-dose KC +G. 
tp < 0.005 compared with single-dose KC. 
:j:p < 0.025 compared with single-dose KC +G. 
ina! level is that some statistics for comparisons may be declared 
significant when chance alone is operating over essentially 
equivalent groups. However, we relied on the fact that the num-
ber of statistically significant comparisons was a large fraction 
of the total number of comparisons studied, too large to be 
explicable in the vagaries of chance and the nominal level. 
In the dose-response relationship of AO and CO recovery to 
glucose concentration, the evidence of some ordinal effect of 
dose was assessed by the nonparametric "runs-up-and-down" 
test. Thereafter suitable multiple-comparison t tests were used 
to establish significance. 
Appropriate tables were then used to determine p values for 
comparisons of interest. Statistical significance was assumed 
when the p value was <0.05, and those p values reported are 
conservative. 
Results 
ANOV A suggested that the main effect of all three 
factors ( cardioplegic solution, addition of glucose, and 
provision of multidose cardioplegia) were statistically 
significant for the variables AO, CO, and SV. Two-way 
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Table III. St Thomas' Hospital cardioplegic solution 
Single-dose cardioplegia 
ST (n = 7) ST +GIn= 10) 
Preischemic control values 
AO (mlfmin) 47.0 ± 1.9 43.5 ± 2.3 
CO (ml/min) 65.6 ± 2.7 61.7 ± 2.1 
SV (ml) 0.24 ± 0.01 0.23 ± O.QJ 
AP (mm Hg) 104 ± 2 104 ± 3 
Postischemic functional recovery 
AO 57.4% ± 5.2% 65.9% ± 2.9% 
co 63.8% ± 4.9% 74.6% ± 3.8% 
SV 58.1% ± 4.0% 76.2% ± 3.2% 
AP 95.0% ± 1.7% 91.9% ± 1.8% 
Postischemic LDH loss (mUfgm/min) 
0-10 min 42.9 ± 8.0 66.4 ± 7.7 
Multidose cardioplegia 
ST (n = 9) ST + G (n = 8) 
Preischemic control values 
AO (mlfmin) 48.6 ± 2.0 
CO (mlfmin) 66.4 ± 1.3-
SV (ml) 0.25 ± 0.02 
AP (mm Hg) 107 ± 3 
Postischemic functional recovery 
46.3 ± 1.2 
63.8 ± 1.5 
0.21 ± O.QJ. 
101 ± 3 
NS 
NS 
P < O.QJ 
NS 
p < 0.05 
AO . 74.6% ± 1.9%* 87.4% ± J.9%t p < 0.005 
CO 80.0% ± 1.6%* 88.7% ± 2.2%:j: p < O.QJ 
SV 89.4% ± 2.6%§ 93.8% ± 5.0%t NS 
AP 93.7% ± 1.2% 99.9% ± 2.3%:j: p < 0.025 
Loss in coronary sinus effluent with each reinfusion of cardioplegic 
solution 
LDH (mUjgm/ 
dose) 
72.6 ± 3.6 
Lactate (!lmol/ gm/ 1.86 ± 0.1 I 
dose) 
Postischemic LDH loss (mUfgm/min) 
82.2 ± 6.6 
2.49 ± 0.16 
0-10 min 148.0 ± 18.1§ 109.5 ± 18.811 
NS 
p < 0.05 
NS 
Mean preischemic control values and postischemic functional and metabolic 
recovery (expressed ·as a percentage of each individual preischemic value) and 
standard errors o(perecntage means in isolated rat hearts aftef 3-hour I oo C car-
dioplegii: arrest. Hearts were protected with St Thomas' Hospital cardioplegic 
solution (ST), with or without II mmoi/L glucose (G), and multidose rein fusions 
of cardioplegic solution every 30 minutes throughout the ischemic period in the 
groups indicated. AO, Aortic output; CO, cardiac output; SV, stroke volume; AP, 
maximum developed systolic aortic pressure; LDH. lactate dehydrogenase); Ns. 
not significant at 5% level. · 
•p < 0.05 compared with single-dose ST. 
t p < 0.005 compared with single-dose ST + G. 
~P < 0.025 compared with single-dose ST + G. 
§p < 0.005 compared with single-dose ST. 
~p < 0.05 compared with single-dose ST +G. 
interaction between cardioplegic solution and either glu-
cose or multidose infusion was found with AO, and 
between glucose and multidose infusion for aortic pres-
sure. 
Effect of glucose with single-dose cardioplegia. 
Hearts were subjected to a single coronary infusion of 
cardioplegic solution at the onset of the 3-hour ischemic 
period. The initial groups were protected with KC car-
dioplegic solution without glucose (n = 6). The mean 
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Table IV. High-energy phosphate content taken at 
end of reperfusion 
N ATP CP 
Control 6 3.91 ± 0.25 5.05 ± 0.46 
KC 6 2.67 ± 0.23* 5.19 ± 0.64 
KC+G 7 2.90 ± 0.09* 4.98 ± 0.31 
ST 9 3.22 ± 0.14*t 4.99 ± 0.34 
ST+G 8 3.39 ± 0.08:!:§ 4.90 ± 0.28 
Mean concentrations of adenosine triphosphate (A TP) and creatine phosphate 
(CP) expressed as).lmolfgm wet weight after 1 0-minute recovery following 3-hour 
1 oo C cardioplegic arrest. protected with 30-minutc multidose rein fusions of car-
dioplegic solution. Hearts were protected with Krebs-Henseleit cardioplcgic solu-
tion (KC) ± II mmoi/L glucose (G) or StThomas· Hospital cardioplcgic solu-
tion (ST) ± II mmoljL G. Preischcmic control values for A TP and CP were 
obtained by freeze clamping six hearts before the ischemic period in the experi-
mental protocol. · 
*p < 0.005 compared with control. 
tp < 0.02 compared with KC. 
:j:p < 0.05 compared with KC +G. 
§p < 0.05 compared with control. 
recovery of AO was 50.6% ± 1.5%, and for CO, 
56.5% ± 1.8%. The addition of glucose (11 mmol/L) 
(n = 7) did not improve recovery of AO (51.7% ± 1.7%) 
or CO (60.9% ± 2.7%) (Table II). 
A similar protocol was followed when protecting hearts 
with either ST (n = 7) or ST + G (n = 10). The mean 
recoverywithSTfor AOwas 57.4% ± 5.2%andfor CO, 
63.8% ± 4.9%. The addition of glucose again did not sig-
nificantly improve AO (65.9% ± 2.9%) or CO 
(74.6% ± 3.8%), but did improve SV from 
58.1% ± 4.0% to 76.2% ± 3.2%; p < O.Ql (Table III). 
However, postischemic lactate dehydrogenase loss, a 
measure of damage to membrane integrity, increased 
with· the addition of glucose from 42.9 ± 8.0 mU/ 
gmjmin to 66.4 ± 7.7 mUjgmjmin; p < 0.05. 
Hence the effect of adding glucose to ST with single-
dose cardioplegia was questionably beneficial, and in fact 
possibly harmful. 
Effect of glucose with multidose cardioplegia. 
Hearts received the initial cardioplegic solution bolus at 
the onset of the ischemic period, together with reinfusions 
every 30 minutes throughout the 3-hour hypothermic 1 oo 
C period. The addition of glucose, 11 mmol/L, to KC 
improved AO recovery, from 57.0% ± 1.8% (n = 6) to 
65.8% ± 2.2% (n = 7); p < 0.025. CO and SV were 
unchanged (see Table II). 
The addition of glucose, 11 mmol/L, to ST improved 
recovery of AO from 74.6% ± 1.9% (n = 9) to 
87.4% ± 1.9% (n = 8); p < 0.005, and CO from 
80.0% ± 1.6% to 88.7% ± 2.2%; p < 0.01 (see Table 
Ill). The postischemic leakage of lactate dehydrogenase 
was unchanged (ST 148.02 ± 18.09 mUjgmjmin and 
ST + G 109.50 ± 18.84 mU/gm/min). Including glu-
cose in this cardioplegic solution increased end products 
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Fig. 2. Composite dose response graph for glucose added to ST. Additional values were superimposed on earlier 
studies; thus at glucose concentration 0 mmoi/L (n = 13), 5 mmoi/L (n = 4), 7.5 mmol/L (n = 4), 9 mmoljL 
(n = 4), II mmol/L (n = 27), 15 mmoljL (n = 9), 20 mmoi/L (n = 17). Multidose reinfusions ofcardioplegic solu-
tion were given every 30 minutes throughout a 3-hour I 0° C ischemic period. Values represent the mean postischem-
ic recovery of both AO and CO, expressed as a percentage of each individual preischemic value. Vertical bars rep-
resent standard errors of percentage means. * p < 0.005 compared with 0 mmoljL and 20 mmoljL concentrations 
of glucose. 
of glycolysis, as lactate efflux (released during the ischem-
ic period in the coronary sinus effluent, with each reinfu-
sion of cardioplegic solution) increased from 1.86 ± 0.11 
,umolfgmfdose to 2.49 ± 0.16 ,umolfgm/dose of car-
dioplegic solution; p < 0.05, in the presence of glucose. 
Tissue adenosine triphosphate content of all groups 
given multidose cardioplegia was statistically lower after 
reperfusion than the preischemic level; p < 0.05 (Table 
IV). Recovery of adenosine triphosphate was greater 
after hearts were protected with ST + G, 3.39 ± 0.08 
,umolfgm, when compared with KC + G, 2.90 ± 0.09 
,umolfgm; p < 0.05. However, the addition of glucose to 
KC or ST did not significantly improve postreperfusion 
adenosine triphosphate cantent. There was no statistical 
difference in the creatine phosphate content between any 
of the groups, including the control group. 
If multidose cardioplegia was provided, addition of 
glucose to either cardioplegic solution was beneficial in 
terms of functional recovery. 
Dose:.response curve for glucose. With the same 
experimental model with regular multidose reinfusions, a 
dose-response graph for incremental amounts of glucose 
(0 mmolfL, 5 mmolfL, 7.5 mmolfL, 9 mmolfL, 11 
mmol/L, 15 mmolfL, 20 mmol/L) was constructed for 
the ST + G cardioplegic solution. No adjustments were 
made to correct for osmolarity differences. Additional 
values for 0 mmolfL, 11 mmolfL, and 20 mmol/L were 
superimposed from previous and later studies. The 
observed percentage means of the preceding seven dose 
levels are shown in Fig. :2. A bell-shaped dose-response 
curve was seen for both AO and CO, and the appropriate 
statistical test rejected absence of pattern; p < 0.05. Each 
of the medial dose levels (7.5 mmolfL, 9 mmol/L, 11 
mmol/L) gives a higher response than each of the 
extreme dose levels (p < 0.005) for AO and CO. Aver-
ages of responses for these medial dose levels exceed 
averages for the 5 mmol/L and 15 mmol/L dose levels; 
p < 0.05. Furthermore, although a 9 mmol/L concentra-
tion of glucose was associated with the optimal postis-
cherillc CO recovery of 93.6% ± 0.8%, n was only 4. 
Therefore we conclude that glucose was beneficial in the 
designated concentration range of 7 to 11 mmolfL. 
Effect of multidose cardioplegia either with or 
without glucose. The independent beneficial effect on 
functional recovery associated with multidose cardiople-
gia is clear, both with and without added glucose. Provid-
ing multidose cardioplegia with KC improved the recov-
ery of CO from 56.5% ± 1.8% to 70.5% ± 3.0%; 
p < 0.005. Furthermore, with KC + G, apart from aor-
tic pressure, all indices of mechanical recovery improved; 
p < 0.025 (see Table II). 
Multidose cardioplegia with either ST or ST + G 
increased postischemic recovery of AO, CO, and SV; 
p < 0.025 (see Table III). However, the provision of 
/ 
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multidose cardioplegia increased postischemic lactate 
dehydrogenase loss with ST from 42.9 ± 8.0 mUjgmj 
min to 148.0 ± 18.1 mUjgmjmin; p < 0.005, and with 
ST + G from 66.4 ± 7.7 mU/gm/min to 109.5 ± 18.8 
mUjgmjmin; p < 0.05. 
Furthermore, ST + G gave superior protection to that 
of KC + G with respect to both AO, CO, and SV; 
p < 0.005. The solution providing the best overall myo-
cardial protection was the ST + G cardioplegic solution 
when multidose infusions were given. 
Discussion 
We studied the effect of adding glucose to two differ-
ent cardioplegic solutions, in the absence or presence of 
multidose reinfusions of cardioplegic solution. 
The primary function of a cardioplegic solution is to 
maximize energy conservation. This conservation is 
achieved by using hypothermia and manipulating elec-
trolyte concentrations to halt all electromechanical activ-
ity. We demonstrated the superiority of ST ± G over 
KC ± G, thereby establishing the importance of using a 
properly formulated cardioplegic solution that optimizes 
all ion concentrations, not just potassium. 
The second function of a cardioplegic solution is to 
prevent ischemically induced damage. A balance must be 
established between energy conservation and the mainte-
nance of essential basal metabolic requirements, to con-
trol ionic homeostasis. Thus a milieu for ongoing energy 
production should be provided. Anaerobic metabolism is 
efficient in neonatal myocardium and can supply most of 
the energy requirements. 11 • 12 In the mature heart anaer-
obic metabolism is not as efficient, but can contribute to 
energy needs, provided glycolysis is not inhibited by met-
abolic end products. 
The addition of glucose ( 11 mmol/L) to KC cardiople-
gic solution was beneficial only in the presence of multi-
dose reinfusions. The addition of glucose to ST cardiople-
gic solution, a "well-formulated" solution, was of 
questionable benefit with single-dose cardioplegia, 
improving only SV but also increasing postischemic lac-
tate dehydrogenase loss and therefore possibly indicating 
some cellular membrane damage. However, in the pres-
ence of multidose cardioplegia, glucose improved 
mechanical recovery and did not alter postischemic lac-
tate dehydrogenase leakage. Furthermore, we showed 
that glucose was beneficial only in the concentration 
range 7 to 11 mmol/L. Higher or lower concentrations 
had no effect. Multidose reinfusions of either cardiople-
gic solution during the 3-hour ischemic period also 
improved functional recovery, independently of any glu-
cose effect, but were associated with increased lactate 
dehydrogenase loss. 
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Is glucose beneficial? In the study by Hearse, Stew-
art, and Braimbridge2 the addition of glucose (1 0 mmol/ 
L) to an ST-like solution was detrimental, and this dele-
terious effect increased progressively with higher 
concentrations. Their experiments were conducted at 28 o 
C with a 70-minute ischemic period and single-dose car-
dioplegia, and were therefore without washout of meta-
bolic end products. In total ischemia in the isolated rat 
heart there is no noncoronary collateral flow; thus there 
will be progressive accumulation of inhibitory end prod-
ucts of metabolism. 10• 13 Increases of both lactate and 
hydrogen ions independently produce feedback inhibition 
of glycolysis and other metabolic reactions.9 However, in 
contrast to Hearse, Stewart, and Braimbridge,2 we did 
not find a diminished functional recovery with single-dose 
ST cardioplegia and a glucose concentration of 11 
mmoljL, although postischemic lactate dehydrogenase 
loss was increased. 
The ·solution tested by Hearse, Stewart, and 
Braimbridge2 contained a higher HC03 and lower sodi-
um concentration than the standard ST solution we test-
ed. The provision of more HC03 buffer was probably not 
an important variable in their model because lactate is the 
greater inhibitory factor. However, their study was con-
ducted at 28 o C, which could have contributed to the dis-
crepant findings, because metabolic rate is proportional to 
temperature. We selected 10° C in our experimental pro-
tocol because the optimum temperature for myocardial 
preservation during cardioplegic arrest is less than 18° 
C. 14• 15 Moreover, in the clinical situation it is extremely 
difficult to achieve a myocardial temperature below 10° 
C.14• 16 Glycolysis does continue at this temperature 
because we demonstrated increased lactate efflux in the 
multidose cardioplegia group with the addition of glucose. 
However, it is possibly less than at 28° C. 
We would concur with Hearse, Stewart, and 
Braimbridge2 that in totai ischemia glucose is of ques-
tionable benefit and possibly harmful. However, we have 
now demonstrated that if multidose cardioplegia was 
provided, the addition of glucose (11 mmol/L) improved 
postischemic recovery and did not alter lactate dehydro-
genase leakage. In the human clinical situation, because 
of noncoronary collateral flow, total ischemia occurs 
rarely even if single-dose cardioplegia is administered. 
This produces variable washout of both metabolic end 
products and the cardioplegic solution. Therefore our 
multidose model probably parallels the clinical situation 
more closely than the totally ischemic single-dose iso-
lated rat heart model. 
We were unable to demonstrate a beneficial effect of 
glucose on postreperfusion high-energy phosphate con-
tent. However, adenosine triphosphate and creatine phos-
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phate were measured after 20-minute postischemic reper-
fusion, and therefore we had allowed for possible repletion 
of energy stores. Only severe cellular damage affecting 
continued postischemic metabolism would have been 
detected. However, glycolysis derived adenosine triphos-
phate could be important, because of possible adenosine 
triphosphate compartmentation and the need for glyco-
lytic adenosine triphosphate for membrane function. 17 
We showed a 34% increase of lactate effiux with each 
multidose reinfusion of cardioplegic solution if glucose 
was included. Glycolysis derived adenosine triphosphate 
was increased. Furthermore, as the cardioplegic solution 
was aerated (mean oxygen tension 150 mm Hg) and not 
anoxic, one must postulate that some aerobic metabolism 
was taking place, consequent to each reinfusion. Aerobic 
metabolism would have used additional lactate as sub-
strate, and the total amount of energy derived from the 
inclusion of glucose was probably even greater than is 
suggested by calculations from the reported data. In 
addition, Rosenkranz and coworkers18 have shown the 
poor correlation of postischemic adenosine triphosphate 
levels and functional recovery. Thus we can conclude that 
glucose (11 mmol/L) is beneficial in ST provided meta-
bolic end products are removed. 
Is multidose cardioplegia beneficial? The removal of 
inhibitory end products of anaerobic metabolism, by 
multidose reinfusions of cardioplegic solution with or 
without glucose, independently improved functional 
recovery in our study, but it also increased postischemic 
release of lactate dehydrogenase. Loss of the intracellular 
enzyme lactate dehydrogenase is thought to reflect mem-
brane damage. Hence reinfusions of cardioplegic solution 
may have affected membrane integrity, even though 
. accumulating end products of metabolism were removed 
and postischemic recovery improved. 
It is possible that multidose reinfusions of a crystalloid 
· solution such as ST, which does not balance colloid 
oncotic pressure, might increase protein flux from the 
interstitium with each reinfusion. In addition, improved 
mechanical function could also lead to improved washout 
of lactate dehydrogenase. Furthermore, the lost lactate 
dehydrogenase might be derived from the endothelium 
and not the myocyte, which would explain these findings 
that appear discrepant with the improved functional 
recovery. Alternatively, harmful free radicals are possibly 
generated with each reinfusion of cardioplegic solution. 
Further work would be necessary to explain these obser-
vations. However, 'the· policy of periodically reinfusing 
cardioplegic solution throughout the arrest interval has 
generally been accepted by cardiac surgeons in the clin-
ical situation. This strategy counteracts intraoperative 
problems of constant rewarming of the in situ heart and 
St. Thomas' Hospital cardioplegic solution 4 1 1 
variable washout of cardioplegic solution by noncoronary 
collateral flow. 
A dose-response graph was established to determine 
the concentration range within which glucose was bene-
ficial in ST. Other studies have used a variety of concen-
trations in different cardioplegic solutions. Our results 
indicate that glucose in the range 7 to 11 mmoljL is ben-
eficial in ST cardioplegic solution. Concentrations lower 
or higher had no significant effect. Although the thera-
peutic range is narrow~ glycolytic adenosine triphosphate 
is essential for sarcolemmal function if ionic homeostasis 
is to be maintained17; thus inhibition of glycolysis either 
pharmaceutically or by lack of substrate would be detri-
mental. At lower concentrations there is perhaps insuffi-
cient glycolysis, and at higher glucose concentrations 
there is possibly insufficient washout of harmful products, 
. which rriay outweigh any initial beneficial effects. It would 
therefore appear that the beneficial effect of glucose is 
dependent on the balance between the rate of glycolysis 
and efficiency of removal of end products. Any imbalance 
would be harmful; Hearse, Stewart, and Braimbridge2 
showed that total ischemia (metabolites not removed) or 
addition of insulin (glycolysis stimulated) in the presence 
of glucose ( 10 mmoljL) was harmful. 
These experiments were performed in the isolated rat 
heart, which is not an equivalent physiologic model for the 
heart in human beings, although we believe our multidose 
procedure more closely parallels the clinical situation. 
Therefore we must caution direct clinical extrapolation. 
Studies in the dog and rabbit, however, have also demon-
strated improved recovery when glucose is included in a 
variety of multi dose cardioplegic solutions. 3• 4 We have 
shown that the beneficial effect of including glucose at a 
concentration of 7 to 11 rnmoljL in ST is seen only when 
intermittent multidose reinfusions of cardioplegic solu-
tion are provided to wash out end products of metabolism. 
Although one can argue that the beneficial effect of glu-
cose is minor in clinical effects, it was statistically signif-
icant in our multidose model. In addition, in the clinical 
situation noncoronary collateral flow would not only assist 
with washout of metabolic end products, but also would 
supply glucose at a similar concentration to that which we 
tested. However, one should not rely on noncoronary col-
. lateral flow to modulate the composition of either a good 
or bad cardioplegic solution, because of its inherent vari-
ability. 
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Effect of oxygenation and consequent pH changes 
on the efficacy of St. Thomas' Hospital cardioplegic 
solution 
The hypothesis tested is that shifts in pH, induced when a cardioplegic solution is oxygenated, can be 
detrimentaL We added either 100% nitrogen, 95% nitrogen and 5% carbon dioxide, 100% oxygen, 
or 95% oxygen and 5% carbon dioxide to the cardioplegic solution (St. Thomas' Hospital No. 2 plus 
glucose 11 mmol/L), and determined postischemic recovery of isolated rat hearts after 3 hours of 
10° C cardioplegic protected ischemia. Hearts were arrested and reinfused every 30 minutes through-
out the ischemic period with cardioplegic · solution. When 5 % carbon dioxide was added to nitrogen, 
the pH of the cardioplegic solution decreased from 9.1 (100% nitrogen) to 7.0 (95% nitrogen: 5% 
carbon dioxide), a change associated with improved postischemic functional recovery. Aortic output 
improved from 52.3% ± 2.7% to 63.9% ± 2.8%, p < 0.05, and cardiac output from 60.8% ± 3.6% 
to 75.4% ± 3.3%, p < 0.01. This improvement was associated with diminished efflux of lactate during 
, ischemia but increased postischemic release of lactate dehydrogenase. When nitrogen wa5 replaced 
with oxygen, the addition of 5% carbon dioxide resulted in a similar decrease of pH, ·which again was 
associated with improved postischemic functional recovery. Aortic output improved from 
66.3% ± 2.8% (100% oxygen) to 88.9% ± 3.7% (95% oxygen: 5% carbon dioxide), p < 0.005, 
and cardiac output from 75.3% ± 4.1% to 88.9% ± 2.4%, p < 0.01. The efflux of lactate during 
ischemia and the postiscbemic release of lactate dehydrogenase were similar in both groups. Further-
more, provision of additional oxygen with perfluorocarbons in an electrolyte solution identical to the St. 
Thomas' Hospital plus glucose solution and oxygenated with 95% oxygen : 5 % carbon dioxide 
conferred no extra protection. In conclusion, the St. Thomas' Hospital No. 2 plus glucose cardioplegic 
solution should be oxygenated but with 95% oxygen : 5% carbon dioxide and not 100% oxygen 
because of the additive effect of a relatively "acidotic" pH. 
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substantially decrease myocardial cellular oxygen 
demand. However, there is still a basal metabolic require-
ment of the cardioplegia arrested heart, approximately 
0.3 mloxygen per 100gmjmininthedogheartat22° C. 1 
In the absence of oxygen anaerobic metabolism continues 
during ischemia, despite the use of cold cardioplegia. This 
anaerobic metabolism can be lessened by supplying oxy-
gen, either bound to hemoglobin in blood cardioplegic 
solution or as dissolved oxygen in a crystalloid cardiople-
gic solution. The beneficial effect of oxygenating crystal-
loid cardioplegia, specifically St. Thomas' Hospital (ST) 
solution, has already been demonstrated?· 3 However, the 
introduction of any gas into a solution containing bicar-
bonate alters the partial pressure of carbon dioxide 
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Table I. Composition of solutions 
Composition 
NaCl (mmol/L) 
NaHC03 (mmolfL) 
KCI (mmol/L) 
MgS04 (mmol/L) 
MgC(z (mmol/L) 
CaC(z (mmol/L) 
Glucose (mmol/L) 
KH2P04 (mmol/L) 
FC-43 (weight/volume) 
K-H buffer 
118 
25 
4.8 
1.2 
1.2 
11.1 
1.2 
St. Thomas' Hospital cardioplegic solution 3 9 7 
Solution 
ST + G cardioplegia 
110 
10 
16 
16 
1.2 
11.0 
FC cardioplegia 
110 
10 
16 
16 
1.2 
11.0 
20% 
K-H buffer. Krcbs-Henseleit buffer used for perfusion of isolated rat hearts; FC cardioplegia, a cardioplegic solution containing Fluosol-43 (FC-43). (An emul-
sion of the perfluorocarbon perfluorotributylamine and emulsifying agent Pluronic F-68, Green Cross Corporation. Osaka. Japan.) 
(Pco2) in the solution, thereby produdng a change in 
hydrogen ion concentration and thus pH. Altering the pH 
of a cardioplegic solution can affect functional recovery. 
Alkalosis in an acalcemic cardioplegic solution can result 
in the calCium paradox~4 and consequently poor recovery. 
In addition, as the dissociation constant for any solution 
is temperature dependent, 5 a change in temperature alters 
the hydrogen ion concentration. Thus when a gas is intro-
duced into a cardioplegic solution, both the temperature 
at which the gas is added and the temperature at which 
the solution is delivered interact to determine the final pH. 
The object of this study was to determine the effect of 
pH on postischemic recovery with a calcium-containing 
cardioplegic solution. We added glucose ( 11 mmoljL) to 
ST cardioplegia (ST +G), because glucose at this con-
centration is beneficial, provided the end products of gly-
colytic metabolism are removed.5a To examine the effect 
of pH, independent of oxygen, initial experiments used 
the ST + G gassed with either 100% nitrogen or 95% 
nitrogen : 5% carbon dioxide and thereafter 100% oxygen 
or 95% oxygen : 5% carbon dioxide. A mixture contain-
ing 97% oxygen : 3% carbon dioxide was also investi-
gated. Finally, we tested whether a perfluorocarbon, with 
its greater oxygen-carrying capacity, would be of benefit 
in ST + G cardioplegic solution. 
Materials and methods 
Preparation of hearts. The isolated perfused working rat 
heart model described by Neely and colleagues6 was used. 
Hearts were obtained from male Long-Evans rats (250 to 400 
gm). The care of the animals was in accordance with the "Prin-
ciples of Laboratory Animal Care" of the National Society for 
Medical Research and the "Guide for the Care and Use of 
Laboratory Animals" prepared by the National Academy of 
Sciences and published by the National Institutes of Health 
(NIH Publication No. 80-23, revised 1978). 
The animals were anesthetized with diethyl ether, the femo-
ral vein exposed, and 200 IU of heparin injected. The hearts 
were then rapidly excised and placed into 4 o C Krebs-Henseleit 
buffer solution (Table I). The aorta was cannulated within 1 
minute and perfusion initiated at a constant pressure of 100 em 
H20 by the Langendorff method. Krebs-Henseleit buffer solu-
tion gassed with 95% oxygen: 5% carbon dioxide and main-
tained at a constant temperature of 37° C was used. 
During this period the left atrium was cannulated and the 
pulmonary artery incised to ensure adequate ejection of coro-
nary effluent. The hearts were stabilized for 10 minutes by 
Langendorff aortic retrograde perfusion before conversion to a 
working preparation. The left atrial filling pressure was then 20 
em H 20, and the left ventricle ejected against a hydrostatic 
pressure of 100 em H20. The aortic pressure was measured by 
a Statham P23dB pressure transducer (Spectramed Inc., Crit-
ical Care Division, Oxnard, Calif.) connected to a side arm from 
the aortic cannula. During the 1 0-minute atrial perfused work-
ing period control values for aortic and coronary flow rate, sys-
tolic aortic pressure, and heart rate were rei:orded. Any heart 
that did not achieve a stable level of function was rejected. 
At the end of the working period the atrial and aortic cannu-
las were closed, and 10 in! of 10° C cardioplegic solution was 
infused at a pressure of 60 mm Hg by means of a side arm in 
the aortic cannula. Simultaneously the hearts were placed into 
a 10° C water-jacketed chamber to maintain 10° C hypother-
mia during ischemia. 
Cardioplegic arrest and recovery. Cardioplegic arrest was 
maintained over a 3-hour ischemic period by infusing 6 ml of 
cardioplegic solution at 10° C every 30 minutes. At the end of 
the ischemic period each heart was reperfused for 10 minutes at 
3 7 o C in the nonworking Langendorff mode. The coronary sinus 
effluent during each reinfusion of cardioplegic solution and 
during the first and second 5-minute reperfusion periods was 
collected, and the oxygen tension (Po2), pH, and lactate dehy-
drogenase values were determined. Thereafter the heart was 
switched over to the working mode for another 10 minutes; 
Postischemic mechanical recovery was compared with preis-
chemic values. At the end of the experiment the hearts were 
freeze-clamped with Wollenberg tongs for enzymatic analysis of 
high-energy phosphates, expressed as micromoles per gram (wet 
weight). Control values for adenosine triphosphate and creatine 
phosphate were obtained in six hearts by freeze-clamping before 
the ischemic period in the experimental protocol. 
Cardioplegic solutions. The composition of all solutions used 
is shown in Table I. The induced pH shift, produced by the con-
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Fig. 1. The effect of temperature and oxygenation on the pH of the ST + G cardioplegic solution with varying con-
centrations of oxygen and carbon dioxide. Measurements made with IL system 1302 pH/blood gas analyzer (Instru-
mentation Laboratory System, Milan, Italy). Measurements were automatically corrected for temperature by the 
analyzer. In addition, the pH of intracellular neutrality and for blood with respect to temperature was calculated with 
the following equations: pH;oC H20 = -0.017, and pH;oc = -0.0147 (Rosenthal factor), respectively. 
tinuous gassing of the ST + G solution with 100% oxygen, 97% 
oxygen : 3% carbon dioxide, or 95% oxygen : 5% carbon diox-
ide was studied at different temperatures, in the range of 4o C 
to 37° C. Gas was added to the cardioplegic solutions for a 
minimum period of 30 minutes before the pH was measured 
with an IL system 1302 pH/blood gas analyzer (Instrumenta-
tion Laboratory System, Milan, Italy), which automatically 
corrected all pH measurements for temperature. The control 
"nongassed" ST + G solution was gassed with 95% oxygen : 5% 
carbon dioxide when initially prepared, and thereafter it was 
exposed and equilibrated to atmospheric partial pressures for at 
least 24 hours. 
The buffering capacity of these solutions at 10° C was exam-
ined by adding incremental amounts of IN hydrochloric acid 
(HCI) and recording the pH change. Titration curves were 
plotted and the buffering capacity (mmol HCl/L/U pH 
change) calculated as the instantaneous (three-point derivative) 
slope of the titration curve. 
The perfiuorocarbon cardioplegic solution tested was a solu-
tion containing Fluosol-43,7 modified to have .an electrolyte 
concentration identical to the ST + G solution. Bubble oxygen-
ation of this solution produces foam, and it was therefore oxy-
genated and defoamed with a Bentley Bio 2 bubble oxygenator 
(Baxter Healthcare Corporation, Bentley Laboratories Inc., 
Irvine, Calif.). 
Calculations and expression of results 
The following indices of cardiac mechanical function were 
measured: aortic output (milliliters per minute), coronary flow 
, (milliliters per minute), and heart rate (beats per minute). Car-
diac output (milliliters per minute) was aortic output plus cor-
onary flow, and stroke volume (milliliters) was cardiac output/ 
heart rate. 
Oxygen content of the cardioplegic solutions and oxygen 
uptake by the hearts were calculated with these formulas: 
0 2 content (ml) = Po2 • Solubility coeffi.cient/760 mm Hg 
0 2 uptake (ml) = (02 content of cardioplegic solution- 0 2 
content of coronary sinus effluent) 
The solubility coefficient for oxygen in 0.16N saline at 1 oo C 
is 0.037 ml of oxygen dissolved per milliliter of solution at 760 
mm Hg pressure,7 and for Fluosol-43 it is 0.077.8 
Exclusion criteria. In the preis<:_hemic control period the 
following values were used to discard hearts: aortic output less 
than 30 ml/min, heart rate less than 200 beats/min or irregular 
rhythm, and coronary sinus flow greater than 22 ml/min. 
In the postischemic period any heart with a coronary flow that 
increased significantly (>50% pre ischemic value) was excluded 
because of the probability of a left atrial leak. 
Extreme observations or "outliers," based only on pestis-
chemic aortic output, were tested by Dixon's criteria with a sig-
nificance of <5%. The entire heart was then excluded from fur-
ther analysis so that the mean was not distorted by inflating the 
error variance as a result of major experimental errors. Values 
obtained during the postischemic working period were 
expressed as a ratio of each individual preischemic control val-
ue. 
Results are presented as the mean ± the standard error of the 
mean. The statistical test used was the two-way analysis of vari-
ance, and if overall statistical significance was obtained, pairwise 
comparisons of means were done by theftest. Statistical signif-
icance was taken asp < 0.05. 
Results 
pH Shifts induced by temperature and oxygenation 
of a cardioplegic solution. Decreasing the temperature 
of the ST + G cardioplegic solution, as well as adding 
either 100% oxygen, 97% oxygen: 3% carbon dioxide, or 
95% oxygen : 5% carbon dioxide, altered the pH of the 
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Table II. Postischemic recovery of hearts and the effects of cardioplegic solution pH induced by adding gas 
mixtures 
100% Nz 95% Nz: 5% COz 100% Oz 95% Oz: 5% COz 
(n = 6) (n = 7) (n = 8) (n = 9) 
Cardioplegic solution 
JOO C pH 9.1 ± 0.1 7.0 ± 0.01 9.3 ± 0.1 7.0 ± O.Q2 
Functional recovery 
Aortic output (%) 52.3 ± 2.7 63.9 ± 2.8b 66.3 ± 2.83 88.9 ± 3.7<· e 
Cardiac output (%) 60.8 ± 3.6 75.4 ± 3.33 75.3 ± 4.1 3 88.9 ± 2.4c. e 
Stroke volume (%) 59.9 ± 4.6 74.2 ± 2.7b 74.7 ± 4.0b 88.2 ± 5.Jd.f 
Postischemic LDH loss (mU/min) 
0-5 min 57.6 ± 12.6 184.6 ± 15.63 77.0 ± 10.9 90.0 ± 10.6< 
5-10 min 37.5 ± 6.0 103.0 ± 10.1 3 50.8 ± 5.7 52.0 ± 10.8° 
Postischemic recovery expressed as mean ratios of individual preischemic values and standard error of the mean of isolated rat hearts after 3 hours of 1 o• C 
cardioplegic arrest. Hearts were protected with ST + G cardioplegic solution gassed with one of the above gases. LDH, Lactate dehydrogenase. 
•p < 0.01 compared with I 00% N2 group .. 
bp < O.OS compared with I 00% N2 group. 
'p < 0.01 compared with 95% N2 and 5% C02 group. 
dp < 0.05 compared with 95% N2 and 5% C02 group. 
•p .< O.DJ compared with 100% 02 group. 
fp < 0.05 compared with 100% 02 group. 
solution (Fig. 1 ). Reducing the temperature of the 
"ungassed" ST + G solution (aerated on preparation but 
thereafter allowed to equilibrate with the atmosphere) 
resulted in an increase in pH. At 37° C the pH was 7.4 
but at 10° Cit increased to 8.0, which is only marginally 
more alkalotic than biologic neutrality for blood (pH 7.4 
at 37° C and pH 7.8 at 10° C, as LlpH;o C for blood is 
-0.047, Rosenthal factor5). 
In addition to the temperature effect, oxygenating this 
solution with gas mixtures containing carbon dioxide 
progressively decreased the pH at I oo C from 8.0 
(ungassed) to 7.25 with 97% oxygen: 3% carbon dioxide 
and to 7.0 with 95% oxygen: 5% carbon dioxide, which 
is relatively acidotic with respect to intracellular neutral-
ity (pH 7.46 at 10° C5). In contrast, gassing with IOO% 
oxygen accentuated the hypothermia-induced alkalosis to 
pH 9.2 at 10° C (Fig. 1). Similar results were obtained 
with IOO% nitrogen and 95% nitrogen: 5% carbon diox-
ide having a pH of 9.I and 7.0, respectively (Table II). 
The maximum buffering capacity of ST + G car-
dioplegic solution was found in the range pH 6 to 7 (Fig. 
2), with the pK of the bicarbonate buffer being ± 6.5. 
Consequently, the relatively "acidotic" solution, that is, 
gassed with 9 5% oxygen : 5% carbon dioxide would be the 
better buffered solution, inasmuch as its I 0° C pH of 7.0 
is closer to the observed pK of ± 6.5 compared with the 
solution gassed with 100% oxygen having a 10° C pH of 
9.2. 
Recovery of cardioplegic arrested rat hearts 
Effect of pH in the absence of oxygen. Hearts were 
protected with ST + G cardioplegic solution gassed with 
either IOO% nitrogen or 95% nitrogen: 5% carbon diox-
ide, to determine the effect of altering pH without the 
addition of oxygen (Tables II and III). 
The preischernic control values for the IOO% nitrogen 
group were. as follows: aortic output 47.5 ± 4.0 mljrnin, 
cardiac output 64.5 ± 5.1 mljrnin, heart rate 270 ± 9 
beats/min. Two extreme observations were excluded 
from the original eight hearts-one highest and one low-
est-and further analysis was done on the remaining six 
hearts. The postischemic aortic output recovery was 
52.3% ± 2.7% and cardiac output 60.8% ± 3.6% with 
this "alkalotic" (pH= 9.1) solution. 
With 95% nitrogen: 5% carbon dioxide the control val-
ues were as follows: aortic output 39.6 ± 3.62 ml/min, 
cardiac output 57.4 ± 3.9 ml/rnin, heart rate 276 ± 22 
beats/min. Again two outliers were excluded from the 
original group of nine hearts-one highest and one low-
est-and therefore seven hearts remained. Postischernic 
recovery of aortic output was 63.9% ± 2.8% and cardiac 
output 75.4% ± 3.3%. This relatively "acidotic" 
(pH = 7 .0) cardioplegic solution (95% nitrogen : 5% car-
bon dioxide) was associated with significantly improved 
functional recovery, p < 0.05. 
The pH of the coronary sinus effluent decreased from 
9.1 ± 0.1 (arterial value) to 8.1 ± 0.1 in the group 
gassed with 100% nitrogen. This large pH change of 1.0 
unit indicated that protons were produced arid that t!te 
cardioplegic solution was poorly buffered. In contra~t. 
when 95% nitrogen: 5% carbon dioxide were added, the 
pH of the coronary sinus effluent (7 .1 ± 0.01) was rela-
tively unaltered compared with the arterial pH of 
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Fig. 2. The buffering capacity of the nongassed ST + G cardioplegic solution and alternatively ST + G oxyge-
nated with either 100% oxygen or 95% oxygen and 5% carbon dioxide is shown. Buffering capacity is expressed as 
the instantaneous (three-point derivative) slope of the titration curve. Solution was titrated with 1 N HCI at 10° C. 
Table III. Metabolic.effects of cardioplegic solution pH induced by adding gas mixtures 
. 100% N2 
(n = 6) 
95% N2: 5% co2 
(n = 7) 
100% 02 
(n = 8) 
95% Ch5% co2 
(n = 9) 
Cardioplegic solution 
10° C pH 9.1 ± O.J 
10° C Po2 (mm Hg) 
02 content (ml 02/6 ml) 
Coronary sinus effluent during 180 min ischemia 
pH 8.1 ± 0.1 
LDH (mUjml) 9.6 ± 1.3 
Lactate (pmoljml) 0.80 ± 0.08 
02 uptaked (ml 02/dose) 
7.0 ± 0.01 
7.1 ± 0.01 
10.9 ± 0.9 
0.30 ± 0.02b 
9.3 ± 0.1 
629 ± II 
0.184 ± 0.003 
8.4 ± 0.1 
I 1.9 ± 0.9 
0.35 ± 0.02b 
0.080 ± 0.002 
7.0 ± 0.02 
640 ± 26 
0.187 ± 0.008 
7.1 ± 0.02 
7.3 ± 0.5•·c 
0.25 ± 0.02 
. 0.097 ± 0.004C 
Loss of metabolites during 3 hours of I 0' C cardioplegic arrest expressed as mean and standard error of the mean of isolated rat hearts protected with ST + G 
cardioplegic solution gassed with one of the above gases. The solution was infused at the onset of ischemia and every 30 minutes throughout this period. Po2, 
02 tension; LDH, lactate dehydrogenase. 
'p < 0.01 compared with 95% N2 and 5% C02 group. 
bp < 0.01 compared with 100% N2 group. 
•p < 0.0 I compared with I 00% 02 group. 
dExpressed as mea11 volume of 0 2 (milliliters) taken up by the hearts from each 6 ml rein fusion dose of maintenance cardioplegia. 
7.0 ± O.oi, indicating that either fewer protons were 
formed or that there was better buffering at pH 7 .0. 
E./feci of pH in the presence of oxygen. Similar pH 
changes were seen when nitrogen was replaced with oxy-
gen. Hearts were protected with ST + G cardioplegic 
solution gassed with either 100% oxygen or 95% oxy-
gen : 5% carbon dioxide (Tables II and III). 
Preischemic control values for the 100% oxygen group 
were as follows: aortic output 43.3 ± 2.5 mljmin, cardi-
acoutput60.4 ± 2.7mljmin,heartrate263 ± 12beats/ 
min. Three outliers were excluded from the original group 
of 11 hearts-two lowest and one highest-and therefore 
eight hearts remained. Postischemic recovery of aortic 
· output was 66.3% ± 2.8% and cardiac output 
75.3% ± 4.1%. 
For the 95% oxygen : 5% carbon dioxide group, con-
trol values were as follows: aortic output 43.1 ± 2.4 
mljmin, cardiac output 60.3 ± 2.5 mljmin, heart rate 
273 ± 17 beats/min. No outliers were detected, and all 
nine hearts were analyzed. Postischemic aortic output 
recovery was 88.9% ± 3.7% and cardiac output 
88.9% ± 2.4%. This relatively "acidotic" (pH= 7.0) 
cardioplegic solution (95% oxygen: 5% carbon dioxide) 
produced a significantly better postischemic functional 
recovery than the "alkalotic" (pH= 9.3) solution (100% 
oxygen), p < O.Ql. 
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Table IV. Postischemic recovery of hearts and effects of cardioplegic solution pH and oxygen content 
ST + G with 97% 0 2: 3% C02 ST + G with 95% 02:5% C02 FC cardioplegia with 
(n = 7) (n = 11) 95% 0 2:5% C02 (n = 6) 
Cardioplegic solution 
JOO C pH 7.25 ± 0.03 7.0 ± 0.02 7.1 ± 0.01 
10° C Po2 (mm Hg) 618 ± 20 620 ± 15 490 ± 14 
02 content (ml 02/100 ml) 3.01 ± 0.10 3.02 ± 0.07 4.96 ± 0.148 
Preischemic control values 
AO (mlfmin) 38.9 ± 1.7 46.2 ± 1.1 47.2 ± 2.4 
CO (mlfmin) 55.4 ± 2.0 63.1 ± 1.4 65.5 ± 3.2 
HR (beats/min) 262 ± 15 261 ± 8 278 ± 13 
Postischemic functional recovery(%) 
AO (%) 84.0 ± 1.6 92.1 ± J.2b 91.2 ± 0.8 
co(%) 87.3 ± 1.5 91.3 ± 1.2° 90.2 ± 0.9 
SV (%) 89.2 ± 4.8 93.3 ± 4.5 91.4 ± 0.5 
Preservation of high-energy phosphates 
ATP (!Lmolfgm) 3.38 ± 0.11 3.51 ± 0.09 3.24 ± 0.20 
CP (!Lmolfgm) 4.54 ± 0.23 5.17 ± 0.24 3.98 ± 0.37d 
Functional and metabolic recovery expressed as mean ratios of individual preischemic values and standard error of the mean of isolated rat hearts after 
3 hours of 10° C cardioplegic arrest. Hearts were protected with ST + G cardioplegic solution oxygenated with 02 and either 3% or 5% C02 or with a per-
fluorocarbon containing cardioplegic solution having an electrolyte concentration identical to ST +G. Control values for A TP and CP were obtained by 
freeze-clamping six hearts before the ischemic period in the experimental protocol. Controls (n = 6), ATP 3.91 :1: 0.25~tmoljgm, CP 5.05 :1: 0.46~tmoljgm. 
FC, Perfluorocarbon; Po2, 0 2 tension: AO, aortic output: CO. cardiac output; SV, stroke volume; ATP, adenosine triphosphate; CP, creatine phosphate. 
'p < 0.001 s;ompared with ST + G and 95% 0 2 and 5% C02. 
bp < 0.01 compared with ST + G and 97% 0 2 and 3% C02. 
•p < 0.05 compared with ST + G and 97% 0 2 and 3% C02. 
dp < 0.02 compared with ST + G and 95% 02 and 5% C02. 
In the group with 100% oxygen the arterial pH of 
9.3 ± 0.1 decreased to 8.4 ± 0.1 in the coronary sinus 
effluent, whereas with 95% oxygen: 5% carbon dioxide 
the arterial pH of 7.0 ± 0.02 was relatively unaltered 
(Table III). 
Providing oxygen with or without carbon dioxide, thus 
independent of any alterations in pH, resulted in 
improved functional recovery of all indices of mechanical 
recovery of aortic output, cardiac output (p < 0.01 ), and 
stroke volume (p < 0.05) compared with the anoxic 
(nitrogen) pH equivalent groups (Table II). 
A separate group of experiments with an identical pro-
tocol, and therefore tabulated separately, was performed 
to further define the optimal pH range (Table IV). The 
pH was altered when the cardioplegic solution was gassed 
with either 97% oxygen : 3% carbon dioxide (n = 7) to 
pH 7.25 or again with 95% oxygen: 5% carbon dioxide 
(n = 11) to pH 7.0 at 10° C. The preischemic control 
values were similar to the previous groups, and no outli-
ers were detected (Table IV). 
The more acidotic solution (95% oxygen : 5% carbon 
dioxide) again gave the best postischemic recovery, an 
aortic output of 92.1% ± 1.2% and cardiac output of 
91.3% ± 1.2% compared with the solution to which 97% 
oxygen : 3% carbon dioxide was added, with an aortic 
output of 84.0% ± 1.6% and cardiac output of 
87.3% ± l.5%,p < 0.01 andp < 0.05, respectively. This 
confirmed our initial data that pH 7.0 "at 10° C is the 
optimal pH for the oxygenated ST + G cardioplegic 
solution. 
Lactate and lactate dehydrogenase loss associated 
with cardioplegic pH. The loss of lactate in the absence 
of oxygen in the coronary sinus effluent during each infu-
sion of cardioplegic solution gives an indication of the rate 
of glycolysis. The "acidotic" pH (95% nitrogen : 5% car-
bon dioxide) had a decreased efflux of lactate, 
0.30 ± 0.02 }Lmoljml as opposed to 0.80 ± 0.08 }Lmol/ 
ml with the "alkalotic" cardioplegic solution ( 100% 
nitrogen), p < O.Ql. 
In contrast, in the presence of oxygen, and thus possi-
ble lactate-consuming aerobic metabolism, the lactate 
efflux was equivalent in both the "acidotic" (95%oxygen: 
5% carbon dioxide) and "alkalotic" (100% oxygen) 
groups (Table III). The loss oflactate dehydrogenase (an 
indicator of damage to membrane integrity) during the 
cardioplegic arrest period was no different in the absence 
of oxygen. However, in the presence of oxygen the 
"acidotic" (pH 7 .0) solution (95% oxygen : 5% carbon 
dioxide) was associated with diminished loss (Table III). 
In the postischemic period the total 10 minutes of lac-
tate dehydrogenase release in the absence of oxygen was 
increased with the "acidotic" solution (95% nitrogen : 5% 
carbon dioxide) to 143.8 ± 14.4 mU/min, as opposed to 
the "alkalotic" cardioplegic solution ( 100% nitrogen) of 
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47.6 ± 7.4 mUjmin,p < O.Ql. However, when nitrogen 
was replaced with oxygen this elevated lactate dehydro-
genase loss seen with 95% nitrogen: 5% carbon dioxide 
decreased to 71.0 ± 9.2 mUjmin with 95% oxygen: 5% 
carbon dioxide,p < O.Ql, which was nodifferentfrom the 
"alkalotic" (100% oxygen) group. In all groups the 
postischemic lactate dehydrogenase loss was highest in 
the first 5 minutes, which then decreased by ± 40% in the 
next 5 minutes. 
Oxygen uptake during cardiop/egic arrest. The oxygen 
content of the coronary sinus effluent, produced during 
each 6 ml reinfusion of cardioplegic solution, was mea-
sured to determine the oxygen uptake of the myocardium 
during hypothermic cardioplegic arrest. More oxygen 
was taken up by the hearts oxygenated with 95% oxygen : 
5% carbon dioxide, 0.097 ± 0.004 ml oxygen per dose, as 
opposed to 0.080 ± 0.002 ml oxygen per dose if gassed 
with 100% oxygen, p < 0.01. This occurred despite the 
fact that the oxygen content of the infused "arterial" car-
dioplegic solution was similar in both groups (Table III). 
Specifically noteworthy is the observation that only 44% 
to 52% of available oxygen was actually taken up. 
Addition of perfluorocarbon to the ST + G cardiop/e-
gic solution. We protected a final group of hearts with 
similar control preischemic values and no outliers with 
perfluorocarbons added to the cardioplegic solution 
(n = 6) (Table IV). Oxygenation of this solution with 
95% oxygen : 5% carbon dioxide resulted in a 10° C pH 
of7 .1 ± 0.01 and a Po2 of 490 ± 14 mm Hg. Despite this 
lower Po2. the perfluorocarbon solution contained more 
oxygen, 4.96 ± 0.14 ml oxygen per 100 ml solution, than 
the oxygenated ST + G solution containing 3.02 ± 0.07 
ml oxygen per 100 ml solution, p < 0.00 1. Perfluorocar-
bon cardioplegia with its greater oxygen content did not 
improve functional recovery of either aortic output, car-
diac output, or stroke volume. In addition, although the 
postischemic creatine phosphate content was lower 
(3.98 ± 0.37 J.Lmoljgm) compared with the ST + G car-
dioplegia (5.17 ± 0.24 J.Lmoljgm,p < 0.02), the adenos-
ine triphosphate and creatine phosphate contents of both 
groups were no different from the control concentrations 
(Table IV). The addition of perfluorocarbon to the 
ST + G cardioplegic solution conferred no extra benefit. 
Discussion 
We studied the effect of the pH of a cardioplegic solu-
tion on postischemic recovery in the isolated rat heart. In 
the absence of oxygen a relatively acidotic cardioplegic 
solution, induced by adding 95% nitrogen: 5% carbon 
dioxide, improved functional recovery. However, at this 
"acidotic'' pH (10° C pH= 7.0) glycolysis was less, as 
evidenced by a diminished efflux of lactate. Either energy 
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demand was lower or alternatively glycolysis was inhib-
ited, as previous studies have demonstrated that a pH of 
6.8 at 37° C (10° C pH <7.25) inhibits glycolysis.9 
In the anaerobic heart the primary source of energy is 
from glycolysis, and inhibition could result in sarcolemma 
injury, manifested by the observed increased postischem-
ic loss oflactate dehydrogenase in the 95% nitrogen : 5% 
carbon dioxide group. Our results further suggest that 
sarcolemma injury occurred on reperfusion after protec-
tion with an "acidotic" anoxic solution, inasmuch as lac-
tate dehydrogenase loss during ischemia was similar in 
both groups. However, other advantageous "acidotic" pH 
effects contributed to an overall improved postischemic 
recovery, despite these observed detrimental effects with 
the anoxic cardioplegic solution. 
Hearts protected with a cardioplegic solution gassed 
with oxygen with or without carbon dioxide as opposed to 
nitrogen with or without carbon dioxide showed improved 
recovery. The high lactate efflux seen when 100% nitro-
gen was added to the cardioplegic solution diminished 
when 100% oxygen (p < 0.01), was added, which sug-
gested that lactate was now being utilized by oxidative 
phosphorylation. We also demonstrated that the 
increased postischemic lactate dehydrogenase loss, asso-
ciated with possible diminished glycolysis seen in the 
anoxic "acidotic" (95% nitrogen: 5% carbon dioxide) 
group, was also reversed by the addition of oxygen (95% 
oxygen: 5% carbon dioxide). Oxygen, by allowing more 
efficient aerobic metabolism, was therefore beneficial in a 
cardioplegic solution. 
In the presence of oxygen the "acidotic" cardioplegic 
solution pH, induced by gassing with 95% oxygen : 5% 
carbon dioxide, improved functional recovery and dimin-
ished lactate dehydrogenase loss during ischemia. This 
beneficial effect was not caused by a difference in Po2 
inasmuch as both the acidotic (95% oxygen : 5% carbon 
dioxide) and alkalotic (100% oxygen) solutions had 
equivalent oxygen content. The full beneficial effect of 
oxygenating a cardioplegic solution can thus be altered by 
factors such as an induced pH shift, consequent to the 
oxygenating gas mix used. 
The oxygen consumption for an average 1 gm rat heart 
during 30 minutes of 10° C cardioplegic arrest, based on 
a basal metabolic demand of 0.3 rnl oxygen/ 100 gmj 
min, 1 • 10 would be ± 0.09 ml oxygen/30 min. We demon-
strated that the oxygen taken up by the hearts on each 
reinfusion of cardioplegic solution approximated this val-
ue and was only ±50% of the available oxygen dissolved 
in the cardioplegic solution. Previous studies11 • 12 have 
shown perfluorocarbon cardioplegia to be superior to 
crystalloid and blood cardioplegia. However, as these 
crystalloid solutions were not oxygenated and had differ-
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ent electrolyte compositions, these studies only demon-
strated the beneficial effect of supplying oxygen. We were 
able to show that the increased oxygen-carrying capacity 
of perfluorocarbon cardioplegia, with an identical elec-
trolyte composition to that of a good oxygenated crystal-
loid solution (ST +G), conferred no extra protection. 
Therefore, as in the study by Tabayashi and colleagues, 13 
we cannot recommend the use of perfluorocarbon in a 
cardioplegic solution. In addition, it has the risk of adverse 
reactions and requires a more complex oxygenation and 
delivery system. 
The "correct" systemic pH during hypothermic car-
diopulmonary bypass has been a contentious point in the 
literature.5• 14 Ectotherms ("cold-blooded" animals) tend 
to maintain biologic neutrality, defined as OH-/H+ = 1, 
in relation to temperature. Biologic neutrality at 37° Cis 
pH 7.4; however, as the dissociation constant for water 
decreases with diminishing temperature, thus reducing 
the concentration of hydrogen ions, the neutral pH at 10° 
C will be 7.8.5 This optimizes enzymatic reactions15 and 
helps maintain constant cellular volume. 14 In contrast, 
hibernating endotherms ("warm-blooded" animals) 
maintain a blood pH 7.4 regardless of temperature. 
Hence a pH of 7.4 at 10° C is relatively acidotic with 
respect to biologic neutrality (pH of 7.8 at 10° C), with 
consequent inhibition of metabolism and therefore possi-
ble conservation of energy. 16 Although biologic neutral-
ity and its advantages might be appropriate for hypoth-
ermic systemic pH, the aim of cardioplegia-induced 
ischemic arrest is to diminish metabolic demand maxi-
mally. Therefore the "metabolic inhibitory" effect of a 
relatively acidotic pH might be more appropriate for a 
cardioplegic solution. 
Intracellular pH can be rapidly modulated by the free 
sarcolemma passage of carbon dioxide and therefore a 
so-called respiratory acidosis has a more pronounced 
effect than a "metabolic" acidosis. 17 A reduction of 
intracellular pH markedly decreases sarcolemma calci-
um transport by sodium/calcium exchange18 and 
decreases potassium efflux. 17 Furthermore, calcium bind-
ing to the phospholipid of sarcolemma sites is pH depen-
dent: At a 37° C pH of 5.5 there is 0% calcium binding; 
at pH 7.0, 50%; and at pH 8.5, 100% binding. 19 In con-
trast, extracellular alkalosis could promote intracellular 
calcium accumulation by sodium/hydrogen and calci-
um/sodium exchange.20 These pH-dependent ionic 
effects would support the use of a slightly acidotic 
cardioplegic solution. 
Our cardioplegic solution ST + G contained glucose 
(11 mmol/L), which has been postulated to be damaging 
because of glycolytic lactate and proton formation. 21 In 
the anoxic groups the diminished functional recovery of 
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pH 9.1 (100% nitrogen)-protected hearts was associated 
with increased lactate efflux. Therefore the superior 
postischemic function associated with pH 7.0 (95% 
nitrogen : 5% carbon dioxide) might have been caused by 
inhibition of glycolysis at this pH. However, in the oxy-
genated groups the lower recovery of pH 9.3 (1 00% oxy-
gen)-compared with pH 7.0 (95% oxygen : 5% carbon 
dioxide)-protected hearts, was not associated with 
increased lactate formation. Therefore we do not believe 
the presence of glucose accounted for the poor recovery at 
high pH in the oxygenated solutions. 
Reservations 
These experiments were performed on the isolated rat 
heart model, which differs physiologically from the 
human. In particular, the presence ofnoncoronary collat-
eral flow in the human would provide some glucose in 
addition to washout of metabolic end products between 
multidose cardioplegia. Hence care must be taken when 
extrapolating to the clinical situation. 
Conclusion 
A relatively acidotic pH of the ST + G cardioplegic 
solution at 10° C was superior to a more alkalotic pH. 
Improved postischemic recovery was shown in a 3-hour 
isolated rat heart model with intermittent reinfusions of 
cardioplegic solution given throughout the ischemic peri-
od. Providing oxygen, dissolved in the cardioplegic solu-
tion, was beneficial, and furthermore, oxygenation with 
95% oxygen: 5% carbon dioxide (which induces an 
"acidotic" pH shift) was superior to 100% oxygen. The 
addition of a perfluorocarbon, an oxygen-carrying vehi-
cle, to the optimally gassed ST solution confers no addi-
tional protection. 
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I. Experimental 
Effect of pH Shifts Induced by Oxygenating 
Crystalloid Cardioplegic Solutions 
U. 0. von Oppel!, MB, ChB, FCS(SA), L. M. King, BSc (Hons), E. F. Du Toit, MSc, 
P. Owen, PhD, B. Reichart, MD, and L. H. Opie, MD, PhD 
Ischaemic Heart Disease Laboratory and Department of Cardiothoracic Surgery, University of Cape Town, Cape Town, South 
Africa 
Oxygenation of a bicarbonate-containing crystalloid car-
dioplegic solution alters the partial pressure of both 
oxygen (02 ) and carbon dioxide (C02). Therefore, oxy-
genating St. Thomas' Hospital II plus glucose (11 
mmol/L) cardioplegic solution with 95% 0 2 + 5% C02 
induces a pH shift to 7.0 (10°C) as opposed to pH 9.3 with 
100% 0 2 • In an isolated working rat heart model, we 
show that pH 7.0 (10°C) improves mechanical postisch-
emic recovery in the absence or presence of 0 2 • However, 
in the absence of 0 2 , pH 7.0 appears to inhibit glycolysis 
Oxygenating St. Thomas' Hospital II cardioplegic so-lution has previously been shown to improve post-
ischemic myocardial recovery (1]. The more efficient aer-
obic metabolic pathways are able to produce a greater 
amount of high-energy phosphate, which can then be 
used to meet the ongoing basal metabolic requirements of 
the arrested myocardium [2]. 
The partial pressures of gases in a solution are depen-
dent on those to which the solution is exposed. Oxygen-
ating a crystalloid cardioplegic solution will increase the 
partial pressure of oxygen but must also alter the partial 
pressures of the other gases contained in the solution, as 
the total pressure of a mixture of gases cannot exceed 
ambient pressure (Dalton's law) (3]. Thus oxygenation 
will alter the partial pressure of 0 2 and, also of specific 
interest, partial pressure of carbon dioxide. In turn, the 
total C02 content will be dependent on the partial pres-
sure of C02 as well as its temperature-dependent solubil-
ity coefficient for that solution (Henry's law) [3, 4]. Fur-
thermore, if the primary buffer in the cardioplegic 
solution is HC03, any change in the total C02 content will 
change the pH, which is the negative log[H+], according 
to the following equation: 
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and diminish the stability of cellular membranes. The 
provision of 0 2 independently improved mechanical 
recovery and at pH 7.0, improved the preservation of the 
sarcolemma. Increasing the 0 2 content by including a 
perfluorocarbon (FC-43) in the oxygenated St. Thomas' 
plus glucose cardioplegia is not additionally beneficial. 
St. Thomas' Hospital plus glucose cardioplegic solution 
should be oxygenated, but with 95% 0 2 + 5% C02 and 
not 100% 0 2 • 
(Ann Thorac Surg 1991;52:903-7) 
Therefore, the pH of a bicarbonate-containing cardiople-
gic solution will be altered by both a change in tempera-
ture and a change in oxygenation. 
We examined the effect of oxygenating St. Thomas' 
Hospital II plus glucose (11 mmol!L) cardioplegic solution 
(ST+G), which has the following composition: 
Na 120 mmoUL 
K 16 mmol/L 
Mg 16 mmol/L 
Ca 1.2 mmol/L 
HC03 10 mmol/L 
Glucose 11 mmol!L 
This solution has a pH of 7.8 at room temperature. 
However, oxygenating with 100% 0 2 displaced C02 and 
therefore shifted the pH to 9.3 (10°C). However, when 
95% 0 2 + 5% C02 was used, the addition of C02 induced 
a shift in pH to 7.0 (10°C). Oxygenation with either 100% 
0 2 or 95% 0 2 + 5% C02 produced similar 0 2 tensions of 
± 635 mm Hg (at 10°C). 
To examine the effect of pH independent of 0 2 , ST+G 
solution was also gassed with either 100% N2 or 95% N2 + 
5% C02, which induced pH shifts similar to those just 
mentioned [5]. Finally, we also determined the effect of 
increasing the 0 2 content of the oxygenated ST+G solu-
tion by including an 0 2 carrier, 20% wt/vol perfluoro-
carbon (FC-43) [6], in an otherwise identical solution [5]. 
Material and Methods 
The experimental model used was the isolated, perfused, 
working rat heart as previously described [5]. In brief, 
hearts were removed from anesthetized male Long-Evans 
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rats, cannulated, and perfused retrogradely with Krebs-
Henseleit buffer for 10 minutes. In the following 10-
rninute working period (left atrial pressure, 20 ern H20; 
afterload, 100 ern H20), control values for cardiac output 
and stroke volume were determined. The hearts were 
then arrested with W rnL of the appropriately gassed 
ST + G cardioplegic solution (infusion pressure, 
60 rnrn Hg). During the ensuing 3-hour ischemic period, 
the hearts were maintained at woe, and reinfusions of 
cardioplegia (6 rnL) were given every 30 minutes. Lactate 
levels, lactate dehydrogenase (LDH) levels, and partial 
pressure of 0 2 in the coronary sinus effluent during each 
reinfusion of cardioplegia were measured. A 10-rninute 
Langendorff reperfusion period followed, during which 
coronary sinus LDH washout in each 5-rninute interval 
was again determined. Assessment of hemodynamic re-
covery was made at the end of a subsequent 10-rninute 
working period. 
Postischernic hemodynamic values were expressed as a 
ratio of each individual preischernic control value. Per-
centage means and standard errors of means were ana-
lyzed by two-way analysis of variance, with pairwise 
comparisons by acceptance intervals of means by the F 
test. Significance was taken asap value of less than 0.05. 
Results and Comment 
Effect of pH on Mechanical and Metabolic Postischemic 
Recovery 
The preischernic control values were similar between the 
four groups (95% 0 2 + 5% C02 , n = 9; 100% 0 2, n = 8; 
95% N2 + 5% C02, n = 7; WOo/o N2, n = 6) and ranged 
from 57.4 ± 3. 9 rnLirnin to 64.5 ± 5.1 rnLirnin for cardiac 
output and from 0.212 ± 0.012 rnL to 0.238 ± 0.015 rnL for 
stroke volume [5]. A pH of 7.0 {10°C) in the ST+G 
cardioplegic solution, induced by gassing with 5% C02, 
was associated with superior postischernic recovery of 
both stroke volume (p < 0.05) and cardiac output (95% N2 
+ 5% C02 , 75.4% ± 3.3%; 95% 0 2 + 5% C02, 88.9% ± 
2.4%) compared with pH 9.1 (WO% N2, 60.8% ± 3.6%; p 
< 0.01) or pH 9.3 (100% 0 2,75.3% ± 4.1%; p < 0.01) (Fig 
1). Thus a cardioplegic solution with a pH of 7.0, which is 
comparatively acidotic to intracellular pH 7.46 (corrected 
for temperature W0 C), improved mechanical recovery in 
the absence or presence of 0 2 • In addition, the use of 0 2 
as opposed to N2 also improved functional recovery (p < 
0.05) independent of any pH effect (see Fig 1). 
A number of mechanisms can explain the observed 
beneficial effect of a relatively acidotic cardioplegic solu-
tion other than inhibition of enzyme-dependent energy-
consuming metabolic processes and therefore conserva-
tion of energy [7]. A respiratory acidosis rapidly alters 
intracellular pH as C02 passes freely across the sarco-
lemma, and slight acidosis decreases K+ efflux, inhibits 
Na + /Ca2 + exchange, and diminishes sarcolemmal calcium 
transport [8, 9]. These ionic effects would be beneficial 
during cardioplegic arrest, when attempts must be made 
to prevent the redistribution of ions and specifically to 
prevent intracellular calcium accumulation [10]. In con-
trast, extracellular alkalosis promotes intracellular calcium 
~ 
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Fig 1. Effect of cardioplegic solution pH on postischemic mechanical 
recovery, expressed as mean ratios of individual preischemic values, of 
isolated rat hearts after 3 hours of 10°C cardioplegic arrest. Hearts 
were protected with multidose St. Thomas' Hospital plus glucose (11 
mmo/IL) cardioplegic solution gassed with 100% N2 (n = 6), 95% N2 
+ 5% C02 (n = 7), 100% 0 2 (n = 8), or 95% 0 2 + 5% C02 (n = 
9), which induced the indicated pH shifts. The vertical bars represent 
the standard errors of the means. (" = p < 0.01 compared with 95% 
N2 + 5% C02 and 100% 0 2; o = p < 0.05 compared with 95% N 2 
+ 5% C02 and 100% 0 2 .) 
accumulation by Na+/H+ and Na+/Ca2 + exchange [11]. 
Furthermore, in contrast to ST +G, if a crystalloid car-
dioplegic solution is calcium free, the pH must be acidotic, 
as alkalosis increases the propensity for the calcium par-
adox to occur (12]. 
Comparisons in Anoxia 
In the absence of 0 2 the efflux of lactate from the coronary 
sinus, consequent to each reinfusion of cardioplegia, 
approximates the rate of glycolysis. We observed that the 
"acidotic" pH 7.0 (95% N2 + 5% C02) was associated with 
a diminished mean efflux of coronary sinus lactate (0.30 ± 
0.02 ,urnol/rnL, n = 35 samples) during the cardioplegic 
arrest period compared with pH 9.1 (0.80 ± 0.08 ,umoU 
rnL, n = 29 samples, WO% N2; p < 0.01), thus implying 
inhibition of glycolysis at pH 7.0 at woe. This is in accord 
with a previous study [13] that demonstrated that a pH of 
6.8 at 37"C (pH < 7.25 corrected for temperature 10°C) 
inhibits hypoxic-accelerated glycolysis. 
Hearse and co-workers [14] suggested that the inclusion 
of glucose in a cardioplegic solution is harmful because of 
accumulation of inhibitory metabolites, lactate, and pro-
tons. Therefore, it could be postulated that in the absence 
of 0 2 (95% N2 + 5% C02), the inhibition ofglycolysis by 
pH 7.0 partly accounted for its associated improved func-
tional recovery by preventing lactate accumulation in 
addition to possible inhibition of calcium entry into the 
cell. However, we observed increased postischernic wash-
out of LDH, 143.8 ± 14.4 rnU/rnin (n = 14 samples), with 
pH 7.0 (95% N2 + 5% C02) as opposed to 47.6 ± 7.4 
rnU/rnin (n = 10 samples) (p < 0.01) with pH 9.1 (WO% 
N2). This increased postischernic LDH loss associated 
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Fig 3. Effect of cardioplegic solution pH on washout of lactate with 
each reinfusion of cardioplegia. The mean washout in the coronary 
sinus effluent consequent to each multidose reinfusion of St. Thomas' 
plus glucose cardioplegic solution administered every 30 minutes dur-
ing a 3-hour l0°C cardioplegic arrest period is indicated. The car-
dioplegic solution was oxygenated with either 95% 0 2 + 5% C02 
(pH 7.0) or 100% 0 2 (pH 9.3). The vertical bars represent the stan-
dard errors of the means. (* = p < 0.01 compared with 100% 0 2 at 
that time interval; o = p < 0.05 compared with the respective 120-
minute interval.) 
appear that the inclusion of glucose was no longer harm-
ful at·pH 7.0 in the presence of 0 2 • Our study therefore 
supports the use of a relatively acidotic pH for the 
cardioplegic solution. Furthermore, the presence of 0 2 
was synergistic to the relatively acidotic pH in improving 
postischemic mechanical myocardial recovery. 
Utilization of 0 2 in Oxygenated Crystalloid 
Cardioplegic Solutions 
The 0 2 contents of both oxygenated solutions (95% 0 2 + 
5% C02 and 100% 0 2 ) were similar at 3 mL 0 2/100 mL 
solution. The mean 0 2 uptake for pH 7.0 (95% 0 2 + 5% 
C02) was 0.097 ± 0.004 mL 0 2/6 mL dose (n = 39 
samples), which was greater than for pH 9.3 (100% 0 2), 
0.08 ± 0.002 mL 0 2/6 mL dose (n = 39 samples) (p < 0.01). 
However, the amount of 0 2 taken up by the myocardium 
was only approximately 50% of the available 0 2 in the 
solution. Early in ischemia, more 0 2 was taken up by the 
myocardium when it was oxygenated with 95% 0 2 + 5% 
C02 (p < 0.01), but this 0 2 uptake diminished with each 
subsequent multidose reinfusion of cardioplegia (Fig 4). 
However, the 0 2 uptake with 95% 0 2 + 5% C02 tended 
to remain higher at each reinfusion compared with 100% 
0 2 (pH 9.3) (see Fig 4). Thus oxidative metabolism de-
creased over time with 95% 0 2 + 5% C02, but there did 
not appear to be any compensatory increase in anaerobic 
glycolysis with pH 7.0 (95% 0 2 + 5% C02), as lactate 
washout did not increase during the ischemic period (see 
Fig 3). At pH 9.3 (100% 0 2), 0 2 uptake at the end of the 
ischemic period was no different from the initial 0 2 
uptake, and similarly lactate efflux remained constant. 
Our observations suggest that a defect in 0 2 utilization 
occurs in the cardioplegia-protected ischemic period and 
may occur more readily at pH 9.3. These abnormalities in 
mitochondrial 0 2 metabolism may be similar to those 
previously identified in the postischemic reperfusion pe-
Oxygen Uptake (ml 02/6ml infusion) 
30 60 90 120 
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Fig 4. Effect of cardioplegic solution pH on myocardial oxygen (02) 
uptake from each reinfusion of cardioplegia. The mean amount of 0 2 
taken up by isolated rat hearts during each reinfusion of St. Thomas' 
Hospital plus glucose cardioplegic solution is shown. The cardioplegic 
solution was oxygenated with either 95% 0 2 + 5% C02 (pH 7.0) or 
100% 0 2 (pH 9.3) and was reinfused every 30 minutes throughout 
the 3-hour ischemic arrest period. The vertical bars represent the 
standard errors of the means. The initial 0 2 content of both cardiople-
gic solutions was 0.18 mL 0 216 mL solution before infusion. (* = p 
< 0.05 compared with 100% 0 2 at that time interval; ** = p < 0.01 
compared with 100% 0 2 at that time interval; o = p < 0.01 com-
pared with the respective 30-minute interval.) 
riod [16]. It is possible that these mitochondrial defects are 
due to lactate, as lactate ions can produce morphological 
mitochondrial abnormalities within 10 minutes (37"C) of 
exposure [17]. Furthermore, in our study, oxygenated 
cardioplegia was infused only intermittently (every 30 
minutes) during the ischemic period, at which time lactate 
loss was measured. Therefore it is possible that in the 
intervening periods, transient lactate fluxes similar to 
those observed with the anoxic groups occurred. The 
tendency for lactate loss to be higher with pH 9.3 (see Fig 
3) might be an important correlation. 
The addition of perfluorocarbon (FC-43), an 0 2 carrier 
that releases 0 2 linearly with changes in partial pressure 
of 0 2, increased the 0 2 content of the oxygenated ST+G 
solution (95% 0 2 + 5% C02) from 3 mL 0 2/100 mL 
solution to 5 mL 0 2/100 mL solution. The ST+G + FC-43 
cardioplegic solution (n = 6, pH 7.1) gave a postischemic 
recovery of cardiac output of 90.2% ± 0.9% and stroke 
volume of 91.4% ± 0.5%, which were not significantly 
different from the cardiac output of 91.3% ± 1.2% and 
stroke volume of 93.3% ± 4.5% with the ST+G solution (n 
= 11, pH 7.0) [5]. This finding may indicate that sufficient 
0 2 was contained in the standard ST+G solution gassed 
with 95% 0 2 + 5% C02 • Previous studies [18, 19] sug-
gested that cardioplegic solutions containing perfluoro-
carbons are superior; however, the crystalloid cardiople-
gic solutions in those studies were not oxygenated, and 
the electrolyte compositions of the test solutions with or 
without perfluorocarbons were not kept constant. We 
have shown that the addition of perfluorocarbons to an 
otherwise identical solution is not beneficial. 
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with the "acidotic" solution suggests that sarcolemmal 
injury became manifest during the reperfusion period, as 
LDH is a measure of cellular membrane integrity. It has 
been suggested that the cell membrane is maintained by 
glycolytic-derived adenosine triphosphate (ATP) because 
of functional compartmentation [15] and that inhibition of 
energy production in the presence of continued energy 
requirements might therefore be detrimental. Thus anoxia 
and inhibition of anaerobic-accelerated glycolysis by this 
acidotic pH 7.0 (lOoq were possibly harmful to the 
cellular membrane, despite the improved postischemic 
functional recovery observed. 
Comparisons at pH 9 
In the pre~ence of 0 2 , a large amount of the pyruvate 
produced would be oxidized by aerobic metabolism, thus 
removing the inhibitory effects of protons and lactate on 
glycolysis. Consequently, the efflux of lactate will grossly 
underestimate the rate of glycolysis in the presence of 
ongoing aerobic metabolism. 
At pH 9, we observed that the addition of 0 2 reduced 
the mean lactate efflux by more than 50% from 0.8 ± 0.08 
p.moVmL (n = 29 samples, 100% N2) to 0.35 ± 0.02 
p.moVmL (n = 38 samples, 100% 0 2) (p < 0.01). Assuming 
similar rates of glycolysis at pH 9, if not higher in the 
presence of 0 2, as inhibitory effects of glycolysis are being 
removed by aerobic metabolism, then the total amount of 
ATP being generated in the aerobic hearts would be 
considerably higher. (For each molecule of extracellular 
glucose metabolized through glycolysis, a net number of 
two ATP molecules are generated, and aerobic metabo-
lism produces an additional 36 ATP molecules.) Lactate 
dehydrogenase loss during ischemia (9.6 ± 1.3 mU/mL, 
100% N2; 11.9 ± 0.9 mU/mL, 100% 0 2) and reperfusion 
(47.6 ± 7.4 mU/min, 100% N2; 66.5 ± 7.9 mU/min, 100% 
0 2) was similar in both anaerobic and aerobic conditions 
at pH 9, a finding possibly indicating sufficient glycolytic 
ATP to maintain sarcolemmal integrity in both cases. 
Furthermore, the additional improved recovery in the 
presence of 0 2 at this pH was probably due to increased 
A TP production as well as removal of potentially harmful 
end-products of glycolysis by aerobic metabolism. 
Comparisons at pH 7 
At pH 7.0, .lactate efflux was similar for both anaerobic 
(0.30 ± 0.02 p.moVmL, n = 35 samples, 95% N2 + 5% 
C02) and aerobic (0.25 ± 0.02 p.moVmL, n = 44 samples, 
95% 0 2 + 5% C02) conditions. However, the true rate of 
glycolysis was probably considerably higher in the pres-
ence of 0 2, as glycolysis is less susceptible to inhibition by 
a low pH in the presence of 0 2 as opposed to anoxia and 
has been previously shown to be inhibited only below a 
pH of 6.5 at 376C (pH 6.95 at 10°C) if 0 2 is present (13]. 
Aerobic metabolism would remove glycolytic end-
products and consequently their inhibitory effects, as 
already mentioned. Thus it is also reasonable to assume 
increased ATP production at pH 7.0 in the presence of 0 2 • 
Furthermore, LDH loss during ischemia was dimin-
ished at pH 7.0 in the presence of 0 2, 7.3 ± 9.2 mU/mL (n 
= 45 samples, 95% 0 2 + 5% C02) as opposed to 10.9 ± 
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Fig 2. Effect of cardioplegic solution pH on washout of lactate dehy-
drogenase with each reinfusion of cardioplegia. The mean washout in 
the coronary sinus effluent consequent to each multidose reinfusion of 
St. Thomas' plus glucose cardioplegic solution administered every 30 
minutes during a 3-hour 10°C cardioplegic arrest period is indicated. 
The cardioplegic solution was oxygenated with either 95% 0 2 + 5% 
C02 (pH 7.0) or 100% 0 2 (pH 9.3). The vertical bars represent the 
standard errors of the means. (• = p < 0.05 compared with 100% 0 2 
at that time interval; o = p < 0.05 compared with the respective 3D-
minute interval.) 
0.9 mU/mL (n = 35 samples, 95% N2 + 5% C02) (p < 
0.01). Moreover, during reperfusion, LDH release was 
also diminished in the aerobic hearts, 71.0 ± 9.2 mU/min 
(95% 0 2 + 5% C02, n = 12 samples) compared with 143.8 
± 14.4 mU/min (95% N2 + 5% C02, n = 14 samples) (p < 
0.01). Thus sarcolemmal integrity improved at pH 7.0 in 
the presence of 0 2, possibly indicating that in the pres-
ence of 0 2 , there was sufficient glycolytic ATP at this pH 
7.0 in contrast to anoxia. 
Comparisons of pH 7 and pH 9 in the Presence of 
Oxygen 
In aerobic conditions, pH 7.0 as opposed to pH 9.3 was 
associated with the better postischemic mechanical recov-
ery (see Fig 1). In addition, LDH loss in the coronary sinus 
effluent during the ischemic period was less with pH 7.0 
(95% 0 2 + 5% C02) as opposed to pH 9.3 (100% 0 2) (p < 
0.01) for the majority of multidose reinfusions of oxygen-
ated cardioplegia (Fig 2). Postischemic LDH loss was 
similar at both pHs (71.0 ± 9.2 mU/min, n = 12 samples; 
and 66.5 ± 7.9 mU/min, n = 10 samples, for pH 7.0 and 
9.3, respectively). Consequently, sarcolemmal integrity 
was better maintained in the presence of 0 2 at pH 7.0 as 
opposed to pH 9.3. The lactate washo'ut during the 
cardioplegic arrest period tended to be lower with pH 7.0 
(95% 0 2 + 5% C02) at every reinfusion of cardioplegia 
compared with pH 9.3 (100% 0 2) (Fig 3). However, the 
mean washout of lactate (0.25 ± 0.02 p.moVmL, n = 44 
samples) at pH 7.0 did not attain significance compared 
with pH 9.3 (0.35 ± 0.02 p.moVmL, n = 38 samples). 
Therefore, although we could not show increased glyco-
lysis at pH 9.3 in the presence of 0 2, it i~ possible that the 
inclusion of glucose in our cardioplegic solution ac-
counted for some of the diminished mechanical recovery 
with this alkalotic pH (100% 0 2). However, if so, it would 
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Conclusion 
St. Thomas' Hospital II plus glucose (11 mmol!L) crystal-
loid cardioplegic solution should be oxygenated. How-
ever, it is recommended that 95% 0 2 + 5% C02 and not 
100% 0 2 be used with multidose cardioplegia administra-
tion because of the synergistic beneficial effect of a rela-
tively acidotic induced pH shift and the provision of 0 2 • 
The induced shift in pH to 7.0 (10°C) observed when 
oxygenating with 95% 0 2 + 5% C02 is associated with 
increased myocardial 0 2 uptake, better maintenance of 
membrane integrity, and ultimately, improved postische-
mic functional recovery. Although the presence of glucose 
in our cardioplegic solution may have accounted for some 
of our observations, in the clinical situation, noncoronary 
collateral flow would supply some glucose in this physi-
ological range. Therefore, we believe extrapolation to the 
standard ·st. Thomas' solution may be justified. A perflu-
orocarbon 0 2 carrier is of no additional benefit in a 
well-formulated oxygenated crystalloid can;l.ioplegic solu-
tion. 
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Endothelial cell cytotoxicity of cardioplegic 
solutions used in South Africa 
ULRICH 0. VON OPPELL, STEFFEN PFEIFFER, PETRA PREISS, DIETER BOEHM, 
TIMOTHY DUNNE, PETER ZILLA 
Abstract 
The hypothesis tested is that cardioplegic solutions, 
used to protect the myocardium during open-heart 
surgery, could be cytoto;xic to endothelial cells. Vascular 
endothelial damage would be detrimental to postopera-
tive myoca.rdial function. Cultured monolayers of 
human endothelial cells were exposed for 12 hours at 
room temperature (22° C) to crystalloid cardioplegic 
solutions currently in use in South Africa, and to two 
internationally used solutions. 
The international St Thomas' Hospital No. 2 (ST) 
and Bretschneider (B-HTK) cardioplegic solutions pro-
duced 24-hour post-exposure endothelial cell survivals 
of 81,0 ± 1,9% and 76,5 ± 4,1% respectively. The ST + 
glucose (10 mM) cardioplegic solution used at Groote 
Schuur Hospital produced a similar survival - 78,8 ± 
. 2,9%. The best endothelial survival of 87,1 ± 2,2% was 
obtained with a modified ST plus glucose solution 
containing histidine (50 mM), the more powerful buffer 
included in B-HTK, which was significantly better than 
STand B-HTK (P < 0,05). 
In contrast, crystalloid cardioplegic solutions used 
elsewhere in South Africa were all cytotoxic to endothe-
lial cells. SABAX cardioplegia was associated with a 
24-hour survival of 0,6 ± 0,3%, which was significantly 
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worse than that obtained with ST (P< 0,001). Plasma-
lyte B-based formulations produced no survival, and 
were also significantly worse than ST (P < 0,001). The 
cytotoxicity of these solutions was due to acalcaemia, 
excessively high potassium concentrations and too little 
magnesium. 
Today after prolonged periods of ischaemia cardiac 
surgeons expect near-normal postoperative recovery of 
myocardial function, if protective cardioplegic solutions 
were used. These solutions induce diastolic myocardial 
arrest and in conjunction with hypothermia, drama-
tically reduce myocardial energy needs. 1 Therefore, they 
have been primarily formulated to protect the myocyte, 
and little attention has been given to their effect on 
other cells. 
However, the vascular endothelium is an extremely 
important integral component of all organs, and in the 
heart endothelial injury could be detrimental to myocar-
dial function. Vascular endothelial cells form the first 
element in the blood barrier to the interstitium, and 
modulate a variety of biological functions. 2 The normal 
endothelial surface is antithrombogenic/ and also pro-
vides mediators that· act on the underlying vascular 
smooth muscle to modulate vascular tone and blood 
flow. 4 Ischaemia alone damages the endothelium, and 
results in increased vascular permeability, interstitial 
oedema/ and release of endothelial enzymes.6 These 
enzymes (e.g. xanthine oxidase) are associated with the 
production of toxic oxygen free radicals7 that in turn 
damage adjacent myocytes. Therefore, isolated injury 
to the endothelium will predispose to thrombosis, vaso-
constriction and myocardial infarction and adversely 
affect myocardial function. Furthermore, these harmful 
effects occur even in the absence of cell death. 3 
Cardioplegic solutions, by virtue of being infused 
intravascularly, should therefore not only protect the 
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myocyte but also the endothelium. However, previous 
studies have shown that these solutions can in fact be 
cytotoxic to endothelial cells. 8' 9 Endothelial cells are 
attachment-dependent cells, and cytotoxicity in mono-
layer cultures can be observed with light microscopy as 
loss of cellular attachment and cellular disruption. 
This study was undertaken to determine the endothe-
lial cytotoxic potential of crystalloid cardioplegic solu-
tions currently in use in South Africa. Although these 
solutions are usually at a temperature of 4° C when 
infused into the heart, during clinical cardiac surgery 
the heart is continually rewarmed by transmitted heat 
and the myocardial temperature therefore varies be-
tween l4°C and 20°C. We therefore elected to examine 
the effect of these solutions at room temperature (22° C). 
Furthermore, the cardioplegic-solution is maintained in 
the coronary circulation throughout the surgical cross-
clamp period of I - 3 hours by intermittent reinfusions, 
and in transplantation units hearts are stored in these 
solutions for up to 6 hours. Therefore, an extended 
exposure period of 12 hours was used in this study. 
Finally, in order to establish the components that 
were either harmful or beneficial, modifications of these 
solutions were tested. 
The majority of endothelial functions stated above 
occur universally throughout the vascular tree, although 
various vascular beds might be associated with special 
characteristics, e.g. an increased rate of prostacyclin 
production by the internal mammary artery endothe-
lium.10 However, the majority of these studies were 
performed in different animal models which in turn 
may be associated with differences between species. 
Therefore, we elected to study human cells and were 
thus limited to venous endothelial cells. 
Materials and methods 
Endothelial cells were harvested from unused segments 
of saphenous veins obtained from patients undergoing 
coronary artery bypass graft surgery, as described by 
Zilla et a!. 11 The venous segment was flushed with 
incomplete culture medium (Medium I99 - Earle's 
salts (Flow Laboratories; Irvine, Scotland), with neither 
additional serum nor endothelial growth factor 
(ECGF)), then distended with O,I% collagenase (Cooper 
Biomedical; Malvern, Pennsylvania) for approximately 
I5 minutes, which was then inactivated by flushing 
with culture medium containing 30% fetal calf serum 
(Delta Bioproducts; Johannesburg). This fluid was col-
lected and centrifuged at 800 rpm for 10 minutes; the 
resultant cellular pellet was then resuspended in 2 ml 
complete culture medium \Medium I99 plus 20% fetal 
calf serum and ECGF' (Collaborative Research Inc.; 
Lexington, Mass:)). This suspension was placed into a 
9,6 cm2 culture plate well, precoated for 2 hours with 
human fibronectin (lnotech; Zurich, Switzerland). All 
cultures were kept in a 37°.C, 90% humidity, 5% C02 
incubator, and were always handled sterilely under a 
laminar flow hood. 
The primary culture was rinsed after 24 hours with 
Dulbecco's phosphate-buffered saline (Flow Labora-
tories) and thereafter 'fed' twice weekly by replacing 
50% of the supernatant with fresh complete culture 
medium. Endothelial cells were passaged at 80% pre-
confluence, designated by a microgrid technique. Mono-
layer confluence was usually obtained within 2 - 4 
weeks of the endothelial cell harvest. Primary cultures 
were then split at a ratio of I:22, using trypsin EDTA 
(Flow Laboratories) at 37°C for cell detachment. The 
cells were then seeded into a 175 cm2 flask precoated 
for 12 hours with gelatin (Difco Laboratories, Detroit, 
Michigan), or onto 9 mm cover-slips for immunohisto-
chemical staining of von Willebrand factor (factor 
VIII-related antigen), which is a typical cell marker for 
endothelial cells. This culture was managed as before, 
and confluence obtained within± IO days. 
The cells were again passaged, but now in a I: I or 
1:2 ratio, into 12-well culture plates (3,5 cm2 per well) 
precoated with gelatin. Complete mixing of the cellular 
suspension was obtained by agitation and by using a 
bulb syringe in order to ensure uniform seeding of all 
wells in this tertiary culture. Confluence of I: 1 passage 
was obtained after 2- 3 days. 
Cardioplegic solutions 
Our unit has previously documented the variety of 
crystalloid cardioplegic solutions used in South Africa 
and the paucity of reported objective comparisons re-
garding their effectiveness. 12 These include the SABAX 
cardioplegic solution (SBX) (SABAX Ltd, Samuel 
Evans Rd., Aeroton, Johannesburg), Plasmalyte B plus 
15 ml 15% KCI per litre (PB-I), Plasmalyte B plus 
15 ml I5% KCl, 10 ml 8,5% NaHC03 and 20 ml 50% 
dextrose per litre (PB-2), and at Groote Schuur Hospital 
the St Thomas' Hospital No. 2 solution plus 3,6 ml 
50% dextrose per litre (ST + G). The SBX cardioplegia 
tested was their multidose solution that has a K+ con-
centration of 12,0 mM, as opposed to their induction 
solution that has a K+ content of 24,1 mM. These 
solutions were compared with two internationally 
accepted cardioplegic solutions: the St Thomas' Hos-
pital No. 2 (ST) and the European Bretschneider HTK 
(B-HTK) (Dr F. Koehler, Chemie GmbH, Alsbach, 
West Germany). ST should not be confused with the St 
Thomas' Hospital No. I (Macarthy Medical, John Bell 
and Croyden, London, UK) solution, made up by 
adding a 20 ml ampoule containing MgCl, KCI and 
procaine to Ringer's solution; this is a different formu-
lation and has been shown to be an inferior solution. 13 
All solutions were gassed with 95% 02, 5% C02, and 
then allowed to equilibriate with the atmosphere for 12 
hours before being filtered (0,22 U) before use. Osmo-
larities were measured with a crystalloid osmometer 
(Osmomat 030; Gonotec, Berlin, West Germany) and 
pH (after gassing) with a blood gas analyser (IL System 
1302 pH/ blood gas analyser; Instrumentation Labora-
tory System, Milan, Italy). The compositions of these 
cardioplegic solutions are given in Table I. 
184 CARDIOVASCULAR JOURNAL OF SOUTHERN AFRICA VOLUME 1 NO.4 NOVEMBER 1990 
TABLE I. COMPOSITION OF CARDIOPLEGIC SOLUTIONS USED IN SOUTH AFRICA 
SF ST+G SBX PB-1 PB-2 B-HTK 
Na 120 120 140,7 130 140 15 
K 16 16 12,0 34 34 10 
HCO, 10 10 38,3 27 37 
Mg 16 16 1,5 1,5 1,5 4,0 
Ca 1,2 1,2 0,9 
C1 160. 160 119,3 140 140 50 
so, 
PO, 
Glucose 10 50,5 56 
Mannitol 68,4 30 
Histidine 198 
Tryptophan 2 
KH-2-oxygluterate 
Osmolarity (mOsml/1) 293 302 416 302 357 302 
pH (22°C) 7,1 7,1 7,7 7,7 7,8 7,0 
All values are given in mrnol/l, and pH was measured after gassing with 95% 02, 5% C02. 
In order to further define any specific electrolyte 
concentration associated with endothelial cytotoxicity, 
we examined modifications of P:S-1 and ST. In addi-
tion, a modified ST + G solution with a lower sodium 
content of 100 mM (to allow for osmotic space), plus 
histidine 50 mM (an integral component of B-HTK), 
was examined. 
Experimental protocol 
Cultures of confluent monolayers of human endothe-
lial cells that had not been 'fed' in the preceding 24 
hours were used (Fig. 1). A baseline grid count of each 
well was done using an inverted phase contrast micro-
scope (ID 02 MT; Zeiss, West Germany). The cell 
count in '20 grid squares' was the total number of cells 
seen in each four corner squares of a marker grid, and 
counted in five different areas of each well. · 
The culture medium was then removed and the car-
dioplegic solution applied initially as a rinse to ensure 
removal of all medium, and then a 1 ml aliquot reintro-
Fig. 1. Appearance on light microscopy of a confluent 
monolayer culture of human venous endothelial cells. A 
typical 'cobblestoned' surface with no intercellular gaps 
is observed (X 1 00). 
duced. The initial temperature of the cardioplegic solu-
tions was 10° C, and after application the cell cultures 
were kept at room temperature (22°C) for 12 hours. 
The morphological appearance of the cells was then 
examined by light microscopy before removing the 
cardioplegic solution. Thereafter the cultures were 
rinsed with incomplete culture medium, and I ml com-
plete medium but without ECGF was introduced. All 
cell cultures were now placed back in the 37°C 5% C02 
incubator to allow for a period of continued metabolism 
and for any delayed expression of cell injury. 
The post-exposure cell survival was determined after 
rinsing the cells with incomplete culture medium to 
remove debris and dead cells at 24 hours and again at 
36 hours after exposure. 
Expression of results 
The cell count/ cm2 was calculated by multiplying the 
'20 grid square count' by 125. The percentage of sur-
viving cells at each time period was expressed as a ratio 
of each individual post-exposure grid count to the 
respective baseline grid count. Values are presented as 
percentage means and standard errors of percentage 
means. 
The total number of wells tested is given as N. In 
addition, to ensure reproducibility each solution was 
tested in a number of different culture plates (P), and 
on cells obtained from different primary cultures (C). 
Student's t-test was used to compare differences on 
the assumption of equal variance. Appropriate tables 
were then used to determine P values .. Statistical signifi-
cance was assumed when the P value was < 0,05. 
Confidence intervals are reported. 
Results 
A confluent monolayer of cultured human endothelial 
cells seen on light microscopy is shown in Fig. I, and 
exhibits a typical 'cobblestoned' appearance. These cells 
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TABLE II. ENDOTHELIAL CELL SURVIVAL AFTER 12 HOURS' EXPOSURE AT 22°C TO CARDIOPLEGIC SOLUTIONS 
USED IN SOUTH AFRICA 
Solution N Baseline count %survival %survival 
(cells/em') at 24 h at 36 h 
ST 16 71 890 ± 5 299 81,0 ± 1,9 77,1 ± 1,7 
B-HTK 12 58 010 ± 3 946 76,5 ± 4,1 73,8 ± 4,2 
ST+G 12 62 750 ± 2 746 78,8 ± 2,9 75,3 ± 2,2 
SBX 15 61 042 ± 5 536 0,6 ± 0,3* 0,2 ± 0,2* 
PB-1 15 62 375 ± 7 003 0* 0* 
PB-2 12 46 938 ± 5 251 0* 0* 
Cell survival at 24 and 36 hours after exposure is presented, as a ratio to each individUal baseline pre-exposure cell count/cm2• Results are presented as means 
and standard errors of means. 
•p < 0,001 compared with ST or B-HTK, at respective post-exposure times. 
were then exposed to cardioplegic solutions for 12 
hours at room temperature (22° C). The internationally 
used cardioplegic solutions ST and B-HTK produced 
similar endothelial cell survivals 24 .hours after expo-
sure. 
Exposure to ST cardioplegia (N = 16, P = 6, C = 4) 
caused the cells to contract and a more granular cyto- · 
plasm was seen (Fig. 2). However, this appearance was 
reversible after removal of the cardioplegic solution 
and an 81,0 ± 1,9% survival was recorded at 24 hours, 
which was no different to the 36-hour survival. When 
exposed to B-HTK (N = 12, P = 4, C = 3) the cellular 
morphology did not differ significantly from the pre~ 
exposure baseline appearance, and a 24-hour survival 
of 76,5 ± 4,1% and similar 36-hour survival was ob-
tained. These survivals were no different from those 
obtained with ST. 
Cardioplegic solutions used in South Africa 
The inclusion of glucose (10 mM) in the St Thomas 
solution (N = 12, P = 4, C = 3) produced a similar 
morphological effect on the endothelial cells after 12 
hours of exposure as seen with ST, and a similar 24-
hour survival of 78,8 ± 2,9%. Likewise, the 36-hour 
survival was no different (Table II). 
In contrast, all the other crystalloid cardioplegic 
solutions used in South Africa produced extremely 
Fig. 2: Appearance on light microscopy of endothelial 
cells after 12 hours' exposure at 22°Cto ST cardioplegic solution. 
The cells have contracted and intercellular gaps are now 
seen (X 1 00). · 
poor endothelial cell survivals. The SBX solution (N = 
15, P = 5, C = 3) caused the cells to lose adherence, 
become round and swollen and disrupt (Fig. 3). The 
24-hour survival of 0,6 ± 0,3% was markedly inferior 
to those obtained with ST, ST + G and B-HTK; P < 
0,00 I. Both the plasmalyte B-based solutions, PB-1 (N 
= 15, P = 5, C = 3) and PB-2 (N.= 12, P = 4, C = 2) 
caused loss of cellular adherence, and floating round, 
Fig. 3. Appearance on light microscopy of endothelial 
cells after 12 hours' exposure at 22°C to SBX cardioplegic 
solution. The cells have lost adherence and are round 
and swollen, and some have fragmented (X 1 00). 
Fig. 4. Appearance on light microscopy of endothelial 
cells after 12 hours' exposure at 22°C to a Plasmalyte B 
plus potassium (30 mM) formulation (PB-1 ). There is 
complete loss of cellular adherence and all cells are 
round and swollen (X 100). 
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swollen cells could be seen on light microscopy (Fig. 4). 
There was no survival 24 hours after exposure with 
both PB-1 and PB-2, in contrast to the two international 
solutions; P < 0,001. 
Experimental modifications of Plasmalyte B 
The addition of calcium (1 ,2 mM) to the acalcaemic 
PB-1 solution (N = 15, P = 5, C = 2) resulted in a 
mixed appearance of the cells after 12 hours' exposure. 
Portions of the culture showed loss of adherence with 
round swollen cells, while in other areas dense con-
tracted cells were seen. In contrast to the 0% survival 
observed with PB-1, the 24-hour survival now increased 
to 31,7 ± 7,3%; P < 0,005. In another experimental 
solution the potassium concentration of PB-1 was 
decreased to 16 mM (N = 6, P = 2, C = l) and similar 
to PB-1, no survival was obtained (Fig. 5). 
However, if both of the above modifications were 
combined (N = 9, P = 3, C = 1), i.e. PB-(K = 16 mM, 
Ca = 1,2 n;tM) then endothelial cell survival increased 
to 50,5 ± 6,6% at 24 hours, although in comparison 
with PB-(Ca = 1,2 mM) it just failed to achieve signi-
ficance (P = 0,07). This solution was also still inferior 
to ST (P < 0,005), which has a higher concentration of 
magnesium (!6 m~). 
Experimental modifications of 
St Thomas' solution 
In contrast to ST, both SBX and PB-2 contain a 
high concentration of glucose (± 50 mM) and sodium 
(± 140 mM) (Table I). However, in ST the addition of 
50 mM glucose (N = 11, P = 4, C = 2) ·was not 
% 
100 
60 
40 
Endothelial cell survival after 12hr exposure 
to modifications of Plasmalyte Cardioplegia 
Post exposure survival 
PB-1 
p<0.005 
-----
p•0.07 
------
PB·(K•HI) PB-(Co=1.2) .(K• 1 :.~·._ 1 _ 2 ) 
Cardioplegic solutions 
ST 
c:::J 24hr survival ~ 36hr survival 
Fig. 5. Mean percentage survival of cultured human endo-
thelial cells 24 hours and 36 hours after 12 hours' 
exposure at 22°C to experimental modifications of Plas-
malyte B cardioplegic solutions. The vertical bars repre-
sent standard errors of means. PB-1 - Plasmalyte B with 
a K+ concentration of 34 mM; PB-(K = 16) - Plasmalyte 
B with a K+ concentration of 16 mM; PB-(Ca = 1 ,2) -
Plasmalyte B with a K+ concentration of 34 mM and Ca2• 
of 1,2 mM; PB-(K = 16, Ca = 1 ,2)- Plasmalyte B with a 
K+ concentration of 16 mM and Ca2• of 1 ,2 mM. 
Endothelial cell survival after 12hr exposure 
to modifications of St Thomas' Cardioplegia 
% Post exposure survival 
100 
ST ST+G(10) ST+G(50) ST(No-140) ST(K-34) ST+G+Hiolldlno 
Cardioplegic solutions 
c:::J 24hr survival ~ 36hr survival 
Fig. 6. Mean percentage survival of cultured human endo-
thelial cells 24 hours and 36 hours after 12 hours' 
exposure at 22°C to experimental modifications of cardio-
plegic solutions. The vertical bars represent standard 
errors of means. ST + G (10)- ST plus 10 mM glucose; 
ST + G (50) - ST plus 50 mM glucose; ST (Na-140) -
ST plus 20 mM NaCI (therefore has an Na• concentration 
of 140 mM); ST (K-34) - ST plus 18 mM KCI (therefore 
has a K+ concentration of 34 mM); ST + G + histidine -
ST + G plus 50 mM histidine, but has an Na• con-
centration of only 100 mM. (* P X 0,05 compared with 
either ST or ST + G, at both 24 and 36 hours after 
exposure.) 
detrimental, and resulted in a 24-hour post-exposure 
endothelial cell survival of 77,4 ± 1,7%. Similarly, 
increasing the sodium content of ST to 140 mM (N = 
10, P = 4, C = 2) by adding 20 mM NaCl also did not 
decrease survival (82,8 ± 2,6% at 24 hours) (Fig. 6).-
Although a lower potassium concentration tended to 
be beneficial in the calcium-containing plasmalyte B 
solution (PB-(K = 16 mM, Ca = I ,2 mM)), if the 
potassium concentration of ST was increased to 34 
mM (N = 12, P == 4, C = 2) by adding 18 mmol KCl, 
the 24-hour survival of 77,9 ± 2,8% was no different to 
that obtained with the standard ST, which has a potas-
sium concentration of 16 mM. 
Finally, 12 hours' exposure of endothelial cells to a 
modified ST + G (10 mM) solution containing 50 mM 
histidine (the more powerful buffer included in B-
HTK) but with an Na• concentration of only 100 mM 
(N = 15, P = 5, C = 4), produced less retraction and a 
more normal appearance on light microscopy. The 24-
hour cell survival of 87,1 ± 2,2% and 36-hour survival · 
of 86,0 ± 2,1% were better than those obtained with 
both ST and ST + G cardioplegic solutions, at both · 
post-exposure periods (P < 0,05) (Fig. 6). 
Discussion 
When confluent monolayers of cultured endothelial 
cells were exposed to various cardioplegic solutions for 
12 hours at room temperature (22°C), the two inter-
nationally used solutions, ST and B-HTK, were asso-
ciated with acceptable 24-hour post-exposure cell sur-
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vivals of 81% and 76,5% respectively. The cardioplegic 
solution in use at Groote Schuur Hospital, ST + G, 
which contains 10 mM glucose and has been shown to 
be superior to ST in a multidose isolated rat heart 
model/5 produced a similar cell survival. In contrast, 
the other crystalloid cardioplegic solutions used in six 
other units in South Africa, 12 namely SBX and Plas-
malyte B-based solutions (PB-1, PB-2), were cytotoxic 
to endothelial cells. This would be detrimental to post-
operative myocardial function. 
We have shown that in terms of endothelial cell 
survival, the most important omission in the com-
position· of PB-1 and PB-2 is that of calcium. Acal-
caemia has been previously reported to be harmful in 
cardioplegic solutions, by predisposing to the calcium 
paradox. 14 The calcium paradox is the phenomenon of 
severe morphological, functional and biochemical cellu-
lar damage that occurs when hearts are reperfused with 
a fluid containing calcium ions after a period of cal-
cium-free perfusion. 15 Furthermore, this phenomenon 
has also been noted in canine kidney perfusions, and 
produced changes in the vessel walls and cell mem-
branes.16 Therefore, it is not specific to the myocyte 
and could affect other cells. We observed that the 
acalcaemic PB-1 produced loss of cellular adherence 
before calcium was reintroduced, and therefore cannot 
be interpreted as the calcium paradox. However, since 
endothelial cells are attachment-dependent, 17 this loss 
can be interpreted as cytotoxicity. The addition of 
calcium I ,2 mM to PB-1 improved survival. In contrast, 
the acalcaemic B-HTK solution was not cytotoxic, 
possibly because it has a low sodium content, which is 
beneficial in an acalcaemic solution. 18 
In addition, although we were unable to show that a 
high potassium concentration of 34 mM was detrimental 
in ST, a high potassium has been associated with 
endothelial damage19 and appeared to contribute to 
some of the observed cytotoxicity of PB-1. It is also 
relevant to note that the experimental protocol of 
Follette et al., which closely resembled the clinical situa-
. tion (i.e. 500 ml crystalloid cardioplegia infused over 5 
minutes, every 20 minutes for 2 hours), also induced 
endothelial damage. 19 Unfortunately they did not docu-
ment the entire composition of their cardioplegic 
solution. 
Clinically, non-coronary collateral flow would mode-
rate this observed toxicity since it not. only reintroduces 
calcium but also continually washes out the cardio-
plegia.20 However, one should not rely on this variable 
to avert cytotoxicity. 
In this study ST + G (10 mM) produced similar 
endothelial survivals to those of ST, and increasing the 
glucose content to 50 mM wa;s not detrimental to the 
endothelial cells. Furthermore, an increased sodium 
concentration (140 mM) was also nor detrimental when 
tested in an ST-based solution. Therefore, it would 
appear that neither the high glucose content nor' the 
high sodium content of SBX and PB-2 were maj_or 
contributory factors in their observed cytotoxicity. The 
major reason for endothelial damage by SBX is pro-
bably its low magnesium content, although we have not 
examined the possible cytotoxic potential of high osmo-
larity. This interpretation would support the findings of 
Hearse et a/. 21 with regard to the optimum concen-
tration of magnesium in a cardioplegic solution. 
Cardioplegic solutions have been primarily formu-
lated in isolated rat heart and in situ dog heart prepara-
tions by measuring post-ischaemic functional and meta-
bolic recovery. Dose-response curves for each individual 
electrolyte finally resulted in the present formulation of 
ST.22 Our observations on endothelial cytotoxicity sup-
port these findings. However, in contrast to B-HTK, 
ST initially altered the morphological appearance of 
the cells. Although this change was reversible and 
resulted in similar post-exposure survivals, it could well 
be deleterious in vivo. Minor reversible injurious altera-
tions of the endothelial surface can increase vascular 
permeability, and release activating enzymes,6·23 and 
furthermore has been postulated to accelerate athero-
genesis. 24 The experimental modification to ST, i.e. 
ST + G + histidine (50 mM), improved both the 
cellular morphology and post-exposure survival, and 
might well be a significant enhancement. It would 
appear that the greater buffering capacity provided by 
histidine was beneficial, since endothelial cells are 
known to be high lactate producers.6 However, further 
experimental work would have to be done to confirm 
these observations in other models. 
We recognise that venous endothelial cells differ 
from coronary artery endothelial cells. However, our 
model examined universal characteristics of endothelial 
cells, namely cell death, attachment dependence and 
morphological changes such as cellular contraction, in 
response to exposure to physiological solutions. There-
fore, we believe extrapolation to the arterial system is 
justifiable. 
In conclusion, the only crystalloid cardioplegic solu-
tion presently in use in South Africa that is not toxic to 
endothelial cells is the St Thomas' Hospital No. 2 
solution with or without glucose (10 mM). All other 
solutions, i.e. the SABAX cardioplegic solution and 
various Plasmalyte B formulations, are cytotoxic to 
endothelial cells. 
This study was supported by the Chris Barnard Foundation 
and Pfrimmer and Co. Pharmaceutical Works, Erlangen, 
Germany. Furthermore, we wish to thank Dr F. Koehler 
Chemical Ltd. and SABAX Ltd. for donating their cardio-
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Endothelial Cell Toxicity of Solid-Organ 
Preservation Solutions 
Ulrich 0. von Oppell, MB, ChB, FCS, Steffen Pfeiffer, Petra Preiss, MD, 
Timothy Dunne, FIS, PhD, Peter Zilla, MD, PhD, and Bruno Reichart, MD 
Departments of Cardiothoracic Surgery and Mathematical Statistics, University of Cape Town, Cape Town, South Africa 
Endothelial cell damage caused by myocardial cardiople-
gic solutions (Bretschneider HTK and St. Thomas' Hos-
pital No. 2) or renal and hepatic cold storage solutions 
(modified Collins and University of Wisconsin solution) 
was assessed in monolayer cultures of adult human 
venous endothelial cells at 4° to 10°C with phase-contrast 
microscopy. St. Thomas' Hospital solution caused the 
cells to contract, resulting in disruption of monolayer 
integrity and opening of intercellular gaps, and resulted 
in a 24-hour postexposure survival of 51.0% ± 2.4%. 
Bretschneider HTK solution altered cellular morphology 
less and produced the best postexposure survival (80.2% 
± 2.6%; p < 0.001). Although morphology was altered 
the least with University of Wisconsin solution, postex-
posure survival with this solution, which was similar to 
that with modified Collins solution, was superior to that 
Techniques used for solid-organ preservation primarily involve decreasing basal cellular energy require-
ments by selectively manipulating specific energy-con-
suming processes in conjunction with hypothermia. Thus 
the majority of centers store kidneys and livers at 4° to 
10°C and flush these organs intravascularly with "intra-
cellular" electrolyte equivalent preservation solutions to 
abolish energy-consuming transmembranous electrolyte 
gradients. Simple hypothermic storage periods of 12 to 24 
hours are now clinically achievable for- the liver and 
kidney. 
In contrast, the myocardium has a much higher rate of 
energy consumption because of myocyte electromechan-
ical activity. Thus cardioplegic solutions have been pri-
marily formulated to produce diastolic arrest by increas-
ing the extracellular concentration of potassium and 
magnesium, or alternatively decreasing the concentration 
of sodium and calcium. Despite electromechanical arrest 
the heart is only viable clinically for 4 to 8 hours with 
simple hypothermic storage. Such periods have been 
achieved with both intracellular and extracellular electro-
lyte equivalent cardioplegic solutions. 
The endothelium, which is common to all organs, is 
possibly even more vulnerable to ischemia than cardio-
myocytes [1]. Endothelial cells form the primary interface 
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with St. Thomas' (p < 0.01) but inferior to that with 
Bretschneider HTK (p < 0.05). The superior protection 
provided by Bretschneider HTK was due to its additives 
histidine, tryptophan, and KH-2-oxygluterate (p < 
0.005), and to its low chloride content (p < 0.005). 
Furthermore, modifying St. Thomas' solution by de-
creasing its chloride content improved cell survival to 
71.2% ± 2.3% (p < 0.001). Normothermic (37"C) exposure 
to Bretschneider HTK, modified Collins, and University 
of Wisconsin solution was cytotoxic, whereas nor-
mothermic exposure to St. Thomas' cardioplegia was 
not. In conclusion, the preservation solution that is the 
least harmful to endothelial cells at hypothermia is 
Bretschneider HTK cardioplegic solution. 
(Ann Thorac Surg 1990;50:902-10) 
between the blood and interstitium, and modulate a 
variety of biologic functions [2]. The normal endothelial 
surface is antithrombogenic and also provides mediators 
that modulate vascular tone [3]. Ischemia and intravascu-
lar infusion of solutions can cause endothelial damage 
[4-6]. Injury can result in a procoagulant endothelium, 
vasoconstriction [7, 8], release of enzymes associated with 
the production of toxic free radicals, increased vascular 
permeability which predisposes to interstitial edema [9], 
and accelerated atherogenesis [10]. Furthermore, gradual 
cell damage leads to the manifestation of these deleterious 
effects before total loss of the endothelium occurs [11]. 
Therefore, it is extremely important that organ preserva-
tion solutions express minimal toxicity to endothelial 
cells, and they should in fact protect this structure. The 
preservation of the endothelium might well be a domi-
nant factor in lung storage, if one considers the extent of 
the pulmonary vascular bed. 
To date, few studies have determined to what extent 
commonly used preservation solutions influence the 
endothelium. Furthermore, electrolyte concentrations in 
cardioplegic solutions are specific for the myocyte and are 
not necessarily suitable for the preservation of endothelial 
cells, which do not have inward voltage-dependent so-
dium or calcium currents [12]. Thus modifications that 
additionally diminish basic membrane energy require-
ments, improve buffering, or diminish cellular edema 
might be of more direct benefit to the endothelium. 
This study was undertaken to examine the effects of 
0003-4975/90/53.50 
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prolonged endothelial cell contact with various standard 
solutions used for myocardial, renal, and hepatic preser-
vation. Endothelial cells are attachment-dependent cells, 
and cytotoxicity can . be observed in monolayer cultures 
with light microscopy as loss of cellular attachment and 
cellular disruption. We elected to study human venous 
endothelial cells as they were easily obtainable and the 
majority of endothelial functions stated herein occur uni-
versally throughout the vascular tree. 
We examined the effect of these solutions both at 4° to 
10°C and at 37"C, as the majority of centers infuse these 
solutions at a temperature of 4°C into the normothermic 
(37"C) organ to induce hypothermia W to 10°C). In 
addition, modified cardioplegic solutions are also used at 
normothermia as reperfusion solutions. Finally, in an 
attempt to establish the primary components that were 
either harmful or beneficial, modifications to these solu-
tions were developed and tested. 
Material and Methods 
Endothelial Cell Culture Techniques 
Endothelial cells were harvested from human saphenous 
vein segments obtained from adult patients undergoing 
coronary artery bypass grafting or from organ transplan-
tation donors as previously described [13]. After cannu-
lation, the venous segment was flushed with incomplete 
culture medium (Medium 199-Earle's salts; Flow Labo-
ratories, Irvine, Scotland), then filled with 0.1% collage-
nase (CLS II; Cooper Biomedical, Malvern, P A) and incu-
bated at 37°C for 15 minutes. The collagenase-cell 
suspension was then inactivated by flushing with culture 
medium containing 30% fetal calf serum (Delta Bioprod-
ucts, Johannesburg, South Africa), collected, and centri-
fuged for 10 minutes at 120 g. The pellet was resuspended 
in 2 mL of complete culture medium (Medium 199 plus 
20% fetal calf serum and endothelial cell growth factor; 
Collaborative Research Inc, Lexington, MA) and plated 
into a 9.6-cm2 well of a six-well culture plate precoated 
with human fibronectin (Inotech, Zurich, Switzerland; 18 
J.Lg/mL). All cultures were incubated at 37°C in a 5% C02 
atmosphere. 
To remove erythrocytes and cell debris the primary 
culture was rinsed after 24 hours with Dulbecco's phos-
phate-buffered saline (Flow Laboratories). Thereafter, 
complete culture medium (2 mL) was added, and 50% of 
the supernatant was replaced twice weekly with fresh 
complete culture medium. Endothelial cells were pas-
saged at 80% partial cell coverage, designated by a micro-
grid technique [13]. This partial cell coverage was usually 
obtained 10 days after endothelial cell harvest. 
To reduce the cell-damaging effect of multiple passages 
[14], primary cultures were passaged at a ratio of 1:22, 
using trypsin ethylenediaminetetraacetic acid (Flow Lab-
oratories). These first-passage endothelial cells were ei-
ther seeded into a 175-cm2 flask precoated for 12 hours 
with gelatin (Difco Laboratories, Detroit, MI; 10 ng/mL in 
0.1 mol!L NaHC03 buffer) or onto 9-mm glass cover-slips 
for immunohistochemical staining with von Willebrand 
factor (factor VIII-related antigen), which is a typical cell 
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Table 1. Composition of Preservation Solutionsa 
UW-
Component ST COL css 
Na J20 10 20 
K 16 115 140 
HC03 10 10 
Mg 16 3 5 
Ca 1.2 
CI 159 15 
Glucose · H 20 139 
Histidine HCI · H20 
Histidine 
Tryptophan 
KH-2-oxygluterate 
Mannitol 
Lactobionic acid 100 
Raffinose · 5H20 30 
Adenosine 5 
Glutathione (reduced) 3 
Allopurinol 
Pentafraction 50 g/L 
Osmolarity 300 300 320 
(mosmoi/L) 
pH (37"C)b 7.26 7.27 7.27 
903 
B-HTK 
15 
10 
4 
50 
18 
180 
2 
30 
298 
7.33 
• Concentrations are given in mmol/L, unless otherwise indicated. 
b The pH was measured after gassing with 95% 0 2 and 5'7c C02 . 
B-HTK = Bretschneider HTK; COL = modified Collins solution; 
ST = St. Thomas' Hospital No. 2; UW-CSS = University of Wisconsin 
cold storage solution. 
marker for endothelial cells [15]. Cultures were managed 
as before, and confluence was again obtained within 10 
days. 
The cells were passaged once more, but in a 1:1 ratio 
into 12-well culture plates (3.5 cm2 per well) precoated 
with gelatin. Confluence of second-passage monolayers 
was obtained after 2 to 3 days. Individual wells were 
assessed microscopically for completeness and homoge-
neity of cell coverage, and unevenly covered wells were 
excluded. 
Preservation Solutions 
Preservation solutions tested were the St. Thomas' Hos-
pital No. 2 (ST; Sabax Ltd, Johannesburg, South Africa) 
and Bretschneider HTK (B-HTK; Dr F Koehler Chemie 
GmbH, Alsbach, Federal Republic of Germany) cardiople-
gic solutions, the modified Collins (COL) kidney preser-
vation solution, made up by adding 50 mL of 50% 
dextrose and 1.2 mL of 50% MgS04 to the standard 
Collins solution (Baxter Health Care Corporation, Deer-
field, IL), and the University of Wisconsin cold storage 
solution (UW-CSS; Du Pont Pharmaceuticals, Wilming-
ton, DE), but without the recommended additional addi-
tives (penicillin, insulin, dexamethasone). The composi-
tions of these solutions are given in Table 1. 
Modifications of these primary preservation solutions 
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Table 2. Composition of Modified Experimental Solutionsa 
In cell 
ST-Low ST-Ca High No 
Component ST Cl (?) Cl HTK 
Na 120 120 120 10 15 
K 16 16 16 126 10 
HC03 10 10 10 10 
Mg 16 16 16 16 4 
Cl 159 34 158 158 50 
Ca 1.2 1.2 0 
0.05 
0.6 
Gluconate 126 
Mannitol 30 
Sucrose 208 
Osmolarity 300 276 300 288 312 
(mosmol/L) 
pH (37"C)b 7.26 7.28 7.23 7.27 7.27 
• Concentrations are given in mmol/L, unless otherwise indicated. 
b The pH was measured after gassing with 95% 0 2 and 5% C02 . 
lnceli-High Cl = an experimental intracellular electrolyte equivalent solu-
tion with a high chloride ion content. No-HTK = Bretschneider HTK 
cardioplegic solution, but without histidine, tryptophan, and KH-2-
oxygluterate. Sucrose was used to maintain equivalent osmolarity. ST 
= St. Thomas' Hospital No. 2 cardioplegic solution, and modifications as 
indicated. 
were made up in our laboratory to examine the specific 
effect of chloride ion concentration and to examine B-HTK 
in more detail. St. Thomas' cardioplegia with a low 
chloride concentration (ST-Low Cl) was made with so-
dium and potassium gluconate instead of the respective 
chloride salt. However, gluconate binds calcium and 
therefore affects the free ionized calcium ion content, thus 
ST with varying calcium concentrations (ST-Ca 0 mmol/L, 
0.05 mmol/L, 0.6 mmol/L) were also tested. The "free" 
ionized calcium of these solutions was measured using a 
calcium-ion-selective electrode (Ciba Corning 288 Blood 
Gas System, Ciba Corning Diagnostics Corporation, Med-
field, MA). However, because of the high magnesium 
concentration of ST, an estimate of the magnesium ion 
interference in the calcium ion measurements had to be 
subtracted from the initial values. The estimate was ob-
tained by measuring the "ionized calcium" in two acalce-
mic solutions that did or did not contain magnesium (16 
mmol/L) but were otherwise identical to the correspond-
ing modified ST solution. This "corrected" estimate of the 
free ionized calcium is the reported value. In addition, an 
acalcemic "intracellular" solution with a high chloride 
content (Incell-High CI) was prepared. Apart from a 
substantially higher chloride concentration this solution 
was not markedly dissimilar to COL (Tables 1, 2). Finally, 
a solution matching the electrolyte content of B-HTK but 
without the additives histidine, tryptophan, or KH-2-
oxygluterate (No-HTK) was prepared. Sucrose was used 
in No-HTK to maintain equivalent osmolarity. The com-
positions of these experimental solutions are given in 
Table 2. 
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All solutions were gassed with 95% 0 2 and 5% C02 30 
minutes before use to ensure pH stability and uniform 
oxygen content. Gassing with 95% 0 2 and 5% C02 will 
induce a slight acidotic pH shift if the primary buffer in 
the solution is bicarbonate (ST, COL). The pH of the ST 
cardioplegic solution was therefore slightly acidotic (pH, 
7.26 at 37°C) compared with the value reported for clinical 
use, but was similar to that of the other solutions (Tables 
1, 2). However, we have previously shown that this 
acidotic shift in pH improves postischemic recovery of the 
isolated rat heart after protection with an oxygenated ST 
plus glucose (11 mmol/L) cardioplegic solution [16]. 
Experimental Protocol 
A baseline in situ grid count of each well was performed 
[13], using an inverted-phase contrast microscope (ID 02 
MT, Zeiss, Oberkochen Federal Republic of Germany). 
The cell count in "20 grid squares" was the total number 
·of cells seen in each of the four corner squares of a marker 
grid and counted in five different areas of each well. The 
culture medium was then removed and the preservation 
solution applied initially as a rinse to ensure removal of all 
medium, and then a 1-ml aliquot was reinserted. 
In the normothermic experiments, preservation solu-
tions at room temperature were introduced onto the cells, 
which were then incubated at 37'C in a 5% C02 atmo-
sphere. Preservation solutions for the hypothermic exper-
iments were cooled to woe before application, and the 
cultures were then stored in a refrigerator at 4° to woe in 
a normal atmosphere. 
The cells were exposed to the preservation solutions for 
12 hours, and the morphology of the cells was then 
examined by light microscopy. Thereafter the solution 
was removed and the cells were rinsed with incomplete 
culture medium; and 1 mL of complete medium, but 
without endothelial cell growth factor, was reapplied. All 
cell cultures were again placed in a 3rC, 5% C02 incuba-
tor to assess cell survival and allow for any delayed 
expression of cell damage. A postexposure cell count was 
performed after the cells were rinsed with incomplete 
culture medium, to remove debris and dead cells, at 24 
hours and again at 36 hours. 
Expression of Results 
The cell count per square centimeter was calculated at 
each of three time periods from in situ microgrid counts as 
previously described [13]. The percentage of surviving 
cells in each well at the 24-hour and 36-hour postexposure 
time periods was derived from the ratio of each individual 
postexposure count to the corresponding initial preexpo-
sure count for that well. Values are presented as survival 
percentage means and standard errors of survival per-
centage means. 
The total number of wells tested is given as N, and to 
ensure reproducibility each solution was tested in anum-
ber of different culture plates (P). Cells were obtained 
from three separate human donors, and we attempted to 
test each solution on cells from at least two different 
primary cultures (C), where these were available. Stu-
dent's t test was used to compare differences on the 
Ann Thorac Surg 
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assumption of equal variances. Appropriate tables were 
then used to determine p values. Statistical significance 
was assumed when the p value was less than 0.05. Several 
comparisons were of a priori interest, and the stated level 
of significance was used without multiple comparison 
adjustments on the basis of the a priori intentions. Many 
of the p values of interest are exceptionally small, and 
even the crudest adjustment for multiple comparisons 
will leave the conclusion of significant differences un-
changed. The wells were treated as though they demon-
strably generated independent observations. Although 
this is not theoretically optimal, the low variation between 
primary cultures in the same treatment regimen ensures 
that the approximate method generates valid conclusions 
for these data. 
Results 
The phase contrast microscopy appearance of a confluent 
monolayer of cultured human endothelial cells is shown 
in Figure 1, which shows the tYpical "cobblestone" mor-
phology. 
Hypothermic Exposure (10°C) 
Exposure at 10°C for 12 hours to ST (N = 16, P = 5, C = 
3) caused the cells to contract, and denser cytoplasmic 
granulations and intercellular gaps were seen (Fig 2). 
However, this appearance was reversible after removal of 
the cardioplegic solution and reincubation in culture me-
dium, and the 24-hour postexposure survival was 51.0% 
± 2.4%. The 36-hour survival was no different (Table 3). 
In contrast, exposure to B-HTK (N = 13, P = 4, C = 3) 
altered the morphological appearance of the endothelial 
cells less; contraction of the cells was less but intercellular 
gaps still appeared. The 24-hour postexposure endothelial 
cell survival was 80.2% ± 2.6%; after 36 hours it was 
slightly lower at 73.5% ± 1.6% (p < 0.05). This was 
superior to ST (p < 0.001). 
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Fig 1. Phase contrast microscopic 
appearance of a confluent monolayer 
of adult human saphenous vein endo-
thelial cells. Typical cobblestone mor-
phology and monolayer growth of a 
pure endothelial cell culture are 
shown. (X100 before 25% reduction.) 
Exposure to UW-CSS did not alter the cells' appearance 
and preserved their morphology the best, whereas COL 
induced prominent nuclei with otherwise minimal cellular 
changes. Collins solution (N = 9, P = 3, C = 2) was 
associated with a 24-hour endothelial cell survival of 
62.4% ± 3.1%, which was no different than the 69.7% ± 
2.9% survival of cells exposed to UW-CSS (N = 13, P = 4, 
C = 3). Cell survival with both these alternative solid-
organ preservation solutions was better than with ST (p < 
0.01), but inferior to that with B-HTK (p < 0.05 at both 
postexposure periods) (see Table 3). 
MODIFICATIONS TO BRETSCHNEIDER HTK .CARDIOPLEGIC SO-
LUTION. When endothelial cells were exposed for 12 hours 
at l0°C to No-HTK (see Table 1), the 24-hour cell survival 
was 69.0% ± 2.3% (N = 9, P = 3, C = 2). This survival 
was inferior to that with the standard B-HTK formulation 
(p < 0.01) and no different than that with COL (see Table 
3). The morphological appearance of the cells was similar 
to those treated with B-HTK. 
MODIFICATIONS TO INTRACELLULAR PRESERVATION SOLU-
TIONS. Incell-High Cl (N = 11, P = 3, C = 2) is an 
intracellular electrolyte equivalent solution with a high 
chloride concentration, and produced a diminished 24-
hour endothelial cell survival of 43.6% ± 4.5% (p < 0.005), 
in contrast to COL (see Table 3). This high concentration 
of chloride caused the cells to contract, and intercellular 
gaps were now easily seen, similar to the morphology 
observed with ST. 
MODIFICATIONS TO ST. THOMAS' CARDIOPLEGIC SOLUTION. 
Endothelial cells were exposed for 12 hours at 10°C to 
ST-Low Cl (N = 11, P = 4, C = 2) and 24-hour survival 
increased to 71.2% ± 2.3% (p < 0.001 compared with ST, 
which has a high chloride content [see Tables 2, 3]), but 
ST-Low Cl was still inferior to B-HTK (p < 0.05). Although 
the postexposure morphological appearance of cells ex-
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Fig 2. Phase contrast microscopic 
appearance of a monolayer of adult 
human endothelial cells after 12-hour 
exposure at 4" to 10°C to St. Thomas' 
Hospital No. 2 cardioplegic solution. 
Endothelial cells show condensed cy-
toplasmic granulations and have con-
tracted, causing disruption of mono-
layer integrity and the opening of 
wide intercellular gaps. (xlOO before 
25% reduction.) 
posed to ST-Low Cl showed some cellular contraction 
with intercellular gaps, this was less than that seen after 
exposure to ST. 
The aniori gluconate (used to replace chloride ions in 
ST-Low CI) binds calcium, and the estimated free ionized 
calcium of ST (0.9 mmol/L) decreased to 0.16 mmol!L in 
ST-Low Cl. Therefore, to independently examine the 
effect of a lowered Ca2 + concentration in ST, we tested a 
hypocalcemic ST-Ca 0.6 mmol!L (N "' 6, P = 2, C = 2) 
having a free Ca2 + of 0.5 mmol!L, and ST-Ca 0.05 mmol!L 
solution (N = 7, P = 2, C = 2) with a free Ca2 + of less than 
0.05 mmol/L. Cell survivals of 60.4% ± 4.2% and 59.9% ± 
Ann Thorac Surg 
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4.3%, respectively, were obtained 24 hours after expo-
sure, and these hypocalcemic ST solutions were not 
statistically superior to ST (Fig 3), in contrast to ST-Low 
Cl. The estimated free ionized calcium of ST -Low Cl (0.16 
mmol/L) fell between those of the hypocalcemic ST solu-
tions. 
However, an ''acalcemic" ST solution, ST-Ca 0 mmol!L 
(N = 8, P = 3, C = 2) improved 24-hour cell survival to 
64.8% ± 2.1% (p < 0.001) and 36-hour cell survival (p < 
0.001) compared with ST. These cells also showed less 
contraction with smaller intercellular gaps; however, cel-
lular contraction was least with ST-Low Cl. A note of 
Table 3. Endothelial Cell Survival After 12-Hour Hypothermic Exposure" 
Baseline Count 
Solution N (cells/cm2) % Survival at 24 h % Survival at 36 h 
Primary preservation solutions 
B-HTK 13 21,231 :±: 1,780 80.2% :±: 2.6%b 73.5% ::!:: 1.6%b 
UW-CSS 13 21,510 :!:: 2,328 69.7% :!:: 2.9%b.< 65.5% :!:: 1.5%b,d 
COL 9 26,486 :±: 2,139 62.4% :!:: 3.1 %d.e 61.1% :!:: 2.3%d.c 
ST 16 20,758 :!:: 1,545 51.0% :!:: 2.4% 49.6% :!:: 2.5% 
Modifications 
ST-Low Cl 11 25,557 :!:: 2,341 71.2% :±: 2.3%b,c 67.0% :!:: 2.2%b,< 
Incell-High Cl 11 26,330 :!:: 2,423 43.6% :!:: 4.5% 41.3% :!:: 4.4% 
No-HTK 9 26,306 :!:: 2,418 69.0% ± 2.3%b.d 66.3% :!:: 1.6%b.d 
• Cultured human endothelial cell survival after exposure to organ preservation solutions for 12 hours at hypothermia (4° to 10°C). The cell survival at 24 hand 36 hours after exposure is presented as a percentage of each individual baseline preexposure cell count per square centimeter. Results are presented as survival percentage means and standard errors of percentage means. b p < 0.001 compared with STat corresponding time periods. c p < 0.05 compared with B-HTK at corresponding time periods. d p < 0.005 compared with B-HTK at corresponding time periods. • p < 0.01 compared with STat corresponding time periods. 
B·HTK = Bretschneider HTK cardioplegic solution; COL = modified Collins solution; Incel!-High Cl = an experimental intracellular electrolyte equivalent solution with a high chloride ion content; No-HTK = B-HTK without histidine, tryptophan, and KH-2-oxygluterate; ST = St. Thomas' Hospital No.2; UW-CSS = University of Wisconsin cold storage solution. 
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~ 24hr Post exposure ~ 36hr Post expos~e 
Fig 3. Mean perce11tage survival of cultured 
adult human endothelial cells 24 and 36 hours 
after 12-hour hypothermic w to 10°C) expo-
sure to 51. Thomas' Hospital No. 2 cardiople-
gic solution (ST). The effect of varying calcium 
(Ca) concentrations (0, 0.05, and 0.6 mnw/IL) 
compared with the standard ST (Ca = 1.2 
mmol/L) and with an ST solution with a low 
chloride content (a/so containing Ca = 1.2 
mmol/L) is shown. The vertical bars represent 
standard errors of percentage means. The esti-
mated free ionized calcium of each solution is 
indicated separately. (*p < 0.001 compared 
with ST<Ca-1.2); 0 p < 0.05 compared with 
ST-Low Cl.) 
* 
70 
(i3 
.2: 
:> 
~ 
:::1 60 C/) 
?fi 
50 
ST(Ca-1.2) Ca-0.6 Ca-0.05 Ca-0.0 ST -Low Cl 
Free Calcium 
(mmol/.t) 0.9 
0.5 <0.05 <0.05 
caution must be mentioned though, as the measured free 
ionized calcium of ST-Ca 0 mmol/L was not zero; even 
deionized distilled water contains trace amounts of cal-
cium. 
Normothermic Exposure (3rC) 
For the normothermic experiments the endothelial cells 
were maintained for 12 hours at 37°C in a buffered 5% 
C02 atmosphere. In contrast to the hypothermic experi-
ments, ST (N = 9, P = 3, C = 3) was now associated with 
the best 24-hour endothelial survival of 72.0% ± 2.3% (p < 
0.001 for all comparisons) (Table 4). In addition, these 
cells showed only prominent nuclei with otherwise min-
0.16 
imal changes in the immediate postexposure period, in 
contrast to the marked changes observed with hypother-
mic exposure. 
The intracellular preservation solutions, ie, COL (N = 
6, P = 2, C = 1), UW-CSS (N = 6, P = 2, C = 2), and 
B-HTK (N = 9, P = 3, C = 3}, all produced immediate loss 
of adherence and cellular disruption (Fig 4}, and 24-hour 
postexposure endothelial cell survivals were less than 
20% (see Table 4). However, the high-chloride intracellu-
lar solution Incell-High Cl (N = 6, P = 1, C = 1) was 
associated with a 24-hour survival of 51.1% ± 3. 9% (p < 
0.001 compared with COL, UW-CSS, B-HTK) (see Table 
4). 
Table 4. Endothelial Cell Survival After 12-Hour Normothermic Exposure" 
Baseline Count 
Solution N (cells/cm2) o/o Survival at 24 h o/o Survival at 36 h 
Primary preservation solutions 
B-HTK 9 25,472 ::!: 3,762 19.1%::!: 3.5%b,c 18.3% ::!: 3.4%b,c 
UW-CSS 6 17,146::!: 825 7.7% ::!: 1.3'7ob.c 6.7% ::!: 1.3%b.c 
COL 6 26,771 ::!: 952 6.1%::!: 0.4'7ob,c 2.8% ± 0.4%b,c 
ST 9 25,097 ::!: 3,612 72.0% ± 2.3% 70.1% ± 2.1% 
Modifications 
ST-Low Cl 8 27,313 ± 2,410 74.6% ::!: 1.6%d 64.3% ::!: 1.8%c 
lnceli-High Cl 6 29,333::!: 696 51.1% ± 3.9%b 45.8% :!:: 3.3%b 
ST-Acalcemic 8 28,828 ::!: 2,332 66.4% ± 2.0%d 56.1% ± 2.1%b,d 
• Cultured human endothelial cell survival after exposure to organ preservation solutions for 12 hours at normothermia (37"C). The cell survival at 24 and 
36 hours after exposure is presented as a percentage of each individual baseline preexposure cell count per square centimenter. Results are presented as 
survival percentage means and standard errors of percentage means. b p < 0.001 compared with ST at corresponding time periods. c p < 0.001 
compared with lncell-High Cl at corresponding time periods. d p < 0.05 compared with lnceli-High Cl at corresponding time periods. 
Abbreviations as in Table 3. 
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Fig 4. Phase contrast microscopic 
appearance of a monolayer of adult 
human endothelial cells after 12-hour 
exposure at 37"C to modified Collins 
preservation solution. All endothelial 
cells are detached from the surface of 
the culture plate, and the majority 
show swelling, membrane disruption, 
or karyorrhexis. (xlOO before 27'1o 
reduction.) 
Finally, exposure to ST-Low Cl (N = 8, P = 3, C = 2) for 
12 hours at normothermia produced a postexposure sur-
vival of 74.6% ::!:: 1.6%, which was similar to that seen with 
ST. In addition, the 24-hour survival with ST-Ca 0 rnrnol/L 
(N = 8, P = 3, C = 2) of 66.4% ::!:: 2.0% was also no 
different than that with ST, although at 36 hours it was 
inferior (p < 0.001) (see Table 4). Postexposure morphol-
ogy was similar to that seen with ST. 
Comment 
We studied the effect of various internationally used 
organ preservation solutions on cultured adult human 
venous endothelial cells. We recognize that arterial endo-
thelial cells differ from venous endothelial cells; however, 
similarities also exist (17]. Furthermore, many reported 
differences between cells derived from distinct vascular 
beds have been observed in various culture conditions 
and animal models, which in turn may be associated with 
interspecies differences {18]. We based our model on the 
assessment of morphological alterations and evaluation of 
cell detachment, as indicators of cell damage and ulti-
mately cell death. Both these criteria are common to 
arterial and venous endothelium. Therefore, we believe 
extrapolation to the arterial system is justifiable. 
When confluent rnonolayers of endothelial cells were 
exposed to these solutions for 12 hours at hypothermia (4° 
to 10°C), Bretschneider HTK cardioplegic solution was 
associated with the best 24-hour postexposure cell sur-
vival (80%), although cellular morphology was initially 
altered by the solution. Bretschneider HTK provided 
better endothelial preservation than St. Thomas' Hospital 
No. 2 cardioplegic solution (51%). In addition, both the 
modified Collins kidney preservation solution and the 
University of Wisconsin liver and pancreatic storage solu-
tion, although superior to ST, were inferior to B-HTK. 
Hence the intracellular electrolyte equivalent solutions 
Ann Thorac Surg 
1990;50:902-10 
(B-HTK, COL, UW-CSS) designed to abolish transrnern-
branous electrolyte gradients provided better hypother-
mic endothelial protection than an extracellular solution 
(ST). However, the solution that preserved rnorp1"tology 
the best (UW-CSS) was not associated with the best 
postexposure survival. 
Nevertheless, if the cells were exposed to these solu-
tions for 12 hours at normothermia (37°C), the intracellu-
lar electrolyte equivalent preservation solutions were cy-
totoxic, with less than 20% 24-hour postexposure 
survival. St. Thomas' cardioplegia solution was now su-
perior, producing 72% endothelial cell survival. 
An atmosphere of 5% C02 was used for the normother-
mic experiments in order to ensure pH stability, because 
of the substantially lower solubility coefficient of C02 at 
this higher temperature. In our opinion this would have 
improved normothermic cell survivaL and therefore 
might have accounted for the apparent superior endothe-
lial protection afforded by ST at 37°C, in contrast to 10°C. 
However, we infer that the observed diminished survival 
responses with the intracellular solutions at normother-
mia were determined by the interaction of solution corn-
position and temperature. These contrasting findings 
possibly support the hypothesis of Kohno and associates 
(19], who suggest that two types of solutions are required 
for optimal myocardial preservation, a solution for nor-
mothermic arrest and then another for hypothermic pres-
ervation. In addition, it would imply that standard car-
dioplegic solutions (eg, B-HTK) should not necessarily be 
used as the convenient basic composition for normother-
mic reperfusion solutions. 
To further define the differences between these two 
groups of solutions we examined various modifications. 
Primary disparities between intracellular electrolyte equiv-
alent solutions and extracellular solutions are acalcernia, 
low sodium concentration, and low chloride concentra-
tion of the former. 
Ann Thorac Surg 
1990;50:902-10 
Calcium and Sodium 
A sodium-poor solution must essentially be calcium-free 
(B-HTK, UW-CSS, COL) for it to be effective [20], as low 
extracellular sodium concentrations open calcium chan-
nels, which could increase cytosolic calcium and thus 
activate injurious reactions (21]. Thus acalcemia appears 
to be a prerequisite for an intracellular formulation. How-
ever, in extracellular-formulated cardioplegic solutions 
acalcemia is reported to be harmful by predisposing to the 
calcium paradox [20], a phenomenon of severe cellular 
damage that occurs when hearts are reperfused with a 
fluid containing calcium ions after a period of calcium-free 
perfusion [22]. Furthermore, this phenomenon is not 
specific to the myocyte as it has been noted in canine 
kidney perfusions, where it produced changes to the 
vessel walls and cell membranes [23]. 
Although we demonstrated a benefiCial effect of an 
acalcemic ST solution on endothelial cells at hypothermia, 
this solution was possibly not truly acalcemic as it prob-
ably contained trace amounts of calcium as mentioned 
previously. However, survival decreased at normother-
mia with the acalcemic ST in contrast to ST, possibly as 
the likelihood of the calcium paradox increases with high 
extracellular sodium concentration and elevated temper-
ature [24]. 
Chloride 
We have shown that the low chloride content of intracel-
lular solutions is an important feature in their composi-
tion, as Incell-High Cl, which had a higher chloride 
concentration than COL, resulted in diminished hypother-
mic endothelial cell survival. However, at normothermia 
Incell-High Cl produced better endothelial cell survival 
(51%) than the other intracellular solutions ( <20% ). Thus 
a low chloride content was beneficial at hypothermia in 
terms of endothelial cell survival and was associated with 
diminished morphological alterations. In contrast, at nor-
mothermia a low chloride concentration appeared to con-
tribute to the observed cytotoxicity of the intracellular 
solutions. 
In the extracellular solution ST, a low chloride concen-
tration improved endothelial cell survival at hypothermia 
(71%) and was not detrimental at normothermia. How-
ever, the improved hypothermic endothelial cell survival 
provided by ST-Low Cl might have been partly due to a 
lower free ionized calcium as a result of calcium binding 
by gluconate [25]. Nevertheless, ST-Ca 0.05 mmol/L and 
ST-Ca 0.6 mmol/L, with free ionized calciums of less than 
0.05 mmol!L and 0.5 mmol/L, respectively, thus bracket-
ing the free calcium content of ST-Low Cl (free Ca2 + = 
0.16 mmol!L), did not themselves significantly improve 
ST. 
Chloride is a freely permeable extracellular anion, and 
ischemia-induced intracellular acidosis or elevated so-
dium level will encourage chloride to enter the cell, down 
its electrochemical gradient (26]. This entry would pro-
mote intracellular edema, as impermeate intracellular 
anions cannot leave the cell. Decreasing the chloride 
content of organ preservation solutions, by replacement 
with high-molecular-weight impermeate anions, helps 
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regulate cellular edema [27]. Furthermore, these anions 
may bind calcium and magnesium and thus alter their free 
ionized concentrations, as we have demonstrated. Never-
theless a low chloride concentration was beneficial in both 
intracellular and extracellular solutions. 
Additives: Buffers, Substrates 
To determine why 8-HTK was superior to the other 
intracellular solutions we examined No-HTK, a basic elec-
trolyte formulation without the additives of 8-HTK (histi-
dine, tryptophan, KH-2-oxygluterate). This was inferior to 
B-HTK, and no better than COL or UW-CSS at both 24 
hours and 36 hours after exposure. The beneficial effect of 
the HTK additives might have been wholly or in pa1t due to 
the greater buffering capacity of histidine, as endothelial 
cells are known to be high lactate producers (1]. 
Potassium 
The No-HTK solution has a potassium concentration of 10 
mmol/L, in contrast to the otherwise similar COL solution 
(potassium concentration, 115 mmol/L) (see Tables 1, 2). 
Because both solutions gave similar results, we infer that 
the high potassium concentration of 115 mmol/L in the 
intracellular COL solution did not contribute to hypother-
mic cytotoxicity. However, a high potassium concentra-
tion has been reported to be harmful in extracellular 
solutions [25]. Furthermore, the observed cytotoxicity of 
the standard intracellular preservation solutions at nor-
mothermic exposure was not wholly due to a high potas-
sium level, as 8-HTK (normothermic survival <20%) only 
contains a potassium concentration of 10 mmol/L. 
Temperature 
In a previous study ST solution and the original 
Bretschneider-Procaine solution showed similar cytotox-
icity, which increased equally when the temperature was 
raised from 19°C to 37°C [6]. However, this study evalu-
ated endothelial cell suspensions by a method of dye 
exclusion (trypan blue). Furthermore, the Bretschneider-
Procaine solution differs from the 8-HTK solution now 
used internationally and in our study. In contrast, we 
show increased survival and adherence of the cells at 
normothermic (as opposed to hypothermic) exposure 
with ST. However, this increase might have been due to 
the improved buffering provided by the 5% C02 atmo-
sphere used in all the normothermic groups. 
As discussed in this report, the observed normothermic 
cytotoxicity of the intracellular solutions was related more 
to a low concentration of sodium, as well as a low con-
centration of chloride, than to a high concentration of 
potassium. These observations may be important when 
considering using cardioplegic solutions as reperfusion 
solutions at 37°C. 
Conclusion 
This study used a basic index, morphology and cell 
survival, to assess the endothelial response to preserva-
tion solutions, and more sensitive endothelial functions 
should also be assessed even if indirectly [7, 8], to 
highlight differences between less toxic solutions. Fur-
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thermore, although we do not suggest altering the com-
position of cardioplegic solutions on the basis of these 
findings, in a similar endothelial study assessing car-
dioplegic solutions used in South Africa [28], we showed 
poor endothelial preservation with some cardioplegic 
solutions being used clinically. This in turn correlated 
with another study that assessed postischemic myocardial 
function in an in vivo baboon heart model after protection 
with similar cardioplegic solutions [29]. We did not examine 
blood cardiopleg{a, which is not routinely used for long-
term organ storage, because of the possibility of immuno-
logical incompatibility if not autologous. However, Harjula 
and associates [30] showed good endothelial preservation 
after 2 hours of exposure to blood cardioplegia at 22°C. 
The best available solution for hypothermic endothelial 
cell preservation is the B-HTK cardioplegic solution; how-
ever, it should not be used at normothermia. Its superi-
ority at hypothermia appears to be due to the low chloride 
content of intracellular solutions and to the additives 
histidine, tryptophan, and KH-2-oxygluterate in B-HTK. 
Furthermore, we were able to improve the efficacy of the 
extracellular ST cardioplegic solution in terms of endothe-
lial cell survival by replacing chloride ions with gluconate. 
This study was supported by Pfrimmer and Company Pharma-
ceutical Works, Erlanger, Federal Republic of Germany, in addi-
tion to the Chris Barnard Foundation. Furthermore, we wish to 
thank Du Pont Pharmaceuticals, Dr F Koehler Chemie GmbH, 
and Sabax Ltd for donating their respective organ preservation 
solutions. 
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Cardiovascular Topics 
. Practicalities of delivering crystalloid 
cardioplegic solutions (I) 
Oxygenation 
ULRICH 0. VON OPPELL, GERALDINE FRIEDMANN, ELRINA JOUBERT, 
DIETER BOEHM, JOHAN VAN HEERDEN 
Abstract 
Oxygenation of crystalloid cardioplegic solutions has 
been shown to improve post-ischaemic myocardial reco-
very by supplying oxygen dissolved in solution. We com-
pared the oxygen content of 'unoxygenated' StThomas' 
Hospital No. 2 cardioplegic solution (0,45 - 0,84 ml 
Oj100 ml solution) with the oxygen contents obtained by 
various oxygenating methods at different gas flow rates. 
Oxygenating St Thomas' cardioplegia with 95% 0 2, 5% 
C02 at 1,0 Vmin at hypothermia (4°C) in a standard 1 
litre glass vacolitre kept in ice, produced an oxygen con-
tent of 3,48 ± 0,14 ml Oz/100 ml solution within 30 
minutes. This oxygen content was no different to that 
obtained by means of a more complex hypothermic 
recirculation oxygenating method. 
In the clinical situation these saturated cardioplegic 
solutions could rewarm in the cardioplegic delivery tub-
ing in between each dose, and thus cause gas to come out 
of solution as bubbles. We therefore oxygenated St 
Thomas' cardioplegia with 95% 0 2, 5% C02 at 1,5 Vmin 
at room temperature (19°C - 24°C) either in an oxygena-
ting reservoir or in its 1 litre glass vacolitre. Both pro-
duced similar oxygen contents - 2,32 ± 0,16 and 2,07 ± 
Department of Cardiothoracic Surgery, University of 
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0,11 ml 0/100 ml solution respectively -:- representing 
60% of that obtained with hypothermic oxygenation. 
Clinically, the solution would then have to be cooled to 
4°C - 6°C before infusion. However, there would be no 
potential for bubble formation if rewarming occurred 
during clinical use. 
Cardioplegic solutions are used to protect the myocardium 
during routine open-heart surgery while the aorta is cross-
clamped. The chemical composition of these solutions in 
conjunction with hypothermia stops electromecha~ical 
activity, and thereby conserves energy .t." However, the 
arrested hypothermic myocardium still has a basal meta-
bolic requirement, and therefore cardioplegic solutions 
should contain substrates that can be metabolised to meet 
these ongoing energy needs.3 Furthermore, if a cardioplegic 
solution is oxygenated the more efficient aerobic metabolic 
pathways will produce greater amounts of high-energy 
phosphates, despite the fact that these solutions are only 
infused intermittently during the ischaemic period." 
There are two primary categories of cardioplegic solu-
tions, viz. blood and crystalloid cardioplegic solutions, both 
of which can carry oxygen.5 Blood cardioplegia, a combina-
tion of a crystalloid concentrate and oxygenated blood with-
drawn from the cardiopulmonary bypass circuit, will supply 
oxygen bound to haemoglobin. The delivery system for 
blood cardioplegia has been fairly well standardised, and 
depends upon the ratio in which the crystalloid concentrate 
is added to the blood component, either as a 1:2 or 1:4 dilu-
tion. The international gold standard is the 1 :4 blood cardio-
plegia developed by Buckberg,6 and delivered using tubing 
of differing internal diameters passed through the same 
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'roller-pump head' (Fig. 1). One revolution of a standard 
roller-pump using 1:4 delivery would provide 15 ml of 
'blood cardioplegia' by combining 3 ml concentrate (1/8" 
tubing) and 12 ml oxygenated blood (1/4" tubing). However, 
only a limited amount of oxygen is actually available, since 
blood cardioplegia has a low haematocrit and at low tem-
peratures less oxygen is released because of a leftward shift 
of the oxyhaemoglobin dissociation curve.7 This more com-
plex blood cardioplegia delivery system must also contain a 
heat exchanger that can adjust the temperature of the final 
mixed cardioplegic solution to 4°C- 10°C before infusion. 
On the other hand, crystalloid cardioplegic solutions can 
supply oxygen dissolved in solution, and oxygenation of 
these solutions has previously been shown to improve post-
ischaemic myocardial recovery.'·8·9 In order to supply the 
maximum amount of dissolved oxygen, the crystalloid 
cardioplegic solution should be oxygenated at a low tem-
perature (4°C - 6°C), because of increased solubility of 
gases at low temperatures.'0 Therefore, complex hypother-
mic recirculation systems have been designed to ensure 
maximal oxygenation of crystalloid cardioplegic solutions 
(Fig. 2). However, a hypothermic maximally oxygenated 
cardioplegic solution has the potential to form gaseous 
emboli if the solution rewarms in the delivery tubing before 
infusion. The solubility coefficient for oxygen diminishes as 
temperature increases, and thus oxygen will escape from the 
now supersaturated solution and form bubbles. These bub-
bles are potentially harmful if then infused into the coronary 
circulation. This danger could be avoided by oxygenating 
the cardioplegic solution at a temperature equal to or higher 
1 :4 BLOOD CARDIOPLEGIA 
crystalloid 
concentrate 
than that it is likely to be rewarmed to, but this would pos-
sibly imply accepting a lower oxygen content. 
We therefore compared the oxygen content of the 
StThomas' Hospital No. 2 cardioplegic solution (ST; Sabax 
Ltd, Johannesburg) when oxygenated by three different 
methods. The advantages, disadvantages and precautions 
that should be taken when oxygenating crystalloid cardio-
plegic solutions by these three methods are discussed. 
Methods 
Oxygen was supplied as 95% 0 2, 5% C02 for all cardioplegic 
oxygenating systems and gas flow was kept constant with a 
gas flow meter (Air-Shields Vickers; Hatboro, Pennsylvania, 
USA) during each evaluation. The oxygen tension (Po2) was 
measured at 5-minute Intervals for 30 minutes from the onset 
of oxygenating ST, with a Ciba Corning 288 blood gas 
analyser (Ciba Coming Diagnostics Corporation; Medfield, 
Massachusetts, USA). Each method was evaluated (N = 6) 
using a gas flow rate of 1,0 1/min. Thereafter alternative gas 
flow rates (0,5, 1,5 or 2,0 1/min) were tested. 
Oxygenation at hypothermia 
The first method evaluated was the aforementioned 
hypothermic recirculation system (CCAS-OC oxygenated 
crystalloid cardioplegic administration system, American 
Bentley; Irvine, California, USA). The cardioplegic solution 
is oxygenated in a hard shell reservoir (OxyHi reservoir) 
and continuously recirculated through an aluminium cooling 
oxygenator 4oc water 
J t 
1/8" roller pump 
1/4" 
heat exchanger 
Fig. 1. A blood cardioplegia delivery system. One part crystalloid concentrate and four parts blood taken from the cardio-
pulmonary bypass oxygenator are combined and then cooled by a heat exchanger, before infusion into the coronary circula-
tion. The composition of the crystalloid concentrate would depend upon the intended delivery ratio. 
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HYPOTHERMIC RECIRCULATING OXYGENATING SYSTEM 
0, 
crystalloid 
cardioplegia 
roller pump 
clamps 
Fig. 2. A delivery system for crystalloid cardioplegia that ensures cold (4°C) cardioplegia and maximal oxygenation thereof, 
by continually recirculating the solution through a cooling coil placed in ice. The removal/application of the indicated clamps 
allows the cardioplegic solution to be recirculated continuously or alternatively delivered to the patient. 
coil placed in ice, thus assuring continuous maximal hypo-
thermic oxygenation (Fig. 2). In order to standardise the 
experiments, oxygenation was only commenced once the 
temperature of the ST had been decreased to less than 4°C 
by recirculation through the coil in ice. 
The second method evaluated was simple bubble oxyge-
nation of the cardioplegic solution in its original manufac-
turer's container (I litre glass bottle). Cold ST that had been 
stored in the fridge had a mean temperature of 13°C, and 
was therefore kept in a bucket of ice for 30 minutes to 
ensure a temperature of less than 4°C before use. The 
cardioplegic solution was then oxygenated in its container 
while kept in ice. Oxygen was introduced into the 1 litre ST 
glass vacolitre through the 'venting port', thus the gas was 
introduced into the bottom of the upright container, bubbled 
through the solution and exhausted via two needles inserted 
in the 'injection port'. 
Oxygenation at room temperature 
The third method evaluated consisted of oxygenating ST 
at room temperature {19°C- 24°C) either in an OxyHi reser-
voir or its 1litre glass vacolitre. In clinical practice the cardio-
plegic solution would thereafter have to be cooled to 4°C -
6°C before infusion, by either a cooling coil or heat 
exchanger. 
Calculations and statistics 
Blood gas analysers measure pH and Po2 at an electrode 
temperature of 37°C. 'These values were therefore corre~ted 
to the temperature of the sample (T), either automatically by 
the analyser or by using the formulae described by Kelman 
and Nunn:" 
pH (corrected)= pH- 0,015 * (T- 37) 
Po2 (corrected)= Po2 * 10" (0,0052 + 0,027 * (1 - 10" 
(- 0,13 * (100-% 0 2 saturation)))* (T- 37)) 
These corrections are not precise since the above formu-
lae were devised for blood as opposed to physiological 
crystalloid solutions. However, they will approximate 
the true value more closely than if coefficients for pure 
water were used. 12 Oxygen content was then calculated 
from the corrected P02 (mmHg) by using the formula: 
oxygen content = Po2 (corrected)/760 mmHg * solubility 
coefficient (see Table I). 
Means and standard error of means for N = 6 observa-
tions are presented, and were analysed by two-way analysis 
of variance, with pairwise comparisons by acceptance inter-
vals of means using the F test. Statistical significance was 
taken asP< 0,05. 
Results 
The Po2 of 'unoxygenated' St Thomas' Hospital No. 2 
cardioplegic solution, exposed to the atmosphere and thus 
equilibrated to ambient partial pressure, was approximately 
150 mmHg. This corresponded to an oxygen content of 
0,45 - 0,84 ml 0/100 ml solution, depending on the tem-
perature of the solution. The pH of 'unoxygenated' ST 
(corrected to a temperature of l0°C) ranged from pH 7,6 to 
pH 8,3, again depending upon temperature and thus C02 
content. The oxygen content and pH of ST were then mea-
sured during oxygenation at different gas (95% 0 2 5% C02) 
flow rates with N = 6 for each evaluation. 
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Oxygenation at hypothermia 
When ST was oxygenated at a gas flow of 1,0 llmin at 
hypothermia (temperature less than 4°C) with the CCAS-
OC recirculation system, the oxygen content increased 
from the above baseline values to 3,35 ± 0,22 ml 0/100 ml 
solution within 20 minutes, P < 0,01. This was not signifi-
cantly different to the final maximum oxygen content of 
3,47 ± 0,14 ml 0/100 ml solution obtained after 30 minutes 
of oxygenation. The oxygen content produced by oxyge-
nating at a lower gas flow rate of 0,5 l/min was no different 
(Table II). 
Alternatively, cold ST (temperature less than 4°C) was 
simply oxygenated (1 ,0 I/ min gas flow) in its original 1 litre 
glass vacolitre. The oxygen content increased to a maximum 
of 3,48 ± 0,14 ml 0/100 ml within 30 minutes. This was no 
different to the above more complex recirculation system, 
either in time taken to stabilise or final oxygen content 
(Table II). 
The final pH of ST (corrected to a temperature of 10°C) 
after oxygenating with 95% 0 2, 5% C02 was similar with 
both methods, namely 7,03 ± 0,03 and 7,06 ± 0,02, respec-
tively. 
Oxygenation at room temperature 
Oxygenating ST in the OxyHi reservoir (no recirculation) 
at room temperature at a gas flow rate of 1,0 llmin produced 
an oxygen content of 2,39 ± 0,12 ml 0/100 ml solution 
within 30 minutes. This oxygen content was lower than 
when ST was oxygenated at hypothermia (P < 0,01). 
Furthermore, the major increase in oxygen content was 
obtained within 15 minutes of commencing oxygenation 
(P < 0,01), and there was no significant increase thereafter 
(Table III). The pH (corrected to a temperature of 10°C) of 
ST after oxygenation at room temperature was 7,32 ± 0,03, 
TABLE I. SOLUBILITY COEFFICIENT: ml OF 
OXYGEN DISSOLVED PER 100 ml OF 0,155 N NaCI 
AT 760 mmHg PRESSURE 10 
4,256 WC). 
3,689 (10°C) 
3,048 (19°C) 
2,989 (20°C) 
2,931 (21°C) 
2,875 (22°C) 
2,821 (23°C) 
2,768 (24°C) 
2,273 (37°C) 
which was more alkalotic than that observed with the above 
hypothermic oxygenation methods (P < 0,01). Increasing the 
gas flow rate to I ,5 llmin did not alter either the interim or 
final oxygen contents (Table Ill). However, increasing the 
aas flow further to 2 l/min resulted in higher initial values in 
0 0 
the first 15 minutes of oxygenation, but the final 30 mmutes 
oxygen content of 2,63 ± 0,04 ml 0/100 ml solution was no 
different to the final values observed with the lower gas flow 
rates. Similarly, the final pHs (corrected to a temperature of 
10°C) when oxygenating with either 1,5 or 2,0 l/min were 
identical at pH 7,27 ± 0,01, and no different to that observed 
at a flow rate of 1,0 llmin. 
Oxygenating STat 1,5 llmin (95% 0 2, 5% C02) at room 
temperature in its 1 litre glass vacolitre as opposed to the 
OxyHi reservoir resulted in a more gradual increase in oxy-
gen content (P < 0,05), but the final 30-minute value of 2,07 
± 0,11 ml 0/100 ml solution was no different to the values 
observed with the same gas flow rate in the OxyHi reservoir 
(Table III). The final pH of 7,27 ± 0,03 was also no different. 
These oxygen contents obtained by oxygenating the 
cardioplegic solution at room temperature were approxi-
mately 60% of that observed when ST was oxygenated at 
hypothermia (4°C). 
Maintenance of oxygen dissolved in solution 
Hypothermic oxygenation of ST using the CCAS-OC 
recirculation system ensures not only a cardioplegic solution 
temperature of less than 4°C, but also that maximal oxygen 
content is maintained over any time period. In contrast, after 
oxygenating a cardioplegic solution in a glass bottle, it must 
be vented with a large-bore needle to the atmosphere when 
used clinically, thus potentially allowing contained gases to 
equilibrate to atmospheric partial pressures. ST was there-
fore fully oxygenated in its original 1 litre glass vacolitre for 
30 minutes at a temperature of less than 4 oc. The glass 
bottle was then kept in ice (4°C) but vented to the atmos-
phere without further oxygenation, and after 2 hours _the 
oxygen content was still 3,51 ± 0,12 ml 0/100 m1 solut10n. 
Thus we observed no significant loss of oxygen from cold 
(4°C) ST in the 2-hour period following full oxygenation 
(Fig. 3). In addition, the pH of ST after 2 hours was 7,07 ± 
0,02, which was no different to the initial pH on completion 
of oxygenation (pH 7,06 ± 0,02). 
Similarly, initially oxygenating ST for 30 minutes at room 
TABLE II. OXYGEN CONTENT OF CARDIOPLEGIA OXYGENATED AT HYPOTHERMIA 
Method 0 5 
CCAS-OC 0,5 1/min 0,78 ± 0,16 2,10 ± 0,10* 
CCAS-OC 1 ,0 I/ min 1,05 ± 0,04 2,11 ±0,18* 
GL-B 1,0 1/min 0,60±0,12t 1,66 ± 0,30*t 
GL-B = I litre glass bottle. 
•p < 0,01 compared to the preceding time interval. . 
••p < 0,05 compared to the !().minute time interval. 
Duration of oxygenation (min) 
10 15 20 
2,76 ± 0,10* 3,41 ± 0,14* 3,58 ±0,11 
2,88 ±0,10* 3,24±0,17 3,35 ± 0,22** 
2,62 ± 0,13* 2,98 ± 0,18 3,23 ± 0,18** 
t p < 0.05 compared to CCAS-OC 1,0 Vmin at the corresponding time interval. 
25 30 
3,55 ± 0,14 3,69 ±O,Ql 
3,45 ± 0,15 3,47 ± 0,14 
3,48 ± 0,14 3,48 ± 0,14 
(ml 0/100 ml solution) 
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LOSS OF OXYGEN FROM OXYGENATED CARDIOPLEGIA 
Oxygen 
content-
ml 0/100ml 
4 
3 
solution 2 
GL-8 1,0 Vmin cold 
*+ 
GL-8 1,5 1/min warm 
+ 
! ! I 1 ·····±"""'"'''"···! I ... ·:E................ ........... . ...... . I . . ......... .. 
. ~ 
Oxygenation stopped 
0~~~--------~------~~--------r---------r---------r--
-30 0 30 60 90 120 
Time - minutes 
Fig. 3. Loss of oxygen from oxygenated cardioplegia. The ST was fully oxygenated with 95% 0 2 , 5% C02 for 30 minutes, 
at either hypothermia (4°C; at 1 ,0 1/min) or room temperature (20°C - 22°C; at 1 ,5 1/min) in its original 1 litre glass vecolitre 
(GL-8). Thereafter, oxygenation was discontinued and the glass bottle was vented with a large-bore needle to the atmos-
phere, and oxygen content monitored. Means for 6 evaluations, with the vertical bars representing standard error of means, 
are presented. (* P < 0,01 compared to GL-8 1 ,5 1/min warm, at the respective time period; t P = NS compared to time = 0.) 
temperature and thereafter maintaining STat room tempera-
ture, in its 1 litre glass vacolitre vented with a needle to the 
atmosphere, also did not result in any significant loss of oxy-
gen content in the subsequent 2 hours (Fig. 3) .. 
. Discussion 
If a crystalloid cardioplegic solution contains bicarbonate 
(viz. StThomas' Hospital No.2 cardioplegic solution), then 
oxygenation should be with 95% 0 2, 5% C02 and not 100% 
0 2•9 The addition of 5% C02 stabilises the pH optimally at 
7,0 (corrected to 10°C), without any drop in Po2• We there-
fore used 95% 0 2, 5% C02 to oxygenate ST in each system 
being evaluated, and in addition monitored pH. 
We have shown that a maximum oxygen content in ST 
(3,5 ml 0/100 ml solution) could be obtained by means of 
a hypothermic (4°C) recirculation oxygenating system 
(CCAS-OC) at a gas flow rate of either 0,5 or 1,0 1/min. 
However, simply oxygenating cold ST (4°C) in its original1 
litre glass vacolitre for 30 minutes with 95% 0 2 5% C02 at 
1,0 l/min while immersed in ice, also resulted in a similar 
final oxygen content. After initially oxygenating the cardio-
plegic solution for 30 minutes with the latter system and 
TABLE ill. OXYGEN CONTENT OF CARDIOPLEGIA OXYGENATED AT ROOM TEMPERATURE 
Duration of oxygenation (min) 
Method 0 5 
OxyHi 1,0 1/min 0,72 ± O,Q7 1,50± 0,25* 
OxyHi 1,51/min 0,38 ± 0,15 1,89±0,14* 
OxyHi 2,0 1/min 0,79±0,07t 2,14 ± 0, 14*:j: 
GL·B 1,51/min 0,35 ±0,08 1 ,40 ± 0,20*t 
GL~B = I litre glass bottle. 
*P < 0,01 compared to the preceding time interval. 
** P < 0,05 compared to the 5-minute time interval. 
10 
1,82 ± 0,26 
2,23 ± 0,16 
2,49 ± 0,07:j: 
1,91 ± 0,09* 
tP < 0,05 compared to OxyHi 1,5 Vmin at the corresponding time interval. 
tP < 0,05 compared to OxyHi 1,0 Vmin at the corresponding time interval. 
15 20 
2,14 ± 0,22** 2,24 ± 0,17 
2,26 ± 0,18 2,36 ± 0,14** 
2,63 ± 0,07**:j: 2,54±0,09 
1,99 ± 0,13 2,10±0,13 
25 30 
2,18 ± 0,13 2,39 ± 0,12 
2,40±0,13 2,32 ± 0,16 
2,60±0,07:j: 2,63 ±0,04 
2,11±0,14 2,07 ±0,11 
(m1 0/100 ml solution) 
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then discontinuing oxygenation (e.g. to administer the initial 
dose of cardioplegia), the oxygen content of ST (exposed to 
the atmosphere but still kept in ice) did not decrease signifi-
cantly during the subsequent 120 minutes before subsequent 
doses of cardioplegia). In addition, the final pH of ST 
(pH 7,06 at l0°C) was also maintained at this previously 
determined optimal value.9 Therefore, the more complex 
recirculation system for oxygenating crystalloid cardio-
plegia does not appear to be necessary. 
If a solution is fully saturated with a gas at a low tem-
perature, rewarming of the solution results in the gas com-
ing out of the now supersaturated solution as bubbles. In the 
clinical situation, cardioplegic solution contained in the 
cardioplegic delivery line rewarms to the prevailing theatre 
environment temperature of I 9°C - 24 °C, in the period 
between each reinfusion of cardioplegia. If gaseous emboli 
are formed, they would be harmful to the myocardium if 
infused with subsequent doses of cardioplegia. Therefore, if 
a crystalloid cardioplegic solution is maximally oxygenated 
the delivery system should incorporate a means of removing 
these bubbles before successive reinfusions. Bubbles can 
be removed by either a microfilter (CAS-filter; American 
Bentley, Irvine, California, USA) inserted immediately 
before the ascending aorta or alternatively the 'warm cardio-
plegic solution containing gaseous emboli in the line' can be 
removed through an aortic vent, before administering each 
subsequent reinfusion. Hearse et a/.' 3 advise routine use of 
an 0,8 11ffi microfilter in order to ensure removal of poten-
tially harmful microparticles, contained in the majority of 
crystalloid cardioplegic solutions'3 as well as microbubbles. 
However, as there will always be a potential site for bubble 
formation in the short length of tubing connecting the filter 
to the aorta, the use of only a microfilter to prevent infusion 
of formed microbubbles will not be 100% effective. In con-
trast, venting the cardioplegic solution contained in the 
delivery line leading to the operating table to waste before 
each reinfusion, removes all bubbles and also removes 
cardioplegic solution that has potentially rewarmed after the 
previous dose of cardioplegia. This volume of cardioplegia 
could, depending upon the patient's weight, be a significant 
percentage of the next dose of cardioplegia. Infusion of 
warm cardioplegia would itself decrease the protective 
effect of multidose cardioplegia. However, this method 
requires a special cardioplegic delivery cannula (Aortic root 
cannula with vent line, 12GA: DLP, Grand Rapids, 
Michigan, USA), as well as the removal/ reapplication of 
appropriate clamps before and after each bolus of cardio-
plegia. Nevertheless, one should consider using both of 
these methods routinely when administering oxygenated 
crystalloid cardioplegia. In addition, an 0,2 11ffi bacterial fil-
ter (Pall Biomedical Products Corporation, Glen Grove, 
New York, USA) should be interposed in the 95% 0, 5% 
C02 gas line to prevent possible contamination of the solu-
tion. 
Alternatively, if the cardioplegic solution is oxygenated at 
a temperature equal to or higher than it is likely to be 
rewarmed to, the solution would not become supersaturated 
and therefore gas bubbles would not form. Thus, if the 
cardioplegic solution is oxygenated at room temperature and 
only then cooled to 4°C before infusion, the tendency for 
subsequent bubble formation would be diminished. 
However, oxygenating at room temperature ( I9°C - 24 °C) 
produces an oxygen content of only 2,1 ml 0/100 ml solu-
tion, which is 60% of the maximal obtainable oxygen con-
tent, and also does not induce a shift in pH (pH 7,27; cor-
rected to l0°C) to the previously determined optimal value 
(pH 7,0 at 10°C) for oxygenated ST.9 Whether an oxygen 
content of 2, I ml 0/100 ml solution will produce equivalent 
beneficial effects, as previously shown with maximal 
hypothermic (4°C- l0°C) oxygenated cardioplegic solutions 
(oxygen content 3,0 - 4,0 vol %);·7•9 would still have to be 
determined. As yet we can only postulate that this 'submaxi-
mal' oxygen content might be sufficient, since in an isolated 
rat heart model we previously showed that only approxi-
mately 50% of available oxygen is in fact taken up upon 
each reinfusion of a well oxygenated (Po, ± 550 mmHg at 
l0°C) cardioplegic solution! Oxygen dissolved in solution is 
released in a linear fashion, and theoretically all contained 
oxygen is available to the myocyte.7 Furthermore, lower oxy-
gen contents might be beneficial since high partial pressure 
of oxygen can increase the formation of oxygen free 
radicals,' 5 which are potentially harmful to the myocardium. 
However, other studies have shown that oxygen contents that 
are lower than those obtained by oxygenating cardioplegic 
solutions with 95% 0,, 5% CO, at 20°C are associated with 
diminished myocardial protection. 14 
Other alternative techniques that have been proposed in 
order to obtain high cardioplegic solution oxygen contents 
include overnight cold pressurisation of the solution with 
oxygen, after displacement of nitrogen by prior warming of 
the solution.'6 However, the sterility 'seal' of the vacolitre 
would have been broached for more than 12 hours at the time 
of use,. and this would therefore be a point of concern. 
Alternatively, Daggett'7 suggested that the amount of oxygen 
dissolved in solution could be increased by hyperbaric 
oxygenation; a 15 em H,O PEEP bottle is connected to the 
vent of the container in which the cardioplegic solution is 
oxygenated. We have not evaluated either of these methods. 
In conclusion, simple oxygenation of cold (4°C) St 
Thomas' Hospital No. 2 cardioplegic solution with 95% 0 2, 
5% CO, at 1,0 1/min in its original 1 litre glass vacolitre is as 
effective as more complex hypothermic recirculation oxy-
genating delivery systems, with respect to oxygen content. 
However, with both of these methods measures should be 
taken to ensure that gaseous emboli formed in the cardio-
plegic delivery line are not infused into the coronary circula-
tion, with subsequent doses of cardioplegia. 
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ABSTRACT 
Profound cardiac hypothermia (10°C - 15°C) is an essential component of most techniques used to provide 
myocardial protection when the aorta is cross-clamped during open heart surgery. cardiac hypothermia is 
induced and maintained primarily by infusing cold cardioplegic solutions into the heart. We evaluated 
whether crystalloid cardioplegic delivery systems do indeed deliver the solution to the heart at a 
temperature of less than 6°C. 
crystalloid·cardioplegic solutions stored in a standard fridge are often too warm (11.1 ± 0.6°C). 
Therefore, solutions stored in a fridge should additionally be immersed in ice for at least 30 min before 
use, to ensure a sufficiently low temperature (3.0 ± 0.6°C1 p < 0.01). Alternatively, if cardioplegic 
solutions are stored at room temperature then a cooling mechanism must be used in the delivery system. 
However, a cooling coil immersed in ice may not be adequate at cardioplegic flow rates greater than 200 
ml I min (p < 0.01). 
In addition, cardioplegic solution contained in the delivery lines leading to the heart rewarms towards 
ambient room temperature (19°C - 23°C) during the interval (10 min - 30 min) in between each reinfusion 
of cardioplegia (14.1 ± 0.8°C and 20.1 ± 0.6°C respectively, p < 0.01).· This volume of "warm 
cardioplegia" (temperature of greater than 6°C) subsequently infused varied from 66 ± 7 ml to 129 ± 4 ml, 
and was proportional to thetotal volume of cardioplegia contained in the lines (72- 105 ml). Infusion 
of a significant percentage of "warm cardioplegia" (16 ± 2% to 51 ± 1% of the total dose of cardioplegic 
solution reinfused), would decrease the efficacy of myocardial protection. 
INTRODUCTION 
Cardiac surgeons rely primarily on two fundamental principles to ensure adequate intra-
operative myocardial protection during open heart surgery whilst the aorta is cross 
clamped; uniform delivery of a cardioplegic solution throughout the myocardium, and 
profound cardiac hypothermia (1,2)_ Energy demands are thus drastically diminished 
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during the ischaemic aortic cross clamp period. Optimal protection is attained by 
arresting the myocardium in diastole with a cold cardioplegic solution, and maintaining 
the in situ heart at a temperature of 10°C- 15°C (3)_ Although myocardial temperatures 
should be kept as low as possible though not below zero (4), in the clinical situation it is 
difficult to maintain the nonisolated heart at temperatures below IQOC (5). 
Noncoronary collateral flow, surgical handling, the theater environment (room 
temperature, operating room lights) and conducted heat from adjacent organs (liver, 
descending thoracic aorta) constantly rewarms the myocardium (6). Therefore, the 
majority of cardiac surgeons reinfuse cold cardioplegic solution intermittently 
throughout the aortic cross clamp period. This not only maintains cardioplegic arrest, 
but is also the primary means of maintaining the heart hypothermic. Nevertheless, other 
modalities (systemic and topical hypothermia) are also used to assist in keeping the 
myocardial temperature below 15°C whilst the aorta is cross clamped (4,7), 
Systemic hypothermia implies cooling the entire body to a temperature of 22oc- 32°C 
after commencing cardiopulmonary bypass, by means of a heat exchanger in the 
extracorporeal circulation. Energy requirements for all organs are thus diminished, and 
cardiopulmonary bypass is safer as the period the brain can withstand total circulatory 
arrest (without sustaining neurological dysfunction) is prolonged from 3 min at 37°C to 
45 min at 18°C (8), should the need arise. However, of specific importance to the 
cardiac surgeon is that the gradient along which the myocardium is constantly being 
rewarmed by adjacent organs is decreased, and flow rates can be decreased thus 
diminishing noncoronary collateral flow. Nevertheless, prolonging cardiopulmonary 
bypass because of the time required for induction and reversal of systemic hypothermia 
can be harmful. Topical hypothermia improves epicardial cooling and reduces 
conducted heat, but can also be harmful; phrenic nerve palsy, increased postoperative 
respiratory complications, and epicardial frostbite injury. Thus, the infusion of cold 
cardioplegic solution remains the most important means of producing and maintaining 
uniforllltmyocardial hypothermia, in addition to producing diastolic cardiac arrest 
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Hypothermia is an essential synergistic factor when crystalloid cardioplegic solutions are 
used. The majority of cardioplegic solutions rely on a high potassium concentration to 
induce diastolic arrest but too high a concentration (greater than 20 mmol/L) can be 
detrimental, as this concentration of potassium then promotes intracellular calcium 
influx which is harmful during ischaemia (9,10). However, if one assumes that the 
myocardium will always be maintained hypothermic (10°C- 15°C), then the lowest. 
possible concentration of potassium can be used, as hypothermia potentiates potassium 
arrest by itself inducing partial membrane depolarization ( 11,12). Therefore, it is 
essential that optimally formulated crystalloid cardioplegic'solutions should be infused 
into the heart at temperatures of 4°C- 6°C. This is achieved by either maintaining the 
vacolitre of cardioplegia below 4°C in ice, before and in between each multidose 
reinfusion, or alternatively the delivery system must include a device that cools the 
solution; viz a heat exchanger or cooling coil immersed in ice .. We determined whether 
methods of infusing crystalloid cardioplegic solutions do indeed deliver the solution to 
the myocardium at the correct temperature, that is less than 6°C. 
We also evaluated the degree and amount of cardioplegic solution contained in the 
delivery line leading to the heart, that rewarms towards ambient theater temperature 
(19°C- 23°C) in between each reinfusion of cardioplegia. The efficacy of multidose 
cardioplegia is diminished if a significant volume of warm cardioplegia is inadvertently 
infused with subsequent reinfusions of cardioplegia. 
METHODS 
A) Assessment of means used to ensure a cardioplegic solution temperature of less than 
_GQC. 
Two primary means of delivering crystalloid cardioplegic solutions were evaluated:-
i) Infusion of cardioplegic solutions stored in the fridge. 
The temperature of cold StThomas' Hospital No 2 cardioplegic solution (Sabax 
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Laboratories; Aeroton, Johannesburg) stored in a fridge can vary considerably. 
The cardioplegic solution removed from the fridge was th.erefore additionally 
immersed in ice for 30 min (to ensure a temperature of less than 4ot) prior to 
infusion. We also evaluated whether this cold cardioplegic .solution (less than 
4°C) should thereafter in addition be infused by a single pass .through a cooling 
coil (1/4", 65 ml aluminium coil: American Bentley; Irvine, California, USA) 
immersed in ice. 
ii) Infusion of warm cardioplegia stored at room temperature. 
The cardioplegic solution was either infused after a single pass through the 
American Bentley cooling coil, or through a 3/16", 150 ml plastic coil (Sarns: 3M 
Health Care; Ann Arbor, Michigan, USA). 
The temperature of the "delivered" cardioplegic solution was measured with ari 
electronic temperature probe (B-A-Therm-A Bentley OXYG; American Bentley), 
inserted into the aortic end of the cardioplegic delivery line, 0.5 min and 1 min after 
starting the infusion which was kept at a constant flow rate by an extracorporeal roller 
pump (Sarns: 3M Health Care). In order to assess the efficiency Of each system this was 
repeated at different flow rates:- 100 ml!min, 200 ml/min, 300 mllmin, 400 ml/min, and 
500 ml/min. N = 6 for each flow rate, and thus N == 12 for recorded observations at 
each flow rate. 
B) Assessment of volume of "warm cardioplegic solution" infused during subsequent 
reinfusions of cardioplegia. 
The cardioplegic solution delivery lines were positioned similar to the clinical situation, 
~xposed to the operating theater lights and ambient temperature. Cold (less than 4°C) 
cardioplegic solution was infused through a 1/4", 3.0 meter, cardioplegic delivery set 
incorporating a CAS-filter (American Bentley), and the "delivered temperature" of the 
solution at the "aortic end" was recorded every 10 seconds. 
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The clinical situation was simulated by initially flushing the cardioplegic solution 
through the lines immediately before infusion of an "induction dose" of cardioplegia. An 
appropriate interval was then designated before two reinfusions of cardioplegia, without 
removal I flushing of the cardioplegic solution contained in the delivery lines. Each 
"dose" of cardioplegia was infused for one minute at the predetermined rate of delivery. 
The volume of infused "warm cardioplegic" solution having a temperature of greater 
than 6°C was then calculated. 
Variables examined were:-
i) The effect of increasing the time interval in between each multidose reinfusion of 
cardioplegia, from 10 minto 30 min. 
ii) The effect of increasing the infusion flow rate of the cardioplegic solution from 250 
mllmin to 400 mllmin. Hence, each "dose" of cardioplegia was either 250 ml or 400 ml 
iii) The effect of decreasing the diameter of the tubing of the cardioplegic infusion set, 
from 1 14" to 3 /16". The volume of cardioplegic solution contained in the 1 14" set was 
105 ml, and in the 3 I 16" set 72 ml. 
STATISTICAL ANALYSIS 
Means and standard errors of means were analysed by the Anova one or two way 
analysis of variance, with pair wise comparisons of means by acceptance intervals with 
the f-test Statistical significance was taken asp < 0.05. 
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RESULTS 
A) Assessment of means used to ensure a cardioplegic solution temperature of less than 
.6~ <Figure 1). 
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Cardioplegic solution removed from the fridge was infused, after being kept in ice for 30 min (A), or in addition infused through a co
oling coil immersed in ice (B) to ensure 
a temperature ofless than 6°C. Ahematively. cardioplegic solution that was initially at room temperature ( 19oc- 23oq was infused
 through either an American Bentley 
(C) or Sams (D) cooling coil immersed in ice. The temperature of the cardioplegic solution at the "aortic end" of the cardioplegic 
delivery line 'IVas measured 0.5 and 1.0 min 
after commencing the infusion, at different flow rates. The recommended temperature below which cold cry
staDoid cardioplegia should be infused (60C) is indicated (solid 
straight line). Means and standard errors of means (vertical bars) for N = 12 observations are presented. 
• • p < 0.01 compared to A at similar flow rate. 
• - p < 0.01 compared to 200 ml/ min flow rate. 
i) Infusion of cardioplegic solutions stored in the fridge. 
Cardioplegic solutions removed from the fridge (stored for a minimum period of 12 hr) 
had temperatures of 11.1 ± 0.6°C. However, after immersion in ice for 30 min the 
temperature decreased to 3.0 ± 0.6°C, p < 0.01. When no additional cooling method 
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was used the "delivered temperature" of the cardioplegic solution was 4.2 ± 0.3°C, if 
infused at a rate of 200 mllmin. This did not vary significantly when the flow rate was 
increased to 500 mllmin (3.4 ± O.JOC). 
Alternatively, cold cardioplegic solution removed from the fridge and immersed in ice 
(temperature 5. 7 ± 0.6°C) was in addition infused through a cooling coil immersed in 
ice. The "delivered temperature" was 0.8 ± 0.2°C at 200 ml/rnin flow rate, which was 
lower than the previous method (p < 0.01), but at 500 mllmin the "delivered 
temperature" was 2.9 ± 0.5°C, which was no different to the previous method. 
ii) Infusion of cardioplegic solutions stored at room temperature. 
In contrast, if the cardioplegic solution was initially at room temperature (20 ± 0.4°C) 
and cooling was only by means of a single pass through a cooling coil immersed in ice 
(American Bentley), then the "delivered temperature" varied significantly with flow rate. 
At an infusion flow rate of 200 ml I min the "delivered temperature" of the cardioplegic 
solution was 4.5 ± 0.5°C, which was no different to infusion of cold (less than 4°C) 
cardioplegia without ancillary cooling mechanisms. However, at a higher flow rate of 
500 ml/min the "delivered temperature" increased to 8.6 ± 1.2°C (p < 0.01 compared to 
200 ml/min flow rate), which was not only higher than the aforementioned method (p < 
0.01), but also greater than the recommended temperature for delivering crystalloid 
cardioplegic solutions ( 6°C). 
The plastic cooling coil (Sarns) was larger and thus more efficient; at 200 mllmin the 
delivered temperature was 0.5 ± 0.2°C, and at500 ml/minit was 4.1 ± 0.7°C (p < 0.01, 
compared to the American Bentley coil). The "delivered temperature" produced by the 
Sarns coil at 500 ml /min was no different to the values obtained previously with the 
infusion of the aforementioned cold (less than 4°C) cardioplegia, when no additional 
cooling mechanism was used. 
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B) Assessment of volume of "warm cardioplegic solution" infused during subsequent 
reinfusions of cardioplegia. 
Cardioplegic solutions were stored for at least 24 hr in either of two fridges. The mean 
temperature of the solutions when removed from the fridges were 14.9 ± 0.4oc and 11.5 
± 0. 7°C respectively. Therefore, in order to ensure the correct infusion temperature 
( 4 °C - 6°C), the vacolitre of cardioplegia was then immersed in a bucket of ice for at 
least 30 min prior to each experiment Thereafter, the temperature of the cardioplegic 
solutions were consistently below 4°C irrespective of the fridge in which stored, viz 2.6 
± 0.5°C. 
The cardioplegic delivery lines were flushed immediately before administering the 
"induction dose" of cardioplegia. This ensured that the "induction dose" was infused at a 
temperature of less than 6°C. However, after infusion of this "induction dose" the 
cardioplegic solution contained in the delivery lines rewarmed towards ambient room 
temperature (Figure 2). This resulted in a significant volume of "warm cardioplegia" (66 
- 129 ml) being initially infused with each subsequent reinfusion of cardioplegia. This 
was effected by the following variables:-
i) Effect of time interval, in between each reinfusion of cardioplegia (Figure 2). 
An "induction dose" of cardioplegic solution at a temperature of 2.6 ± 0.5°C was infused 
through the 1/4", 3.0 m set (volume 105 ml), at a rate of250 ml/min for one minute. 
Thereafter, during the following 10 minute interval the temperature of the cardioplegic 
solution in the delivery line increased to 13.1 ± 0.9°C (p < 0.01), and upon infusion of a 
second "dose" of cardioplegia (250 mlY a volume of 117 ± 21 ml was infused at a 
temperature of greater than 6°C. This was 46.8 ± 8.4% of the 250 m1 dose of 
cardioplegia If the intervening interval between doses was increased to 30 min, then the 
solution rewarmed to a higher temperature of 19.5 ± 0.8°C (p < 0.01), which was no 
different to ambient room temperature (21.7 ± 0.3°C). The volume of "warm 
cardioplegic solution" subsequently infused was 125 ± 1 m1, which corresponded to 50 ± 
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0.4% of the 250 ml dose, and was no different to the volume of "warm cardioplegia" 
infused after a 10 min interval. 
Similar intervals were allowed, prior to administering another multidose of cardioplegia, 
and similar temperatures and volumes of "warm cardioplegia" were again recorded 
(Figure 2). 
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The temperature of the cardioplegic solution at the 'aortic end' of. a 1/4', 3.0 m (plus CAS-filter) cardioplegic delivery line was measured during infusion of cardioplegia. 
Cardioplegic solution removed from the fridge (F) was kept in ice for 30 min (I) to ensure a temperature of less than 4°C. An 'induction dose' was infused (250 mllmin for 
1 min) immediately after flushing the lines. Thereafter, a second and third multidose of cardioplegia (250 ml/min for I miil) was iilfused-after either a 10 miil (A) or 30 min 
(B) interval (lnt). Means and standard errors of means (vertical bars) for N = 6 observations are presented. The recommended temperature at which crystalloid 
cardioplegic solutions should be infused (6°C), and the temperature range of operating theaters is iildicated. 
•- p < 0.01 compared to A at corresponding time. ·- p < 0.05 compared to A at corresponding time. 
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ii) Rate of Administration. 
The cardioplegic solution was again infused through the 1 /4", 3.0 m, 105 ml set, an 
interval of 10 min was allowed in between each reinfusion, but the solution was now 
infused at a rate of 400 ml/min. Again during the 10 min interval the cardioplegic 
solution in the line rewarmed to a similar temperature 15.6 ± 0.4oc (Table 1).· The 
volume of "warm cardioplegic solution" then infused was also similar Ill ± 9 ml 
However, because of the higher volume infused ( 400 ml) this formed only 28 ± 2% of 
the dose, a smaller percentage compared to the 250 ml dose (p < 0.01). 
Table I 
VOLUME OF WARM CARDIOPLEGIC SOLUTION INFUSED WITH 
SUBSEQUENT REINFUSIONS OF CARDIOPLEGIA .. 
VARIABLES •. 
Cardioplegic delivery set: 
Time interval in between each reinfusion (min): 
Flow rate of cardioplegia infused (mljmin): 
Volume of cardioplegia contained in 
the delivery line (ml): 
Temperature of cardioplegic solution in ice prior 
to each reinfusion (0c): 
EFFECT OF VARIABLES. 
A 
1/4" 
30 
250 
105 
0.5 ± 0.5 
B c 
1/4" 1/4" 
10 10 
250 400 
105 105 
0.9 ± 0.2 0.4 ± 0.3 
Temperature of cardioplegia at aortic end of 
delivery line before each reinfusion (°C): 20.1a ± 0.6 14.1 ± 0.8 ± 15.6 0.4 
Volume of cardioplegia reinfused which had a 
temperature of greater than 6°C (ml): 129 ± 4 
Expressed as percentage of total volume infused: 1% ± 1% 
Expressed as percentage of volume of contained 
in delivery line: 122% ± 3% 
Legend: 
117 ± 13 111 ± 9 
47% ± 5% 28%b ± 2% 
112% ± 12% 106% ± 9% 
A 3.0 m cardioplegic infusion set consisting of either 1/4' or 3/16' tubing, plus CAS-fiher was evaluated. The effect of alteri
ng 
the time interval (10 min or 30 min) in between each reinfusion of cardioplegia, or increasing the dose of cardioplegia (250 
ml/min or 400 ml/min for 1 min), on the amount of "warm cardioplegic solution" subsequently infused was assessed. Means and 
sundard errors of means for N = 12 observations are presented. 
a. p < 0.01 comparing A with B, b. p < 0.01 comparing C with B c • p < 0.01 comparing D with C 
D 
3/16" 
10 
400 
72 
1.1 ± 0.4 
16.2 ± 0.4 
16%c ± 2% 
91.0% ± 10% 
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iii) Volume of solution contained in the cardioplegic delivery line. 
The cardioplegic solution was now infused through the 3/16", 3.0 m set which had a 
volume of 72 ml, at a rate of 400 ml/ min. The interval in between each reinfusion of 
cardioplegia was limited to 10 min, and as before the solution rewarmed to 16.2 ± 0.4°C 
during this period. However, the total volume of warm cardioplegia now reinfused was · 
less, 66 ± 7 ml (p < 0.01), which was only 16 ± 2% of the "dose" infused, p < 0.01 
(Table I). 
DISCUSSION 
If crystalloid cardioplegic solutions are used to provide intra-operative myocardial 
protection, these solutions should be infused into the heart at temperatures of 4°C- 6°C 
(2,11)_ We have shown thatif the temperature of the vacolitre of cardioplegia is less 
than 4°C, then simple infusion without any accessory cooling coils will deliver the 
cardioplegic solution at the recommended temperature over a flow rate of 100-500 
ml/min. However, the temperature of a vaco1itre of cardioplegic solution removed from 
a fridge can vary significantly, depending upon fridge temperature, duration of storage, . 
or presence of additional insulating packaging material ( eg. manufacturer's surrounding 
plastic bag). Therefore, either the cardioplegic solution that has been stored in the 
fridge should additionally be immersed in ice fora minimum period of30 min prior to 
use, or a cooling coil should be used in the cardioplegic delivery circuit, in order to 
ensure infusion at the correct temperature. 
If crystalloid cardioplegic solutions stored at room temperature are used, then it is 
essential that some method of cooling is provided prior to infusion. We have 
demonstrated that if cooling is by a single pass through an ice immersed cooling coil, this 
might not provide sufficient cooling at higher flow rates. This is a manifestation of the 
efficiency 9f the cooling coil or heat exchanger. In the clinical situation, the usual flow 
rate for prograde cardioplegia delivery is 250-400 ml/min, and may be higher if there is 
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any minor aortic incompetence. Therefore, a larger cooling coil (eg. Sarns) or more 
efficient heat exchanger would be necessary, in order to consistently ensure a "delivered 
temperature" of less than 6oc. 
Although the vacolitre of cardioplegic solution can be kept iri ice, in between each 
reinfusion of cardioplegia, the solution contained in the delivery line leading to the heart 
will rewarm towards ambient room temperature ( 19°C - 23 oc). We have shown that 
within a 10 minute interval, the cardioplegic solution contained in the delivery line 
rewarms significantly, and that by 30 min approximates room temperature. This in turn 
implies that with subsequent reinfusions of cardioplegia, a significant volume of "warm 
cardioplegia" (i.e. cardioplegia with a temperature of greater than 6°C) would be 
infused. This may be as much as 50% of the total dose of cardioplegic solution 
reinfused. This percentage of "warm cardioplegia" reinfused was similar whether there 
was a 10 min or 30 min interval in between reinfusions, and is dependant upon the 
volume of cardioplegic solution contained in the delivery line, and the total dose 
reinfused each time. This is especially important in paediatric cardiac surgery where 
small volumes (5- 10 ml/kg) of cardioplegic solution are reinfused. If the dose of 
cardioplegia is equal or less than the volume of cardioplegic solution contained in the 
delivery line, then it is possible that the entire dose reinfused with each subsequent dose 
could be at temperatures approximating 20°C as opposed to less than 6°c: 
In order to diminish this potentially detrimental rein fusion of "warm cardioplegia", the 
volume of cardioplegic solution that rewarms to room temperature should be reduced as 
much as possible. Thus the cardioplegic delivery lines should be short, narrow diameter 
tubing (3 I 16"), but should also not limit flow. In addition, to further diminish the 
potential volume of cardioplegic solution that rewarms, either a cooling coil can be 
incorporated in the line as close as possible to the operating table, or a recirculation type 
delivery system could be used. The more complex continuous hypothermic recirculation 
system will not only ensure that the cardioplegic solution is always at a sufficiently low 
temperature prior to infusion, but can also be designed to limit "dead space" where the 
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solution could rewarm. Alternatively, the "warm cardioplegic solution" contained in the 
delivery line should be vented to waste before each reinfusion; by using a special aortic 
cardioplegic infusion catheter (aortic root cannula with vent- DLP; Grand Rapids, 
Michigan, USA). 
In conclusion, crystalloid cardioplegic solutions should be oxygenated (13,14), delivered 
through an 0.8 u filter (15), at a temperature of 4°C- 6°C, and sufficient pressure 
(greater than 50 mm Hg, but less than 150 mm Hg (16)) for prograde infusion, to ensure · 
optimal myocardial preservation. If retrograde cardioplegia is to be used, to ensure · 
uniform delivery in the presence of critical coronary stenoses ( 11); then apart from a 
maximum retrograde perfusion pressure of 40 mm Hg (measured in the coronary sinus) 
similar conditions would apply ( 17). Crystalloid cardioplegic solutions stored in a fridge 
may not necessarily be at a sufficiently cold temperature. Therefore, it is advisable that 
they be additionally immersed in ice for 30 min prior to use, to ensure a vacolitre 
temperature of less than 4°C. The delivered temperature of the cardioplegic solution 
will then be acceptable (4°C- 6°C) over the flow range of 100-500 ml/min. However, 
a significant volume of cardioplegic solution contained in the delivery line rewarms to 
ambient room temperature (19°C -23°C) in the interval (10- 30 min) in between each 
reinfusion of cardioplegia. This volume of "warm cardioplegia" would diminish the 
efficacy of intraoperative myocardial protection if infused, and should therefore be 
limited by the design of the administration set, or alternatively vented to waste prior to 
each reinfusion of cardioplegic solution. 
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.A..PPEN.D::CX B-.2.. 
IN VIVO PRIMATE STUDY: THE EFFECT OF ADDING GLUCOSE 
TO THE STTHOMAS' CARDIOPLEGIC SOLUTION 
INTRODUCTION 
We previously showed that the addition of glucose to the StThomas' Hospital No 2 
cardioplegic solution was beneficial in the isolated rat heart model (see Appendix A-2). 
However, glucose was only beneficial in the concentration range 7- 11 mmol/L and only 
if multidose reinfusions of cardioplegic solution were provided, in order to wash out end 
products of metabolism. 
This study was therefore undertaken to investigate whether the addition of glucose ( 10 
mmol/L) to the StThomas' car.dioplegic solution was also beneficial in the non-human 
primate model. 
MATERIALS AND METHODS 
The in vivo primate model as described in Chapter 2 was used. The chacma baboon 
(Papio ursinus) was selected because of its close evolutionary relationship to man. 
Animals weighing 15 - 24 kg were used, and six experiments were performed in each 
group. 
Experimental Protocol 
The animals were anaesthetised, intubated, and ventilated. A median sternotomy was 
performed and the heart cannulated for cardiopulmonary bypass. Control 
haemodynamic and metabolic variables were measured prior to commencing 
cardiopulmonary bypass. Systemic temperature was then lowered and maintained at 
26oc, the aorta was cross-clamped and cold (4°C) cardioplegic solution (15 ml/kg; 
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Table I) was infused. In addition, intermittent iced saline was used for topical 
hypothermia, and maintenance cardioplegia (100 ml) was reinfused every 30 minutes 
throughout a 3-hour ischaemic cross-clamp period. Additional ventricular biopsies were 
taken prior to the release of the aortic cross-clamp. A 15-minute normothermic 
reperfusion period followed, and the animals were then weaned from cardiopulmonary 
bypass and postischaemic haemodynamic and metabolic variables measured 5 and 30 
minutes after termination of cardiopulmonary bypass. 
The dose of cardioplegic solution administered in these experiments approximated the 
clinical situation. On induction; 15 ml/kg body weight or 2.2-2.6 ml/gm heart weight, 
and with multidose reinfusions 100 ml; 4.2- 6. 7 mllkg body weight or 0.6- 1.14 ml/gm 
heart weight, was administered. 
Table I 
COMPOSITION OF CARDIOPLEGIC SOLUTIONS 
uol/L 
Glucose 
Os1olarity (IOsm/L) 
Osmolality (IOS1jkg H20) 
pH (10°C) 
Legend: 
st Tho1as' No 2 
120 
16 
10 
1.2 
16 
323.6 
293 
7.4 
st Tho1as' + Glucose 
120 
16 
10 
1.2 
16 
10 
333.6 
304 
7.4 
Osmolarity was calculated assuming 100% ionic dissociation, whereas osmolality was measured by freezing point depressi
on with 
a cryoscopic osmometer (Osmomat 030; Gonotec, Berlin, Germany). 
Expression of results 
Values of functional parameters obtained during the postischaemic working period were 
expressed as a percentage of each individual preischaemic control value. Tissue high 
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energy phosphate content was expressed in absolute values (umol/g wet weight). 
Results were then presented as percentage means and standard errors of percentage 
means. 
Statistics 
Statistical test used was the two way analysis of variance (ANOV A-2), and if overall 
statistical significance was obtained pair wise comparisons were then done by acceptance 
intervals of means with theftest Statistical significance was taken asp< 0.05. 
RESULTS 
Postischaemic recovery of mechanical function 
The preischaemic control values of both groups were similar, and are shown in Table II. 
The addition of glucose (10 mmol/L) to the StThomas' Hospital No 2 cardioplegic 
solution did not alter the postischaemic recovery at 5-min after termination of 
cardiopulmonary bypass (Table II). However, 30-min after termination of 
cardiopulmonary bypass, the presence of glucose in the cardioplegic solution was 
associated with a significant decrease in the postischaemic recovery of both CI, SVI and 
SWI (p < 0.05; Table II). 
424 U OVon OppeU PhD Thesis; University of Cape Town, 1992 
Table II 
POSTISCHAEMIC MECHANICAL RECOVERY 
cardiac Index 
Preischaemic 
(L/minjm2) 
% Recovery 5-lin 
% Recovery 30-min 
Stroke Volume Index 
Preischaemic 
(mljbeatjm2) 
% Recovery 5-min 
% Recovery 30-min 
Left Ventricular dp/dt 
Preischaemic 
(mm Hgjsec) 
% Recovery 5-Iin 
·% Recovery 30-Jin 
stroke Work Index 
Preischaemic 
(gm.mjbeatjm2) 
% Recovery 5-min 
% Recovery 30-lin 
Legend: 
st Thotas' Ho 2 
H = 6 
3.18 ± 0.54 
99.79 ± 15.19 
93.55 ± 11.05 
28.09 ± 4.13 
73.98 ± 12.64 
93.17 ± 10.13 
1044.4 ± 61.0 
118.2 ± 16.3 
103.4 ± 9.8 
43.58 ± 6.90 
75.50 ± 18.55 
93.10 ± 13.56 
st 'rhomas I + Glucose 
H = 6 
3.33 ± 0.24 
77.08 ± 6.25 
60.8 ± 8.86a 
31.5 ± 3.17 
71.58 ± 6.59 
60.02 ± 8.97a 
961.4 ± 69.8 
107.0 ± 16.7 
82.3 ± 10.7 
47.42 ± 4.76 
73.38 ± 14.84 
52.27 ± 12.11a 
Animals were subjected to a 3-hour hypothermic cross-<:lamp period protected with multidose reinfusions of indicated 
cardioplegic solutions. H aemodynamic variables were measured at a left atrial pressure of 5 mm Hg. Postis
chaemic recovery is 
expressed as mean percentage recoveries of each individual preiscbaemic value, and standard errors of p
ercentage aieans. 
a· p <·0.05 compared to StThomas No 2. 
Left ventricular function curves (CI & SWI) were determined both prior to and after the 
ischaemic cross-clamp period (30-minute post cardiopulmonary bypass), by measuring 
haemodynamic variables at different left atrial preloads. Although the preischaemic 
control values at a left atrial pressure of 5 mm Hg were similar between the two groups 
(StThomas' with or without glucose), some of the preischaemic control values for the St 
Thomas' plus glucose group were greater at higher left atrial filling pressures (Table III). 
Nevertheless, the percentage recovery of both CI and SWIat the majority of the left 
Myocardial protection during cardiac surgery; Appendix 8-1 UOVooOppell 425 
atrial filling pressures recorded, was significantly lower if glucose was added to the St 
Thomas' cardioplegic solution (p < 0.05). 
Table III 
LEFT VENTRICULAR FUNCTION CURVE 
LAP 5 
CI (L/minjm2) 
st Tho1as' 
Pre 3.18 ± 0.54 
% Rec 93.6 ± 11.1 
St Thotas' plus Glucose 
10 
3.62 ± 0.38 
81.5 ± 8.5 
15 
4.07 ± 0.43 
78.6 ± 6.9 
Pre 3.33 ± 0.24 4.45 ± 0.21a 5.30 ± 0.36a 
% Rec 60.8 ± 8.9b 56.8 ± 6.4a 41.9 ± 6.7b 
Data noraalized to the integrated preischaemic control curve 
Cont. 3.25 ± 0.28 4.04 ± 0.24 4;69 ± 0.33 
ST 3.04 ± 0.36 3.29 ± 0.34 3.68 ± 0.32c 
ST+G · 1.98 ± 0.29de 2.29·± 0.26de 1.96 ± 0.31df 
SWI (gm·mjbeatjm2) 
st Thomas' 
Pre 43.58 ± 6.90 
% Rec 93.10 ± 13.56 
st Thomas' pius Glucose 
Pre 47.42 ± 4.76 
% Rec 52.27 ± 12.1b 
53.74 ± 4.28 
74.87 ± 9.02 
63.01 ± 5.34 
57.59 ± 9;05 
55.61 ± 4.43 
76.29 ± 8.68 
74.16 ± 9.28a 
43.14 ± 7.05a 
Data normalized to the integrated preischaemic control curve 
cont. 45.50 ± 4.04 58.38 ± 3.55 64.88 ± 5.65 
ST 42.36 ± 6.17 43.71 ± 5.26c 49.50 ± 5.63c 
ST+G 23.78 ± 5.51df 33.62 ± 5.28d 27.99 ± 4.6df 
Legend: 
20 (mm Hg) 
4.38 ± 0.52 
59.9 ± 6.1 
4.84 ± 0.32 
44.4 ± 5.2 
4.61 ± 0.30 
2.76 ± 0.28d 
d 2.04 ± 0.24 
56.73 ± 4.41 
56.89 ± 5.44 
67.21 ± 8.38 
42.16 ± 5.24 
61.97 ± 4. 78 
d 35.25 ± 3.37 
26.·13 ± 3.25d 
A postischaemic left ventricular function curve was obtained 30 min after weaning from cardiopulm~nary bypass at increasing left 
atrial pressures (LAP), and compued to a similar preischaemic curve. Mean percentage Postischaemic recovery (% Rec) was 
calculated from each individual postischaemic and preischaemic ratio. An average preischaemic control function curve (Cont) 
was derived by pooling tbe data from botb curves, and postischaemic function for each group normalized to tliis curve for display . 
purposes. 
ST- StThomas' cardioplegic solution (N = 6); ST+G- ST plus glucose (10 mmol/L) cardioplegicsolution (N = 6) .. 
a- p < 0.05; b- p < 0.01; compared to StThomas', 
c- p < 0.05; d- p < 0.01; compared to Coot, 
e- p < 0.05; f- p < 0.01; compared to ST. 
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These ventricular function curves were normalized for display purposes as described in 
Chapter 2. In summary, the preischaemic control values of both groups were pooled and 
thereafter the percentage recovery of each individual group normalized to this average 
preischaemic control curve. Statistical analysis of this normalized data showed that the 
postischaemic recovery of hearts protected with the St Thomas' cardioplegic solution 
was no different from control preischaemic values at atrial filling pressures of 5- 10 mm 
Hg (Table Ill). However, at higher left atrial filling pressures (greater than 10- 15 mm 
Hg) postischaemic recovery was depressed (p < 0.05). In contrast, postischaemic 
recovery associated with the St Thomas' plus glucose cardioplegia was depressed at all 
left atrial filling pressures compared to the preischaemic control (p < 0.01), and 
recovery was less than that associated with the standard StThomas' Hospital No 2 
cardioplegic solution. 
Post ischaemic recovery of metabolic parameters 
Myocardial A TP content decreased from a preischaemic control value of 2. 98 ± 0.4 
umol/gm wet heart weight to 1.49 ± 0.32 umol/gm at the end of the 3-hour ischaemic 
period (prior to release of the aortic cross-clamp), p < 0.01, when hearts were protected 
with StThomas' Hospital No 2 cardioplegic solution. However, after reperfusion and 
termination of cardiopulmonary bypass the A TP levels had recovered to 2.38 ± 0.27 
umol/gm (p < 0.01). Myocardial CP content showed a similar pattern, p < 0.05 (Table 
IV). In contrast, when hearts were protected with St Thomas' plus glucose cardioplegia 
A TP content at the end of the 3-hour ischaemic period (2.84 ± 0.17 umol/gm) was no 
different from the preischaemic value (2.26 ± 0.39). However, following the release of 
the aortic cross-clamp and after weaning from cardiopulmonary bypass the A TP content 
decreased to 1.62 ± 0.36 umol/gm (p < 0.05). No significant change in CP 
concentrations was detected (Table IV). In addition, no significant difference in tissue 
lactate was detected. 
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Table IV 
METABOLIC PARAMETERS 
Control 
ATP (umoljgm ·Wet heart weight) 
st Tho11as' 
2.98 ± 0.4 
St Thomas 1 plus Glucose 
2.26 ± 0.39 
CP (umoljgm wet heart weight) 
StThomas' 
5.75 ± 0.49 
st Thosas' plus Glucose 
4.04 ± 0.3 
End 
Iscbaemic 
1.49 ± 0.32d 
2.84 ± 0.17b 
2.49 ± 1.86c 
2.49 ± 1.31 
Lactate (umoljgm wet heart weight) 
St Thomas' 
10.92 ± 2.39 
st Thotas'·plus Glucose 
5.28 ± 3.52 
Legend: 
14.66 ± 2.28 
9.30 ± 2.25 
Post 
Ischaemic 
5-lin 
2.38 ± 0.27f 
1.62 ± 0.36e 
5.41 ± 0.88e 
3.55 ± 0.67• 
12.26 ± 3.58 
7.75 ± 2.78 
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Post 
Ischaemic 
30-l!in 
2.67 ± 0.44 
1. 77 ± o.o9a 
5.37 ± 0.74 
3.96 ± 0.36 
8.31 ± 1.76 
6.31 ± 2.06 
Myocardial concentrations of A TP, CP and lactate were measured prior to a 3-bour hypothermic ischaemic period protected with 
multidcnes of either StThomas' (N; 6) or StThomas' plusgluccne (10 mmo1/L; N; 6) cardioplegicsolutions (Control), at the 
end of the iscbaemic period and 5 min and 30 min after weanilig from cardiopulmonary bYI'ass. 
a- p < 0.05; b- p < 0.01; compared to StThomas', 
c- p < 0.05; d -p < 0.01; compared to control, 
e- p < 0.05; f- p < 0.01; compared to End 1scbaemic. 
COMMENT 
The addition of glucose (10 mmol/L) to the StThomas' Hospital No 2 cardioplegic 
solution decreased postischaemic recovery following a 3-hour hypothermic ischaemic 
period protected with multidoses of cardioplegia. Nevertheless, the StThomas' plus 
glucose cardioplegic solution resulted in better preservation of myocardial A TP during 
the ischaemic period_ However, in the postischaemic period ATP content was 
depressed_ This suggests that the presence of glucose in the cardioplegic solution 
augmented A TP production during the ischaemic period, but suppressed A TP 
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production and decreased myocardial function during reperfusion of the postischaemic 
myocardium. 
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APPEN.D..T.X .B-.2 
ISOLATED RAT HEART STUDY: THE EFFECT OF ALTERING THE pH 
OF THE STTHOMAS' CARDIOPLEGIC SOLUTION 
INTRODUCTION 
This study was undertaken as a pilot study to determine the effect of altering the pH of a 
modified StThomas' Hospital No 2 cardioplegic solution on postischaemic mechanical 
recovery. Glucose (11 mmol/L) was included in the cardioplegic solution and pH was 
altered by adding either 1 N HCl or NaOH to the cardioplegic solution. 
MATERIALS AND METHODS 
The isolated perfused working rat heart model as described in Chapter 2 was used. 
Hearts were removed from male Long Evans rats weighing between 250 gm- 350 gm. 
Experimental Protocol 
The aorta was cannulated and Langendorff perfusion with 95% 02 5% C02 gassed 
Krebs Henseleit buffer commenced and maintained for 10 min, prior to conversion to 
the working preparation (left atrial filling pressure 20 em H20, left ventricle afterload 
100 em H20). Haemodynamic variables were measured after 10 minutes of work The 
atrial and aortic cannulae were then closed and ·10 ml cardioplegic solution ( 10°C) was 
infused at a pressure of 80 em H20, and simultaneously the hearts wereplaced into a 
10°C chamber for a 3-hour period ·Of global ischaemia. Multidose reinfusions of 
cardioplegic solution (6 ml) were administered every 30 minutes throughout the 3-hour 
ischaemic period. Hearts were then reperfused at 37°C in the non working Langendorff 
mode for 10 min at 100 em H20, and thereafter switched to the working mode for a 
further 10 min prior to measuring postischaemic functional recovery; 
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Cardioplegic solutions. 
The "control" cardioplegic solution tested was a modified StThomas' Hospital No 2 
cardioplegic solution containing 11.0 mmol/L glucose (pH -7.4). The experimental 
cardioplegic solutions were made up by adding either IN HCI or 1 N NaOHto the St 
Thomas' plus glucose ( 11.0 mmol/L) cardioplegic solution to obtain the indicated pH. 
pH was measured at 37°C with a Radiometer pH- M-83 autocal pH meter (Radiometer, 
Copenhagen, Denmark). Alterations of pH would therefore also have altered the 
osmolality, sodium concentration and buffering capacity of the cardioplegic solution 
slightly. 
Expression of results 
Values of functional parameters obtained during the postischaemic working period were 
expressed as a percentage of each individual preischaemic control value. Results are 
presented as percentage means and standard errors of percentage means. 
Statistics 
The statistical test used was the one way analysis of variance (ANOVA-1), and if overall 
statistical significance was obtained pair wise comparisons were then done by acceptance 
intervals of means with the f test Statistical significance was taken as p < 0. 05. 
RESULTS 
Postischaemic recovery of mechanical function 
The preischaemic control values of all groups were similar, and are shown in Table I. 
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pH - 6.0 
pH - 6.8 
pH - 7.0 
(N =7) 
pH- 7.4 
pH- 7.8 
Table I 
POSTISCHAEMIC MECHANICAL RECOVERY 
U! ~ u 
Pre Percentage Pre Percentage Pre 
Ischaemic Recovery Ischaemic Recovery Ischaemic 
Ill/min mljmin Ill 
45.5 ob 62.0 ob 0.224 
± 1.5 ± 1.4 ± 0.014 
50.5 9.5b 69.5 18.8b 0.238 
± 1.9 ± 5.6 ± 2.2 ± 9.3 ± 0.012 
45.4 70.1b 61.1 76.3a 0.232 
± 2.5 ± 3.5 ± 2.8 ± 4.1 ± 0.013 
45.0 85.8 61.5 90.2 0.237 
± 3.7 ± 1. 4 ± 4.3 ± 1.8 ± 0.017 
45.0 91.5 60.0 94.5 0.236 
± 3.7 ± 0.9 ± 4.5 ± 1.4 ± 0.012 
Legend: 
Isolated rat hearts (N = 4, unless otherwise indicated) were subjected to 3-hour !QOC ischaemia protected with multidosc 
cardioplegic solutions. The cardioplegic solution evaluated was the StThomas' plus glucose \11.0 mmol/L) cardioplegic solution, 
and pH was altered by the addition of either I N HCl or NaOH. 
a- p < 0.05 compared to pH -7.4, 
b- p < 0.01 compared to pH -7.4. 
The pH of the standard St Thomas' plus glucose cardioplegic solution was 7A. 
Percentage 
Recovery 
ob 
26.4b 
± 12.0 
81.5 
± 3.0 
95.9 
± 4.6 
90.2 
± 5.8 
Increasing the pH to 7.8 by the addition of NaOH tended to increase postischaemic 
recovery but significance was not obtained (Table I). However, decreasing the pH to 7.0 
or less decreasedpostischaemic recovery of both AO and CO (p < 0.05). However, this 
might have also been as a result of the concomitant decrease in the buffering capacity of 
the cardioplegic solution. 
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APPENDIX B-.3 
ISOLATED RAT HEART STUDY: SODIUM AND OSMOLAL DOSE 
RESPONSE CURVES FOR THE STTHOMAS' CARDIOPLEGIC SOLUTION 
INTRODUCTION 
This study was undertaken as a pilot study to confirm the optimal sodium concentration 
and osmolality for the StThomas' Hospital No 2 cardioplegic solution. 
MATERIALS AND METHODS 
The isolated perfused working rat heart model as described in Chapter 2 was used. 
Hearts were removed from male Long Evans rats weighing between 250 gm- 350 gm. 
Experimental Protocol 
The aorta was cannulated and Langendorff perfusion with 95% 02 5% C02 gassed 
Krebs Henseleit buffer commenced and maintained for 10 min, prior to conversion to 
the working preparation (left atrial filling pressure 20 em H20, left v~ntricle afterload 
100 em H20). Haemodynamic variables were measured after 10 minutes of work. The 
atrial and aortic cannulae were then closed and 10 ml cardioplegic solution (10°C) was 
infused at a pressure of 80 em H20, and simultaneously the hearts were placed into a 
I0°C chamber for a 3-hour period.of global ischaemia. Multidose reinfusions of 
cardioplegic solution (6 ml) were administered every 30 minutes throughout the 3-hour 
ischaemic period. Hearts were then reperfused at 37°C in the non working Langendorff 
mode for 10 min at 100 em H20, and thereafter switched to the working mode for a 
further 10 min prior to measuring postischaemic functional recovery. 
Cardioplegic solutions. 
The "control" cardioplegic solution tested was the StThomas' Hospital No 2 cardioplegic 
solution. The experimental cardioplegic solutions were modified St Thomas' 
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cardioplegic solutions containing varying concentrations of sodium (osmolality kept 
constant with sucrose), or varying osmolality by the addition of sucrose (sodium kept 
constant). Osmolality was measured by freezing point depression with an automatic 
cryoscopic osmometer ( Osmomat 030: Gonotec; Berlin, Germany). 
Expression of results 
Values of functional parameters obtained during the postischaemic working period were 
expressed as a percentage of each individual preischaemic control value. Results are 
presented as percentage means and standard errors of percentage means. 
Statistics 
The statistical test used was the one way analysis of variance (AN OV A-1 ), and if overall 
statistical significance was obtained pair wise comparisons were then done by acceptance 
intervals of means with theftest Statistical significance was taken asp < 0.05. 
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RESULTS 
Sodium concentration of the StThomas' Hospital No 2 cardioplegic solution 
Na - 120 
Na - 110 
Na - 100 
Na - 90 
Na - 80 
Na - 60 
Na - 40 
Table I 
POSTISCHAEMIC MECHANICAL RECOVERY 
l...Q Q_Q u 
Pre Percentage Pre . Percentage Pre 
Ischaemic Recovery Ischaemic Recovery Ischaemic 
mljmin mljmin ml 
49.0 76.1 67.0 82.9 0.262 
± 1.3 ± 2.2 ± 1.3 ± 2.5 ± 0.016 
42.0 85.8b 53.5b 93.5b 0.228 
± 2.2 ± 1.5 ± 2.6 ± 2.3 ± 0.006 
. 
43.5 86.1b 61.0 88.5 0.226 
± 2.6 ± 1.1 ± 1. 7 ± 1.0 ± 0.004 
36.5b 80.6 50.5b 88.3 0.200 
± 2.9 ± 1.3 ± 3.8 ± 2.5 ± 0.021 
50.0 76.0 66.0 81.9 0.234 
± 0.8 ± 1.5 ± 1.4 ± 0.9 ± 0.126 
49.5 67.2a 66.5 74.ob 0.251 
± 1.3 ± 2.4 ± 1.0 ± 1.7 ± 0.013 
45 4.8b 64.5 22.2b 0.246 
± 5.1 ± 4.8 ± 4.3 ± 3.1 ± 0.026 
Legend: 
Isolated rat hearts (N = 4) were subjected to 3-bour 10oc ischaemia protected with multidose cardioplegic solutions, either St-
Thomas' or modified StThomas' cardioplegic solutions containing varying concentrations of sodium ions (osmolality kept 
constant by addition of sucrose). 
a - p < 0.05 compared to Na- 120, 
b- p < 0.01 compared to Na- 120. 
Percentage 
Recovery 
85.3 
± 6.9 
105.5a 
± 5.8 
93.4 
± 7.2 
90.4 
± 6.6 
84.3 
± 3.8 
75.4 
± 2.7 
24.4b 
± 1.5 
The sodium concentration of the standard StThomas' Hospital cardioplegic solution was 
decreased from 120 mmol/L to 110 mmol/L, and this modification improved the 
postischaemic recovery of both AO, CO and SV (p < 0.05; Table 1). Thus, this pilot 
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study suggested that the optimal sodium content for the StThomas' Hospital No 2 
cardioplegic solution was 110 mmol!L. Furthermore, the sodium concentration of the 
standard St Thomas' cardioplegic solution could be decreased to a concentration of 80 
mmol/L before postischaemic recovery diminished significantly. 
Osmolality of the StThomas' Hospital No 2 cardioplegic solution 
osmol-300 
osmol-350 
Table II 
POSTISCHAEMIC MECHANICAL RECOVERY 
A_Q Q_Q u 
Pre Percentage Pre Percentage Pre 
Iscbaemic Recovery Iscbaemic Recovery Ischaemic . 
mljmin mljmin ml 
49.0 76.1 67.0 82.9 0.262 
± 1.3 ± 2.2 ± 1.3 ± 2.5 ± 0.016 
I 
47.3 86.6a 62.7a 92.1a 0.244 
± 0.7 ± 2.1 ± 0.7 ± 2.3 ± 0.019 
Legend: 
Isolated rat hearts (N = 4) were subjected to 3-hour !0°C ischaemia protected with multidose cardioplegic infusions, either St 
Thomas· or a modified StThomas· cardioplegic solution containing a higher osmolality. The sodium con
centration was kept 
constant atl20 mmol/L in both solutions. Osmol-300: standard StThomas' Hospital No 2 cardioplegic solut
ion that has a 
measured osmolality of29S- 300 mOsm/kg H20. Osmol-350: modified StThomas' with a measured osmolal
ity of3SO mOsm/kg 
H20 due to the addition of sucrose (SO mmol/L). 
a- p < 0.05 compared to Osmol-300. 
Percentage 
Recovery 
85.3 
± 6.9 
95.6 
± 5.4 
The St Thomas' Hospital No 2 cardioplegic solution is an isotonic solution with an 
osmolality of 295 - 300m Osm /kg H 2 0. Increasing the osmolality to 350 m Osm /kg H 2 0 
improved postischaemic mechanical recovery of both AO and CO (p < 0.05; Table II). 
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Osmolality of a modified StThomas' cardioplegic solution containing a sodium 
concentration of 100 mmol!L 
OSmol-260 
OSmol-310 
OSmol-340 
(N = 7) 
Osmol-360 
Table III 
POSTISCHAEMIC MECHANICAL RECOVERY. 
A..Q ~ u 
Pre Percentage Pre Percentage Pre 
Ischaemic Recovery Ischaemic Recovery Ischaemic 
mljmin mljmin ml 
51.0 81.5a 70.5 '83.2a 0.246 
± 4.0 ± 0.5 ± 5.3 ± 1.3 ± 0.016 
43.5 86.1 61.0 88.5 0.226 
± 2.6 ± 1.1 ± 1. 7 ± 1.0 ± 0.004 
47.1 87.7 64.9 91.5 0.243 
± 1.6 ± 1.3 ± 2.6 ± 1.0 ± 0.014 
46.5 81.8a 64.5 86.1 0.248 
± 1. 9 ± 0.4 ± 1.3 ± 2.0 ± 0.017 
Legend: 
Isolated rat hearts (N = 4, unless otherwise indicated) were subjected to 3-hour I ooc ischaemia protected with multidose 
infusions of modified StThomas' cardioplegic solutions containing a sodium concentration of 100 mmoi/L in all solutions. The 
osmolality was altered by the addition of sucrose and the measured osmolality (Osmol-; m Osm /leg H2 0) of the solution is 
indicated. 
a- p < 0.05 compared to Osmol-310. 
Percentage 
Recovery 
91.9 
± 8.4 
93.4 
± 7.2 
96.0 
± 1.9 
85.2 
± 5.7 
The sodium concentration of the StThomas' cardioplegic solution was decreased to 100 
mmol/L and osmolality altered by the addition ofsucrose. Hypo-osmolality (less than 
300 mOsm/kg H20) was associated with a decreased postischaemic recovery of both 
AO and CO (p < 0.05). However, moderate hyperosmolality (340 m:Osm/kg H20) d~d 
not alter postischaemic mechanical recovery (Table III). 
/ 
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APPENDIX B-4 
ISOLA TED RAT HEART STUDY: DECREASING THE CHLORIDE 
CONTENT OF 
THE STTHOMAS' CARDIOPLEGIC SOLUTION 
INTRODUCTION 
This study was undertaken to determine whether decreasing the chloride concentration 
of the St Thomas' cardioplegic solution would alter postischaemic mechanical recovery. 
The chloride content of the solution was diminished by replacing the chloride salt of the 
sodium and potassium contained in the solution with the gluconate salts. 
MATERIALS AND METHODS 
The isolated perfused working rat heart model as described in chapter 2 was used. 
Hearts were removed from male Long Evans rats weighing between 270 gm- 400 gm. 
Experimental Protocol 
The aorta was cannulated and Langendorff perfusion with 95% 02 5% C02 gassed 
Krebs Henseleit buffet commenced and maintained for 10 min, prior to conversion to 
the working preparation (left atrial filling pressure 20 em H20, left ventricle afterload 
100 em H20). Haemodynamic variables were measured after 10 minutes of work. The 
atrial and aortic cannulae were then closed and 10 ml cardioplegic solution (10°C) was 
infused at a pressure of 80 em H20, and simultaneously the hearts were placed into a 
I0°C chamber containing the relevant cardioplegic solution for a 3-hour period of global 
ischaemia. No reinfusions of cardioplegic solution were administered. Hearts were then 
reperfused at 37°C in the non working Langendorff mode for 10 min at 100 em H20, 
and thereafter switched to the working mode for a further 10 min prior to measuring 
postischaemic functional recovery. 
440 U 0 Von Oppell PhD Thesis; Univer.;ity of Cape Town, 1992 
Cardioplegic solutions. 
The "control" cardioplegic sohition tested was the St Thomas' Hospital No 2 cardioplegic 
solution (ST). The experimental solution evaluated was a modified St Thomas' solution 
containing a low concentration of chloride (ST-Low Cl; Table 1). 
Table I 
COMPOSITION OF CARDIOPLEGIC SOLUTIONS 
(mmol/L) St Thomas' No 2 St Thomas' - Low Cl 
Na+ 120 120 
K+ 16 16 
HCO- 10 10 3 
ca2+ 1.2 1.2 
Mg2+ 16 16 
Cl- 160.4 34.4 
Gluconate 126 
Expression of results 
Values of functional parameters obtained during the postischaemic working period were 
expressed as a percentage of each individual preischaemic control value. Results are 
presented as percentage means and standard errors of percentage means. 
Statistics 
The statistical test used was the one way analysis of variance (AN OV A-1 ), and if overall 
statistical significance was obtained pair wise comparisons were then done by acceptance 
intervals of means with the ftest Statistical significance was taken asp <: 0.05. 
RESULTS 
Postischaemic recovery of mechanical function 
The preischaemic control values of all groups were similar, and are shown in Table II. 
ST 
ST-Low Cl 
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Table II 
POSTISCHAEMIC MECHANICAL RECOVERY 
!_Q LQ u 
Pre Percentage Pre Percentage Pre 
Ischaemic Recovery Ischaemic Recovery Ischaemic 
1111/min mljmin ml 
50.43 49.8 68.43 62.8 0.228 
± 2.02 ± 5.1 ± 2.09 ± 6.9 ± 0.011 
51.71 55.5 67.14 66.7 0.243 
± 1.82 ± 4.7 ± 2.24 ± 4.3 ± 0.009 
Legend: 
Isolated rat hearts (N ~ 7) were subjected to 3-hour 10°C ischaemia after a single dose of either StThomas" (ST) or a modified 
StThomas' cardioplegic solution containing a low concentration of chloride (ST -Low Cl). 
All comparisons p ~ NS. 
Percentage 
Recovery 
66.6 
± 8.0 
63.7 
± 5.7 
The chloride concentration of the StThomas' Hospital No 2 cardioplegic solution was 
decreased from 160 .4 mmol/L to 34.4 mmol/L by replacing chloride with gluconate. 
This modification did not alter the mechanical postischaemic recovery of hearts 
protected with this solution (Table II). 
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Metabolic indices of postischaemic recovery 
Table III 
POSTREPERFUSION METABOLIC CONCENTRATIONS 
ATP CP Percent H2o 
umoljgm umoljgm % 
ST 3.14 ± 0.12 6.04 ± 0.18 86.5 ± 0.2 
ST - Low Cl 3.19 ± 0.10 6.50 ± 0.20 86.5 ± 0.3 
Legend: 
Isolated rat hearts (N = 7) were subjected to 3-hour 10°C ischaemia after a single dose of either StThomas, or a modified 
cardioplegic solutions containing a low concentration of chloride. Post-ischaemic values of ATP, CP (umol/gm fresh weight) and 
percentage water content were measured by freeze-clamping at the end of the postischaem~~ reperfusion period after measuring 
the haemodynamic variables. 
All comparisons p = NS. . 
The concentrations of the cellular high energy phosphates and percentage water content 
after 20 min reperfusion following the 3-hour ischaemic period were not altered by 
decreasing the chloride concentration of the StThomas' Hospital No 2 cardioplegic 
solution (Table III). 
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APPENDIX .B-.5 
ISOLATED RAT HEART STUDY: THE ADDITION OF HISTIDINE 
TO THE STTHOMAS' CARDIOPLEGIC SOLUTION 
INTRODUCTION 
The buffer contained in STThomas' Hospital No 2 cardioplegic solution is bicarbonate 
which has a weak buffering capacity, in contrast to the high buffering capacity of 
histidine contained in Bretschneider HTK4 cardioplegic solution (B-HTK4). However, 
the electrolyte composition of B-HTK4 is closer to that of an intracellular electrolyte 
equivalent solution (Table I), because of osmotic considerations due to the high 
concentration of histidine (198 mmol/L) used in this solution. This study was 
undertaken to investigate whether a modified St Thomas' cardioplegic solution with an 
increased buffering capacity, albeit lower than B-HTK4 but retaining an extracellular 
electrolyte equivalent composition, would improve postischaemic myocardial recovery. 
We examined the effect of including histidine (50 mmol!L) in a modified ST solution 
containing 10 mmol/L glucose (to ensure that substrate for glycolysis was present) and a 
slightly lower sodium concentration of 100 mmol/L (in order to create osmotic space), in 
the isolated rat heart model 
MATERIALS AND METHODS 
The isolated perfused working rat heart model as described in Chapter 2 was used. 
Hearts were removed from male Long Evans rats weighing between 220 gm- 420 gm. 
Experimental Protocol 
The aorta was cannulated and Langendorff perfusion with 95% 02 5% C02 gassed 
Krebs Henseleit buffer commenced and maintained for 10 min, prior to conversion to 
the working preparation (left atrial filling pressure 20 em H20, left ventricle afterload 
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100 em H20). Haemodynamic variables were measured after 10 minutes of work. The 
atrial and aortic cannulae were then closed and· 10 ml cardioplegic solution (lOOC) was 
infused at a pressure of 80 em H20, and simultaneously the hearts were placed into a 
10°C chamber containing the relevant cardioplegic solution for a 3-hour period of global 
ischaemia. No reinfusions of cardioplegic solution were administered. Hearts were then 
reperfused at 37°C in the non working Langendorff mode for 10 min at a pressure of 80 
em H20 initially and thereafter for 10 min at 100 em H20. Hearts were then switched 
to the working mode for a further 10 min, prior to measuring postischaemic functional 
recovery. 
A similar protocol was followed with a second series of hearts, but each heart was 
freeze-clamped with Wollenburg tongs at the end of the 3-hour ischaemic period before 
reperfusion, for determination of myocardial content of A TP, CP and tissue lactate. 
Control values for A TP and CP were obtained in six hearts by freeze-clamping prior to 
the ischaemic period in the experimental protocol. 
Cardioplegic solutions 
The "control" cardioplegic solutions tested were the StThomas' plus 10 mmol/L glucose 
(ST +G) and B-HTK4 cardioplegic solutions. The addition of 50 mmol!L histidine to 
this modified StThomas' cardioplegic solution (ST+G+Histidine) was then evaluated. 
In order to create osmotic space for the inclusion of histidine in this experimental 
solution, the sodium concentration of the St Thomas' cardioplegic solution was 
decreased from 120 mmol/L to 100 mmol!L (see appendix B-3). Furthermore, to 
ensure that any beneficial effect was not consequent to this change in sodium 
concentration or altered osmolality, a further "control" solution identical to 
ST+G+Histidine but containing sucrose instead of histidine (ST+G+Sucrose) was 
tested (Table I). All cardioplegic solutions were gassed with 95% 02 5% C02 when 
initially prepared, but thereafter allowed to equilibrate with atmospheric partial 
pressures prior to use. 
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Table I 
COMPOSITION OF CARDIOPLEGIC SOLUTIONS 
ST+G ST+G + ST+G + 
(uol/L) Histidine Sucrose 
Na+ 120 100 100 
K+ 16 16 16 
HCO-3 10 10 10 
ca2+ 1.2 1.2 1.2 
Mg2+ 16 16 16 
Glucose 10 10 10 
Histidine -- 50 --
Sucrose -- -- 50 
Mannitol -- -- --
KH-2-oxyglutarate -- -- --
Tryptophan -- -- --
Osmolarity (mOsm/L) 333.6 343.6 343.6 
Osmolality (mOsmfkg H20) 304 320 320 
pH (10°C) 7.4 7.2 7.4 
~ 
Legend: 
The composition of the StThomas plus glucose (ST+G) and Bretschneider HTK4 (B-HTK4) cardioplegic solutions, as well as 
two experimental solutions containing either histidine (ST+G +Histidine) or sucrose (ST+G +Sucrose) is shown. Osmolarity was 
calculated by assuming 100% ionic dissociation and osmolality measured by freezing point depression (Osmomat 030 automatic 
cryoscopic osmometer: Gonotec, Berlin, Germany). 
B-HTK4 
15 
10 
--
--
4 
--
198 
--
30 
1 
2 
310 
298 
7.0 
The titration curve of each of these cardioplegic solutions was determined by adding 0.5 
ml aliquots of 1 N HCI to 500 ml of solution at 22°C (continually stirred and gassed with 
95% 02 5% C02 to maintain C02 constant), andrecording the pH change (Radiometer 
pH- M-83 autocal pH meter: Radiometer, Copenhagen, Denmark). The actual 
buffering capacity of the bicarbonate containing solutions when in the myocardium 
might well have been overestimated, as C02 cannot escape in the myocardium during 
ischaemia. Titration curves were plotted and thereafter the buffering capacity (mmol 
HCl/L I o pH) calculated as the instantaneous three point derivative of the titration 
curve (Figure 1). 
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Figure 1 A 
TITRATION CURVES OF CARDIOPLEGIC 
SOLUTIONS 
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Legend: 
Titration (A) curve oftbe StThomas plus glucose (ST +G), Bretschneider HTK4 (B-HTK) and ST +G+ Histidine cardioplegic 
solutions. 
8 
The maximum buffering capacity of the bicarbonate containing ST + G cardioplegic 
solution was 6 mmol HCl/L/ o pH at pH 6.0. The addition of 50 mmol/L histidine to· 
ST +G increased the buffering capacity to 30 mrnol HCl/L/ o pH over the pH range 6.0-
6.3. In contrast, the highly buffered B-HTK4 cardioplegic solution containing 
approximately four times the concentration of histidine of our experimental solution, 
had a maximum buffering capacity of 100 mmol HCIIL/ o pH between pH 5.8- 6.6. 
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Legend: 
Buffering capacity (B) curve of the StThomas plus glucose (ST +G), Bretschneider HTK4 (B-HTK) and ST +G +Histidine 
cardioplegic solutions. Buffering capacity is expressed as the instantaneous three point derivative slope of the titration curve (A). 
Expression of results 
Values of functional parameters obtained during the postischaemic working period were 
expressed as a percentage of each individual preischaemic control value. Results are 
presented as percentage means and standard errors of percentage means. 
Statistics 
The statistical tests used were either the one way or if appropriate the two way analysis 
of variance (ANOVA-1, ANOVA-2), and if overall statistical significance was obtained 
pair wise comparisons were then done by acceptance intervals of means with the f test 
Statistical significance was taken asp < 0.05. 
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RESULTS 
Postischaemic recovery of mechanical function 
Hearts (N = 9) were protected with a single coronary infusion of cardioplegic solution at 
the onset of the 3-hour ischaemic period. One low "outlier" was excluded from further 
analysis in each group by Dixon's criteria (see Chapter 2), and further analysis was done 
on N = 8 for each group. The preischaemic control values of all groups were similar, 
and are shown in Table II. 
Table II 
POSTISCHAEMIC MECHANICAL RECOVERY 
A..Q co u 
Pre Percentage Pre Percentage Pre 
Ischaemic Recovery Ischaemic Recovery Ischaemic 
ml/min ml/min ml 
ST+G 49.3 61.8%a 68.0 71.9%b 0.263 
± 3.7 ± 2.3% ± 4.9 ± 2.2% ± 0.016 
ST+G+Histidine 45.8 75.1% 61.8 82.5% 0.258 
ST+G+Sucrose 
B-HTK4 
± 3.2 ± 3.7% ± 3.5 ± 5.4% ± 0.011 
53.4 56.6%a 71.0 66.0%a 0.247 
± 3.2 ± 2.4% ± 3.7 ± 2.2% ± 0.010 
50.5 53.2%a 70.3 67.9%a 0.245 
± 2.5 ± 3.5% ± 2.5 ± 3.5% ± 0.008 
Legend: 
Isolated rat hearts were subjected to 3-hour !0°C ischaemia after a single dose of either StThomas plus glucose (ST+G), or 
Bretschneider HTK4 (B-HTK4) crystalloid cardioplegic solutions, or the experimental solutionsST+G plus histidine or sucrose. 
a -p < 0.01 compared with ST+G+Histidine 
b- p < 0.05 compared with ST+G+Histidine 
Percentage 
Recovery 
70.0% 
± 4.3% 
79.5% 
± 4.8% 
68.5% 
± 6.3% 
65.5%b 
± 2.9% 
The addition of histidine to the modified ST + G solution improved postischaemic 
recovery of both aortic output from 61.8% ± 2.3% to 75.1% ± 3.7% (p < 0.01), and 
cardiac output from 71.9% ± 2.2% to 82.5% ± 5.4% (p < 0.05). Although stroke 
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volume also increased from 70.0% ± 4.3% to 79.5% ± 4.8 %, statistical significance was 
not achieved. In contrast, Bretschneider HTK4 cardioplegic solution having a threefold 
higher buffering capacity than ST + G +Histidine, did not provide better myocardial 
protection than ST+G (Table II). Postischaemic recovery of aortic output was 53.2% ± 
3.5 %, cardiac output 67.9% ± 3.5% and stroke volume 65.5% ± 2.9 %. 
ST + G +Histidine provided superior myocardial protection compared to B-HTK4 in all 
comparisons, p < 0.05 (Table II).' 
The improved recovery with ST + G +Histidine was due to the addition of the amino acid 
histidine and not because of any osmotic or low sodium effect, as a similar solution 
containing sucrose (ST + G +Sucrose) as opposed to histidine was not more effective 
than ST+G. Postischaemic recovery following protection with ST+G+Sucrose was 
inferior to ST +G +Histidine; aortic output 56.6% ± 2.4% (p < 0.01), cardiac output 
66.0% ± 2.2% (p < 0.01) and stroke volume 68.5% ± 6.3 %. 
Metabolic indices of postischaemic recovery 
Preservation of high energy phosphates 
Preischaemic control values of ATP and CP were 3.96 ± 0.07 umol/gm fresh weight and 
5.65 ± 0.19 umol I gm fresh weight respectively (Table III). A TP and CP content 
decreased in all groups by the end of the three hour ischaemic period (p < 0.01). 
However, hearts protected with ST + G +Histidine retained a significantly higher end-
ischaemic concentration of ATP (2.17 ± 0.24 umol/gm) than those protected with 
ST+G (1.42 ± 0.15 umol/gm, p < 0.01), or B-HTK4 (0.42 ± 0.09 umollgm, p < 0.01). 
The end-ischaemic CP contents were similarly decreased with both ST+G and 
ST+G+Histidine, but with B-HTK4 the decrease was further reduced (p < 0.05). 
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Table III 
END-ISCHAEMIC METABOLIC CONCENTRATIONS 
ATP CP Lactate 
Preischaemic Control 3.96 ± 0.07 5.65 ± 0.19 0.14 ± 0.04 
ST+G 1.42 ± 0.15a 0.53 ± o.o7a 19.98 ± 0.84a 
ST+G+Histidine 2.17 ± 0.24 abd 0.50 ± 0.04ae 21.07 ± 0.56ad 
B-HTK4 o.42 ± o.o9ab 0.18 ± o.o2ac 13.41 ± 1.31ab 
Legend: 
Isolated rat hearts (N ~ 6) were subjected to 3-hour 10°C ischaemia after a single dose of either StThomas plus glucose (ST+G), 
or Bretschneider HTK4 (B-HTK4) crystalloid cardioplegic solutions, or the experimental solution ST+G+ Histidine. End-
ischaemic values of ATP, CP and lactate (umol/gm fresh weight) were measured by freeze-<:lamping at the end of the ischaemic 
period, prior to reperfusion. Control concentrations were measured in six hearts by freeze-clamping prior to the ischaemic 
period. 
a - p < 0.01 compared with Control 
b- p < 0.01 compared with ST+G. 
c- p < 0.05 compared with ST+G. 
d- p < 0.01 compared with B-HTK4. 
e- p < 0.05 compared with B-HTK4. 
End-ischaemic lactate content 
Continued anaerobic glycolysis during the 3-hour period of total ischaemia resulted in a 
significant increase of total tissue lactate (Table III)_ Lactate content increased from a 
preischaemic value of0_14 ± 0.04 umollgm fresh weight to 19.98 ± 0.84 umol/gm when 
hearts were protected with ST +G (p < 0.01). This was no different from 
ST +G +Histidine (21.07 ± 0.56 umollgm). However, B-HTK4 which does not contain 
any glucose was associated with less lactate accumulation (13.41 ± 1.31 umol/gm, p < 
0.01). 
Postischaemic LDH washout 
The mean washout of LDH, a measure of damage to membrane integrity, throughout 
the 20 min reperfusion period for ST+G was 58.55 ± 6.74 mU /gm/min which was no 
different from the washout associated with ST + G +Histidine, namely 42.79 ± 3. 30 · 
mU /gm /min. However, LDH washout increased significantly if hearts were protected 
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with B-HTK4, to 87.44 ± 11.96 mU /gm/min (p < 0.05). This was primarily due to an 
initial high washout of LDH in the first five minutes of reperfusion, which then 
decreased linearly during the subsequent reperfusion period, p < 0.01, (Figure 2). 
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Isolated rat hearts were subjected to 3-hour I0°C ischaemia after a single dose of either StThomas plus glucose (ST+G) or 
Bretschneider HTK4 (B-HTK) crystalloid cardioplegic solutions, or the experimental solutions ST+G plus Histidine or Sucro~e . 
(50 mmol/L). The mean and standard error of mean postischaemlc washout of lactate dehydrogenase (LDH), during each 5 min 
interval of a 20 min postischaemic reperfusion peri~d in the Langendorff mode, for each group are shown. 
a- p < 0.01 compared with ST+G. 
b- p < 0.01 compared with ST+G+Histidine. 
c- p < 0.05 compared with ST+G +Histidine. 
d- p < 0.05 compared with 0-5 min value. 
d 
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COMMENT 
We studied the effect of adding histidine (50 mmol!L) to a modified StThomas' 
Hospital No.2 cardioplegic solution that also contained glucose (10 mmol!L), to 
enhance ongoing anaerobic glycolysis during cardioplegic arrest The addition of 
histidine to ST + G increased buffering capacity fivefold, increased end-ischaemic A TP 
content although end-ischaemic lactate content was unaltered, and improved 
postischaemic mechanical recovery. In contrast, the even more highly buffered 
Bretschneider HTK4 cardioplegic solution:, having a buffering capacity threefold higher 
than ST + G +Histidine, but an electrolyte composition more closely approximating 
intracellular values, was associated with diminished end-ischaemic ATP, CP and lactate 
contents, increased LDH loss during reperfusion, and a mechanical recovery no better 
than ST+G. 
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A.P.P..END.IX B-6 
IN VIVO PRIMATE STUDY: PILOT STUDIES ON THE EFFECT OF 
MODIFIED STTHOMAS' CARDIOPLEGIC SOLUTIONS CONTAINING 
HISTIDINE 
INTRODUCTION 
We previously showed that the addition of histidine (50 mmol/L) to a modified St 
Thomas' Hospital No 2 cardioplegic solution was beneficial in the isolated rat heart 
model (see Appendix B-5). In addition, we also showed that glucose (7- 11 mmol/L) 
was beneficial In the isolated rat heart model (see Appendix A-2) but not in the in vivo 
primate model (see Appendix B-1). One postulate for this later discrepancy in results 
between the two models was an inadequate buffering power of the St Thomas' · 
cardioplegic solution, which is possibly detrimental in the presence of glucose and 
therefore enhanced anaerobic metabolism. 
A pilot study was therefore undertaken to evaluate the addition of histidine (50 
mmol/L) and histidine plus glucose (10 mmol/L) tothe StThomas' cardioplegic 
solution, in the in vivo primate model. 
MATERIALS AND METHODS 
The in vivo primate model as described in Chapter 2 was used. The chacma baboon 
(Papio ursinus) was selected because of its close evolutionary relationship to man. · 
Animals weighing 10-29 kg were used. 
Experimental Protocol 
The animals were anaesthetised, intubated, and ventilated. A median sternotomy was 
performed and the heart cannulated for cardiopulmonary bypass. Control 
haemodynamic and metabolic variables were measured prior to commencing 
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cardiopulmonary bypass. Systemic temperature was then lowered and maintained at · 
26°C, the aorta was cross-clamped and cold (4°C) cardioplegic solution (15 ml/kg; 
Table I) was infused. In addition, intermittent iced saline was used for topical 
hypothermia, and maintenance cardioplegia was reinfused every 30 minutes throughout 
a 3-hour ischaemic cross-clamp period. Additional ventricular biopsies were taken prior 
to the release of the aortic cross-clamp. A 15-minute normothermic reperfusion period 
followed, and the animals were then weaned from cardiopulmonary bypass and 
postischaemic haemodynamic and metabolic variables measured 5 and 30 minutes after 
termination of cardiopulmonary bypass. 
Table I 
COMPOSITION OF CARDIOPLEGIC SOLUTIONS 
ST ST ST + Glucose 
(mmol/L) + Histidine + Histidine 
Na+ 120 100 100 
K+ 16 16 16 
HCO- 10 10 10 
. 3 
ca2+ 1.2 1.2 1.2 
Mg2+ 16 16 16 
Glucose -- 10 
Histidine -- 50 50 
Osmolarity (mOsm/L) 323.6 333.6 343.6 
Osmolality (mOsmjkg H20) 293 310 320 
pH (10°C) 7.4 7.2 7.2 
Legend: 
The composition of the StThomas cardioplegic solution (ST), as well as two experimental solutions containing histidine (ST + 
Histidine) or histidine plus glucose (ST + Glucose + Histidine) is shown. Osmolarity was calculated by assuming 100% ionic 
dissociation and osmolality measured by freezing point depression ( Osmomat 030 automatic cryoscopic osmometer: Gonotec, 
Berlin, Germany). 
The addition of 50 mmol/L histidine to the St Thomas' cardioplegic solution increased 
the buffering capacity from 6 mmol HCIIL/ o pH, to 30 mmol HCIIL/ o pH (see 
Appendix B-5). 
Myocardial protection during cardiac surgery; Appendix B-6 U OVon OppcD 455 
Expression of results 
Values of functional parameters obtained during the postischaemic working period were 
expressed as a percentage of each individual preischaemic control value. Tissue high 
energy phosphate content was expressed in absolute values (umol/g wet weight). 
Results were then presented as percentage means and standard errors of percentage 
means. 
Statistics 
The statistical test used was the two way analysis of variance (ANOVA-2), and if overall 
statistical significance was obtained pair wise comparisons were then done by acceptance 
intervals of means with theftest. Statistical significance was taken asp < 0.05. 
RESULTS 
Postischaemic recovery of mechanical function 
The preischaemic control values of all three groups were similar, and are shown in Table 
II. Three experiments were performed in each group. However, in the StThomas' plus 
Histidine plus Glucose group one experiment was abandoned due to technical factors 
and one animal could not be weaned from cardiopulmonary bypass. In contrast, all 
animals in the other two groups could be successfully weaned from cardiopulmonary 
bypass. 
In this pilot study only a few experiments were performed in each group, and although 
the addition of histidine to the St Thomas' cardioplegic solution tended to improve 
postischaemic recovery, significance was not obtained. However, the addition of glucose 
to the St Thomas' plus histidine solution caused profound depression of postischaelnic 
recovery of all indices compared to both the standard St Thomas' and St Thomas' plus 
histidine cardioplegic solutions, p < 0.05 (Table II). 
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Table II 
POSTISCHAEMIC MECHANICAL RECOVERY 
cardiac Index 
Preischaemic 
(L/minjm2) 
% Recovery 5-min 
% Recovery 30-min 
Stroke Volume Index 
Preischaemic 
(mljbeatjm2) 
% Recovery 5-min 
% Recovery 30-min 
Left Ventricular dp/dt 
Preischaemic 
(mm Hgjsec) 
% Recovery 5-min 
% Recovery 30-min 
Stroke Work Index 
Preischae11ic 
(gm.mjbeat;m2) 
% Recovery 5-ain 
% Recovery 30-min 
Legend: 
st Thomas' 
No 2 
N = 3 
3.08 ± 0.22 
79.56 ± 15.64 
84.03 ± 9.28 
26.93 ± 4.35 
78.27 ± 3.33 
77.79 ± 7.51 
1092.8 ± 36.6 
131.04 ± 38.19 
119.0 ± 9.73 
42.95 ± 6.71 
83.15 ± 13.21 
82.14 ± 4.50 
st Thomas' 
+ Histidine 
N = 3 
3.34 ± 0.50 
104.33 ± 13.12 
94.59 ± 16.50 
25.94 ± 2.93 
107.54 ± 16.14 
96.61 ± 17.40 
1107.0 ± 36.47 
142.44 ± 21.69 
105.27 ± 15.80 
43.97 ± 5.91 
114.75 ± 16.63 
85.13 ± 16.06 
St Thomas' + Histidine 
+ Glucose 
N = 2 
3.48 ± 0.85 
19.86 ± 19.86ac 
23.40 ± 23.40ac 
33.53 ± 11.59 
15.28 ± 15.28ac 
22.65 ± 22.65ac 
1162.0 ± 83.0 
35.02 ± 35.02ac 
28.35 ± 28.35a 
47.40 ± 10.87 
bd 9.22 ± 9.22 
11.32 ± 11. 32bd 
Animals were subjected to a 3-hour hypothermic cross~lamp period protected with multidose reinfusions of indicated 
cardioplegic solutions. Haemodynamic variables were measured at a left atrial pressure of.5 mm Hg. Postischaemic recovery iS; 
expressed as mean percentage recoveries of each individual preischaemic value, and standard errors of percentage means. 
a- p < 0.05 compared to StThomas' No 2, 
b- p < 0.01 compared to StThomas' No 2, 
c- p < 0.05 compared to StThomas' plus Histidine, 
d- p < 0.01 compared to StThomas' plus Histidine. 
Left ventricular function curves (CI & SWI) were determined both prior to and after the 
ischaemic cross-clamp period (30-minute post cardiopulmonary bypass), by measuring 
haemodynamic variables at different left atrial preloads. The preischaemic control 
curves were similar in all groups (Table III). 
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Table III 
LEFT VENTRICULAR FUNCTION CURVE 
LAP 5 
CI (L/min;m2) 
st Thomas' 
Pre 3.08 ± 0.22 
% Rec 84.03 ± 9.28 
St Thomas' plus Histidine 
Pre 3.34 ± 0.50 
% Rec 94.59 ± 16.50 
St Thomas' plus Glucose plus Histidine 
Pre 3.48 ± 0.85 
% Rec 23.4 ± 23.40bd 
10 
3.86 ± 0.43 
70.07 ± 9.90 
4.39 ± 0.27 
73.91 ± 5.30 
3.62 ± 0.13 
21.39 ± 21.39bd 
Data normalized to the integrated preischaemic control curve 
Cont. 3.28 ± 0.25 4.00 ± 0.21 
ST 2.76 ± 0.3 2.80 ± 0.4 
ST+H 
ST+G+H 
3.10 ± 0.54 
bdf 0.77 ± 0.77 
SWI (gm·mjbeat;m2) 
St Thomas' 
Pre 42.95 ± 6.71 
% Rec 82.14 ± 4.50 
St Thomas' plus Histidine 
Pre 43.97 ± 5.91 
% Rec 85.13 ± 16.06 
St Thomas' plus Glucose plus Histidine 
2.96 ± 0.21 
bdf 0.86 ± 0.86 
48.89 ± 10.33 
74.94 ± 7.15 
66.17 ± 2.81 
63.07 ± 5.01 
Pre 47.40 ± 10.87 54.95 ± 10.91 
% Rec 11.32 ± 11.32bd 12.37 ± 12.37bd 
Data normalized to the integrated preischaemic control curve 
Cont. 44.44 ± 3.64 56.89 ± 4.97 
ST 36.51 ± 2.0 42.63 ± 4.07 
ST+H 
ST+G+H 
37.84 ± 7.14 
bdf 5.03 ± 5.03 
Legend: 
35.88 ± 2.85 
7.03 ± 7.03bcf 
15 
4.26 ± 0.49 
62.54 ± 4.48 
4.61 ± 0.59 
71.19 ± 4.50 
3.55 ± 0.65 
23.87 ± 23.87ad 
4.21 ± 0.32 
2.63 ± 0.19e 
3.00 ± 0.19 
1.01 ± !.Olaf 
54.05 ± 8.80 
64.53 ± 7.19 
70.78 ± 9.63 
66.17 ± 3.72 
51.80 ± 16.70 
13.70 ± 13. 70bd 
59.76 ± 6.22 
38.56 ± 4.3 
39.54 ± 2.22 
8.19 ± 8.19 bdf 
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20 (mm Hg) 
4.59 ± 0.63 
43.11 ± 2.50 
4.67 ± 0.77 
64.31 ± 4.56 
3.44 ± 0.83 
17.86 ± 17.86c 
4.33 ± 0.41 
f 1.87 ± 0.11 
2.79 ± 0.20e 
0.77 ± 0.77acf 
52.66 ± 9.69 
47.58 ± 4.40 
64.80 ± 16.45 
70.95 ± 16.08 
43.93 ± 13.62 
13.82 ± 13. 82ad 
55.03 ± 7.45 
26.18 ± 2.42e 
39.05 ± 8.85 
7.60 ± 7.60 df 
A postischaemic left ventricular function curve was obtained 30 min after weaning from cardiopulmonary bypass at increasing left 
atrial pressures (LAP), and compared to a similar preischaemic curve. Mean percentage postischaemic recovery (% Rec) was 
calculated from each individual postischaemic and preischaemic ratio. An average preischaemic control function curve (Coot; N = 
8) was derived by pooling the data from all groups, and postischaemic function for each group normalized to this curve for display 
purposes. ST- StThomas' cardioplegic solution ( N = 3); ST + H - ST plus histidine (50 mmoi/L) cardioplegic solution (N = 3); 
ST+G+H- ST+H plus glucose (10 mmoi/L) cardioplegicsolution (N = 2). 
a- p < 0.05, b- p < 0.01; compared to StThomas' No 2, c- p < 0.05, d- p < 0.01; compared to StThomas' plus Histidine, 
e- p < 0.05, f- p < 0.01; compared to Cont 
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The addition of histidine to the StThomas' cardioplegic solution tended to improve 
postischaemic ventricular function, but significance was not obtained. Nevertheless, the 
addition of glucose to this cardioplegic solution depressed postischaemic ventricular 
function (p < 0.05), despite the low experimental numbers. 
In conclusion, the addition of histidine to the St Thomas' cardioplegic solution tended to 
improve postischaemic recovery, although one cannot place full emphasis on the results 
of this pilot study because of the low experimental numbers. However, the addition of 
glucose to this modified St Thomas' cardioplegic solution which had a five-fold greater 
buffering capacity than the standard St Thomas' solution, resulted in significantly lower 
postischaemic myocardial recovery. 
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AJ?P.END.IX B-7 
ISOLATED RAT HEART STUDY: PROVIDING COLLOID 
IN THE STTHOMAS' CARDIOPLEGIC SOLUTION 
INTRODUCTION 
This study was undertaken to determine whether the addition of colloid (Dextran-40) to 
the StThomas' Hospital No 2 cardioplegic solution was beneficial 
MATERIALS AND METHODS 
The isolated perfused working rat heart model as described in Chapter 2 was used. 
Hearts were removed from male Long Evans rats weighing between 280 gm- 380 gm~ 
Experimental Protocol 
The aorta was cannulated and Langendorff perfusion with 95% 02 5% C02 gassed 
Krebs Henseleit buffer commenced and maintained for 10 min, prior to conversion to 
the working preparation (left atrial filling pressure 20 em H20, left ventricle afterload 
100 em H20). Haemodynamic variables were measured after 10 minutes of work. The 
atrial and aortic cannulae were then closed and 10 ml cardioplegic solution (10°C) was 
infused at a pressure of 80cm H20, and simultaneously the hearts were placed into a 
10°C chamber containing the relevant cardioplegic solution for a 3-hour period of global 
ischaemia. No reinfusions of cardioplegic solution were administered Hearts were then 
reperfused at 37°C in the non working Langendorff mode for 10 min at 100 em H20, 
and thereafter switched to the working mode for a further 10 min prior to measuring 
postischaemic functional recovery. 
Cardioplegic solutions. 
The "control" cardioplegic solution tested was the StThomas' Hospital No 2 cardioplegic 
solution (ST). The addition of either 2 gm% or 3 gm% Dextran-40 (Rheomacrodex) to 
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ST was evaluated. The appropriate quantity of Rheomacrodex 10% which contains 
NaC1150 mmol/L was used, and the concentration of sodium chloride (110 mmol/L) in 
the final modified cardioplegic solution was kept constant (Table 1). 
Table I 
COMPOSITION OF CARDIOPLEGIC SOLUTIONS 
(uol/L) 
Dextran-40 
ST 
120 
16 
10 
1.2 
16 
Osmolality (mOsm/kg H20) 298 
Colloid Oncotic Pressure (mm Hg) 0.2 
Legend: 
ST + 2% Dextran-40 
120 
16 
10 
1.2 
16 
2% 
305 
15 
ST + 3% Dextran-40 
120 
16 
10 
1.2 
16 
3% 
306 
25 
The composition of the St Thomas' Hospital No 2 cardioplegic solution (ST), as well as two experimental solutions containing 
either 2% or 3% Dextran-40 is shown. Colloid oncotic pressure was measured by a colloid osmometer (Osmomat 050: Gonotec, 
Berlin, Germany). Osmolality was measured by freezing point depression (Osmomat 030: Gonotec, Berlin, Gennany). 
Expression of results 
Values of functional parameters obtained during the postischaemic working period were . 
expressed as a percentage of each individual preischaemic control value. Results are 
presented as percentage means and standard errors of percentage means. 
Statistics 
The statistical test used was the one way analysis of variance (ANOVA-1), and if overall 
statistical significance was obtained pair wise comparisons were then done by acceptance 
intervals of means with the f test Statistical significance was taken as p < 0. 05. 
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RESULTS 
Increasing the colloid oncotic pressure from 0 mm Hg to 25 mm Hg of the St Thomas' 
Hospital No 2 cardioplegic solution by the addition of 3 % Dextran-40 tended to improve 
postischaemic mechanical recovery, but significance was not obtained (Table II). 
Furthermore, postreperfusion high energy phosphate and water content were not altered 
(Table III). 
ST 
ST + 2% 
Dextran-40· 
ST + 3% 
Dextran-40 
Table II 
POSTISCHAEMIC MECHANICAL RECOVERY 
A._Q ~ 
<Pre Percentage Pre Percentage Pre 
Ischaemic Recovery Ischaemic Recovery Ischaemic 
111/min ml/min ml 
49.13 54.4 63.0 63.8 0.247 
± 1. 75 ± 5.2 ± 2.16 ± 5.4 ± 0.008 
43.75 51.4 57.0 59.8 0.249 
± 2.31 ± 3.6 ± 2.28 ± 3.3 ± 0.011 
50.88a 58.9 67.oa 71.0 0.244 
± 2.40 ± 3.9 ± 2.87 ± 4.2 ± 0.10 
Legend: 
Isolated rat hearts (N = 8) were subjected to 3-hour JOOCischaemia after a single dose of either StThomas' or modified 
solutions containing Dextran-40. 
a - p < 0.05 compared to ST + 2% Dextran-40, 
All other comparisons p = NS. 
u 
Percentage 
Recovery 
63.7 
± 4.3 
63.2 
± 3.4 
70.7 
± 2.8 
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Table III 
POSTREPERFUSION METABOLIC CONCENTRATIONS 
ATP 
umoljgm 
CP 
umoljgm 
Percent n2o 
% 
Preischaemic Control 86.1 ± 0.3 
ST 3.04 ± 0.06 5.94 ± 0.17 86.5 ± 0.2 
ST + 2% Dextran-40 3.03 ± 0.08 6.15 ± 0.23 86.3 ± 0.2 
ST + 3% Dextran-40 3.08 ± 0.09 6.18 ± 0.25 86.5 ± 0.2 
Legend: 
Isolated rat hearts (N = 8) were subjected to 3-bour 10°C ischaemia after a single dose of either StThomas, or modified 
cardioplegic solutions containing Dcxtran-40. Post-ischaemic values of ATP, CP (umol/gm fresh weight) and percentage water 
content were measured by freeze-clamping at the end of the postischaemic reperfusion period after measuring the 
haemodynamic variab1es. Control concentrations of water content were ~casu red in seven hearts by freeze-damping prior to the 
ischaemic period. 
All comparisons p = NS. 
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APPENDIX .B-B 
PRACTICALITIES OF DELIVERING CARDIOPLEGIC SOLUTIONS 
Ill PRESSURE 
METHODS 
We compared the delivered ascending aortic pressure, measured with a 9 Ga (11 French) 
cardioplegic delivery catheter containing an integral pressure monitoring port (aortic 
root cannula- Cat 23009: DLP; Grand Rapids, Michigan, USA), during Clinical 
administration of cardioplegia, with proximally monitored cardioplegic line pressures. 
The StThomas' Hospital No 2 crystalloid cardioplegic solution was used, and infusion 
was at constant pressure. Each of three possible delivery systems; viz gravity (N = 6; 
solution infused from a height of ± 178 em; 133 mm Hg), pressure bag placed around 
the vacolitre of cardioplegic solution (N = 6; inflated to 300 mm Hg) or roller-pump 
infusion method (N = 13), was assessed during routine cardiac surgery. With the roller 
pump method, the perfusionist monitored the ascending aortic root pressure and altered 
the infusion rate of the cardioplegia accordingly, in order to obtain an ascending aortic 
root pressure of at least 80 mm Hg during all infusions. Therefore, the speed of the 
pump was progressively increased to maximum till this aortic root pressure was · 
obtained. The maximal pressure that could be generated was a proximal cardioplegic 
line pressure of 300 mm Hg. 
The cardioplegic infusion set used for the gravity infusions with or without external 
pressurization was a 1.5 m length of 3/16" polyvinyl tubing. Proximal line pressure was 
assumed to be equivalent to either the gravitational height or degree of pressurization·. 
With the roller pump system, a 3.5 m length of 1 /4" polyvinyl tubing incorporating an 0.2 
urn pore size cardioplegic filter was used. The proximal line pressure was measured 4 m 
from the distal end of the tubing. 
464 U 0 Von Oppel! PhD Thesis; University of Cape Town, 1992 
All three of the above methods of infusing cardioplegic solutions were used routinely at 
Groote Schuur Hospital by different perfusionists and surgeons at the time of this study. 
These observations were therefore recorded during routine surgery, and there was no 
randomization of patients, as the method of infusing the cardioplegia was chosen by 
individual surgeons . .During each infusion of cardioplegia, both proximal and distal 
aortic root pressures, and duration of cardioplegic infusion were recorded by ;tn 
independent observer. 
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RESULTS 
Figure 1. 
AORTIC PRESSURE DURING INFUSION OF 
CARDIOPLEGIC SOLUTIONS .. 
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· The measured aortic root pressure during administration of cardioplegia by three methods was compared. When infusing 
cardioplegia by gravity (N = 6), the height of the vacolitrefrom the level of the ri&J>t atrium was 178 em Hz 0 ( 133 mm Hg). If a 
pressure bag was used (N = 6), this was inflated to 300 mm Hg. Alternatively, a roller pump was used (N = 12), in which case the 
perfusionist attempted to maintain the measured aortic root pressure between 80 · 100 mm Hg. 
Gravity Infusion 
Infusion of crystalloid cardioplegia by gravity alone, from a height of approximately 178 
em (above the right atrium) produces a proximal infusion "pressure" of± 133.mm Hg. 
This method was used in 6 patients undergoing coronary artery bypass grafting (N = 5) 
or closure of a traumatic ventricular septal defect (N = 1). Ascending aortic root 
pressures of 86.6 ± 7.4 mm Hg were produced with this method, and rate of infusion of 
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the cardioplegic solution was calculated to be 298.7 ± 17.9 mllmin, on induction of 
cardioplegia With subsequent multidoses of cardioplegia (N = 11) the aortic root 
pressure was 69.0 ± 5.1 mm Hg and infusion rate 372.9 ± 32.9 ml/min (Figure 1). 
Pressure Bag Infusion 
In 6 patients undergoing coronary artery bypass graft (N = 3), or mitral valve 
replacement (N = 3) infusion of cardioplegic solution was achieved by pressurizing the 
vacolitre of cardioplegia, by an external pressure bag (inflated to 300 mm Hg). This 
method produced an aortic root infusion pressure of 75.7 ± 11.0 mm Hg at a calculated 
flow rate of 430.1 ± 19.0 ml/min on induction, and again was no different with 
subsequent multidoses (73.6 ± 7.3 mm Hg at 387.7 ± 26.5 mllmin). On induction, 
although this "pressure bag" method produced a higher cardioplegic flow rate than 
simple gravity infusion (p < 0.05), the infusion pressure at the ascending aorta was not 
increased. 
Roller Pump System 
A roller pump was used to infuse the cardioplegic solution in 13 patients undergoing 
coronary artery bypass grafting. the cardioplegic flow rate was progressively increased 
by the perfusionist till an aortic pressure of 80- 100 mm Hg, oi maximal pump speed was 
achieved. Even if maximal flow was necessary, the distally measured aortic infusion 
pressures varied from 43- 108 mm Hg (Fig 1). The mean pressure on induction of 
cardioplegic arrest was 86.1 ± 3.4 mm Hg at a calculated flow rate of 378.0 ± 51.0 
mllmin and was no different with subsequent multidoses (74.0 ± 3.8 mm Hg at a flow 
rate of 329.9 ± 18.6 mllmin). 
COMMENT 
The measured pressure in the ascending aorta when infusing cardioplegic solutions 
varied from 42 - 126 mm Hg. This pressure range was similar with each of the three 
clinically used methods. 
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However, when simply infusing cardioplegia by gravity (height 178 em; 133 mm Hg) the 
maximum obtainable pressure is limited. Only one patient dose was infused at a 
recorded aortic pressure of greater than 100 mm Hg, but a number of infusions were at 
possibly suboptimal pressures. The external pressure bag method (inflated to 300 mm 
Hg) was also associated with a wide range of measured aortic root pressures; some 
excessively high and others too low. In contrast, with the roller pump delivery system, 
both high and low pressures can too a certain extent be prevented. Low aortic root 
pressures during infusion of cardioplegia may be due to mild aortic regurgitation, which 
can be compensated for by increasing flow rate. Therefore, we believe that the 
preferred method of infusing cardioplegia is by means of a roller pump. 
The aortic root pressure also did not correlate with the proximally me~sured "line 
pressure". The same aortic root cannula, which is also a potentially flow limiting factor 
was used in all groups, although a cardioplegic line filter was only included in the roller 
pump groups. This poor correlation is due to resistance in the cardioplegic delivery line 
tubing, between the proximal measuring port and the ascending aorta, varying with flow. 
Thus, cardioplegic infusion pressures should be monitored directly in the ascending 
aorta, as the proximal cardioplegic "line pressure" is unreliable. 
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APPENDIX B-9 
, 
IN VIVO PRIMATE STUDY: THE EFFECT OF A MODIFIED STTHOMAS' 
CARDIOPLEGIC SOLUTION CONTAINING HISTIDINE 
INTRODUCTION 
We previously showed that the addition of histidine (50 mmol/L) to a modified St 
Thomas' Hospital No 2 cardioplegic solution was beneficial in the isolated rat heart 
model (see Appendix B-5). In vivo non-human primate model pilot studies also 
suggested a beneficial effect of histidine (see Appendix B-6). However, in this model 
the standard St Thomas' solution already provided good protection to the myocardium, 
and larger numbers in each group would have been necessary to achieve statistical 
significance. We therefore elected to change the experimental model by introducing an 
initial global ischaemic period of ventricular fibrillation prior to cardioplegic arrest, in 
order to assess the effects of our experimental cardioplegic solutions on energy depleted 
hearts. 
In addition, two further modifications of the StThomas' Hospital cardioplegic solution 
were introduced; decreasing the calcium content to 0.6 mmol/L (see section 3.1), and 
addition of adenosine 1 mmol/L (Boehm D: unpublished data). The composition of the 
experimental cardioplegic solution; StThomas' plus Histidine plus Adenosine (ST-HA) 
is shown in Table 1. 
MATERIALS AND METHODS 
The in vivo primate model as· described in Chapter 2 was used. The chacma baboon 
(Papio ursinus) was selected because of its close evolutionary relationship to man. 
Animals weighing 15 - 34 kg were used. 
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Experimental Protocol 
The animals were anaesthetised, intubated, and ventilated. A median sternotomy was 
performed and the heart cannulated for cardiopulmonary bypass. Control 
haemodynamic and metabolic variables were measured prior to commencing 
cardiopulmonary bypass. Cardiopulmonary bypass was commenced and systemic 
temperature maintained at 32°C. The hearts were then depleted of energy reserves by 
cross-clamping the aorta for 20 min, in addition to inducing fibrillation (spontaneous 
fibrillation after initial electrical induction). Thereafter cold (4°C) cardioplegic solution 
( 15 ml /kg; Table I) was infused into the coronary circulation, and systemic temperature 
lowered and maintained at 26°C. 
Table I 
COMPOSITION OF CARDIOPLEGIC SOLUTIONS 
(uol/L) 
Histidine 
Adenosine 
Osmolarity (mOsm/L) 
Osmolality (mOsmjkg H2o) 
pH (10°C) 
Buffer capacity (mmol HCl/L/o pH) 
Legend: 
st Thomas' No 2 
120 
16 
10 
1.2 
16 
323.6 
293 
7.4 
6 
st Thomas' + Histidine 
+ Adenosine 
100 
16 
10 
0.6 
16 
50 
1 
332.8 
310 
7.2 
30 
The composition of the StThomas cardioplegic solution, as well as an experimental solution containing histidine, adenosine and a 
lower concentration of calcium is shown~ Osmolarity was calculated by assuming 100% ionic dissociation and osmolality 
measured by freezing point depression (Osmomat 030 automatic cryoscopic osmometer: Gonotec, Berlin, Germany). 
Intermittent iced saline was used for topical hypothermia with each administration of 
cardioplegic solution, and maintenance cardioplegia wasreinfused every 30 minutes 
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throughout a 3-hour ischaemic cross-clamp period. Additional ventricular biopsies were 
taken prior to the release of the aortic cross-clamp. A 15-minute normothermic 
reperfusion period followed, and the animals were then weaned from cardiopulmonary 
bypass and postischaemic haemodynamic and metabolic variables measured 5 and 30 
minutes after termination of cardiopulmonary bypass. 
Expression of results 
Values of functional parameters obtained during the postischaemic working period were 
expressed as a percentage of each individual preischaemic control value. Tissue high 
energy phosphate content was expressed in absolute values (umol/g wet weight). 
Results were then presented as percentage means and standard errors of percentage 
means. 
Statistics 
The statistical test used was the two way analysis of variance (ANOVA-2), and if overall 
statistical significance was obtained pair wise comparisons were then done by acceptance 
intervals of means with theftest Statistical significance was taken asp< 0.05. 
RESULTS 
Postischaemic recovery of mechanical function 
The preischaemic control values of the groups were similar, and are shown in Table II. 
In the St Thomas' group (N = 8) three animals could not be weaned from 
cardiopulmonary bypass. In contrast, all animals in the experimental ST-HA group (N = 
6) could be successfully weaned from cardiopulmonary bypass. 
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Table II 
POSTISCHAEMIC MECHANICAL RECOVERY 
Cardiac Index 
Preischaemic 
(L/min;m2) 
% Recovery 5-min 
% Recovery 30-min 
Stroke Volume Index 
Preischaemic 
(mljbeat;m2) 
% Recovery 5-min 
% Recovery 30-min 
Left Ventricular dp/dt 
Preischaemic 
(mm Hgjsec) 
% Recovery 5-min 
% Recovery 30-min 
Stroke Work Index 
Preischaemic 
(gm.mjbeat;m2) 
% Recovery 5-min 
% Recovery 30-min 
Legend: 
St Thomas' No 2 
N = 8 
4.82 ± 0.47 
42.09 ± 13.39 
38.68 ± 12.07 
40.79 ± 4.62 
30.87 ± 9.83 
29.52 ± 9.08 
1027.25 ± 70.45 
72.70 ± 15.33 
56.30 ± 17.10 
68.31 ± 9.03 
21.91 ± 7.54 
20.67 ± 6.42 
St Thomas' + Histidine 
+ Adenosine 
N = 6 
4.48 ± 0.41 
92.10 ± 12.53a 
86.64 ± 10.93a 
33.64 ± 3.55 
83.81 ± 8.16b 
82.49 ± 9.o5b 
1017.00 ± 111.73 
117.89 ± 10.08a 
103.30 ± 9.3a 
53.59 ± 7.90 
92.05 ± 12.62b 
78.11 ± 10.62b 
Animals were subjected to a 20-min period of ventricular fibrillation witb global ischaemia at 32°C prior to 3-hour hypothermic 
cardiopJegic arrest with multidose reinfusions of indicated cardioplegic solutions. H aemodynamic variables were measured at a left 
atrial pressure of 5 mm Hg. Postischaemic recoverY is expressed as mean percentage re_coveries of each individual preischaemic 
value, and standard errors of percentage means. 
a- p < 0.05 compared to StThomas' No 2, b- p < 0.01 compared to StThomas' No 2. 
The experimental ST-HA cardioplegic solution improved the postischaemic recovery of 
all indices of mechanical recovery, both 5-min and 30-min after weaning from 
cardiopulmonary bypass (Table II). Furthermore, there was no difference between either 
the 5-min or 30-min postischaemic values. Thirty minutes after weaning from 
cardiopulmonary bypass percentage recovery of cardiac index increased from 38.68 ± 
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12_07% with ST to 86.64 ± 10.93% with ST-HA (p < 0.05), and stroke work index
 
increased from20.67 ± 6.42% to78.11 ± 10.62% (p < 0.01). 
Left ventricular function curves were determined both prior to an
d after the ischaemic 
cross-clamp period (30-minute post cardiopulmonary bypass), by measuring 
haemodynamic variables at different left atrial preloads. The prei
schaemic control 
values at all left atrial filling pressures were similar in both groups
 (Table Ill). The 
experimental ST-HA cardioplegic solution was associated with be
tter recovery of 
postischaemic left ventricular function as assessed by cardiac inde
x at both 5 mm Hg and 
10 mm Hg left atrial filling pressures (p < 0.01), and stroke work index at both 5 
mm Hg, 
10 mm Hg (p < 0.01) and 15 mm Hg (p < 0.05) filling pressures. 
The percentage recovery of both groups was then normalized for 
display purposes to an 
integrated preischaemic control curve as discussed in chapter 2. T
he recovery of hearts 
protected with St Thomas' cardioplegic solution was depressed at 
all left atrial filling 
pressures compared to the integrated control curve (p < 0.01). In contrast, with S
T-HA 
recovery was depressed at 10 mm Hg, 15 mm Hg and 20 mm Hg fil
ling pressures (p < 
0.01), but the no different to control at 5 mm Hg. 
In conclusion, the experimental modified St Thomas' cardioplegic
 solution containing 
histidine and adenosine was associated with better recovery of my
ocardial mechanical 
function following 3-hour cardioplegic arrest of energy depleted h
earts. 
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Table III 
LEFT VENTRICULAR FUNCTION CURVE 
LAP 5 
CI (Ljmin;m2) 
St Thomas' No 2 
Pre 4.82 ± 0.47 
% Rec 38.68 ± 12.07 
10 
5. 71 ± 0.27 
37.85 ± 11.98 
St Thomas' plus Histidine plus Adenosine 
Pre 4.48 ± 0.41 6.04 ± 0.90 
% Rec 86.64 ± 10.93b 79.57 ± 12.26b 
Data normalized to the integrated preischaemic control curve 
Cont. 4.68 ± 0.31 5.85 ± 0.40 
sT 1.81 ± o.o4d 2.22 ± o.o5d 
sT-HA 4.05 ± o.o3b 4.66 ± o.o5bc 
SWI (gm·mjbeat;m2) 
St Thomas' No 2 
Pre 68.31 ± 9.03 
% Rec 20.67 ± 6.42 
75.48 ± 6.69 
23.67 ± 7.60 
St Thomas' plus Histidine plus Adenosine 
Pre 53.59 ± 7.90 82.90 ± 16.41 
% Rec 78.11 ± 10.62b 64.94 ± 11.89b 
Data normalized to the integrated preischaemic control curve 
Cont. 62.00 ± 6.28 78.66 ± 7.69 
ST 12.82 ± 0.40d 18.62 ± 0.58d 
ST-HA 48.43 ± 0.67b 51.08 ± 0.91bd 
Legend: 
15 
6.58. ± 0.51 
30.60 ± 10.38 
7.08 ± 0.82 
53.44 ± 5.28 
6.79 ± 0.44 
d 2.08 ± 0.05 
bd 3.63 ± 0.02 
83.90 ± 9.40 
21.68 ± 7.65 
86.68 ± 14.26 
48.44 ± 4.57a 
85.09 ± 7.80 
18.45 ± o.6od 
41.22 ± 0.36ad 
20 (mm Hg) 
7.18 ± 0.48 
25.47 ± 10.40 
7.27 ± 0.90 
42.19 ± 5.70 
7.22 ± 0.45 
d 1.84 ± 0.05 
bd 3.05 ± 0.03 
78.43 ± 8.50 
18.98 ± 7.95 
79.76 ± 13.64 
40.90 ± 7.43 
79.00 ± 7.28 
14.99 ± 0.58d 
32.31 ± 0.54d 
A postischaemic left ventricular function curve was obtained 30 min after weaning from cardiopulmonary bypass at increasing left 
atrial pressures (LAP), and compared to a similar preischaemic curve. Mean percentage postischaemic recovery (% Rec) was 
calculated from each individual postischaemic and preischaemic ratio. An average preischaemic control function curve (Coot; N = 
!4) was derived by pooling the data from all groups, and postischaemic function for each group normalized to this curve for display 
purposes. 
ST- StThomas' cardioplegic solution ( N ~ 8); ST-HA- ST plus histidine (50 mmol/L) plus Adenosine (1 mmol/L) cardioplegic 
solution (N ~ 6). 
a- p < 0.05, b -p < O.OI;compared to StThomas' No2, 
c- p < 0.05, d- p < 0.01; compared to Coot 
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